<SEC-DOCUMENT>0001564590-22-015075.txt : 20220421
<SEC-HEADER>0001564590-22-015075.hdr.sgml : 20220421
<ACCEPTANCE-DATETIME>20220421160552
ACCESSION NUMBER:		0001564590-22-015075
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220421
DATE AS OF CHANGE:		20220421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		22841449

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pstv-10q_20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-21T18:02:55.0200780+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:pstv="http://www.plustherapeutics.com/20220331" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
pstv-10q_20220331.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:EntityCentralIndexKey" contextRef="C_0001095981_20220101_20220331">0001095981</ix:nonNumeric>
			<ix:nonNumeric id="F_000002" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001095981_20220101_20220331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001095981_20220101_20220331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000010" name="dei:AmendmentFlag" contextRef="C_0001095981_20220101_20220331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000228" name="pstv:WarrantsIssuedUnderwrittenPublicOfferingPeriod" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331">2019-09</ix:nonNumeric>
			<ix:nonNumeric id="F_000267" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000275" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001095981_20220331">P2Y9M25D</ix:nonNumeric>
			<ix:nonNumeric id="F_000297" name="pstv:StatementOfWorkTerm" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220330_20220331">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000335" name="pstv:PeriodExercisableFromTheDateOfIssuance" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930">P36M</ix:nonNumeric>
			<ix:nonNumeric id="F_000269" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000358" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001095981_srtRangeAxis_srtMinimumMember_20220101_20220331">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000359" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_20220101_20220331">P4Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001095981_20220331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001095981_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:PreferredStockValue" contextRef="C_0001095981_20220331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:PreferredStockValue" contextRef="C_0001095981_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000372" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001095981_20210101_20211231">P9Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000373" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001095981_20220101_20220331">P8Y9M</ix:nonNumeric>
			<ix:nonNumeric id="F_000374" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001095981_20220101_20220331">P8Y5M19D</ix:nonNumeric>
			<ix:nonNumeric id="F_000375" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001095981_20220101_20220331">P8Y8M23D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="pstv-20220331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001095981_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001095981_20220414">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-04-14</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001095981_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001095981_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-05-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001095981_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-05-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateFloorMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20150528_20150529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-05-28</xbrli:startDate>
					<xbrli:endDate>2015-05-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-05-28</xbrli:startDate>
					<xbrli:endDate>2015-05-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_us-gaapDisposalGroupClassificationAxis_pstvSaleOfJapaneseSubsidiaryAndCertainAssetsMember_us-gaapFinancialInstrumentAxis_pstvLoanAndSecurityAgreementMember_20150528_20150529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pstv:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">pstv:SaleOfJapaneseSubsidiaryAndCertainAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-05-28</xbrli:startDate>
					<xbrli:endDate>2015-05-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-27</xbrli:startDate>
					<xbrli:endDate>2020-03-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-29</xbrli:startDate>
					<xbrli:endDate>2020-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220330_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-30</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-08</xbrli:startDate>
					<xbrli:endDate>2021-01-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_20210622_20210622">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-22</xbrli:startDate>
					<xbrli:endDate>2021-06-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_pstvNanoTxLicensesAgreementMember_20200507">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210920">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-20</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210919_20210920">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-19</xbrli:startDate>
					<xbrli:endDate>2021-09-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210921_20210921">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-21</xbrli:startDate>
					<xbrli:endDate>2021-09-21</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassBMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMinimumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-15</xbrli:startDate>
					<xbrli:endDate>2020-06-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-15</xbrli:startDate>
					<xbrli:endDate>2020-06-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220401">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-04-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114_20220114">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-14</xbrli:startDate>
					<xbrli:endDate>2022-01-14</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-14</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20201023">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:DistributionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20200206">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-06</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20200615_20200616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-15</xbrli:startDate>
					<xbrli:endDate>2020-06-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20210517">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtRangeAxis_srtMinimumMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_srtRangeAxis_srtMaximumMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001095981_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000009" name="dei:DocumentType" contextRef="C_0001095981_20220101_20220331">10-Q</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:DocumentQuarterlyReport" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><span style="margin-left:36pt;font-family:'Times New Roman';"></span><span style="font-weight:bold;font-family:Times New Roman;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000011" name="dei:DocumentPeriodEndDate" contextRef="C_0001095981_20220101_20220331" format="ixt:datemonthdayyearen">March 31, <ix:nonNumeric id="F_000007" name="dei:DocumentFiscalYearFocus" contextRef="C_0001095981_20220101_20220331">2022</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.57%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:DocumentTransitionReport" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><span style="font-weight:bold;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number <ix:nonNumeric id="F_000020" name="dei:EntityFileNumber" contextRef="C_0001095981_20220101_20220331">001-34375</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0001095981_20220101_20220331">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:left;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:46.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:stateprovnameen">
Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:51.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001095981_20220101_20220331">33-0827593</ix:nonNumeric></p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:46.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation or organization)</p></td>
<td valign="bottom" style="width:2.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:51.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:46.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:2.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:51.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:46.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressAddressLine1" contextRef="C_0001095981_20220101_20220331">4200 MARATHON BLVD</ix:nonNumeric>., <ix:nonNumeric id="F_000024" name="dei:EntityAddressAddressLine2" contextRef="C_0001095981_20220101_20220331">SUITE 200</ix:nonNumeric>, <ix:nonNumeric id="F_000025" name="dei:EntityAddressCityOrTown" contextRef="C_0001095981_20220101_20220331">AUSTIN</ix:nonNumeric>, <ix:nonNumeric id="F_000026" name="dei:EntityAddressStateOrProvince" contextRef="C_0001095981_20220101_20220331">TX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:51.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressPostalZipCode" contextRef="C_0001095981_20220101_20220331">78756</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:46.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:2.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:51.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000028" name="dei:CityAreaCode" contextRef="C_0001095981_20220101_20220331">737</ix:nonNumeric>) <ix:nonNumeric id="F_000029" name="dei:LocalPhoneNumber" contextRef="C_0001095981_20220101_20220331">255-7194</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:left;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:37.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style="width:25.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style="width:37.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top" style="width:37.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:Security12bTitle" contextRef="C_0001095981_20220101_20220331">Common Stock, par value $0.001</ix:nonNumeric></p></td>
<td valign="top" style="width:25.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:TradingSymbol" contextRef="C_0001095981_20220101_20220331">PSTV</ix:nonNumeric></p></td>
<td valign="top" style="width:37.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:SecurityExchangeName" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000015" name="dei:EntityCurrentReportingStatus" contextRef="C_0001095981_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000014" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001095981_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,<span style="color:#000000;"> a smaller reporting company or an emerging growth company</span>.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,<span style="color:#000000;"> &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; </span>in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large Accelerated Filer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated Filer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityFilerCategory" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:entityfilercategoryen">Non-Accelerated Filer</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntitySmallBusiness" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:4.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000004" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:EntityShellCompany" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 14, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000006" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001095981_20220414" decimals="INF" format="ixt:numdotdecimal">22,197,635</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:13.2pt;">
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:83.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman Bold;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:83.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#0000FF;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION">FINANCIAL INFORMATION</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:10.25pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:83.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS">Financial Statements (Unaudited)</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_CONDENSED_BALANCE_SHEETS">Condensed Balance Sheets</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_CONDENSED_STATEMENTS_OPERAT">Condensed Statements of Operations </a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_CONDENSED_Statm_Stock_equit">Condensed Statements of Stockholders&#8217; Equity</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_CONDENSED_STATEMENTS_CASH_F">Condensed Statements of Cash Flows</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NotesToConsolidatedFinancialStatemen">Notes to Condensed Financial Statements</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Quantitative and Qualitative Disclosures about Market Risk</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES">Controls and Procedures</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:10.25pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:83.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;color:#0000FF;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II_OR_INFORMATION">OTHER INFORMATION</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:10.25pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS">Legal Proceedings</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:7.35pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS">Risk Factors</a></p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr style="height:16.85pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 6. </p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:74.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:normal;font-size:10pt;color:#0000FF;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS">Exhibits</a> </p></td>
<td valign="top" style="width:0.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:4.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>2<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">This report and the exhibits incorporated herein by reference contain &#8220;forward-looking statements&#8221; which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Statements other than statements of historical fact--constitute &#8220;forward-looking statements.&#8221; These forward-looking statements do not constitute guarantees of future performance. These forward-looking statements may be identified by terms such as &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;initiate,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;designed,&#8221; &#8220;potential,&#8221; &#8220;evaluate,&#8221; &#8220;hypothesize,&#8221; &#8220;plan,&#8221; &#8220;progressing,&#8221; &#8220;proceeding,&#8221; &#8220;exploring,&#8221; &#8220;opportunity,&#8221; &#8220;hopes,&#8221; &#8220;suggest,&#8221; and similar expressions, or the negative of such expressions. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses&#59; the Company&#8217;s strategic collaborations and license agreements, intellectual property, FDA approvals and interactions and government regulation&#59; the potential size of the market for our product candidates&#59; our research and development efforts&#59; results from our pre-clinical and clinical studies and the implications of such results regarding the efficacy or safety of our product candidates&#59; the safety profile, pathways, and efficacy of our product candidates and formulations&#59; anticipated advantages of our product candidates over other products available in the market and being developed&#59; the populations that will most benefit from our product candidates and indications that will be pursued with each product candidate&#59; anticipated progress in our current and future clinical trials&#59; plans and strategies to create novel technologies&#59; our IP strategy&#59; competition&#59; future&#160;development and/or expansion of our product candidates and therapies in our markets&#59; sources of competition for any of our product candidates&#59; our pipeline&#59; our ability to generate&#160;&#160;product or development revenue and the sources of such revenue&#59; our ability to effectively manage our gross profit margins&#59; our ability to obtain and maintain regulatory approvals&#59; expectations as to our future performance&#59; portions of the &#8220;Liquidity and Capital Resources&#8221; section of this report, including our potential need for additional financing and the availability thereof&#59; our ability to continue as a going concern&#59; our ability to remain listed on the Nasdaq Capital Market&#59; our ability to repay or refinance some or all of our outstanding indebtedness and our ability to raise capital in the future&#59; our ability to transfer the drug product manufacture to a contract drug manufacturing organization&#59; and the potential enhancement of our cash position through development, marketing, and licensing arrangements. </span><span style="color:#000000;">The forward-looking statements included in this report are also subject to a number of additional material risks and uncertainties, including but not limited to the risks described under &#8220;Part I &#8211; Item 1A &#8211; Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, and under &#8220;Part II &#8211; Item 1A &#8211; Risk Factors&#8221; in this Quarterly report. These risks and uncertainties could cause actual results to differ materially from expectations or those expressed in these forward-looking statements.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of our product candidates and therapies, the results of our research and development activities, including uncertainties relating to the clinical trials of our product candidates and therapies&#59; our liquidity and capital resources and our ability to raise additional cash, the outcome of our partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to us, market conditions, product performance, potential litigation, and competition within the regenerative medicine field, among others. The forward-looking statements included in this report are also subject to a number of additional material risks and uncertainties, including but not limited to the risks described under &#8220;Part I &#8211; Item 1A &#8211; Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, and under &#8220;Part II &#8211; Item 1A &#8211; Risk Factors&#8221; in this Quarterly report. These risks and uncertainties could cause actual results to differ materially from expectations or those expressed in these forward-looking statements.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">We encourage you to read the risks described under &#8220;Risk Factor Summary&#8221; and &#8220;Part II &#8211; Item 1A &#8211; Risk Factors&#8221; in this report carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report.&#160;&#160;These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law.&#160;&#160;Such forward-looking statements are not guarantees of future performance.<span style="font-style:normal;">&#160;&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>3<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I. FINANCIAL INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">Item 1. Financial Statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_CONDENSED_BALANCE_SHEETS"> CONDENSED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and par value data)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AssetsCurrent" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:AssetsCurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,558</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-use-of assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001095981_20220331" decimals="-3" scale="3">316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001095981_20211231" decimals="-3" scale="3">341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:Goodwill" contextRef="C_0001095981_20220331" decimals="-3" scale="3">372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:Goodwill" contextRef="C_0001095981_20211231" decimals="-3" scale="3">372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OtherIntangibleAssetsNet" contextRef="C_0001095981_20220331" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:OtherIntangibleAssetsNet" contextRef="C_0001095981_20211231" decimals="-3" scale="3">51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001095981_20211231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:Assets" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">24,516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:Assets" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001095981_20211231" decimals="-3" scale="3">111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loan obligation, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:LongTermDebtCurrent" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:LongTermDebtCurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,870</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent operating lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001095981_20211231" decimals="-3" scale="3">269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loan obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,718</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001095981_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:Liabilities" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,874</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:Liabilities" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000063">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000064">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000077" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001095981_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000078" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001095981_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">1,952</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued and outstanding at March 31, 2022 and December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000065">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000066">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000085" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001095981_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000086" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001095981_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">22,197,635</ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and <ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal">15,510,025</ix:nonFraction></ix:nonFraction> issued and outstanding at March 31, 2022 and December</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 31, 2021, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommonStockValue" contextRef="C_0001095981_20220331" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommonStockValue" contextRef="C_0001095981_20211231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">465,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">457,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001095981_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">451,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001095981_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">446,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">24,516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Accompanying Notes to these Condensed Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>4<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_CONDENSED_STATEMENTS_OPERAT"> CONDENSED STATEMENTS OF OPERATIONS&#160;&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,127</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingExpenses" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OperatingExpenses" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:InterestExpense" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:InterestExpense" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of liability instruments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" scale="3">190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" scale="3">241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001095981_20220101_20220331" decimals="2" sign="-">0.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000112" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001095981_20210101_20210331" decimals="2" sign="-">0.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted weighted average shares used in calculating net loss per share</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; attributable to common stockholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001095981_20220101_20220331" decimals="0" format="ixt:numdotdecimal">21,507,061</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001095981_20210101_20210331" decimals="0" format="ixt:numdotdecimal">8,267,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Accompanying Notes to these Condensed Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>5<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_CONDENSED_Statm_Stock_equit"> CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">6,749,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">436,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">433,511</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of common stock, net </p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">2,534,879</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series B Convertible Preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Stock into common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000127" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331" decimals="INF" sign="-">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000128" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000129" name="pstv:StockIssuedDuringPeriodSharesWarrantsExerciseShares" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">896,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="pstv:StockIssuedDuringPeriodSharesWarrantsExercise" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="pstv:StockIssuedDuringPeriodSharesWarrantsExercise" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="pstv:StockIssuedDuringPeriodSharesWarrantsExercise" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">1,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">10,180,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">445,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">436,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">15,510,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">457,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">446,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of common stock, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000149" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">6,687,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,742</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:SharesOutstanding" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">22,197,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">465,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">451,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Accompanying Notes to these Condensed Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>6<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_CONDENSED_STATEMENTS_CASH_F"> CONDENSED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of deferred financing costs and debt discount</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of liability instruments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:ShareBasedCompensation" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:ShareBasedCompensation" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="pstv:NonCashLeaseExpense" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="pstv:NonCashLeaseExpense" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases (decreases) in cash caused by changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" scale="3">650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" scale="3">461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">210</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In process research and development acquired</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001095981_20220101_20220331" decimals="-3" sign="-" scale="3">577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001095981_20210101_20210331" decimals="-3" sign="-" scale="3">84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments of long-term obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of financing lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="pstv:ProceedsFromWarrantExercises1" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="pstv:ProceedsFromWarrantExercises1" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001095981_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001095981_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001095981_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001095981_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001095981_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001095981_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flows information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during period for:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:InterestPaidNet" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:InterestPaidNet" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental schedule of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Unpaid offering cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="pstv:UnpaidOfferingCosts" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="pstv:UnpaidOfferingCosts" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Accompanying Notes to these Condensed Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>7<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NotesToConsolidatedFinancialStatemen">PLUS THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONDENSED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000207" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span><span style="font-size:10pt;">Basis of Presentation and New Accounting Standards</span></p></td></tr></table></div><ix:nonNumeric id="F_000218" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited&#160;&#160;condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;The condensed balance sheet at December 31, 2021 has been derived from the audited financial statements at December 31, 2021, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc., and its subsidiaries (collectively, the &#8220;Company&#8221;) have been included.&#160;&#160;Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&#160;These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.</p></ix:nonNumeric><ix:nonNumeric id="F_000219" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the one-time determination date. Early adoption is permitted beginning in 2019. The Company plans to adopt the new guidance on January 1, 2023, and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000208" name="pstv:UseOfEstimatesTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span><span style="font-size:10pt;">Use of Estimates</span></p></td></tr></table></div><ix:nonNumeric id="F_000220" name="us-gaap:UseOfEstimates" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160; <span style="Background-color:#FFFFFF;">The Company&#8217;s most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring stock-based compensation expense. </span>&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual results could differ from these estimates.&#160;Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary.</p></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000209" name="pstv:DisclosureOfLiquidityTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000209_dcnt_51c1ba0c-fc28-4f4f-9416-af55d7c2b49d">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span><span style="font-size:10pt;">Liquidity</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:NetIncomeLoss" contextRef="C_0001095981_20220101_20220331" decimals="-5" sign="-" scale="6">4.1</ix:nonFraction> million for the three months ended March 31, 2022.&#160;&#160;The Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001095981_20220331" decimals="-5" sign="-" scale="6">451.0</ix:nonFraction> million as of March 31, 2022.&#160; Additionally, the Company used net cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001095981_20220101_20220331" decimals="-5" sign="-" scale="6">3.9</ix:nonFraction> million to fund its operating activities for the three months ended March 31, 2022.<span style="font-weight:bold;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in more detail in Note 9, the Company had entered into various financing agreements, and raised capital by issuing its common stock. <span style="Background-color:#FFFFFF;">The Company believes its current cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued. </span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to seek additional capital through strategic transactions and from other financing alternatives. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>8<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000209_dcnt_51c1ba0c-fc28-4f4f-9416-af55d7c2b49d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000210" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair<span style="font-weight:normal;"> </span>Value Measurements<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements are market-based measurements, not entity-specific measurements.&#160;&#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&#160;&#160;The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&#160;&#160;The basis for fair value measurements for each level within the hierarchy is described below:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level 2: Quoted prices for similar assets or liabilities in active markets&#59; quoted prices for identical or similar instruments in markets that are not active&#59; and model-derived valuations in which all significant inputs are observable in active markets.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain w<span style="color:#000000;">arrants issued in an underwritten public offering&#160;in September 2019 (&#8220;Series U Warrants&#8221;) are classified as liability instruments.&#160;The Company estimated the fair value of the Series U Warrants with the Black Scholes model. Because some of the inputs to the Company&#8217;s valuation model are either not observable or are not&#160;derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series U Warrants will be<span style="color:#000000;"> </span>marked to market as of each balance sheet date until they are exercised or upon expiration, with the changes in fair value recorded as non-operating income or loss in the statements of operations. As of March 31, 2022, the fair value of the Series U Warrants was immaterial, a<span style="color:#000000;">nd the change in the fair value of liability classified Series U Warrants during the three months ended March 31, 2022 and 2021 was not material. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000211" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000211_dcnt_112d6f5a-cff8-4476-bf04-1f679fceccc7">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Term Loan Obligations</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000229" name="us-gaap:DebtInstrumentOfferingDate1" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331" format="ixt:datemonthdayyearen">May 29, 2015</ix:nonNumeric>,&#160;the Company&#160;entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529" decimals="-5" scale="6">17.7</ix:nonFraction> million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least <ix:nonFraction unitRef="U_xbrlipure" id="F_000231" name="pstv:DebtInstrumentFloatingInterestRatePercentage" contextRef="C_0001095981_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529" decimals="INF" scale="-2">8.95</ix:nonFraction>% per annum, comprised of a three-month LIBOR rate with a floor of <ix:nonFraction unitRef="U_xbrlipure" id="F_000232" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001095981_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateFloorMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20150528_20150529" decimals="4" scale="-2">1.00</ix:nonFraction>% plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000233" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529" decimals="4" scale="-2">7.95</ix:nonFraction>%.&#160;&#160;Pursuant to the Loan and Security Agreement, as amended, the Company is required to make interest only payments through <ix:nonNumeric id="F_000234" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529" format="ixt:datemonthdayyearen">May 1, 2021</ix:nonNumeric> and thereafter it is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:DebtInstrumentFeeAmount" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529" decimals="-5" scale="6">3.2</ix:nonFraction> million. In connection with the Term Loan, on May 29, 2015, the Company issued to Oxford warrants to purchase an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000236" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529" decimals="INF">188</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000237" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529" decimals="INF" format="ixt:numdotdecimal">5,175</ix:nonFraction> per share. These warrants became exercisable as of <ix:nonNumeric id="F_000238" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331" format="ixt:datemonthdayyearen">November 30, 2015</ix:nonNumeric> and will expire on <ix:nonNumeric id="F_000239" name="pstv:ClassOfWarrantOrRightExpirationDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331" format="ixt:datemonthdayyearen">May 29, 2025</ix:nonNumeric> and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From September 2017 to March 2019, the Company entered into a total of seven amendments to the Term Loan which, amongst other things, extended the interest only period, required repayment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:PaymentsForLoans" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_us-gaapDisposalGroupClassificationAxis_pstvSaleOfJapaneseSubsidiaryAndCertainAssetsMember_us-gaapFinancialInstrumentAxis_pstvLoanAndSecurityAgreementMember_20150528_20150529" decimals="-5" scale="6">3.1</ix:nonFraction> million using the proceeds received from sale of the Company&#8217;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, and increased the minimum liquidity covenant level to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="pstv:MinimumLiquidityCovenantAmount" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331" decimals="-5" scale="6">2.0</ix:nonFraction> million. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2020, the Company entered into the Ninth Amendment of the Loan and Security Agreement (the &#8220;Ninth Amendment&#8221;), pursuant to which Oxford agreed to defer the start date of principal repayment from&#160;<ix:nonNumeric id="F_000242" name="pstv:DebtPrincipalRepaymentStartDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328" format="ixt:datemonthdayyearen">May 1, 2020</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric id="F_000243" name="pstv:DebtPrincipalRepaymentStartDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329" format="ixt:datemonthdayyearen">May 1, 2021</ix:nonNumeric>&#160;and extended the term of the Term Loan from&#160;<ix:nonNumeric id="F_000246" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328" format="ixt:datemonthdayyearen">September 1, 2021</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric id="F_000247" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329" format="ixt:datemonthdayyearen">June 1, 2024</ix:nonNumeric>.&#160;<span style="color:#000000;">The principal repayment start date was further deferred to November 1, 2021.</span> In addition, pursuant to the Ninth Amendment, on April 1, 2020, the Company made a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="pstv:PrepaymentsOfLongTermDebt" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329" decimals="-5" scale="6">5.0</ix:nonFraction>&#160;million&#160;paydown&#160;of principal upon execution of the Ninth Amendment and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="pstv:RelatedFinalPayment" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million of related final payment.&#160;In addition, an amendment fee of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="pstv:DebtInstrumentAmendmentFee" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329" decimals="-5" scale="6">1.0</ix:nonFraction>&#160;million will be payable in connection with the Ninth Amendment at the earlier of the maturity date, acceleration of the loans and the making of certain prepayments. All other major terms remained consistent.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under authoritative guidance, the Ninth Amendment does not meet the criteria to be accounted for as a troubled debt restructuring. In addition, the Company performed a quantitative analysis and determined that the terms of the new debt and original debt instrument are not substantially different. Accordingly, the Ninth Amendment is accounted for as debt modification. A new effective interest rate that equates the revised cash flows to the carrying amount of the original debt is computed and applied prospectively.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. &#160;The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331" decimals="INF" scale="6">3</ix:nonFraction> million.&#160;As of March 31, 2022, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="pstv:LongTermDebtOutstandingThresholdAmount" contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331" decimals="-5" scale="6">3.6</ix:nonFraction> million principal amount outstanding under the Term Loan, excluding the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:DebtInstrumentFeeAmount" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331" decimals="-5" scale="6">3.2</ix:nonFraction> million final payment fee, and <ix:nonNumeric id="F_000252" name="us-gaap:DebtInstrumentCovenantCompliance" contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</ix:nonNumeric></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>9<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_112d6f5a-cff8-4476-bf04-1f679fceccc7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s interest expense for each of the three months ended March 31, 2022&#160;and 2021&#160;was<span style="color:#000000;">&#160;</span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:InterestExpense" contextRef="C_0001095981_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:InterestExpense" contextRef="C_0001095981_20220101_20220331" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million. Interest expense is calculated using the effective interest method&#59; therefore it is inclusive of non-cash amortization in the amount of<span style="color:#000000;">&#160;</span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001095981_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001095981_20220101_20220331" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended March 31, 2022&#160;and 2021, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of March 31, 2022, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:5pt;">&#160;</p><ix:nonNumeric id="F_000212" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;font-weight:normal;"></span><span style="font-weight:normal;"></span><span style="font-size:10pt;">Loss per Share</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented.</p><ix:nonNumeric id="F_000221" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following were excluded from the <span style="color:#000000;">diluted</span> loss per share calculation for the periods presented because their effect would be anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000257" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">1,170,873</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000258" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">691,263</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000259" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">422,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000260" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">422,867</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000261" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">2,141,378</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000262" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">2,141,378</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000263" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">3,735,118</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001095981_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">3,255,508</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000213" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000213_dcnt_08669b29-7df0-4dbd-be53-ee0c8feb6000">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span><span style="font-size:10pt;">Commitments and Contingencies </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. <span style="Background-color:#FFFFFF;">Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options.&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for finance leases are recorded within property and equipment, net in the condensed balance sheets. Leases with an initial term of 12 months or less are not recorded on the condensed balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the condensed statements of operations. <span style="color:#000000;">&#160;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in <ix:nonNumeric id="F_000265" name="pstv:OperatingLeasesExpiryYear" contextRef="C_0001095981_20220101_20220331">2025</ix:nonNumeric>. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement. On March 1, 2021, the Company entered into a lease agreement for office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). <span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000268" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301">The Charlottesville Lease has a term of <ix:nonNumeric id="F_000266" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301" format="ixt-sec:durmonth">12</ix:nonNumeric> months and is renewable for four additional <span style="-sec-ix-hidden:F_000269">one-year</span> periods.</ix:nonNumeric></span> The minimum lease payment is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301" decimals="INF" format="ixt:numdotdecimal">30,000</ix:nonFraction> for the first twelve months, subject to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000271" name="pstv:AnnualIncreaseInLeaseRate" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301" decimals="INF" scale="-2">3</ix:nonFraction>% annual increase if and when the lease is renewed. The lease commencement date is <ix:nonNumeric id="F_000272" name="pstv:LeaseCommencementDate" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301" format="ixt:datemonthdayyearen">April 1, 2021</ix:nonNumeric> and currently expires on <ix:nonNumeric id="F_000273" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301" format="ixt:datemonthdayyearen">March 31, 2023</ix:nonNumeric>. The Company measured the operating lease right-of-use asset and related lease liability related to the Charlottesville Lease as of the lease commencement date.  In addition, the Company has entered into leases for certain equipment under various operating and finance leases. During 2021, contractual terms of all finance leases had expired and the Company did not have any right-of-use assets or lease liabilities relating to finance leases as of March 31, 2022. The Company&#8217;s existing operating lease agreements&#160;generally provide for periodic rent increases, and renewal and termination options. The Company&#8217;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>10<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000213_dcnt_08669b29-7df0-4dbd-be53-ee0c8feb6000" continuedAt="F_000213_dcnt_9d3d7f2b-655b-4cea-859a-18114eef91d1">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate non-lease components from lease components.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operating lease liabilities and corresponding right-of-use assets are included in the condensed balance sheets. As of March 31, 2022, weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were <ix:nonFraction unitRef="U_xbrlipure" id="F_000274" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001095981_20220331" decimals="3" scale="-2">9.0</ix:nonFraction>% and 2.82%, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000222" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s lease costs from its unaudited  condensed statement of operations, and cash payments from its unaudited  condensed statement of cash flows during the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:OperatingLeaseCost" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:OperatingLeaseCost" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">50</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease expense:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation of right-of-use assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:LeaseCost" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:LeaseCost" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">54</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payment information:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash used for operating leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:OperatingLeasePayments" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:OperatingLeasePayments" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Financing cash used for finance leases</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_0001095981_20220101_20220331" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_0001095981_20210101_20210331" decimals="-3" scale="3">55</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total rent expenses for the three months ended March 31, 2022 and 2021 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001095981_20220101_20220331" decimals="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001095981_20210101_20210331" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction>, respectively, which includes leases in the table above, month-to-month operating leases, and common area maintenance charges.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000223" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000223_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future minimum annual lease payments under operating leases at March 31, 2022 are as follows (in thousands):</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000223_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2022</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001095981_20220331" decimals="-3" scale="3">114</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001095981_20220331" decimals="-3" scale="3">137</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001095981_20220331" decimals="-3" scale="3">113</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001095981_20220331" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001095981_20220331" decimals="-3" scale="3">382</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001095981_20220331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of obligations under leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001095981_20220331" decimals="-3" scale="3">345</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001095981_20220331" decimals="-3" scale="3">235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Services Agreement and Statement of Work with Medidata</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2022, the&#160;&#160;Company and Medidata Solutions, Inc. (&#8220;Medidata&#8221;) entered into a Statement of Work (the &#8220;SOW&#8221;), pursuant to which Medidata will build a Sythetic Control Arm<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;(SCA) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of Rhenium-186 NanoLiposome (<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL) in recurrent glioblastoma (&#8220;GBM&#8221;).&#160;&#160;<span style="Background-color:#FFFFFF;">The SOW is governed under the terms of a services agreement (the &#8220;Services Agreement&#8221;), dated November 5, 2021.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SOW has a term of six (6) months.&#160;&#160;The Company will pay Medidata $<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:ManagementFeePayable" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331" decimals="-4" scale="6">1.45</ix:nonFraction> million in managed services fees and a contingent managed services fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="pstv:ContingentManagedServicesFee" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> if the U.S. Food &#38; Drug Administration approves a path forward for the Company to use the SCA in its clinical trial of&#160;<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL for treatment of GBM.&#160;&#160;The SOW may only be terminated for a material breach by either party or if the clinical study&#8217;s authorization or approval is withdrawn by a regulatory agency.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Piramal Master Services Agreement</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="Background-color:#FFFFFF;color:#000000;">n </span><ix:nonNumeric id="F_000300" name="pstv:MasterServicesAgreementDate" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108" format="ixt:datemonthdayyearen"><span style="color:#000000;">January</span><span style="Background-color:#FFFFFF;color:#000000;"> 8, 2021</span></ix:nonNumeric>, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. </p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>11<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000213_dcnt_9d3d7f2b-655b-4cea-859a-18114eef91d1">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">(&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s RNL-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company</span><span style="Background-color:#FFFFFF;color:#000000;">, which has been initiated </span><span style="color:#000000;">at&#160;Piramal&#8217;s&#160;facility located in Lexington, Kentucky.&#160;</span><span style="color:#000000;"> </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000302" name="pstv:MasterServicesAgreementTermsDescription" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20220101_20220331">The MSA has a term of <ix:nonNumeric id="F_000301" name="pstv:MasterServicesAgreementInitialTerm" contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108" format="ixt-sec:durwordsen">five years</ix:nonNumeric> and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA.&#160;&#160;The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.</ix:nonNumeric>&#160;&#160;Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other commitments and contingencies</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has <span style="color:#000000;">entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of </span>March 31, 2022<span style="color:#000000;">, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:ContractualObligation" contextRef="C_0001095981_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t have any clinical research study obligations.</span> &#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 22, 2021, the Company was named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (&#8220;Lorem&#8221;) in the District Court for the District of Delaware. The complaint alleges false representations were made to Lorem regarding the manufacturing facility in the United Kingdom (the &#8220;UK Facility&#8221;) that Lorem purchased from the Company under the Asset and Equity Purchase Agreement, dated March 29, 2019, between the Company and Lorem (the &#8220;Lorem Agreement&#8221;). Lorem also claims that false representations were made regarding the UK Facility&#8217;s certification to sell and distribute devices in the European Union and export such devices to China. In connection with these allegations, Lorem claims entitlement to at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="pstv:CompensatoryDamagesAndOperational" contextRef="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_20210622_20210622" decimals="0" format="ixt:numdotdecimal">6,000,000</ix:nonFraction> in compensatory damages and operational costs and expenses (collectively, the &#8220;Lorem Claim&#8221;). The Company believes that the Lorem Claim is without merit and is vigorously defending the case. <ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:LitigationSettlementExpense" contextRef="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> liability was accrued as of March 31, 2022.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various claims and contingencies related to legal proceedings.&#160;&#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&#160;&#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000214" name="pstv:LicenseAgreementDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>License Agreements<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UT Health Science Center at San Antonio (&#8220;UTHSA&#8221;) License Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2021, the Company entered into a Patent and Know-How License Agreement (the &#8220;UTHSA License Agreement&#8221;) with The University of Texas Health Science Center at San Antonio, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as in-process research and development acquired in the condensed statement of operations for the year ended December 31, 2021. The upfront payment was paid in cash in January 2022.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NanoTx License Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2020, the Company and&#160;NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and Know-How License Agreement (the &#8220;NanoTx License Agreement&#8221;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and&#160;to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On May 7, 2020, all closing conditions under the NanoTx License Agreement were satisfied and the Company paid an upfront cash payment and issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000306" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001095981_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_pstvNanoTxLicensesAgreementMember_20200507" decimals="INF" format="ixt:numdotdecimal">230,769</ix:nonFraction> shares of its common stock to NanoTx. Cash and the fair value of common stock issued is recorded as in-process research and development expenses, pursuant to authoritative literature for asset acquisition, in the statement of operations and comprehensive loss for the year ended December 31, 2020.&#160; </span></p></ix:nonNumeric><ix:nonNumeric id="F_000215" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000215_dcnt_bb7e6b4e-5988-49ee-ba8a-3f9d97a41ef1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>12<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000215_dcnt_bb7e6b4e-5988-49ee-ba8a-3f9d97a41ef1" continuedAt="F_000215_dcnt_e2c85272-1cfb-4910-bdfb-e61e5d1f61d2">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized <ix:nonFraction unitRef="U_xbrlishares" id="F_000307" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000308" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001095981_20220331" decimals="INF">0.001</ix:nonFraction> per share. The Company&#8217;s Board of Directors is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. &#160;On <ix:nonNumeric id="F_000317" name="pstv:PreferredStockDividendRatePercentageEliminatedDate" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210921_20210921" format="ixt:datemonthdayyearen">September 21, 2021</ix:nonNumeric>, Series A 3.6% Convertible Preferred Stock was eliminated. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000309" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000310" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210920" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of Series A <ix:nonFraction unitRef="U_xbrlipure" id="F_000311" name="us-gaap:PreferredStockDividendRatePercentage" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="3" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000312" name="us-gaap:PreferredStockDividendRatePercentage" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210919_20210920" decimals="3" scale="-2">3.6</ix:nonFraction></ix:nonFraction>% Convertible Preferred Stock immediately prior to September 21, 2021, or December 31, 2020. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000314" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,014</ix:nonFraction></ix:nonFraction> shares of Series B Convertible Preferred Stock outstanding as of March 31, 2022 and December 31, 2021. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000315" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000316" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20211231" decimals="INF">938</ix:nonFraction></ix:nonFraction> shares of Series C Preferred Stock outstanding as of March 31, 2022 and December 31, 2021.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000318" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331" decimals="INF">938</ix:nonFraction> outstanding shares of Series C Preferred Stock that can be converted into an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000319" name="pstv:NumberOfPreferredStockSharesExercised" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">416,889</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000320" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,014</ix:nonFraction> shares of Series B Convertible Preferred Stock that can be converted into an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000321" name="pstv:NumberOfPreferredStockSharesExercised" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">5,978</ix:nonFraction> shares of common stock.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2019, the Company completed an underwritten public offering. The Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000322" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">289,000</ix:nonFraction> shares of its common stock, along with pre-funded warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000323" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassBMember_20220331" decimals="INF" format="ixt:numdotdecimal">2,711,000</ix:nonFraction> shares of its common stock and Series U Warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000324" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">3,450,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000325" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331" decimals="2">5.00</ix:nonFraction> per share. The Series U Warrants have a term of <ix:nonNumeric id="F_000326" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the issuance date. In addition, the Company issued warrants to H.C. Wainwright &#38; Co., LLC, as representatives of the underwriters, to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000327" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331" decimals="INF" format="ixt:numdotdecimal">75,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000328" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331" decimals="2">6.25</ix:nonFraction> per share with a term of <ix:nonNumeric id="F_000329" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" format="ixt-sec:duryear">5</ix:nonNumeric> years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;).&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with authoritative guidance, the pre-funded warrants are classified as equity. The Series U Warrants and the Representative Warrants were initially classified at issuance as liabilities due to a contingent obligation for the Company to settle the Series U Warrants with cash upon certain change in control events. In 2020, all but <ix:nonFraction unitRef="U_xbrlishares" id="F_000330" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,500</ix:nonFraction> Series U Warrants were amended and met the requirements to be classified within stockholder&#8217;s equity. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000331" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220331" decimals="INF" format="ixt:numdotdecimal">2,141,000</ix:nonFraction> outstanding Series U Warrants which can be exercised into an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000332" name="pstv:NumberOfWarrantsExercised" contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">2,141,000</ix:nonFraction> shares of common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Lincoln Park Purchase Agreement </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.66%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On September 30, 2020, the Company entered into the 2020 Purchase Agreement and registration rights </span>agreement<span style="Background-color:#FFFFFF;"> pursuant to which Lincoln Park committed to purchase up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930" decimals="-5" scale="6">25.0</ix:nonFraction> million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930" decimals="-5" scale="6">25.0</ix:nonFraction> million of the Company&#8217;s common stock. </span>Such sales of common stock by the Company were&#160;subject&#160;to certain limitations, and could occur from time to time, at the Company&#8217;s sole discretion, over the&#160;36-month&#160;period commencing on&#160;November 6, 2020, subject to the satisfaction of certain conditions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On June 16, 2020, the Company received stockholder approval to permit issuances of the Company&#8217;s common stock (including the issuance of more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000336" name="pstv:PercentageIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMinimumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616" decimals="4" scale="-2">19.99</ix:nonFraction>% of the Company&#8217;s common stock) to Lincoln Park pursuant to the 2020 Purchase Agreement.&#160;&#160;Based on the closing price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000337" name="us-gaap:SharePrice" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200616" decimals="2">1.05</ix:nonFraction> per share on March 16, 2020, the maximum number of shares the Company could issue and sell under the 2020 Purchase Agreement is approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000338" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616" decimals="INF" scale="6">23.8</ix:nonFraction> million shares.&#160;&#160;Accordingly, the Company requested and received stockholder approval for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000339" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616" decimals="INF" scale="6">23.8</ix:nonFraction> million shares of the Company&#8217;s common stock under the 2020 Purchase Agreement. The Company would seek additional stockholder approval before issuing more than <ix:nonFraction unitRef="U_xbrlishares" id="F_000340" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616" decimals="INF" scale="6">23.8</ix:nonFraction> million shares. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lincoln Park had no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual sales of shares of common stock to Lincoln Park under the 2020 Purchase Agreement depended on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2020 Purchase Agreement to the Company depended on the frequency and prices at which the Company sold shares of its stock to Lincoln Park.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company issued&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000341" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,685,186</ix:nonFraction>&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-5" scale="6">12.5</ix:nonFraction>&#160;million. During the three months ended March 31, 2022, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000342" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">5,665,000</ix:nonFraction>&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="-5" scale="6">7.0</ix:nonFraction> million. The Company <ix:nonFraction unitRef="U_xbrlishares" id="F_000345" name="us-gaap:SharesIssued" contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220401" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement. </p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>13<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000215_dcnt_e2c85272-1cfb-4910-bdfb-e61e5d1f61d2">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">At-the-market Issuances</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 14, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC ( &#8220;Canaccord&#8221;), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114_20220114" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares (the &#8220;Shares&#8221;), with Canaccord acting as an agent for sales. Canaccord will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf. The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="pstv:CommonStockSalesAvailableForIssuance" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> obligation to sell any of the Shares. The Company may instruct Canaccord not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the 2022 Distribution Agreement. During the three months ended March 31, 2022, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000348" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">1,022,610</ix:nonFraction> shares under the 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="-5" scale="6">0.7</ix:nonFraction> million. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On October&#160;23, 2020, the Company entered into an Equity Distribution Agreement (the &#8220;2020 Distribution Agreement&#8221;) with Canaccord. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="pstv:CommonStockSalesAvailableForIssuance" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20201023" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> obligation to sell any of the ATM Shares and it could instruct Canaccord not to sell the ATM Shares if the sales could not be effected at or above the price the Company designated from time to time and the Company could at any time suspend sales pursuant to the 2020 Distribution Agreement.&#160;&#160;</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company issued </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000351" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,179,193</ix:nonFraction><span style="Background-color:#FFFFFF;"> shares under the 2020 Distribution Agreement for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-5" scale="6">6.3</ix:nonFraction> million. The 2020 Distribution Agreement has been terminated. </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000216" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2020, the Company amended the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;) to increase the total number of shares of common stock reserved for issuance under the plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000354" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20200206" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction> shares.&#160;Awards may only be granted under the 2015 Plan to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company.<span style="Background-color:#FFFFFF;color:#000000;"> As of March 31, 2022, there were </span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000353" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20220331" decimals="INF" format="ixt:numdotdecimal">90,389</ix:nonFraction></span><span style="Background-color:#FFFFFF;color:#000000;"> shares of common stock remaining and available for future issuances under the 2015 Plan. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2020, the stockholders of the Company approved the Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan.&#160;The 2020 Plan provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock. The 2020 Plan provides for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20200615_20200616" decimals="INF" format="ixt:numdotdecimal">550,000</ix:nonFraction> shares of common stock, and the number of shares available for issuance will be increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan).&#160;<span style="Background-color:#FFFFFF;color:#000000;">On May 17, 2021, the stockholders of the Company approved an amendment and restatement to the 2020 Plan to increase the total number of shares of common stock reserved for issuance under the 2020 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20210517" decimals="INF" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> shares. As of March 31, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20220331" decimals="INF" format="ixt:numdotdecimal">640,212</ix:nonFraction> shares remaining and available for future issuances under the 2020 Plan.</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, options issued under the 2020 Plan are subject to a <span style="-sec-ix-hidden:F_000358">two-year</span> or <span style="-sec-ix-hidden:F_000359">four-year</span> vesting schedule with <ix:nonFraction unitRef="U_xbrlipure" id="F_000361" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001095981_20220101_20220331" decimals="2" scale="-2">25</ix:nonFraction>% of the options vesting one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of <ix:nonNumeric id="F_000360" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:duryear">10</ix:nonNumeric> years. </p><ix:nonNumeric id="F_000224" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of activity for the three months ended March 31, 2022 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000362" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001095981_20211231" decimals="INF" format="ixt:numdotdecimal">1,170,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001095981_20211231" decimals="2">5.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000372">9.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001095981_20220101_20220331" decimals="INF">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000368" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001095981_20220101_20220331" decimals="2" format="ixt:numdotdecimal">24,706.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">1,170,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001095981_20220331" decimals="2">4.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000373">8.75</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000365" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">460,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="C_0001095981_20220331" decimals="2">8.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000374">8.47</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:16.35pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001095981_20220331" decimals="INF" format="ixt:numdotdecimal">1,102,117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001095981_20220331" decimals="2">4.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000375">8.73</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, the total compensation cost related to non-vested stock options not yet recognized for all the Company&#8217;s plans is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001095981_20220331" decimals="-5" scale="6">1.3</ix:nonFraction> million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of <span><span style="color:#000000;"><ix:nonNumeric id="F_000377" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001095981_20220101_20220331" format="ixt-sec:duryear">2.79</ix:nonNumeric></span> years</span>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000217" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" contextRef="C_0001095981_20220101_20220331" escape="true" continuedAt="F_000217_dcnt_952cde89-4803-48e4-b901-19d66244d703">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160; &#160;&#160;COVID-19 Pandemic and CARES Act<span style="font-size:12pt;font-weight:normal;"> </span></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>14<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_952cde89-4803-48e4-b901-19d66244d703" continuedAt="F_000217_dcnt_80494be0-5eea-430d-a091-c369e6695bdd">

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (COVID-19) was declared a global pandemic by the World Health Organization in March 2020.&#160;&#160;COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. While the Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines, the Company has not experienced a significant impact on its business and operations.&#160;&#160;However, the Company may experience disruptions that could adversely impact its business operations as well as its preclinical studies and clinical trials. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at March 31, 2022. The full extent to which the COVID-19 pandemic will directly or indirectly impact its business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.86%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160;&#160;The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;&#160;The CARES Act had no material impact on the Company&#8217;s income tax provision for the year ended December 31, 2021 or the three months ended March 31, 2022.&#160;&#160;The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>15<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_80494be0-5eea-430d-a091-c369e6695bdd">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read in conjunction with the unaudited financial information and the notes thereto included herein, as well as the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed on February 24, 2022. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the caption &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this report, as well as under "Part I &#8211; Item 1A - Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, in other subsequent filings with the SEC, and elsewhere in this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&#38;A, includes the following sections:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Overview that discusses our operating results and some of the trends that affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Results of Operations that includes a more detailed discussion of our revenue and expenses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Liquidity and Capital Resources which discusses key aspects of our statements of cash flows, changes in our financial position and our financial commitments.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plus Therapeutics, Inc. is a U.S. pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and&#160;difficult-to-treat&#160;cancers.&#160;Our novel radioactive drug formulations and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as Rhenium isotopes within nanoliposomes and microspheres. Our formulations are intended to achieve elevated tumor absorbed radiation doses and extended retention times such that the clearance of the isotope occurs after significant radiation decay, which we believe will contribute and provide less normal tissue/organ exposure and improved safety margins. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Traditional approaches to radiation therapy for cancer such as external beam radiation have many disadvantages including continuous treatment for&#160;4-6&#160;weeks (which is onerous for patients), radiation that inadvertently damages healthy cells and tissue, and a very limited amount of radiation that can be safely delivered, therefore, is frequently inadequate to fully destroy the cancer.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome these disadvantages by directing higher, more powerful radiation doses at the tumor&#8212;and only the tumor&#8212;potentially in a single treatment. By minimizing radiation exposure to healthy tissues while simultaneously maximizing efficacy, we hope to reduce the toxicity of radiation for patients, improving their quality of life and life expectancy. Our radiotherapeutic platform, combined with advances in surgery, nuclear medicine, interventional radiology, and radiation oncology, affords us the opportunity to target a broad variety of cancer types.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead radiotherapeutic candidate,&#160;Rhenium-186&#160;NanoLiposome (&#8220;<sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL&#8221;) is designed specifically to target central nervous system (&#8220;CNS&#8221;) cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access such as with conduction enhanced delivery (&#8220;CED&#8221;) and intraventricular brain catheters (Ommaya reservoir).&#160;&#160;Our recently acquired radiotherapeutic candidate,&#160;Rhenium-188&#160;NanoLiposome Biodegradable Alginate Microsphere (&#8220;<sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM&#8221;)&#160;is designed to treat many solid organ cancers including primary and secondary liver cancers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters and manufacturing facilities are in Texas and are nearby world-class cancer institutions and researchers. Our dedicated team of engineers, physicians, scientists, and other professionals are committed to advancing our targeted radiotherapeutic technology for the benefit of cancer patients and healthcare providers worldwide and our current pipeline is focused on treating rare and&#160;difficult-to-treat&#160;cancers with significant unmet medical needs.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pipeline</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our most advanced investigational drug, </span><span style="Background-color:#FFFFFF;font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span><span style="Background-color:#FFFFFF;">RNL, is a patented radiotherapy potentially useful for patients with CNS and other cancers.&#160;&#160;</span>Preclinical study data describing the use of<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;186</sup></span>RNL for several cancer targets have been published in peer-reviewed journals. Besides glioblastoma, leptomeningeal metastases, and pediatric brain cancer,&#160;<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL has been reported to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal scarcinomatosis. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp. (&#8220;NanoTx&#8221;) on May 7, 2020. The licensed radiotherapeutic has been evaluated in preclinical studies for several cancer targets and we have an active $3.0 million award from U.S. National Institutes of Health/National Cancer Institute which will provide financial support for the continued clinical development of&#160;</span><span style="Background-color:#FFFFFF;font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span><span style="Background-color:#FFFFFF;">RNL for recurrent glioblastoma through the completion of a Phase 2 clinical trial including enrollment of up to 55 patients. Thus far, 23 patients have been treated in the Phase 1 clinical trial and the Phase 2 clinical trial has not yet been </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>16<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">initiated.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are currently conducting the ReSPECT-GBM and ReSPECT-LM clinical trials for recurrent glioblastoma (&#8220;GBM&#8221;) and leptomeningeal metastases (&#8220;LM&#8221;&#8221;), respectively. In addition, we anticipate seeking the U.S. Food and Drug Administration (&#8220;FDA&#8221;) Investigational New Drug (&#8220;IND&#8221;) approval for the </span>ReSPECT-PBC clinical trial for pediatric brain cancer (&#8220;PBC&#8221;) in late 2022 or early 2023<span style="Background-color:#FFFFFF;">.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span><span style="Background-color:#FFFFFF;font-size:10pt;">RNL versus External Beam Radiation Therapy</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span><span style="Background-color:#FFFFFF;font-size:10pt;">RNL is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into glioblastoma tumors in a safe, effective, and convenient manner that may ultimately prolong patient survival.&#160;&#160;</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span><span style="Background-color:#FFFFFF;font-size:10pt;">RNL is composed of the radionuclide Rhenium-186 and a nanoliposomal carrier, and is infused in a highly targeted fashion, directly into the tumor via precision brain mapping and convection enhanced delivery (&#8220;CED&#8221;).&#160;&#160;Potential benefits of <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL compared to standard external beam radiotherapy</span><span style="Background-color:#FFFFFF;font-size:10pt;"> (&#8220;EBRT&#8221;) include:</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95%;">
<tr>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></span><span style="font-size:12pt;font-family:Times New Roman;color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">The&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly used EBRT.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></span><span style="font-size:12pt;font-family:Times New Roman;color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL can be visualized in real-time during administration, possibly giving clinicians better control of radiation dosing and distribution.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></span><span style="font-size:12pt;font-family:Times New Roman;color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL potentially more effectively treats the bulk tumor and microscopic disease that has already invaded healthy tissue.&#160;&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></span><span style="font-size:12pt;font-family:Times New Roman;color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL is infused directly into the targeted tumor, bypassing the blood brain barrier, which reduces radiation exposure to healthy cells, in contrast to EBRT which passes through normal tissue to reach the tumor, continuing its path through the tumor, hence being less targeted and selective.&#160;&#160;&#160;&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:-24.5pt;;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></span><span style="font-size:12pt;font-family:Times New Roman;color:#000000;"></span><span style="Background-color:#FFFFFF;font-family:Times New Roman;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL is given during a single, short, in-patient hospital visit, and is available in all hospitals with nuclear medicine and neurosurgery, while EBRT requires out-patient visits 5 days a week for approximately 4-6 weeks</span><span style="font-family:Times New Roman;color:#000000;">.&#160;&#160;</span></p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ReSPECT-GBM Trial for Recurrent GBM</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GBM is the most common, complex, and aggressive primary brain cancer in adults. Annually in the U.S., there are 12,900 GBM cases diagnosed and approximately 10,000 patients succumb to the disease each year.&#160;The average life expectancy with primary glioblastoma is less than 24 months, with a&#160;one-year&#160;survival rate of 40.8% and a five-year survival rate of only 6.8%.&#160;GBM often causes and presents with headaches, seizures, vision changes and other significant neurological complications.&#160;Despite the best available medical treatments to eliminate the initial brain tumor, some microscopic disease frequently remains, with tumor regrowth within months.&#160; Approximately 90% or more of patients with primary GBM experience tumor recurrence.&#160;Complete surgical removal of GBM is not typically possible and GBM is often resistant or quickly develops resistance to most available therapies. Even today, the treatment of GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease<span style="color:#000000;">.&#160;</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For recurrent GBM, there are few currently approved treatments that in the aggregate, provide only marginal survival benefit.&#160;Furthermore, these therapies are associated with significant side effects, which limit dosing and prolonged use.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">While EBRT has been shown to be safe and effective in many malignancies including glioblastoma, the maximum possible administered dose is limited by toxicity to the normal tissues surrounding the malignancy. In contrast, targeted radiopharmaceuticals that precisely deliver radiation in the form of beta particles such as Iodine-131 for thyroid cancer, are known to minimize exposure to normal cells and tissues which we hope will result in a safer and more effective treatment. </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Interim results from our ongoing Phase 1/2a&#160;ReSPECT-GBM trial, suggest beta particle energy from our lead investigational drug <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL may also have utility in treating GBM and other malignancies. More specifically, the preliminary data from ReSPECT-GBM indicates that radiation, in the form of high energy beta particles or electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor issue without significant or dose limiting toxicities. In</span>&#160;<span style="Background-color:#FFFFFF;">comparison, current EBRT protocols for recurrent GBM typically recommend a total maximum dose of about 35 Gy.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to<sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;186</sup>RNL for the treatment of patients with glioblastoma.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL is presently under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL given by CED to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment (NCT01906385). The study uses a modified Fibonacci dose escalation, followed by a planned expansion at the maximum tolerated dose/maximum feasible dose to determine efficacy. The trial is funded through Phase 2 in large part by a NIH/NCI grant. The planned enrollment in the NIH/NCI grant is 21 patients in the dose-escalation part of the study and 34 patients in the expansion cohort. The study is in its 8<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> dosing administration cohort and is under development </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>17<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">internal </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review to potentially advance to a Phase 2 or registration trial. </span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Society for Neuro-Oncology Annual Meeting in November 2021, we presented patient data which at that time included the results for 22 patients treated in the ReSPECT-GBM trial. The trial, thus far, has shown that CED in recurrent GBM patients is feasible. Median absorbed dose to the tumor volume across all subjects in the first eight cohorts (n&#61;22) was 267.5 Gy (range 8.9-740). In a subset of patients in whom tumor coverage was greater than or equal to 75%, the median absorbed dose was 405 Gy (range 146-593). By contrast, the median absorbed doses to the whole brain and the total body across all subjects were 0.55 Gy (range 0.001-2.728) and 0.09 Gy (range 0.001-0.182), respectively. Small doses, as delivered to the body, are typically well-tolerated. Based on observed and reported patient protocol activity and all available adverse event (&#8220;AE&#8221;) data, <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL has been well-tolerated. No AEs with an outcome of death or study drug-related serious AEs have been reported. Furthermore, no patient has been discontinued from the study because of an AE. All AEs have been mild or moderate (Grade 1 or 2) in intensity, except for one case of Grade 3 vasogenic edema, which was considered by the investigator to be unrelated to the study drug. AEs considered by the investigator to be at least possibly related to <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL have included Grade 1 to 2 skin and soft tissue infection, intermittent cephalgia, neck and jaw pain, nausea with or without vomiting, constipation, increased lethargy, difficulty walking (gait disturbance), worsening double vision, and dysuria. Scalp discomfort and tenderness related to the surgical procedure has also been reported. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the 22 subjects with recurrent GBM receiving a single administration of <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL, the mean &#38; median OS for all 22 patients as of November 2021 was 48.1 &#38; 33.1 weeks, respectively, with 7 patients alive. In a subset of 13 patients receiving a presumed therapeutic absorbed radiation dose to the tumor (&#62;100 Gy), the mean &#38; median OS was 64.8 &#38; 47.1 weeks, respectively, with 7 of 13 patients alive. In contrast, in 9 patients receiving a presumed sub-therapeutic absorbed radiation dose to the tumor (&#60;100 Gy), the mean and median OS was 23.9 &#38; 22.3 weeks, respectively. A Kaplan-Meier curve comparing patients with presumed therapeutic vs. sub-therapeutic radiation dose to the tumor showed a statistically significant difference between the groups (p&#61;.0002). It is hypothesized that <span style="Background-color:#FFFFFF;color:#000000;">targeted infusion of&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL into the tumor by CED, bypassing the blood-brain barrier and normal brain and external tissues, significantly spares normal tissues from radiation exposure and potential toxicity and concentrates radiation to the tumor and surrounding region of interest. </span><span style="Background-color:#FFFFFF;"> </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ReSPECT-LM Clinical Trial for Leptomeningeal Metastases</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The incidence of LM is growing and occurs in approximately 5% of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly lethal with an average&#160;1-year&#160;survival of just 7%. LM occurs with cancers that are most likely to spread to the central nervous system. The most common cancers to spread to the leptomeninges are breast cancer, lung cancer, melanoma and gastrointestinal cancers---though most solid tumors have the potential for LM spread.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ReSPECT-LM Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) is predicated in part upon preclinical studies in which tolerance to doses of<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;186</sup></span>RNL as high as 1,075 Gy was shown in animal models with LM without significant observed toxicity. Furthermore, treatment led to marked reduction in tumor burden in both C6 and&#160;MDA-231&#160;LM models.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the FDA announced clearance of our IND application for<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;186</sup></span>RNL for the treatment of LM. Subsequently, in November 2021, the FDA granted a Fast Track designation for&#160;<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL for the treatment of leptomeningeal metastases. We treated our first patient in the ReSPECT-LM Phase 1 clinical trial in Q1 2022. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ReSPECT-LM multi-center, sequential cohort, open-label, dose escalation study is evaluating the safety, tolerability, and distribution of<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;186</sup></span>RNL via intrathecal infusion to the ventricle of patients with LM after standard surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting toxicities.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ReSPECT-PBC Clinical Trial for Pediatric Brain Cancer</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons (&#8220;AANS&#8221;) Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a&#160;pre-IND&#160;meeting briefing package in which the FDA stated that we are not required to perform any additional preclinical or toxicology studies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, we plan to investigate the use of <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL in 2 pediatric brain cancers. <span style="color:#000000;">High-grade glioma (HGG) is a rare, fast-growing CNS tumor that forms in glial cells of the brain and spinal cord. It can be found almost anywhere within the CNS, but is most commonly within the supratentorium in children ages&#160;15-19.&#160;HGG tumors in children act differently from those in adults, causing headaches, seizures, and difficulty achieving developmental milestones depending on the tumor location. Approximately&#160;360-400&#160;children are diagnosed with HGG annually in North America and the&#160;5-year&#160;survival rate is approximately 20%. In contrast to HGG, ependymoma is a rare, slow- or fast-growing (depending on the grade) primary CNS tumor that forms in ependymal cells in the brain and spinal cord&#8212;and may spread throughout the CNS, though infrequently. All ependymomas can recur, but patients are often tumor-free for years before testing shows tumor regrowth, either at the initial tumor site or elsewhere within the CNS. Symptoms depend on tumor location and size, usually including irritability, sleeplessness, vomiting, nausea, back pain, arm/leg weakness, and headaches.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 250 children are diagnosed with ependymoma annually in the U.S. while 71% of children with Grade II and 57% with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>18<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grade III survive 5 years from diagnosis.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the aggregate preclinical and clinical work completed to date in adult recurrent glioblastoma, we hypothesize that <sup style="font-size:85%;line-height:120%;vertical-align:top">186RNL</sup> may offer potential clinical benefit for PBCs, such as high-grade glioma and ependymoma. We intend to submit an IND application to the FDA for&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL for the treatment of PBC (high-grade glioma and ependymoma) in late 2022 or early 2023<span style="color:#000000;">.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rhenium-188 NanoLiposome&#160;Biodegradable Alginate Microsphere Technology</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we announced that we licensed BAM patents and technology from The University of Texas Health Science Center at San Antonio (&#8220;UT Health Science Center at San Antonio&#8221;) to expand our tumor targeting capabilities and precision radiotherapeutics pipeline. We intend to combine&#160;our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization technology. Initially, we intend to utilize the Rhenium-188&#160;isotope,&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM for the intra-arterial embolization and local delivery of a high dose of targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical data from an&#160;<span style="font-style:italic;">ex vivo</span>&#160;embolization experiment in which&#160;Technetium-99m-BAM&#160;was intra-arterially delivered to a bovine kidney perfusion model was presented at the recent 2021 Society of Interventional Radiology (&#8220;SIR&#8221;) Annual Scientific Meeting. The study concluded that the technology required for radiolabeling BAM could successfully deliver, embolize and retain radiation in the target organ.<sup style="font-size:85%;line-height:120%;vertical-align:top"> 188</sup>RNL-BAM&#160;is a preclinical investigational drug we intend to further develop and move into clinical trials. Specifically, in 2022, we intend to transfer the&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM&#160;technology from UT Health Science Center at San Antonio, fabricate and scale the drug product, and complete certain preclinical studies to support a future FDA IND submission. Our likely initial clinical target is liver cancer which is the 6<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>&#160;most common and 3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>&#160;deadliest cancer worldwide. It is a rare disease with increasing U.S. annual incidence (42,000) and deaths (30,000). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Services Agreement and Statement of Work with Medidata</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2022, we entered into a Statement of Work (the &#8220;SOW&#8221;) with Medidata Solutions, Inc. (&#8220;Medidata&#8221;), pursuant to which Medidata will build a Synthetic Control Arm<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;(SCA) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of <span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL in GBM.&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SOW has a term of six (6) months.&#160;&#160;We will pay Medidata $1.45 million in managed services fees and a contingent managed services fee of $150,000 if the U.S. Food &#38; Drug Administration approves a path forward for us to use the SCA in its clinical trial of&#160;<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL for treatment of GBM.&#160;&#160;The SOW may only be terminated for a material breach by either party or if the clinical study&#8217;s authorization or approval is withdrawn by a regulatory agency.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UT Health Science Center San Antonio (UTHSA) License Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2021, we entered into an exclusive license agreement with UT Health Science Center at San Antonio for the global rights to develop and commercialize <sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM.&#160;&#160;Under the license agreement with UT Health Science Center at San Antonio, we are required to use commercial reasonable efforts to develop the <sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM product candidate acquired under the license agreement. Further, we are subject to future milestone, earn-out and other payments to UT Health Science Center at San Antonio all of which are tied to our commercialization and sale activities for product candidates.&#160;&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recent Financings</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to the &#8220;Liquidity and Capital Resources&#8221; section below for information on our recent financings. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations<span style="font-weight:normal;">&#160;</span> &#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Research and development expenses include costs associated with the design, development, testing, and enhancement of our product candidates, payment of regulatory fees, laboratory supplies, pre-clinical studies, and clinical studies</span><span style="color:#000000;">.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of our research and development expenses for the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-weight:bold;color:#000000;font-size:8pt;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,760</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,106</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,785</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>19<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase of $0.7 million in research and development expenses for the three months ended March 31, 2022 as compared to the same period in 2021 was due primarily to increased expenditures <span style="color:#222222;">related to </span>increase in development costs of <sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL of $0.5 million as we ramp up to plan for the pivotal trial, an increase of $0.1 million in professional expenses and an increase of $0.1 million in personnel expenses<span style="color:#222222;">.</span><span style="Background-color:#FFFFFF;color:#222222;">&#160;</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect aggregate research and development expenditures to increase in absolute dollars during 2022 due to the expected costs of development of the&#160;<sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup>RNL&#8482; therapy acquired from&#160;NanoTx and development expenses related to <sup style="font-size:85%;line-height:120%;vertical-align:top">188</sup>RNL-BAM. </p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate expenses.&#160;&#160;The following table summarizes the general and administrative expenses for the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,986</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:19.25pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,352</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by approximately $0.8 million during the three months ended <span style="color:#000000;">March 31, 2022</span> as compared to the same period in 2021. The increase was primarily due to an increase of $0.6 million of legal, intellectual property and other professional expenses, and an increase of $0.2 million of personnel related expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect general and administrative expenditures to remain generally consistent in 2022 as compared with the year ended December 31, 2021, subject to litigation cost which is not predictable at this time.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense includes charges related to stock options issued to employees, directors and non-employees.&#160;We measure stock-based compensation expense based on the grant-date fair value of any awards granted to our employees. Such expense is recognized over the requisite service period.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the components of our stock-based compensation expenses for the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases in our stock-based compensation was primarily due to increases in grants of stock-based options as well as <span style="color:#000000;">higher grant-date fair value of stock-based awards. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing items</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes interest income, interest expense, and other income and expense for the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of liability instruments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(241</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in interest expense for the three months ended March 31, 2022 as compared to the same periods in 2021 was primarily due to the repayment of debt principal of $0.3 million in 2021 and $0.4 million during the first quarter of 2022. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect interest expense in 2022 to decrease as compared with 2021 due to scheduled debt principal repayments which commenced on November 1, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>20<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Short-term and long-term liquidity</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our key liquidity measures at March 31, 2022 and December 31, 2021 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,239</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,400</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,104</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,724</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,921</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,870</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,183</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,854</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the periods presented, operating losses have been funded primarily from outside sources of invested capital in our common stock. We believe that our cash and cash equivalents of $21.2 million at March 31, 2022 will enable us to fund our current and planned operations for at least the next twelve months and beyond from the date these condensed financial statements were issued. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. Our inability to raise additional cash would have a material and adverse impact on operations and would cause us to default on our loan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 14, 2022, we entered into an Equity Distribution Agreement (the &#8220;2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC (the &#8220;Agent&#8221;, or &#8220;Canaccord&#8221;), pursuant to which we may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000 (the &#8220;Shares&#8221;), depending on market demand, with the Agent acting as an agent for sales. Sales of the Shares may be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq. Since January 14, 2022, we issued 1,022,610 shares under the 2022 Distribution Agreement for net proceeds of approximately $</span>0.7<span style="Background-color:#FFFFFF;"> million. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;23, 2020, we entered into an Equity Distribution Agreement (the &#8220;2020 Distribution Agreement&#8221;) with Canaccord, pursuant to which we could issue and sell, from time to time, our common stock in &#8220;at the market&#8221; offerings, depending on market demand, with Canaccord acting as an agent for sales. <span style="Background-color:#FFFFFF;">During 2021, we issued 2,179,193 shares under the 2020 Distribution Agreement for net proceeds of $6.3 million. The 2020 Distribution Agreement has been terminated. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, we entered into the 2020 Purchase Agreement and a registration rights agreement with Lincoln Park, pursuant to which Lincoln Park committed to purchase up to $25.0 million of our common stock. During 2021, we issued 5,685,186 shares of our common stock under the 2020 Purchase Agreement for total proceeds of $12.5 million. During the three months ended March 31, 2022, we issued 5,665,000 shares of common stock for net proceeds of approximately $7.0 million under the 2020 Purchase Agreement. We no longer have any additional shares of common stock registered to sell under the 2020 Purchase Agreement, and at this time we do not intend to register any additional shares of common stock under the 2020 Purchase Agreement.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to seek additional capital through&#160;strategic transactions and other financing alternatives.&#160;Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this would negatively affect our ability to achieve corporate growth goals. There may be continued market volatility due to the pandemic, downturn in global economy, or other events, which could cause our stock price to decline. This in turn will likely negatively impact our ability to raise funds through equity-related financings. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should we be unable to raise additional cash from outside sources or if we are unable to do so in a timely manner or on commercially reasonable terms, it would have a material adverse impact on our operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash (used in) provided by operating, investing, and financing activities for the three months ended March 31, 2022 and 2021 is summarized as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-size:10pt;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,876</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,006</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,292</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,191</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,839</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,101</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>21<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Material Cash Obligations</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2022, we entered into the SOW with Medidata pursuant to which Medidata will build a Synthetic Control Arm&#174; (SCA) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of 186RNL in GBM.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the six month term of the SOW, we will pay Medidata $1.45 million in managed services fees. Further, if the U.S. Food &#38; Drug Administration approves a path forward for us to use the SCA in its clinical trial of 186RNL for treatment of GBM, we will pay Medidata an additional contingent managed services fee of $150,000.&#160;&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also obligated to make ongoing principal and interest payments under the Term Loan with Oxford&#160;through the maturity date of June 1, 2024 (See Note 5 of the accompanying condensed financial statements for more information). In addition, as described in more detail in Note 7 of the accompanying condensed financial statements, we are obligated to make operating lease payments for our office and laboratory space and we may be required to make payments under certain of our other contractual agreements.&#160;&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the three months ended March 31, 2022 was $3.9 million&#160;compared to $3.0 million in the same period of 2021. Our operational cash use increased during the three months ended March 31, 2022 as compared to the same period in 2021, due primarily to increased expenditures for our research and development activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the three months ended March 31, 2022 were related to <span style="Background-color:#FFFFFF;color:#000000;">cash payments of $0.3 million made for in process research and development assets from UTHSA and </span>purchases of fixed assets and intangible assets of $0.3 million. <span style="Background-color:#FFFFFF;color:#000000;">Net cash used in investing activities for the three months ended March 30, 2021 was primarily related to purchases of fixed assets.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the three months ended March 31, 2022 was primarily related to sales of common stock of $7.7 million, net of offering cost through the 2022 Distribution Agreement with Canaccord and the 2020 Purchase Agreement with Lincoln Park.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the three months ended March 31, 2021 was primarily related to sales of common stock of $7.2 million, net of offering cost through the 2020 Purchase Agreement with Lincoln Park and the 2022 Distribution Agreement with Canaccord, as well as $2.0 million from exercise of warrants.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of our assets, liabilities, revenues and expenses, and that affect our recognition and disclosure of contingent assets and liabilities.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our estimates are based on assumptions we consider reasonable at the time they were made, our actual results may differ from our estimates, perhaps significantly.&#160;&#160;If results differ materially from our estimates, we will make adjustments to our financial statements prospectively as we become aware of the necessity for an adjustment.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. We operate in a single operating segment and reporting unit. We monitor the fluctuations in our share price and have experienced significant volatility during the year.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of liability classified warrants using an option pricing model.&#160;&#160;Following the authoritative accounting guidance, warrants with potential cash settlement outside control of the Company are accounted for as liabilities, with changes in the fair value included in operating expenses. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe it is important for you to understand our most critical accounting policies. <span style="color:#000000;">Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and there have been no material changes during the three months ended </span>March 31, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Item 3. Quantitative and Qualitative Disclosures about Market Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>22<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">Item 4. Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our reports that we file or furnish pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), as appropriate, to allow for timely decisions regarding required disclosure.&#160;&#160;In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.&#160;&#160;Based on the foregoing, our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures (<span style="Background-color:#FFFFFF;color:#333333;">as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) </span>were effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II_OR_INFORMATION">PART II. OTHER INFORMATION</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item 1<span style="font-weight:normal;">. </span>Legal Proceedings</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 22, 2021, we were named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (&#8220;Lorem&#8221;) in the District Court for the District of Delaware. The complaint alleges false representations were made to Lorem regarding the manufacturing facility in the United Kingdom (the &#8220;UK Facility&#8221;) that Lorem purchased from us under the Equity Purchase Agreement, dated March 29, 2019, between us and Lorem (the &#8220;Lorem Agreement&#8221;). Lorem also claims that false representations were made regarding the UK Facility&#8217;s certification to sell and distribute devices in the European Union and export such devices to China. In connection with these allegations, Lorem claims entitlement to at least $6,000,000 in compensatory damages and operational costs and expenses (collectively, the &#8220;Lorem Claim&#8221;). We believe that the Lorem Claim is without merit and we are vigorously defending the case.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of certain factors that could materially affect our business, financial condition, and operating results or that could cause actual results to differ materially from the results described in or implied by the forward-looking statements in this Quarterly Report on Form 10-Q, in addition to the information in the section entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements,&#8221; you should carefully review and consider the information under &#8220;Part I, Item 1A- Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>23<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 6. </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.1%;"></td>
<td style="width:54.56%;"></td>
<td style="width:10%;"></td>
<td style="width:5.83%;"></td>
<td style="width:11.67%;"></td>
<td style="width:10.83%;"></td>
</tr>
<tr>
<td colspan="6" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td colspan="6" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td rowspan="2" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td rowspan="2" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Title</p></td>
<td rowspan="2" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed with this Form 10-Q</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Filed</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312522009885/d656440dex11.htm"><span style="text-decoration:underline;">Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/14/2022</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000114036116057505/ex3_1.htm"><span style="text-decoration:underline;">Composite Certificate of Incorporation</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/11/2016</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000109598116000063/ex3_1.htm"><span style="text-decoration:underline;">Certificate of Amendment to Amended and Restated Certificate</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/10/2016</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000156459018014245/cytx-ex31_6.htm"><span style="text-decoration:underline;">Certificate of Amendment to Amended and Restated Certificate</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/23/2018</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459019026454/cytx-ex31_6.htm"><span style="text-decoration:underline;">Certificate of Amendment to Amended and Restated Certificate</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/29/2019</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000156459019028996/pstv-ex31_18.htm"><span style="text-decoration:underline;">Certificate of Amendment to Amended and Restated Certificate</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/06/2019</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312521277718/d164672dex31.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of Plus Therapeutics, Inc.</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/21/2021</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pstv-ex101_152.htm"><span style="text-decoration:underline;">Medidata Services Agreement and Statement of Work</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312522009885/d656440dex11.htm"><span style="text-decoration:underline;">Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">011-34375</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1.1</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/14/2022</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pstv-ex311_7.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pstv-ex312_6.htm">Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pstv-ex321_8.htm">Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002</a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2.6pt;">
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Schema Document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Calculation Linkbase Document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Definition Linkbase Document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Label Linkbase Document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>24<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.1%;"></td>
<td style="width:54.56%;"></td>
<td style="width:10%;"></td>
<td style="width:5.83%;"></td>
<td style="width:11.67%;"></td>
<td style="width:10.83%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</span></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Presentation Linkbase Document</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:3pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">+&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="Background-color:#FFFFFF;font-style:normal;">Portions of this exhibit have been excluded in compliance with Item 601 of Regulation S-K.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In accordance with Item 601(b)(32)(ii) of Regulation S&#8209;K and SEC Release No. 34&#8209;47986, the certifications furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10&#8209;Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates it by reference.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>25<span style="text-decoration:line-through;"></span></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLUS THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Marc H. Hedrick</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 21, 2022</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President &#38; Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrew Sims</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 21, 2022</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Sims</p></td>
</tr>
<tr>
<td valign="top" style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:line-through;"></span><span style="text-decoration:line-through;"></span>26<span style="text-decoration:line-through;"></span></p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pstv-ex101_152.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pstv-ex101_152.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (&#8220;[***]&#8221;) in this exhibit***</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:85.68%;"></td>
<td style="width:14.32%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000001.jpg" title="" alt="" style="width:253px;height:44px;">&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Medidata Services Agreement</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">_______________</p>
<p style="margin-bottom:5pt;margin-top:5pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Medidata Services Agreement (&#8220;<font style="font-weight:bold;">Agreement</font>,&#8221; including all attachments hereto) is entered into as of November 05, 2021 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;) by and between <font style="font-weight:bold;">Medidata Solutions, Inc.</font>, a Delaware corporation having its principal place of business at 350 Hudson Street, 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Floor, New York, New York 10014<font style="font-weight:bold;"> (</font>together with any of its Affiliates that provide Services pursuant to Sales Orders executed hereunder, collectively, &#8220;<font style="font-weight:bold;">Medidata</font>&#8221;) and <font style="font-weight:bold;">Plus Therapeutics, Inc.</font>, having its place of business at 4200 Marathon Blvd., Suite 200, Austin, Texas, 78756, United States (&#8220;<font style="font-weight:bold;">Customer&#8221;</font>), on behalf of itself and any Authorized Affiliates.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>1.<font style="margin-left:36pt;">DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; means any corporation or other business entity controlled by, controlling, or under common control with Customer or Medidata, as applicable. For this purpose, &#8220;control&#8221; means (i) direct or indirect beneficial ownership of fifty (50%) percent or more of the voting control, or (ii) the power to direct or cause the direction of the management and policies of such corporation or other business entity.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Application Services</font>&#8221; means Medidata&#8217;s provision of (i) access to Medidata software applications and Documentation to Customer and its Authorized Users via Medidata&#8217;s hosted portal applications; (ii) the hosting and support services for such applications; and (iii) Medidata's implementation of any applicable Improvements.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Authorized Affiliate</font>&#8221; means any Affiliate of Customer authorized by Customer to receive Services under the Agreement by entering into a Sales Order, subject in all cases to each such Affiliate being bound by the terms and conditions of the Agreement. Customer shall provide Medidata with advance written notification of any Authorized Affiliates. References in this Agreement to &#8220;Customer&#8221; shall mean, collectively, Customer and each of its Authorized Affiliates.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Authorized Users&#8221;</font> means employees, <font style="color:#000000;">site investigators, study subjects, </font>contractors and third party service providers of Customer, authorized by Customer to access the Subscription Services. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Confidential Information&#8221;</font> means all information provided by the disclosing party to the receiving party or any of its Affiliates for use in connection with the Services or this Agreement, including the terms and conditions of this Agreement, but does not include information that (i) the receiving party already knows prior to its disclosure by the disclosing party; (ii) becomes generally available to the public, except as a result of disclosure by the receiving party in violation of this Agreement; or (iii) becomes known to the receiving party on a non-confidential basis from a source other than the disclosing party.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Customer Data</font>&#8221; means the information that Customer and its Authorized Users have submitted, made available, stored and/or processed in conjunction with utilizing the Services, before or after the Effective Date. In addition, Customer Data includes information relating to Customer's protocols, third-party contracts, third-party data and other descriptive data. Customer Data excludes [***].</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Customer Infringement Event</font>&#8221; means (i) use of the Subscription Services other than as set forth herein and in the then-current version of the Documentation; (ii) combination, operation or use with software, information, data, or other materials, not approved or supplied by Medidata, if infringement (including, without limitation, contributory infringement) would have been avoided by use without such software, hardware, information, data, or other materials; or (iii) use of a superseded release of the Subscription Services if the infringement would have been avoided by use of the most current release of the Subscription Services made available by Medidata.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Device Provisioning</font>&#8221; means mobile technology device rental to Customer<font style="font-family:Arial;"> </font>solely for Authorized Users&#8217; provision of Customer Data for the applicable study during the Sales Order term in conjunction with Application Services, including: (i) device configuration setup, limited to pre-installed apps and (ii) shipment to/from the Customer specified destination.</p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>&#8220;<font style="font-weight:bold;">Device Services</font>&#8221; means mobile device provisioning to Customer for use in conjunction with Application Services, including (i) Device Provisioning and/or (ii) Device Support.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk47013090"></a>&#8220;<font style="font-weight:bold;">Device Support</font><a name="_Hlk47013090"></a>&#8221; means managed service call center support for Authorized Users of Device Services (sites, patients and monitors). </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Documentation</font>&#8221; means Medidata&#8217;s online technical or functional user guides for the operation of the Subscription Services, as modified from time to time.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">iMedidata</font>&#8221; means the hosted portal application (or any such successor application however named) provided, operated and controlled by Medidata, through which Authorized Users create or maintain accounts to access the Application Services.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Improvements</font>&#8221; means all updates, enhancements, error corrections, bug fixes, release notes, upgrades and changes to the Services, including derivative works thereof, as developed by Medidata from time to time (without use of <font style="color:#000000;">Customer</font> Confidential Information (except as set forth in Section 7.4)) in its sole discretion and made generally available for production access or use to Medidata&#8217;s customers. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Instructions</font>&#8221; means all provisions of this Agreement, any Sales Orders, and any written amendments to either, concerning the processing of Customer Data.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Intellectual Property Rights</font>&#8221; or &#8220;<font style="font-weight:bold;">IPR</font>&#8221; means all rights, title and interest to or in patent, copyright, trademark, service mark, trade secret, business or trade name, know-how and rights of a similar or corresponding character. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Managed Services</font>&#8221; means Medidata&#8217;s provision of guidance, analytics and reporting services in conjunction with Application Services on behalf of Customer.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Non-Production Environment</font>&#8221; means a non-production URL computing environment of the most current version of the Application Services that is not used to collect live Customer Data.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Personal Data</font>&#8221; means any <font style="color:#000000;">Customer </font>Data relating to an identified or identifiable natural person, as defined under Privacy Laws. Without limitation of the foregoing, an identifiable person is one who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors specific to such person&#8217;s physical, physiological, mental, economic, cultural or social identity.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Professional Services</font>&#8221; means the implementation and related consulting services provided by or on behalf of Medidata to Customer during a specific period(s) of time for a fixed fee(s), unless otherwise agreed in a Sales Order(s).</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Privacy Laws</font>&#8221; means all laws and regulations, including laws and regulations of the United States and European Union, the European Economic Area and their member states, applicable to the Processing of Personal Data under the Agreement, including the General Data Protection Regulation (Regulation (EU) 2016/679) (the &#8220;GDPR&#8221;), all as amended from time to time. </p></div></div>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Sales Order</font><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean the ordering documentation, including any exhibit, schedule or document attached to or referencing this Agreement, setting forth the specific Services to be provided by Medidata to Customer. </font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Services</font>&#8221; means the provision and development of the Subscription Services and the Professional Services, including any Improvements thereto, provided by Medidata to Customer.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50622322"></a>&#8220;<font style="font-weight:bold;">Subscription Services</font>&#8221; means the Application Services, Managed Services, Device Services, or other subscription services, and any Combined Data (defined below) therein, <a name="_Hlk50622322"></a>provided by Medidata to Customer.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Tax(es)</font>&#8221; means any applicable services, sales, use, excise, goods, property, goods and services, value added (including proxy value added taxes), withholding, or other taxes or duties, whether international, national, state or local, which are levied or imposed by reason of the provision of the Services, excluding taxes on Medidata&#8217;s net income.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">ACCESS TO THE SUBSCRIPTION SERVICES</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Access</font>. Customer <font style="color:#000000;">shall access, and </font>shall enable access to, the Subscription Services for use only by Customer and Authorized Users for <font style="color:#000000;">Customer&#8217;s internal business purposes, including research and commercial analytics, in accordance with a Sales Order, and not for the benefit of any third party or for any other purpose. Customer and its Authorized Users shall access the Application Services and any Combined Data solely through Medidata&#8217;s hosted portal applications. Unless otherwise agreed upon by the parties in an applicable Sales Order, Customer shall have no other access to the </font>Application Services and any Combined Data<font style="color:#000000;"> and shall not be entitled to download or otherwise receive a copy of the </font>Application Services or any Combined Data<font style="color:#000000;">. Customer shall be liable for the acts and omissions of all Authorized Affiliates and Authorized Users relating to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Access Restrictions</font>. Customer shall not (i) modify, copy, translate or create any derivative works based on the Subscription Services; (ii) remove or alter any copyright notices, trademarks or other proprietary rights notices affixed to or contained within the Subscription Services; (iii) use the Subscription Services to provide hosting, service bureau, time sharing, outsourcing or other commercial services on behalf of any third parties; (iv) use or knowingly permit the use of any security testing tools in order to probe, scan or attempt to penetrate or ascertain the security of the Subscription Services; or (v) attempt to gain access to the Subscription Services or related systems or networks in a manner not set forth in the Documentation. Customer shall take all reasonable precautions to <font style="Background-color:#FFFFFF;color:#000000;">prevent any compromise of the&#160;security, integrity, or availability&#160;of the </font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> Data or of any Medidata network or system. </font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> shall notify Medidata&#160;without undue delay&#160;if </font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> has reason to believe that such a&#160;compromise has occurred or is likely to occur. For the avoidance of doubt, such reasonable precautions include, without limitation,&#160;implementing&#160;routine scanning of systems using then-current virus scanning software and virus profiles,&#160;maintaining industry-standard&#160;security&#160;protections for any browsers&#160;or other software&#160;used to access the Subscription Services, and&#160;ensuring that all endpoints that connect to Medidata's&#160;systems are secure.&#160;</font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> will cooperate with Medidata and provide necessary information to Medidata to prevent, investigate and remediate the compromise of the&#160;security, integrity, or availability&#160;of the </font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> Data, or of any Medidata network or system.&#160;If </font>Customer<font style="Background-color:#FFFFFF;color:#000000;"> fails to comply with the requirements of this Section, Medidata may prevent </font>Customer <font style="Background-color:#FFFFFF;color:#000000;">from accessing the</font> Subscription <font style="Background-color:#FFFFFF;color:#000000;">Services until acceptable security controls are implemented. </font>Customer shall only enable access to and allow use of the Subscription Services in accordance with the Documentation.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34222326"></a>2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Production Use</font><a name="_Hlk34222326"></a>. Customer and its Authorized Users may have access to Application Services in a Non-Production Environment, as set forth in a Sales Order. Use of Application Services in a Non-Production Environment is provided &#8220;AS IS,&#8221; with respect to its performance. Section 11.1 of this Agreement shall not apply with respect to Application Services provided in a Non-Production Environment. </p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata Single Sign-On Integration Requirements</font>. Where Customer elects to create a single sign-on (&#8220;SSO&#8221;) integration with iMedidata&#174; (&#8220;SSO Integration&#8221;) for use with Customer&#8217;s credential authorization system, it agrees to: (i) apply minimum technical requirements and comply with the acceptable use parameters (e.g., requirements for usernames, passwords, password reset, end point maintenance, and testing environments) set forth in <font style="text-decoration:underline;color:#0000FF;">https://www.medidata.com/en/medidata-policies/</font><font style="text-decoration:underline;">,</font> as may be updated on reasonable notice by Medidata (&#8220;SSO Specifications&#8221;); (ii) promptly notify Medidata of errors or vulnerabilities discovered in Customer&#8217;s SSO Integration (to security@medidata.com); and (iii) assist Medidata with verifying Customer&#8217;s adherence to the SSO Specifications, including permitting an audit up to once annually on 45-day notice, or such audits as are required for cause. The SSO Integration may be terminated by Medidata on reasonable notice in its sole discretion.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">COMPLIANCE</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Applicable Laws</font>. <font style="color:#000000;">Each party shall comply with laws and regulations that affect its business generally and the provision or receipt of the Services pursuant to the Agreement, including any applicable anti-bribery, export control, clinical research (including generally accepted standards of good clinical practices (&#8220;GCP&#8221;) and Privacy Laws).</font> Customer shall not use the Services in violation of applicable laws. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Industry-Specific Customer Duties with Respect to the Services</font>.&nbsp;&nbsp;Customer shall: <font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.1<font style="margin-left:36pt;"></font>be solely responsible, and assume all liability for, all operational aspects,<font style="color:#000000;"> decisions, results,</font> and outcomes of its clinical trial(s) <font style="color:#000000;">and related businesses including, as applicable </font>(i) the design, structure and content of all protocols for clinical trials conducted pursuant to this Agreement; (ii) <font style="color:#000000;">obtaining the legal basis for processing </font>Customer<font style="color:#000000;"> Data, such as gaining consents or providing notices for study participants and Authorized Users required under Privacy Laws or GCP; </font>(iii) the collection, quality and accuracy of Customer Data, including determination of the specific data collected; (iv) data protection agreements with any other controllers; (v) the manufacture, supply and handling of investigational products; (vi) regulatory submissions; and (vii) ensuring that Customer Data accessible via the Services is accessed only by appropriate Authorized Users;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.2<font style="margin-left:36pt;">obtain and provide Medidata with relevant information and materials, including protocols and amendments, data, third party licenses (including for specific medical dictionaries) or consents, and timely feedback, as reasonably required in order for Medidata to provide the Services; and&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.3<font style="margin-left:36pt;">be responsible for having in place backup processes and mechanisms to perform critical functions to support the safety of subjects or uninterrupted clinical trial operations in the event of an unexpected outage. </font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4<font style="font-family:Times New Roman Bold;text-transform:uppercase;">.</font><font style="font-family:Times New Roman Bold;text-transform:uppercase;margin-left:36pt;"></font>SERVICES.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Sales Orders</font>. Medidata shall perform Services in accordance with Medidata standard processes and policies and its Quality Management System (&#8220;QMS&#8221;). Medidata and Customer shall agree on the scope of Services, including any applications, clinical trial study and other non-study consulting parameters and fees, as well as assumptions, boundaries and service constraints. Prior to any material deviation from the Sales Order, the parties must authorize a written change order setting forth the additional scope of Services. Without limiting the generality of the foregoing, Medidata shall have no obligation to perform Services, and Customer shall have no obligation to accept or receive Services, until such time as the parties have entered into and executed a Sales Order or change order, as applicable.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Subcontractors</font>. Except as limited in the Data Processing Exhibit, [***]. Any subcontracting shall not relieve Medidata from its obligations under this Agreement and Medidata shall be fully responsible and liable for any acts or omissions of its subcontractors in the performance of any Services.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">HOSTING AND SUPPORT SERVICES / SERVICE LEVEL COMMITMENTS&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medidata shall provide access to and support of the Application Services in accordance with the Hosting and Support Services Policy posted at <font style="text-decoration:underline;color:#0000FF;">https://www.medidata.com/en/policies.</font> This Hosting and Support Services Policy provides specific service level commitments which Medidata agrees to meet or exceed during the Term. Medidata shall actively monitor its compliance with these service commitments in accordance with the policy. </p></div></div>
<p style="margin-bottom:0pt;margin-top:12pt; clear:both;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 2</a> of 7 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;">REGULATORY COMPLIANCE AND QUALITY MANAGEMENT; AUDIT </font></p>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>Medidata&#8217;s Services are designed and conducted in accordance with its QMS which specifies the parties&#8217; roles and responsibilities and is designed to assist <font style="color:#000000;">Customer</font> in satisfying its compliance obligations under GCP and/or good post-marketing study practice. Medidata&#8217;s QMS is captured through a set of controlled documents, maintained within Medidata&#8217;s regulatory compliant electronic document management system. These Quality System Documents (&#8220;<font style="font-weight:bold;">QSDs</font>&#8221;) are developed and maintained in accordance with applicable national and international regulatory requirements and industry standards and best practices. The QSDs include policies, standard operating procedures, work instructions, and other forms and templates. Medidata maintains Regulatory and Audit Policies posted <font style="color:#000000;">at </font><font style="text-decoration:underline;color:#000000;">https://www.medidata.com/policies</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;">INTELLECTUAL PROPERTY; DATA RIGHTS</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Title to Services</font>. Medidata and its licensors own all IPR in and to the Services and Documentation. Full ownership of the Services (including in each case any Improvements) are and shall remain the proprietary, copyrighted and trade secret property of Medidata and its licensors. Notwithstanding the foregoing, Customer shall be entitled to independently develop procedures, test scripts, test scenarios, reports and interfaces using application programming interfaces provided by Medidata as part of the Application Services. Medidata reserves to itself all IPR not expressly granted pursuant to this Agreement. Medidata retains all IPR in reports or other materials provisioned to Customer in conjunction with the Services (e.g., incorporated functionality or formatting), exclusive of Customer Data.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Materials</font>. Each party retains all IPR in and to all previously existing or newly created materials, methodologies, operating and applications software, programs, architecture data, processes, methods, creations, developments and technical information and intellectual property developed (&#8220;<font style="font-weight:bold;">Developments</font>&#8221;) by such party, provided any newly created materials do not use or rely on the Confidential Information of the other party other than as expressly set forth in this Agreement or any Sales Order. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Customer Data</font>. All right, title and ownership of Customer Data, including any derivatives thereof, is and shall remain solely and exclusively vested in Customer, including all IPR relating thereto. Medidata shall process Customer Data for the purpose of providing the Services to Customer pursuant to the Instructions.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata Uses</font>. Medidata will also process Customer Data in order to combine it with other data for inclusion in Medidata&#8217;s analytical, statistical or benchmarking services (&#8220;<font style="font-weight:bold;">Medidata Uses</font>&#8221;). [***] (the &#8220;<font style="font-weight:bold;">Combined Data</font>&#8221;). The Medidata Uses are at Medidata&#8217;s sole risk, and Medidata shall not rely upon Customer&#8217;s legal basis in providing any Personal Data to Medidata for the Medidata Uses (e.g., patient consent). Medidata represents and warrants that all Medidata Uses are permitted by Privacy Laws. In addition, the Combined Data shall not disclose, or permit the identification of, any of Customer&#8217;s Personal Data, Customer&#8217;s identity or Customer&#8217;s Confidential Information. The Instructions include that Medidata shall anonymize the Combined Data.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Customer Access to Combined Data</font>. Customer shall only access or use Combined Data as set forth in Sections 2.1, 2.2 and 9.6 of this Agreement and as set forth in a Sales Order. Upon termination or expiration of the applicable Sales Order term, Customer shall (i) cease using the Combined Data and any derivatives; and (ii) destroy or return all copies or extracts thereof to Medidata. Customer represents and warrants that, with respect to Combined Data, it has implemented business processes that specifically prohibit reidentification, and that it will not, and will not permit any entity or person to, reidentify or attempt to reidentify any individual or the source of any data contained within the Combined Data (e.g., through combination with external data sources).</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;">PAYMENT TERMS</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment and Fees</font>. Customer agrees to pay the fees set forth in the Sales Order(s) and in the manner set forth therein. Except as specifically set forth to the contrary under Article 11 (Limited Warranties and Exclusions) and Article 13 (Indemnification), all payment obligations under any Sales Order(s) are non-cancelable and all payments made are non-refundable. Medidata shall electronically invoice Customer at the e-mail address provided by Customer. Customer shall pay all invoices in US dollars or such other currency reflected in the Sales Order within [***]. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Taxes</font>.&nbsp;&nbsp;</p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>8.2.1<font style="margin-left:36pt;">Except as otherwise agreed in an applicable Sales Order, the fees do not include any Taxes. For purposes of reporting or collecting any present or future Taxes owed with respect to or as a result of this Agreement, Customer agrees to treat the Subscription Services as a service (and not as &#8220;royalties&#8221;) and any amounts owed or owing under Section 8.1 as payments for fees from the provision of services. If Medidata has a legal obligation to pay or collect Taxes for which Customer is responsible under Section 8.2.1, Medidata shall invoice the appropriate amount to Customer, unless Customer provides Medidata with a valid tax exemption certificate authorized by the appropriate taxing authority.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2.2<font style="margin-left:36pt;">All payments shall be made to Medidata without deductions or withholding based on any Taxes, unless agreed upon in advance by the parties. If the parties agree that payments made pursuant to Section 8.1 of this Agreement are properly subject to withholding under applicable laws, Customer agrees to provide Medidata with any information, certification, or other documentation as may reasonably be necessary to mitigate, reduce or eliminate any Tax that could be imposed that are attributable to fees paid to Medidata under this Agreement, including (but not limited to) cooperation in obtaining relief or exemption under the applicable double taxation treaty or the claiming of foreign tax credits.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;">TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term</font>. This Agreement shall commence on the Effective Date and continue unless terminated earlier in accordance with the provisions of this Article 9 (the &#8220;<font style="font-weight:bold;">Term</font>&#8221;). Upon execution of any Sales Order, neither party shall have the right to terminate such Sales Order, except as provided in Section 9.2 (Termination for Material Breach) and Section 9.4 (Termination of Sales Orders for Cancelled Studies).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78699768"></a>9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Material Breach</font>. In the event either party defaults in any material obligation in this Agreement or a Sales Order, the non-defaulting party shall give written notice of such default. If the party in default has not cured the default within [***] of receipt of the notice, the non-defaulting party may terminate this Agreement or the applicable Sales Order by delivering notice thereof to the defaulting party.<font style="font-size:12pt;"> </font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Insolvency</font>. Either party may terminate this Agreement, effective immediately upon written notice, in the event that the other party: (i) makes a general assignment for the benefit of creditors; (ii) institutes proceedings seeking relief or reorganization under any laws relating to bankruptcy or insolvency; or (iii) has a court of competent jurisdiction appoint a receiver, liquidator or trustee over all or substantially all of such party&#8217;s property or provides for the liquidation of such party&#8217;s property or business affairs. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Sales Orders for Cancelled Studies</font>. In the event that a regulatory agency withdraws authorization and approval to conduct an individual study which is the subject of a Sales Order under this Agreement or Customer reasonably determines that a study should terminate or be transferred from Customer to a clinical research organization that has been accredited by Medidata pursuant to Medidata&#8217;s partner accreditation program, Customer may terminate the applicable single study Sales Order. In the event of a study termination or such transfer, Customer shall notify Medidata via the Study Termination Request Form posted at <font style="text-decoration:underline;color:#0000FF;">https://www.medidata.com/en/study-termination-form/</font>. Such notification must be electronically signed by an authorized officer, or other duly authorized representative of Customer, and must be received by Medidata at least [***] in advance of the effective date of such study cancellation.&nbsp;&nbsp;For the avoidance of doubt, this Section 9.4 does not apply to multi-study Sales Orders.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Study Suspension</font>. In the event that Customer reasonably determines that a study must be suspended, then Customer may suspend the applicable single study Sales Order (but not, for the avoidance of doubt, a multi-Study Sales Order) in accordance with the Study Postponement and Suspension Policy posted at <font style="text-decoration:underline;color:#0000FF;">https://www.medidata.com/en/study-postponement-suspension-policy.</font></p></div></div>
<p style="margin-bottom:0pt;margin-top:12pt; clear:both;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 3</a> of 7 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effect of Termination</font>. Termination of this Agreement or a Sales Order shall terminate all Services provided by Medidata thereunder, and Customer and its Authorized Users shall cease all use of the applicable Services on the effective date of termination. Medidata shall invoice for Services rendered through the effective date of termination and any non-cancellable third-party fees accrued by Medidata in the provision of the Services prior to the effective date of termination. Notwithstanding the foregoing, if, upon the expiration of the Term or any termination of this Agreement for any reason other than termination by either party under Section 9.2 for a material breach by the other party, there are Sales Orders for ongoing Services which were effective prior to the effective date of such expiration or termination of this Agreement, the terms and conditions of this Agreement shall remain in full force and effect with regard to any such Sales Order(s) until the expiration or termination thereof.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78694210"></a>9.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Ref78694210"></a>Return of Data Post Termination</font>. Medidata shall provide Customer with access to the Application Services during the term of the Sales Order for the purpose of downloading Customer Data in a durable format. If Customer Data is not available for download through the Application Services, upon request from Customer during the Sales Order term Medidata will deliver Customer Data to Customer in a durable format. If Customer requires Medidata&#8217;s assistance to access Customer Data upon the expiration or termination of the Sales Order, Customer may acquire Medidata&#8217;s Services pursuant to a separately executed Sales Order. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font>CONFIDENTIALITY</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Confidential Information disclosed under this Agreement shall remain the exclusive and confidential property of the disclosing party. The receiving party shall not disclose to any third party the Confidential Information of the disclosing party and shall use at least the same degree of care, discretion and diligence in protecting the Confidential Information of the disclosing party as it uses with respect to its own confidential information. The receiving party shall limit access to Confidential Information to: (i) its employees, consultants and advisors on a need-to-know basis and shall instruct those persons to keep such information confidential and (ii) auditors who are bound by confidentiality obligations.&nbsp;&nbsp;Medidata may disclose Customer&#8217;s Confidential Information on a need-to-know basis to (x) Medidata's subcontractors who are performing the Services, provided that Medidata shall remain liable for any unauthorized disclosure of Customer&#8217;s Confidential Information by those subcontractors and (y) employees of Medidata&#8217;s Affiliates, provided such employees are instructed to keep the information confidential as set forth in this Agreement. If the receiving party is compelled to disclose any of the disclosing party&#8217;s Confidential Information by court order or government regulation, it shall disclose only that portion thereof which it is compelled to disclose and shall reasonably cooperate with the disclosing party&#8217;s efforts to obtain an order or other reliable assurance that confidential treatment will be accorded to the Confidential Information so disclosed. Subject to any applicable regulatory requirements, following receipt of a written request, the other party shall return to the requesting party, in whole or in part, the Confidential Information that has been disclosed in tangible form. A party may retain a copy of Confidential Information solely for archival purposes or applicable regulatory requirements.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;">LIMITED WARRANTIES AND EXCLUSIONS</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78693740"></a>11.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata Warranties</font>. Medidata warrants to Customer that during the Term, the Subscription Services (i) will perform materially in accordance with the Documentation when used and accessed in accordance with the terms and conditions of this Agreement and (ii) the functionality of the Subscription Services will not be materially decreased. Customer shall provide Medidata with prompt notice of any claim under the warranties set forth above and, if applicable, provide Medidata with reasonable assistance required for Medidata to identify and repair any performance issues with the Subscription Services. Customer&#8217;s sole and exclusive remedy for a breach of this warranty shall be that Medidata shall be required to use commercially reasonable efforts to provide modifications or fixes with respect to any noncompliant Subscription Services. If Medidata is unable to remedy the noncompliant Subscription Services, then Medidata shall refund pro-rata amounts paid by Customer to Medidata under the applicable Sales Order for such noncompliant Subscription Services and terminate Customer&#8217;s access thereto.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusions</font>. Medidata is not liable for: (i) an Authorized User&#8217;s use of the Subscription Services not in accordance with this Agreement or Sales Order; (ii) use of the Subscription Services by Customer with third party data, software or hardware which is incompatible with the Subscription Services or not recommended by Medidata; (iii) reduced performance or non-availability of the Subscription Services as a result of Customer&#8217;s&nbsp;&nbsp;network connections; or (iv) errors in the Subscription Services resulting from Customer&#8217;s configuration of the Subscription Services, in each case not specifically recommended in writing by Medidata.</p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>11.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Mutual Warranties</font>. Each party represents and warrants to the other party that: (i) such party has the full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby and has taken all necessary corporate action to authorize the execution and delivery of this Agreement and (ii) this Agreement is and shall be the legal, valid, and binding obligation of such party and shall be enforceable in accordance with its terms.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78970256"></a>11.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Disclaimer</font>. It shall be Customer&#8217;s responsibility for determining the suitability of the Services for Customer&#8217;s use. <font style="text-transform:uppercase;">except as expressly stated in [***], AND TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, MEDIDATA AND ITS LICENSORS MAKE NO, AND HEREBY DISCLAIM ANY, REPRESENTATION, WARRANTY OR GUARANTY, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SERVICES PROVIDED UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTY: (1) of merchantability; (2) of fitness for a particular purpose; (3) arising from course of performance, course of dealing, or usage of trade; or (4) Of Non-Inringement of Third Party Rights. EXCEPT AS SET FORTH IN [***], the SERVICES ARE provided without any further warranties of any kind. medidata and its licensors make no warranty that operation of the SUBSCRIPTION SERVICES will be uninterrupted or error free or that all defects will be corrected.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78970258"></a>12.<font style="margin-left:36pt;"></font>DISCLAIMERS OF DAMAGE AND LIMITATIONS OF LIABILITY</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limit on Liability</font>. <font style="color:#000000;">For all claims by either party against the other party, except with respect to [***], whether such claims are made in contract, tort, strict liability, or otherwise, the injured party&#8217;s potential recovery in any [***] period shall be limited to [***] damages suffered by such party up to [***]</font><font style="font-family:Arial;"> </font><font style="color:#000000;">during the [***] prior to such claim(s) for the specific Service(s) giving rise to such claim(s); and (ii) with respect to breaches of [***], an additional amount equal to [***] during the [***] prior to such claim(s) for the specific Service(s) giving rise to such claim(s) (the &#8220;[***] Cap&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusions to the Limitation on Liability</font>. The limitations in Section 12.1 shall not apply to: [***].</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata Liability for Security Incidents.</font> In the event of a Security Incident (as defined in Section 7.2 of the Data Processing Exhibit to this Agreement) that is the direct result of the failure of Medidata to comply with the terms of this Agreement, Medidata shall bear [***]. Medidata and Customer shall mutually agree on the content and timing of any such notifications, in good faith and as needed to meet applicable legal requirements. Notwithstanding the preceding sentence, the parties agree that Medidata shall have no obligation to send notification letters or provide credit monitoring for Customer unless such letters are legally required or otherwise reasonably required to alert individuals of potential harm.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Disclaimer of Certain Damages</font>. IN NO EVENT SHALL CUSTOMER OR MEDIDATA OR ITS AFFILIATES BE LIABLE FOR ANY INDIRECT, INCIDENTAL, PUNITIVE, EXEMPLARY, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFIT OR COSTS OF SUBSTITUTE SERVICES) SUFFERED BY EITHER PARTY, HOWEVER CAUSED, REGARDLESS OF THE THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, OR OTHERWISE, EVEN IF THE OTHER PARTY HAS BEEN PREVIOUSLY ADVISED OF THE POSSIBILITY, OR HAS CONSTRUCTIVE KNOWLEDGE, OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE. The foregoing exclusion shall not apply to claims for [***]; provided, however, that any consequential damages recovered by Customer or Medidata for claims pursuant to Article 10 will be subject to [***]. For the avoidance of doubt, any claim as a result of a breach of Article [***].</p></div></div>
<p style="margin-bottom:0pt;margin-top:12pt; clear:both;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 4</a> of 7 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78694242"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata Indemnity</font>. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Infringement</font>. Subject to Section 13.3, Medidata will defend Customer against any third party claim and will indemnify Customer from any resulting damage awards, settlement amounts and reasonable attorney&#8217;s fees in any cause of action to the extent such cause of action is based on a third party claim alleging that the Subscription Services, as provided by Medidata and used in accordance with the terms of this Agreement, infringe upon any Intellectual Property Rights of a third party. The foregoing infringement indemnity will not apply and Medidata will not be liable for any damages assessed in any cause of action to the extent such cause of action arises from a Customer Infringement Event or Medidata&#8217;s use of Customer Data as contemplated by this Agreement. If any Subscription Service is held or believed to infringe on any third party&#8217;s Intellectual Property Rights, Medidata may, in its sole discretion, (i) [***], (ii) [***], or (iii) if neither (i) nor (ii) are practical, terminate the applicable Sales Order as to the infringing Service and return to Customer any unearned fees prepaid by Customer to Medidata. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnity for Medidata Uses</font>. Subject to Section 13.3, Medidata will defend Customer against any third party claim and will indemnify Customer from any resulting damage awards or settlement amounts in any cause of action to the extent such cause of action is based on a third party claim alleging Medidata Uses as set forth in Section 7.4 violate Privacy Laws.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Customer Indemnity</font>.<font style="font-family:Arial;"> </font>Subject to Section 13.3, Customer will defend and will indemnify Medidata against any third party claim and from any resulting damage awards, settlement amounts and reasonable attorney&#8217;s fees in any cause of action arising out of or relating to: (i) the occurrence of a Customer Infringement Event; (ii) any claim that any materials, software, or other items provided to Medidata by Customer infringes a third party&#8217;s Intellectual Property Rights; (iii) [***]; or (iv) breach of Section 2.4. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Procedures</font>. The indemnities set forth in this Agreement are conditioned on the following: (i) the party claiming indemnification (the &#8220;<font style="font-weight:bold;">Indemnitee</font>&#8221;) shall promptly notify the indemnifying party (the &#8220;<font style="font-weight:bold;">Indemnitor</font>&#8221;) of any matters in respect of which it seeks to be indemnified, and shall give the Indemnitor full cooperation and opportunity to control the response thereto and the defense thereof, including without limitation any settlement thereof; (ii) the Indemnitor shall have no obligation for any claim under this Agreement if the Indemnitee makes any admission, settlement or other communication regarding such claim without the prior written consent of the Indemnitor, which consent shall not be unreasonably withheld; and (iii) the Indemnitee&#8217;s failure to promptly give notice to the Indemnitor shall affect the Indemnitor&#8217;s obligation to indemnify the Indemnitee only to the extent the Indemnitor&#8217;s rights are materially prejudiced by such failure. The Indemnitee may participate, at its own expense, in such defense and in any settlement discussions directly or through counsel of its choice. Each party will take all reasonable steps to mitigate any potential damages. If both the Indemnitor and the Indemnitee are negligent or otherwise at fault, or strictly liable without fault, then the indemnification obligations under this Article 13 shall continue, but the Indemnitor shall indemnify the Indemnitee only for the percentage of responsibility for the damage or injuries attributable to the Indemnitor.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effect</font>. THIS ARTICLE 13 STATES MEDIDATA&#8217;S ENTIRE LIABILITY AND <font style="text-transform:uppercase;">Customer</font>&#8217;S EXCLUSIVE REMEDY FOR THIRD-PARTY INFRINGEMENT AND/OR MISAPPROPRIATION, WHETHER SUCH ACTION, CLAIM OR PROCEEDING IS BASED ON BREACH OF WARRANTY OR ANY OTHER CAUSE OF ACTION. EXCEPT AS STATED ABOVE, MEDIDATA DISCLAIMS ALL INDEMNITIES, EXPRESS, IMPLIED OR STATUTORY FOR INTELLECTUAL PROPERTY INFRINGEMENT AND/OR MISAPPROPRIATION.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref78970264"></a>14.<font style="margin-left:36pt;"></font>DATA PRIVACY AND SECURITY</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1 <font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Data Privacy.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Customer Representations</font>. Customer represents that it is responsible for the legal basis under Privacy Laws of any Personal Data in the Customer Data made available to Medidata for processing pursuant to the Instructions. <font style="color:#000000;">Customer agrees that, as between the parties, it is responsible for compliance as the data controller (or data exporter) under Privacy Laws with respect to the Services.</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Medidata&#8217;s Responsibilities</font>. Medidata shall process Customer&#8217;s&nbsp;&nbsp;Personal Data pursuant to the Instructions, including as set forth in Medidata&#8217;s <font style="text-decoration:underline;color:#0000FF;">Data Processing Exhibit</font>, inclusive of the Standard Contractual Clauses<font style="color:#000000;"> where applicable,</font> which are incorporated herein by reference. Customer&#8217;s Instructions are inclusive of all processing required to execute the Instructions. As set forth in the Data Processing Exhibit, Medidata agrees that it is responsible for compliance as the data processor (or data importer) under all Privacy Laws with respect to the Services.</p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>14.1.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Inapplicability of HIPAA</font>. [***]</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Unauthorized Disclosure</font>. <font style="color:#000000;">Without limitation of Medidata&#8217;s obligations set forth in the Data Processing Exhibit, if either party believes that there has been a material disclosure under Privacy Law of </font>Customer<font style="color:#000000;"> Data to anyone other than an authorized party or Medidata, such party must promptly notify the other party. For the purposes of this Section and the Data Processing Exhibit, Medidata shall notify </font>Customer<font style="color:#000000;"> at lsereno@plustherapeutics.com. Additionally, each party will reasonably assist the other party in remediating or mitigating any potential damage, including any notification required under applicable Privacy Laws to be sent to individuals impacted or potentially impacted. Subject to Article 12, each party shall bear the costs of such remediation or mitigation to the extent the breach or Security Incident was caused by it.</font></p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Data Security</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Business Continuity; Disaster Recovery</font>.<font style="font-weight:bold;"> </font>Medidata maintains a commercially reasonable business continuity and disaster recovery plan and will follow such plan. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:7.03%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Data Security</font>. Medidata utilizes administrative, physical and technical safeguards to protect Customer Data that are no less rigorous than accepted industry practices. Medidata verifies such physical and technical safeguards as described at <font style="text-decoration:underline;color:#0000FF;">https://www.medidata.com/en/trust-and-transparency/</font>.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;">MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment</font>. Except for either party&#8217;s right to transfer this Agreement to an Affiliate, neither this Agreement nor any of the rights or obligations hereunder may be transferred or assigned directly or indirectly by either party without the prior written consent of the other party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, either party may transfer or assign this Agreement in connection with a sale of all or substantially all of its assets that relate to this Agreement or in connection with a change of control of such party. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Waiver</font>. The failure of either party to enforce any of the provisions of this Agreement shall not constitute a waiver of the provisions or of the right of the party to enforce each and every provision contained in this Agreement.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>. If any provision of this Agreement for any reason shall be declared void, illegal, invalid or unenforceable in whole or in part, such provision shall be severable from all other provisions herein and shall not affect or impair the validity or enforceability of any other provisions of this Agreement.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Survival</font>. The following provisions shall survive expiration or termination of this Agreement for any reason: Articles and Sections 7, 8, 9.6, 10, 12, 15.6 and 15.7.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Force majeure</font>. Neither party shall be liable for any delay or failure to perform its obligations under this Agreement (except for Customer&#8217;s obligation to pay fees to Medidata pursuant to Section 8.1 during the pendency of the Force Majeure event) if prevented from doing so by a cause or causes beyond its reasonable control. Without limiting the generality of the foregoing, such causes include, fires, floods, storms, earthquakes, riots, terrorism, strikes, blackouts, wars or war operations, restraints of government, utility or communications failures, computer hackers, denial of service attacks, software viruses, telecommunications slow-downs or failure, erroneous data transmission, or causes which could not with reasonable diligence, including compliance with Medidata&#8217;s commercially reasonable disaster recovery plan, be controlled or prevented by the party. </p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a></div></div>
<p style="margin-bottom:0pt;margin-top:12pt; clear:both;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 5</a> of 7 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:49%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law; Venue</font>. This Agreement and any disputes arising out of or relating to the Agreement shall be governed by the laws of the State of New York without giving effect to its conflict of law provisions. Any disputes that may arise between Medidata and Customer regarding the performance or interpretation of this Agreement shall be subject to the exclusive jurisdiction of the state and federal courts of [***]. The parties hereby irrevocably consent to the exclusive jurisdiction of the state and federal courts [***] and waive any claim that any proceedings brought in such courts have been brought in an inconvenient forum. THE PARTIES HEREBY IRREVOCABLY WAIVE THEIR RIGHT TO TRIAL BY JURY. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Injunctive Relief</font>. The parties acknowledge that violations of Articles 2, 7, 10 and 14.1 of this Agreement may result in irreparable harm to the non-violating party for which remedies other than injunctive relief may be inadequate, and that the non-violating party shall be entitled to seek from a court of competent jurisdiction injunctive or other equitable relief to restrain such unauthorized acts in addition to other appropriate remedies. In the event of any claimed breach of any provisions of this Agreement, and in the event a party requests any injunctive relief or other relief in equity to stop or enjoin any act or acts by the other party, the parties agree that the requesting party shall not be required to post any bond or other surety as a pre-condition to such relief being granted and enacted.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font>. All notices required to be sent or given under this Agreement shall be sent in writing and will be deemed duly given and effective (i) immediately if delivered in person, or (ii) upon confirmation of signature recording delivery, if sent via a nationally recognized overnight courier service with signature notification requested. Notices shall be sent to the addresses set forth in the initial paragraph of the Agreement, or to any other address a party may identify in writing from time to time.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Publicity</font>. Either party may publicly announce the existence of this Agreement and the general, non-confidential business terms contained herein provided that the other party has the opportunity to review and approve such announcement (such review and approval not to be unreasonably delayed or withheld). <font style="color:#222222;">&#160;</font>Customer further agrees to cooperate with Medidata to issue a press release announcing Customer&#8217;s selection and/or usage of Medidata Services, the form of which shall be mutually agreed by both parties within one (1) week following the Effective Date of this Agreement.&nbsp;&nbsp;Medidata, with Customer approval, may identify Customer as a&nbsp;&nbsp;customer in Medidata&#8217;s promotional and informational&nbsp;&nbsp;materials, including, website, presentations and other proposals to current and prospective customers of Medidata.</p></div>
<div style="float:right;width:49%;padding-left:2%">
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>15.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Independent Contractors</font>. Medidata and Customer shall be and shall act as independent contractors, and neither party is authorized to act as an agent of the other party for any purpose. Neither party by virtue of this Agreement shall have any right, power, or authority to act or create any obligation, express or implied, on behalf of the other party.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font>. This Agreement, including any Sales Order(s), constitutes the complete and exclusive statement of the terms and conditions between the parties, and supersedes all prior negotiations, agreements and representations. Each time a Sales Order is executed by the parties, a separate contract is formed between Medidata and Customer expressly incorporating the terms and conditions of this Agreement. The Agreement shall not be modified except by written consent of both parties. In the event of a conflict between the terms of this Agreement and those found within a Sales Order, the Sales Order shall control. Purchase orders or other similar ordering documentation submitted to Medidata by Customer will be for Customer&#8217;s internal administrative purposes only and the terms and conditions contained in any purchase order or statements of work will have no force and effect and will not amend or modify this Agreement. </p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font>. This Agreement and any Sales Order may be signed in two or more counterparts by original, .pdf (or similar format for scanned copies of documents), electronic signature or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Amendment</font>. This Agreement may not be modified, supplemented or amended, except by a writing signed by the authorized representatives of Medidata and Customer.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk47434847"></a>15.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Hlk47434847"></a>No Third Party Beneficiaries</font>. Nothing in this Agreement creates, or will be deemed to create, third party beneficiaries of or under this Agreement. Customer agrees that Medidata's obligations in this Agreement are to Customer only, and Medidata has no obligation to any third party (including, without limitation, Customer's personnel, directors, officers, employees, Authorized Users and any regulatory authorities).</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.15<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Headings</font>. The headings used in this Agreement are for reference only and do not define, limit, or otherwise affect the meaning of any provisions hereof.</p></div></div>
<p style="text-align:justify;margin-bottom:3pt; clear:both;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>&nbsp;</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each party executes this Agreement by its duly authorized representative, is legal, valid and binding obligation of the parties and shall be effective on the Effective Date.</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE PAGE TO FOLLOW</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 6</a> of 7 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.03%;"></td>
<td style="width:39.69%;"></td>
<td style="width:2.33%;"></td>
<td style="width:5.22%;"></td>
<td style="width:45.73%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:bold;color:#auto;text-transform:uppercase;font-variant: normal;font-style:normal;"><strike Style="text-decoration:none;">Plus Therapeutics, Inc</strike><strike Style="text-decoration:none;">.</strike></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:bold;color:#auto;text-transform:uppercase;font-variant: normal;font-style:normal;"><strike Style="text-decoration:none;">Medidata Solutions, Inc.</strike></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Norman LaFrance </p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Olszewski</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Norman LaFrance, MD, ME, FACP</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Olszewski</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer, Senior VP Oncology R&amp;D</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Sales Operations</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 8, 2021</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 8, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laura Modak/ DWK</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:6pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 7</a> of 12 Page</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">11/04/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:6pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Template Version: 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">\DE - 772891/000001 - 3755990 v2 <font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000002.jpg" title="" alt="" style="width:681px;height:526px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AV Medidata Confidential Information Page 1 of 7 March 4, 2022 v. October 2021 <font style="font-style:normal;">&nbsp;&nbsp; Sales Order Number 4159062&nbsp;&nbsp;Customer (&#8220;Client&#8221;) Name: Plus Therapeutics, Inc.&nbsp;&nbsp;Client Address:&nbsp;&nbsp;4200 Marathon Blvd., Suite 200&nbsp;&nbsp;Austin, Texas 78756&nbsp;&nbsp;United States&nbsp;&nbsp;Client Sold To:&nbsp;&nbsp;Plus Therapeutics, Inc.&nbsp;&nbsp;4200 Marathon Blvd., Suite 200&nbsp;&nbsp;Austin, Texas 78756&nbsp;&nbsp;United States&nbsp;&nbsp;Additional Information&nbsp;&nbsp;Account Manager Contact: Laura Modak&nbsp;&nbsp;Medidata Solutions, Inc.&nbsp;&nbsp;350 Hudson Street 9th Floor&nbsp;&nbsp;New York, NY 10014&nbsp;&nbsp;USA&nbsp;&nbsp;www.medidata.com&nbsp;&nbsp;+1 212 918 1800 Sales Order Effective Date:&nbsp;&nbsp;Sales Order End Date:&nbsp;&nbsp;Sales Order term (Services duration # months):&nbsp;&nbsp;Study Protocol Number:&nbsp;&nbsp;Transaction Type:&nbsp;&nbsp;Therapeutic Area:&nbsp;&nbsp;Phase:&nbsp;&nbsp;March 14, 2022&nbsp;&nbsp;September 13, 2022&nbsp;&nbsp;6&nbsp;&nbsp;NCT01906385&nbsp;&nbsp;Single Study&nbsp;&nbsp;Glioblastoma&nbsp;&nbsp;I/II</font></p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000003.jpg" title="" alt="" style="width:681px;height:526px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services&nbsp;&nbsp;A. Subscription Services&nbsp;&nbsp;Service&nbsp;&nbsp;Parameters (metrics reflect maximum scope levels of the Services)&nbsp;&nbsp;Managed Services&nbsp;&nbsp;Synthetic Control Arms (&#8220;SCA&#8221;)&nbsp;&nbsp;Client Access to Application: N&nbsp;&nbsp;As set forth in Exhibit 1&nbsp;&nbsp;&nbsp;&nbsp;B. Subscription Services Terms&nbsp;&nbsp;Subscription Services Terms:&nbsp;&nbsp;Service specific terms applicable to the Services pursuant to this Sales Order are incorporated herein by reference and may be accessed at https://www.medidata.com/en/policies-medidata-services&nbsp;&nbsp;Medidata owns all Intellectual Property Rights (IPR) in and to the Managed Service(s) pursuant to this Sales Order and its component parts (as defined in the Managed Services Scope of Work), including information, methodologies, processes, tools or technical know-how involved in Medidata&#8217;s provision of the Managed Service(s) or any deliverables set forth in this Sales Order.&nbsp;&nbsp;Synthetic Control Arms is not generally available by Medidata to its partners and customers as of the Sales Order Effective Date. Until Synthetic Control Arms becomes generally available by Medidata to its partners and customers, it is provided without any warranty and Support Services. Medidata is not liable or responsible for Client&#8217;s decisions regarding its clinical trials.&nbsp;&nbsp;<font style="font-style:italic;">AV Medidata Confidential Information Page 2 of 7 March 4, 2022 v. October 2021</font>&nbsp;&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000004.jpg" title="" alt="" style="width:681px;height:526px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AV Medidata Confidential Information Page 3 of 7 March 4, 2022 v. October 2021 <font style="font-style:normal;">&nbsp;&nbsp;&nbsp;&nbsp;D. Fees and Billing Billing Information:&nbsp;&nbsp; Plus Therapeutics, Inc.&nbsp;&nbsp; 4200 Marathon Blvd., Suite 200&nbsp;&nbsp; Austin, Texas 78756 United States&nbsp;&nbsp; Delivery Method: ap@plustherapeutics.com&nbsp;&nbsp;&nbsp;&nbsp; Sales Order Fees:&nbsp;&nbsp; Client shall notify Medidata prior to the Sales Order Effective Date of any revisions to the billing information set forth above, such notice to be submitted via https://www.medidata.com/en/customer-support/billing-address. Client shall submit all purchase order documentation, as applicable, to Invoicing@medidata.com within thirty (30) days of the Sales Order Effective Date. Managed Services Fees&nbsp;&nbsp; $1,450,000.00&nbsp;&nbsp; Contingent Managed Services Fees&nbsp;&nbsp; $150,000.00&nbsp;&nbsp; Total Fees&nbsp;&nbsp; $1,600,000.00&nbsp;&nbsp; Currency:&nbsp;&nbsp; USD Billing Schedule&nbsp;&nbsp; Sub-Total Managed Services Fees (invoiced quarterly in advance, at USD $725,000.00, for two (2) quarters)&nbsp;&nbsp; $1,450,000.00&nbsp;&nbsp; Sub-Total Contingent Managed Services Fees (invoiced upon Regulatory Fee Tigger)&nbsp;&nbsp; $150,000.00&nbsp;&nbsp; SUB-TOTAL FEES&nbsp;&nbsp; USD 1,600,000.00&nbsp;&nbsp; TOTAL FEES*&nbsp;&nbsp; USD 1,600,000.00&nbsp;&nbsp; </font>AV Medidata Confidential Information Page 3 of 7 March 4, 2022 v. October 2021<font style="font-style:normal;">&nbsp;&nbsp;</font></p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000005.jpg" title="" alt="" style="width:681px;height:526px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AV Medidata Confidential Information Page 4 of 7 March 4, 2022 v. October 2021 <font style="font-style:normal;">&nbsp;&nbsp;*The Total Fees set forth above reflect the committed Services and associated use parameters set forth herein, and are exclusive of any of the following, to the extent applicable: (i) sales, use, value added, consumption and other indirect taxes which are the responsibility of Client; and (ii) pass-through reimbursable expenses for travel, which shall be charged on an actual cost basis.&nbsp;&nbsp; The terms and conditions of the Medidata Services Agreement dated November 5, 2021, including any amendments executed thereto (&#8220;Agreement&#8221;) executed between Client and Medidata shall apply to the Services provided under this Sales Order and this Sales Order shall be fully incorporated by reference into and made a part of the Agreement. Any attached Exhibit(s) shall be incorporated by reference into and made a part of this Sales Order. Should a conflict arise between this Sales Order and the Agreement, this Sales Order shall control.&nbsp;&nbsp; The parties agree to the terms of this Sales Order and have caused their duly authorized representatives to execute this Sales Order as of the latest date set forth below, and made effective as of the Sales Order Effective Date.&nbsp;&nbsp; SIGNATURE PAGE TO FOLLOW&nbsp;&nbsp;&nbsp;&nbsp;</font></p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gz4fxfn2r2w0000006.jpg" title="" alt="" style="width:681px;height:526px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AV Medidata Confidential Information Page 5 of 7 March 4, 2022 v. October 2021 <font style="font-style:normal;">&nbsp;&nbsp;PLUS THERAPEUTICS, INC.&nbsp;&nbsp; MEDIDATA SOLUTIONS, INC.&nbsp;&nbsp; By:&nbsp;&nbsp; By:&nbsp;&nbsp; Name:&nbsp;&nbsp; Name:&nbsp;&nbsp; Title:&nbsp;&nbsp; Title:&nbsp;&nbsp; Date:&nbsp;&nbsp; Date:&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>pstv-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pstv-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK15"></a><a name="OLE_LINK16"></a><a name="OLE_LINK18"></a><a name="OLE_LINK19"></a>EXHIBIT 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act Rule 13a-14(a),</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">as Adopted Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 302 of the Sarbanes-Oxley Act of 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Marc H. Hedrick, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Plus Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 21, 2022</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Marc H. Hedrick&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick,</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President &amp; Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>pstv-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pstv-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage39"></a><a name="EX31_2_HTM"></a><a name="FIS_EXHIBIT_31_2"></a><a name="OLE_LINK15"></a><a name="OLE_LINK16"></a><a name="OLE_LINK18"></a><a name="OLE_LINK19"></a>EXHIBIT 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act Rule 13a-14(a),</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">as Adopted Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 302 of the Sarbanes-Oxley Act of 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Andrew Sims, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Plus Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 21, 2022</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrew Sims</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Sims</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>pstv-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pstv-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK15"></a><a name="OLE_LINK16"></a><a name="OLE_LINK18"></a><a name="OLE_LINK19"></a>EXHIBIT 32.1</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_CERTIFICATION"></a>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Plus Therapeutics, Inc. for the quarterly period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof, Marc H. Hedrick, as President &amp; Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as VP of Finance and Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">The Form 10-Q report of Plus Therapeutics, Inc. that this certification accompanies fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">The information contained in the Form 10-Q report of Plus Therapeutics, Inc. that this certification accompanies fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Marc H. Hedrick</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 21, 2022</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc H. Hedrick</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President &amp; Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrew Sims </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: April 21, 2022</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Sims</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer &amp; VP of Finance</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gz4fxfn2r2w0000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 2Y!AT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HKR/\ :B_;R_8]_8IN/#]K^U5^T!X?\#R>*IIH
M_#T>M3,K7S1&,2! JM]TRQY)P/G%>L65[::E9PZCI]RDUO<1K)#-&V5=&&0P
M/<$'- $E%%% !17'_'#]H'X)_LU>!9OB9\?/BCHOA+0;=@LFJ:Y?+#'N/15S
MRS?[*@G Z5YW^S?_ ,%-/V!/VO/$\G@K]FS]J[P?XNUB-69M,TW4<3L!U*HX
M4OC_ &0: /=***S?&'B_PUX \*:CXX\9:Q#I^DZ39R7>I7UQG9;PQJ6=VQV
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M%? ]KH/B+QI;V.ZVM?L\:1"29L_(7V;L=LT >P?L;_\ !6K]LC4O^"GVJ_\
M!+C_ (*"_L^>!/#GBJ3PNVN^&M>^&^KW5S8SPA4D\I_M7SL2C$[@$P4(V\@U
M]'?\%7?V?OC1^U+_ ,$]/BI\!_V>];^P^,/$?A>>VT=OM'D_:),9,!D_@\P
MIN[;J^2_&?[)W[2-]_P<[^&_VL;/X,Z[)\-[7X5R:?<>,ULS]ACNC;;1$9/[
MV>,5]A?\%,?V<?C;^U9^Q;XT^#7[.'QJUWX?^.KZS2?POXF\.Z[<:;<0W<,B
MRI&9[=UD2.0KY;X/*L<YH _G-\/^+?\ @G5\ OV>;7]A7_@K1_P1^\??"+QA
M JVEQ\:_"^F@:O),LF3=(+Q LJXX)CDE1EY53Q7ZX?$;_@I[\)O^"9__  3W
M_9I^#O[#6O:A^T)XB^+2Q>'O@A<>)]36)M3AC>*/SKZ1$C*^2UQ;V_E[4?=\
MK;2CD?+OQ'^-O_!Q;\5_V+]1_P"":'QA_P""5"^,-5U'13X?O/BQKFH&ZMYX
M\;!=OY@,;3A>1.9.&P^,U6_:S_X-T_VB/"O_  3B_92\,Z#\/[3XL>)O@/JF
MK77Q&^&\.K26Z:]8ZK?QW]Q:6TR,C#RV0PY1E9Q(74@B@#[G_98_X*I?M8Z!
M^WII_P#P3A_X*8_ ?P3X3\;^*/#K:QX'\2?#;6KBZTC4T7[]LPNOWJRC!YZ$
MCIC!KQG]E#_@L;_P5I_;U_:&^,'P$_98_9=^"[)\(_&WV'5_$?BS5-3M;=M/
M>>2*&-(XI':6[803R$Y2,*@!P67/(_\ !+C_ ()E:3_P\0TG]I+X>?\ !'ZS
M_9S^'?@G2S+97OC[7M9NO$MWJS(R'[.AU22W$.&/,D3\>AZ>K?\ !OI^R9^T
M=^S;^T/^UQXI^.WP8USPK8^-/B?#?>%KS6+/RDU2U5[P^;$?XE'F+S_M"@#M
M?V#O^"Q_Q&^)OQE_::_9Y_;?\$^%?"/BK]GNXN+Y5\.K<0Q:GHL8<B[*W,TC
M!G7R&7!P1..*^9OC'_P5T^.'[3__  0G^)7[?/[2?[''PF\2>%_^%B6VG^!?
M!7B+2+Z?3]5TY+Z.$75VCW.YI!)N*["BY0'!!Q63_P '%'_!+G]MGXB?M@:/
M^T3_ ,$^/A]K6I_\+;\(OX(^+"Z%:[UAMC(H2ZGP1A?+)!?MY2U]!?\ !77_
M ()V?$+1/^#?^/\ 8,_9)^$^I>*-:\/VGA^TL=#T&U\VXN3!<Q//* /O<AV)
MZXH 7XL?\%BOB1\(/!G[+?[&W[$O[,WA77OC+\9OA3H6MZ3X7O+R6Q\.^%M-
MDL(BN[8QE\A=LB(H;*I <DD -ZM^RY_P4<_;+\/^,OB=\,_^"G?[&EQ\/_\
MA6OA6?Q(WQ0\#Z;J-WX/U>P@B,LR07EQ&%$ZH,B(OO;D;00:^1OCI^P)^V]^
MS]\;/V-_^"G_ ,!?V>M3\>:Q\+O@1X?\&?$KX9VDR0ZK D%@5?R4<X:16N;A
M&7/#(O;)'TO\/M<_X*:?\%,[#XS?#']HC]F^R^"/P3\6?#N^T#PII?BJS+>*
M9-0N;<Q?:9FBN&B2%"2VSR\G@!C@T >"Z/\ \%Z_^"E?C;]E[6/^"HW@+]A/
MP!)^S-H^NSP"UOO%5ROBR\TV"Y^S37\84?9MB2!PP*[@8V # ;CZ;_P4,_X+
M_P!A\ M$^ NG_LN^'?!4^H?'[1AJ^B>+/BSKDFE^'=#L\ $WLT7S*P?*'#
MCJ<U^;/PS_X(R?%7X0? BZ_93\>?\$))/B%\<+7Q%+;:/\:]0\8:F/"EY8/=
M;UN+H6FHVX5HXF,:K&J@A$+'=NS][?\ !1#_ ()]_&OPG^S%\!_@;H__  3S
M^&_QS^%7@G1UL_'G@/P_;W\.OZ7.P+/+HEY-?F9(][-\LCN6VC<<'@ ^A/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX2J?_':/^&W?$G_1E?QF_P#"53_X[0![U0!@UX+_ ,-N^)/^C*_C-_X2J?\
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M$JG_ ,=H_P"&W?$G_1E?QF_\)5/_ ([0![U17@O_  V[XD_Z,K^,W_A*I_\
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M)5/_ ([0![U17@O_  V[XD_Z,K^,W_A*I_\ ':/^&W?$G_1E?QF_\)5/_CM
M'O5%>"_\-O>(QU_8K^,W_A*I_P#':[S]F_\ :#\/?M*_#F7XB^'O"^LZ*EOK
MVHZ1>:7K]JL-U;W5E=26TRNBLP'[R-L<YQUQ0!WU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+X]&
M?^"D/PX_[)7XD_\ 2W2Z]ZKP;QY_RDA^'/\ V2KQ)_Z6Z70![S1110 4444
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M].MK7O5>"ZU_RDTT#_LB>H_^G6UH ]ZQSFBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BORS_XB"/VS?$.A?%?XL_"K_@CW/XJ^&OP=\1Z
MEIGB[QE9_'BP@FBCLB3-.MA-8+,V(UW[5+ #C=P37V/\/_\ @J/^Q+XH_9A^
M'?[5_P 0/CUX:^'OASXF:'#J/AV+Q]KUKILS;@-\!$L@5I(VRC;"PR."002
M?0M%>4>//V[?V+?A;I^DZM\2OVK?A[H-KKVD/JNB7&K>+K2W2_L58*US"SR
M21 L 77(!(YIGQ&_;U_8F^$#:''\5?VL_AWX<;Q/91WGAQ=;\86EL=3MY/N2
MP>9(/-1NS+D&@#UJBO*/B3^W=^Q7\&]6ET'XL_M7_#WPW?0Z1;ZK-::YXNM+
M61+&=BL-R5DD!\IR"%?HQ'!JSHG[:?[(7B7XA:-\)?#O[3O@.^\4>(K%;W0?
M#]IXJM9+S4+9DWK-#"KEI$*C<&4$$<T >G45YKKG[9/[)?AGXQ0?L\^(OVE?
M MCX[N2HM_!]UXHM8]2D+#*@6Y?S#GMQ7CO[+W_!7K]E_P#:L_;1^)W[%W@/
M7]-AUCX;LB17LWB*UD.O,N?M+6L*$L8X#M5WSD%L%5[@'U917F/PU_;5_9!^
M,GB?6?!7PE_:=\!^)=8\.QR2:]I>A^*K6ZN-/2/[[3)&Y:,+@Y) Q5#P+^W[
M^P]\3VO$^'/[77PYUPZ=I#:K?_V3XQLY_L]BIPUR^R0[8@1@N>,]Z /7:*\^
M^!7[6/[,7[3\6H3_ +.7[0/@[QTFE2*FIMX3\16^H"U8YP)/)=MA.#U]*XK]
ML#]MW3?V7O'GPO\ @_H'@!O%GC+XK>,(]&T'0UU7[&L-NJF2ZO99/*EPD48+
M!=OSMA=RYS0![M17C6A?\%$_V"?$_B72?!GAW]LOX8WVK:[>2VNBZ;:^-K)Y
M[Z>*1HY(HD$F7975E*@$AE(/(KI/A7^UA^S'\<K?7+OX-?M ^#?%,7AF1H_$
M4F@>([:[73&7.1.8W/E$8/WL=* /0:*\)UW_ (*7?L,6/P?\>?&KPK^U!X&\
M3:3\.-(GO_%"^'?%EE<R6OE@[86Q+M221\1H'*@NZKGFN)_8\_X+#_L8?M3_
M +(7A7]KGQ%\8O!_@&Q\3:I)I<FC>(O&=IYNG:END:.PF<E%%TT"+-Y6-P5^
M-P&X@'U917S?\%/^"B_@7]H7]K?4/@)\'I_ ?B;P;;>#8];LOB!X=^+6F7UQ
M=2%]CP_V5%FXCC4Y_P!(+%">!7H7P[_;4_9"^+GQ%U#X0_"W]IWP'XB\5:2)
M#JGAW1?%5K<WMKL^_P"9"CEUV]\CB@#TZBO,?AS^VI^R#\8/B->?!_X5?M.^
M _$?BK3RXOO#FB^*K6YO8-IPV^&-RZX/7(XKHOC#\>?@G^SWH-CXI^.WQ9\.
M^#]-U35X=*TW4/$NL0V4-S?2AS%;(\K*&E<(Y5 <D(V!P: .LHKR6_\ V]_V
M(M*^$]O\>-3_ &MOAU;^";R^>SM/%DWC"S73YKA#AHEG,FQG!ZJ#D5\[?\%0
M/^"Y_P"SW_P3V^&O@'Q/\/[;PU\4M>^)6J0P>%=%MOB18:1:/9N64ZC-?3"2
M.&U#C;YS+Y8.=SJ%)H ^XZ*^._\ @FQ_P5ITW]NGP3\5O&?Q8^$.E_">'X2^
M)4T?7);GQ_!JUHS>1YLDIND@AA"(<KN5I$8#<KD$5]"?"/\ :P_9C^/OA/4?
M'GP1_:"\&^+=$T@L-4U;P[XCMKRWM-HRWF21.53 &3DB@#T"BOG?Q_\ \%5?
MV#O"?P'\??'_ ,)?M.>!_&&E_#K2I+SQ!:^%_%UC<S1L#M2 XEVI)))B- Q&
M68#K70?L _MO_"S_ (*$_LP^'?VF/A5=V*V^M0$ZAH]KK$5[)I-P"<VL[Q@!
M95&TLI (W?B0#VBBO&?#_P#P45_8'\6>(M(\(^&/VS?ACJ&J>()YH=#T^T\;
M64DU_)%(T<B1(),NRNC*0 2"I!Y%=)\,/VLOV8?C9IVN:O\ ![]H/P;XHM?#
M,C1^(KC0?$EM=1Z8R@[A.T;D1$8.=V.E 'H5%>7_  D_;;_8\^/=UK%E\$?V
MH? 7BZ;P];O<:[#X=\56MXVGQ+]YYA$[&-1@Y)P!573?V]/V)]8\)^'_ !YI
M/[67P\NM%\6:PVD^&-6M_%UH]OJM^IPUK;N),2R@]44EAZ4 >M45\N_ /_@J
M-\&_&VAZOJ?[2'BKX:_"^XM_&VJZ!X=M7^,>E:NNL+8KOEE#P%!#*L?SR6S9
MDB'WJ[J+_@HU^P)/X4TGQU!^V?\ #!]%U_4WT[0]47QO9&WO[M,;X(G\W;)(
M-RY4$D9'K0![117)6OQ[^"5]\3;CX+6?Q9\.R^+[31TU6Z\,QZO"U]%8O]VY
M:$-O$1[.1M/K7%R?\%"/V%8/#>@^,9_VP/ALFD^*&U)?#>I-XRLQ!JAT_'VX
M0/YFV7[/D>;M)\O/S8H ]AHKQNW_ ."A_P"P;=Z1H.OVO[9/PSDL?%5XUIX;
MNT\;61CU2<,%,4#>9B5P2!M7)R:]=O-3T[3M-EUF_OX8;."!IIKJ:0+''&!N
M+ECP% YSTQ0!/17FOP7_ &R_V2_VC=<U#PS\ OVE? WC34-)4MJECX8\46M]
M+:@'!,BQ.Q7GU%-\%?MG?LC_ !(^*EY\#/A_^TSX%UKQGIY<7WA72_%%K/J$
M!3[VZ!'+C'?(XH ],HKS";]M?]C^W^,G_#.\_P"U!X"3QYYOE_\ "'-XJM1J
M6_\ N_9_,\S/MBHOBW^W+^QG\!/$E]X.^-W[5'P_\(ZMIEI#=:CIOB+Q9:6<
M]M#,2(I'260,JO@[21@XXH ]4HKSWQK^UG^R]\-_A-8_'CQ_^T+X,T7P3J:Q
MMIWBS5/$EM#I]T'&4,<[N$?(Z8)S73?#OXE_#WXN^#[/X@_"OQOI/B/0M1CW
MZ?K&BW\=S;7"^J21DJP^AH W**^5_P!G7_@J7\//B[\4?VBO!GQ5\.Z3\.]!
M_9[\;)H&H^+M;\6QM:ZBC*Q^TOYD,2V@RN-A>3K]ZO5=._;A_8XU;X.S_M#:
M9^U)X!N/ =K=+;W'C"'Q9:-IL4S,%6-K@/Y:L20 "<DF@#U.BN-UO]H?X#^&
M_&GAGX<>(/C'X9LO$'C2UEN?".BW6M0I=:S#%&99)+:,MNF58P7+*" HR>*Y
M7PY^W3^R?\28_%6F_!']H7P/XVU[PCIEU=ZMX?\ #OBNUN;F#R49F218F=H^
M5VDE>/2@#URBOE7]D#_@J_\  GX^_L/>'OVW_P!H#5?#7P;T;7KZYM5MO%'C
M2%K>*2*5H\"ZFCMU<MMSC8,>_6OHOX8_%7X9_&KP79_$?X0>/]'\4>']04M8
MZUH.HQW5K< '!V21DJV#QP: -^BO-?C!^V5^R7^S[XHT_P $_'3]I3P/X/UC
M52!INE^)/%%K9SW63@;$E=6;)]!7RC_P4<_X+N?#S]B/]I_X>_L>_"3X6:%\
M4/'/C=#/?6ES\5-.\.VVB0,J/!YUQ=)(GFSHQ:*)O+\SY0C,SJ* /OBBOE__
M (*1?\%5_@#_ ,$SK7P&GQEDM9K[Q[XFATNSM9-<M[-;* L!-?S-*<B"('YF
M"GD@$KG-<W-_P65_9Z\-?MQ^./V5OBKJGA7PCX/\(^ =)\36OQ8UOQW!#8:F
MM_L,<"QR1(B</D.)WWXX44 ?8E%>=^.OVN_V6/AC\+=-^-_Q&_:+\%:'X-UA
M4;2?%&K>);:"PO%<90Q3NX1\CI@G-=9X"^(/@7XI^$[/QY\-?&&FZ]HFHPB7
M3]6T>]2XM[E#_$DB$JP]P: -BBOSE^,G_!>3XIZ=\;?BY\/OV2O^";WB3XN^
M%_@1K$NE?%#Q;!\0K#2)K2ZA#?:%L]/FBDFOA&4=<J5+%#@;2K'ZD\%?\%(O
MV0-?_9=\&?M<^/?C+H?@'PGXXT^.XTF;Q]JT&ENLC9#0-YS@>8K J0"<XR,@
M@T >[45YAXZ_;8_8^^&.@>'?%?Q%_:@\!Z'I?B^TN;KPKJ&J^*K6"'5X+>-9
M9Y+9W<"98T=68J2%# G&:L_"W]K[]E;XWW^H:7\&_P!HKP7XIN=)TN/4]3M]
M!\26UT]K9R#*7$@C<E8F'(<\'UH ]&HKYN\.?\%&? ?Q,_:Z\"_L_P#P,N/
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M_#S5?$MK=?M->%SKEAI>FRW+)IYM]02:601*2D0#X9SA1N&2,U^CF/>C'&*
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MS?!NXD;XG^ +GX3^)-%\*Z.WD:?'.0+.[:.!<111!Y%W8 &0<C%?L-@=*,4
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M#4EOKGC_ %A=3\5:E<WDMQ+>3K&(U^:1CL15 "QKA5[ 9KO* "BBB@ HHHH
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M[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\
M1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?
M_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_
M\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J
M* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_
MX6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?
MO_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^
M&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##
M@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\
M&Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6
MW^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_
M $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?A
MG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q
M?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KW
MJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!
M?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^
MW[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H
M?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\
MPX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_
M !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^
M%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[
M_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'
MX9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX
M,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z
M]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#
MP7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M
M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T
M:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_
M ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7
M_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC
M_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M
M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&
MA^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\
M.#%_\;KWJB@#P7_A;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_Q
MNO>J* /!?^%M_M^_]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH
M \%_X6W^W[_T:'X9_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A
M;?[?O_1H?AG_ ,.#%_\ &Z/^%M_M^_\ 1H?AG_PX,7_QNO>J* /!?^%M_M^_
M]&A^&?\ PX,7_P ;H_X6W^W[_P!&A^&?_#@Q?_&Z]ZHH \%_X6W^W[_T:'X9
M_P##@Q?_ !NC_A;?[?O_ $:'X9_\.#%_\;KWJB@#P7_A;?[?W_1H?AG_ ,.#
M%_\ &ZI_\$T;K6;WX&>*+[Q-ID=CJEQ\8O&4FJ6$4PE2UN3KEV9(E<??56R
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MY]NCUZWML%+\'RD$0D4@A 7 '1S7C/[1_P#P6D^.7AS]K7X@?LH?L9_L,_\
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MG^\H ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O!O'G_ "DA^'/_ &2KQ)_Z6Z77O-?,O[1'Q7^&
M7P9_;]^&_C'XL^/=)\.:4WPU\16RZAK%\EO$TS7>FLL>YR!N(1CC_9- 'TU1
M7C__  \"_8?_ .CK_ /_ (4UO_\ %4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45
MX_\ \/ OV'_^CK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>
M/_\ #P+]A_\ Z.O\ _\ A36__P 51_P\"_8?_P"CK_ /_A36_P#\50![!17C
M_P#P\"_8?_Z.O\ _^%-;_P#Q5'_#P+]A_P#Z.O\  /\ X4UO_P#%4 >P45X_
M_P / OV'_P#HZ_P#_P"%-;__ !5'_#P+]A__ *.O\ _^%-;_ /Q5 'L%%>/_
M /#P+]A__HZ_P#_X4UO_ /%4?\/ OV'_ /HZ_P  _P#A36__ ,50![!17C__
M  \"_8?_ .CK_ /_ (4UO_\ %4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45X_\
M\/ OV'_^CK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\
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M#0D$]0:];_X>!?L/_P#1U_@'_P *:W_^*H_X>!?L/_\ 1U_@'_PIK?\ ^*H
M]@ P, 45X_\ \/ OV'_^CK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\
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M_A36_P#\50![!17C_P#P\"_8?_Z.O\ _^%-;_P#Q5'_#P+]A_P#Z.O\  /\
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M ,50![!17C__  \"_8?_ .CK_ /_ (4UO_\ %4?\/ OV'_\ HZ_P#_X4UO\
M_%4 >P45X_\ \/ OV'_^CK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\
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M  \"_8?_ .CK_ /_ (4UO_\ %4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45X_\
M\/ OV'_^CK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\
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MCK_ /_A36_\ \51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\ #P+]A_\
MZ.O\ _\ A36__P 51_P\"_8?_P"CK_ /_A36_P#\50![!17C_P#P\"_8?_Z.
MO\ _^%-;_P#Q5'_#P+]A_P#Z.O\  /\ X4UO_P#%4 >P45X__P / OV'_P#H
MZ_P#_P"%-;__ !5'_#P+]A__ *.O\ _^%-;_ /Q5 'L%%>/_ /#P+]A__HZ_
MP#_X4UO_ /%4?\/ OV'_ /HZ_P  _P#A36__ ,50![!17C__  \"_8?_ .CK
M_ /_ (4UO_\ %4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45X_\ \/ OV'_^CK_
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M6_\ \51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\ #P+]A_\ Z.O\ _\
MA36__P 51_P\"_8?_P"CK_ /_A36_P#\50![!17C_P#P\"_8?_Z.O\ _^%-;
M_P#Q5'_#P+]A_P#Z.O\  /\ X4UO_P#%4 >P45X__P / OV'_P#HZ_P#_P"%
M-;__ !5'_#P+]A__ *.O\ _^%-;_ /Q5 'L%%>/_ /#P+]A__HZ_P#_X4UO_
M /%4?\/ OV'_ /HZ_P  _P#A36__ ,50![!17C__  \"_8?_ .CK_ /_ (4U
MO_\ %4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45X_\ \/ OV'_^CK_ /_A36_\
M\51_P\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\ #P+]A_\ Z.O\ _\ A36_
M_P 51_P\"_8?_P"CK_ /_A36_P#\50![!17C_P#P\"_8?_Z.O\ _^%-;_P#Q
M5'_#P+]A_P#Z.O\  /\ X4UO_P#%4 >P45X__P / OV'_P#HZ_P#_P"%-;__
M !5'_#P+]A__ *.O\ _^%-;_ /Q5 'L%%>/_ /#P+]A__HZ_P#_X4UO_ /%4
M?\/ OV'_ /HZ_P  _P#A36__ ,50![!17C__  \"_8?_ .CK_ /_ (4UO_\
M%4?\/ OV'_\ HZ_P#_X4UO\ _%4 >P45X_\ \/ OV'_^CK_ /_A36_\ \51_
MP\"_8?\ ^CK_  #_ .%-;_\ Q5 'L%%>/_\ #P+]A_\ Z.O\ _\ A36__P 5
M1_P\"_8?_P"CK_ /_A36_P#\50![!17C_P#P\"_8?_Z.O\ _^%-;_P#Q5'_#
MP+]A_P#Z.O\  /\ X4UO_P#%4 >P45X__P / OV'_P#HZ_P#_P"%-;__ !5'
M_#P+]A__ *.O\ _^%-;_ /Q5 'L%%>/_ /#P+]A__HZ_P#_X4UO_ /%4?\/
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M7D(^%OB1A#=0+(H87FF<X8$9Y/YU]!5X-X\_Y20_#G_LE7B3_P!+=+H ]?\
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M_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\ @KA_^)K:HH Q?^%;_#O_ *$+1?\
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M_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\
M@KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?\*W^'?\ T(6B_P#@KA_^)K:H
MH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T(6B_^"N'_P")K:HH Q?^%;_#
MO_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\
M!7#_ /$T?\*W^'?_ $(6B_\ @KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?
M\*W^'?\ T(6B_P#@KA_^)K:HH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T
M(6B_^"N'_P")K:HH Q?^%;_#O_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\
MXFMJB@#%_P"%;_#O_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\ @KA_^)K:HH Q
M?^%;_#O_ *$+1?\ P5P__$T?\*W^'?\ T(6B_P#@KA_^)K:HH Q?^%;_  [_
M .A"T7_P5P__ !-'_"M_AW_T(6B_^"N'_P")K:HH Q?^%;_#O_H0M%_\%</_
M ,31_P *W^'?_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\ !7#_ /$T?\*W
M^'?_ $(6B_\ @KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?\*W^'?\ T(6B
M_P#@KA_^)K:HH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T(6B_^"N'_P")
MK:HH Q?^%;_#O_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\ XFMJB@#%_P"%
M;_#O_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\ @KA_^)K:HH Q?^%;_#O_ *$+
M1?\ P5P__$T?\*W^'?\ T(6B_P#@KA_^)K:HH Q?^%;_  [_ .A"T7_P5P__
M !-'_"M_AW_T(6B_^"N'_P")K:HH Q?^%;_#O_H0M%_\%</_ ,31_P *W^'?
M_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\
M@KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?\*W^'?\ T(6B_P#@KA_^)K:H
MH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T(6B_^"N'_P")K:HH Q?^%;_#
MO_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\
M!7#_ /$T?\*W^'?_ $(6B_\ @KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?
M\*W^'?\ T(6B_P#@KA_^)K:HH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T
M(6B_^"N'_P")K:HH Q?^%;_#O_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\
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M_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\ !7#_ /$T?\*W^'?_ $(6B_\
M@KA_^)K:HH Q?^%;_#O_ *$+1?\ P5P__$T?\*W^'?\ T(6B_P#@KA_^)K:H
MH Q?^%;_  [_ .A"T7_P5P__ !-'_"M_AW_T(6B_^"N'_P")K:HH Q?^%;_#
MO_H0M%_\%</_ ,31_P *W^'?_0A:+_X*X?\ XFMJB@#%_P"%;_#O_H0M%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU^634K5&EV%U0PJCVJ]#,75MW&S'- 'OE%>7?#W]M?\ 9-^*VL:AH/P\^/\
MX:U2ZTNSEN[R.WU #9;QG]Y,&; =%[LI('K7-:G_ ,%(OV.CX(\6>+?!_P <
MM#UR7PCX;N=9OM/L;AO-D@A4G* K\ZEMJ[ER 6&30![MFBOG/]E__@H'X#_:
MB\$?!?QSX6UWPK8K\5?"]]J<FAWVLS+J,<]K;6\T\%I'Y&VY$!GQ,[-'M!0J
M'W$#O?"7[:7[*7CSXDGX0^#OCUX;U#Q)YTD*:5;WP+R2)]]$/W79<'(4DC%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7@O_!/7_DF?CS_ ++EXX_]/]Y7O5>"_P#!/7_DF?CS_LN7CC_T_P!Y
M0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>#>//^4D/PY_[)5XD_P#2W2Z]YKP;QY_RDA^'/_9*
MO$G_ *6Z70![S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?A%H</ARXT[QAJ&I:)#8HMKJ-PFB:?A[F,#;/E@K'>"&9%)SBOG[6_@%\)/
M7[%/[3'Q-\*>"[2SU[P7^UQ?67@O5(@?.\/VD5_I[I;639_T6$-/,?+CVJ?,
M.017[)/864DT-R]G$TEOD02-&"T8(P0I[9'I4;:-I#PR6SZ5;&*:7S9HS;KM
MD?\ O,,<G@<GGB@#\GOVD+WX6?L\_'OQM\6=!\2_#'XTZAJ/Q.L;VY^&OB6S
MN+/QYI]Z]S @ATF9=LTL,;$.JA?)*ALL5S7UQ_P6F;59?^"=?B2:SCF6R_MK
M07\0(F>-+_M2U-Z&_P!GR/,W>V<U]2R>&O#DVHKK$WA^Q:\7E;IK5#(/^!8S
M^M5?B%X"\*_%/P-JWPW\<Z1'?Z/KFGRV6I6<RY66&12K+^1H T+=[?\ LV.3
M2HXVA$(-LL+ (RX^4 CC&,5^3L<WP+\#> O%GQG_ &6_VW?%O[,?Q"AU34[[
M6OV?_$FHPW]NVL+-(S0Q:9,OF2Q3R?.#: J_F[EY)K]2/A)\.;3X0_#/0_A?
MIWB/5-6M=!TZ.QL[_6IDDNI(8QMC$CHB!RJ!5W;02%!))R3IW7A;PS?7PU2]
M\.6$UTIRMS+9HT@_X$1G]: /SV_9]^,WBWX*?MLZ;^UE^W?HT/@./XR? #P[
M;-K&J*8=/TC6;5GENK">9ODM2WG!U$A4$J5SD5TG[7?_  5-T&Z^%'Q5@_9+
M\&MJ^K7$.C^"?AS\2;7;]AU_Q;K4[6=M9VC[<W2VGF"XDD5C& C $D&ONS4-
M)TO5[?[)JVFV]U%G/EW$*NOY$&HXO#^@P6T-E#HEFD-O,);>%;9 L<@Z.HQ@
M,/4<T ?F'<? ?X_?\$L?'G[//QO^(&H?#]O '@W2[;X7>,)_"5G?1W%YI]\\
M:Q7UX;AV5RMX!*<#[T[GH37Z:6/ASP9H%E<2Z9H.EV5O- /M36]K'&CQ*N!N
MP "H7UX J]>V%EJ4'V74+.&XCW ^7-&&7(Z'!KG/C5\*M-^-_P )?$'P>U?Q
M)JVCV'B32Y-/U"^T&X2&[6VD&V5(Y&1_++QED+ ;E#DH58*P /G3_@ADFK+_
M ,$LOA:VH+,+5DUE_#OG9R-%;6KYM+QG^#[ ;7;_ +.VOK2LWP;X0\-_#[PE
MI?@3P9HUOIVCZ+I\-CI6GVL82*UMXD$<<2*.BJJ@ >@K2H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KP76O^4FF@?]D3U'_TZVM>]5X+K7_*
M330/^R)ZC_Z=;6@#WJBBB@ HHHH **** "B@D]A4-EJ.GZBC2:??0W"QN4=H
M9 P5AU!QT/M0!-11SGI1GC.* "BBF3W$%LGF7,RQJ6"AG8#DG 'U)H ?13+B
MX@M(6N;J9(XT7,DDC!54>I)IEAJ-CJELM[IUY%<0O]R:&0.K?0C@T 34457D
MU3388VEEU"!567RF9I@ '_N]>O/3K0!8HH)QVJ-;RT:[:P6ZC,ZIO:'>-X7.
M-V.N,]Z )***HZGXG\-Z)*L&M>(+&SD9=RQW5VD98>H#$9% %ZBJFEZ]H>N(
MTFB:S:WBQG$C6MPL@4^^TG%3W%Y:6AC%U=1Q^=((XO,<+O<]%&>IX/'7B@"2
MBH[FZMK*!KJ\N(X8DY>21PJK]2:2UOK*]#FRNXIO+?9)Y4@;:WH<=#0!+14$
MVJ:;;S-;SZA DD:!WC:8!E4G )&>A/&:GH **C%W:M<M9+<QF94#M#O&X*2<
M''7!P>?:I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\%_X)Z_\ ),_'G_9<O''_ *?[RO>J\%_X)Z_\DS\>
M?]ER\<?^G^\H ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O!O'G_ "DA^'/_ &2KQ)_Z6Z77O->#
M>//^4D/PY_[)5XD_]+=+H ]YHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"?VF]>^&_B_7O%&LZ%K7PM\?6WBKPWK&@R1).98XI89K20R1N&MKB&9XI4
M!92,$$ @ ^7/ 7_!0#]H:Y_:?NOAO\>/B5X>^&4Z_$:ZT?2_ OC#P+=Q6^KZ
M4L[1VT]IK*N8I9YX@D@0J "^WM7O'_!1GX]_'S]GGX.Z+XO^ _@ZYU!KSQ=:
M6/BK6+/07U670-*=)3+?K91LK7)5UC38",>9N[5G>.?^"<.D?%7Q#:I\6OVF
M?B/XH\(V'BY/$=EX%UR\LIK6*[CG\^)?M1MOMIA1_NQ&<H  N, "O6_CK\']
M8^,?AVQTOPY\9O%G@74--U)+VSUKPC>1)*6"LOERQ3QR0W$1#<QRQNN0IQD
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M>V@/FQCR)/(+!CRH3/); ^>_%]A^T-'^QE\5KV]^+5CXAU3_ (;JMK31TO\
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M@?\ 9$]1_P#3K:T >]4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !FC_AXS^S[_ - #X@?^&YU3_P",U[U10!X+_P /&?V??^@!\0/_  W.J?\
MQFC_ (>,_L^_] #X@?\ AN=4_P#C->]44 >"_P##QG]GW_H ?$#_ ,-SJG_Q
MFC_AXS^S[_T /B!_X;G5/_C->]44 >"_\/&?V??^@!\0/_#<ZI_\9H_X>,_L
M^_\ 0 ^('_AN=4_^,U[U10!X+_P\9_9]_P"@!\0/_#<ZI_\ &:/^'C/[/O\
MT /B!_X;G5/_ (S7O5% '@O_  \9_9]_Z 'Q _\ #<ZI_P#&:/\ AXS^S[_T
M /B!_P"&YU3_ .,U[U10!X+_ ,/&?V??^@!\0/\ PW.J?_&:/^'C/[/O_0 ^
M('_AN=4_^,U[U10!X+_P\9_9]_Z 'Q _\-SJG_QFC_AXS^S[_P! #X@?^&YU
M3_XS7O5% '@O_#QG]GW_ * 'Q _\-SJG_P 9H_X>,_L^_P#0 ^('_AN=4_\
MC->]44 >"_\ #QG]GW_H ?$#_P -SJG_ ,9H_P"'C/[/O_0 ^('_ (;G5/\
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M_#<ZI_\ &:/^'C/[/O\ T /B!_X;G5/_ (S7O5% '@O_  \9_9]_Z 'Q _\
M#<ZI_P#&:/\ AXS^S[_T /B!_P"&YU3_ .,U[U10!X+_ ,/&?V??^@!\0/\
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M&YU3_P",U[U10!X+_P /&?V??^@!\0/_  W.J?\ QFC_ (>,_L^_] #X@?\
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M3_XS1_P\9_9]_P"@!\0/_#<ZI_\ &:]ZHH \%_X>,_L^_P#0 ^('_AN=4_\
MC-'_  \9_9]_Z 'Q _\ #<ZI_P#&:]ZHH \%_P"'C/[/O_0 ^('_ (;G5/\
MXS1_P\9_9]_Z 'Q _P##<ZI_\9KWJB@#P7_AXS^S[_T /B!_X;G5/_C-'_#Q
MG]GW_H ?$#_PW.J?_&:]ZHH \%_X>,_L^_\ 0 ^('_AN=4_^,T?\/&?V??\
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MO_0 ^('_ (;G5/\ XS1_P\9_9]_Z 'Q _P##<ZI_\9KWJB@#P7_AXS^S[_T
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M ?$#_P -SJG_ ,9KWJB@#P7_ (>,_L^_] #X@?\ AN=4_P#C-'_#QG]GW_H
M?$#_ ,-SJG_QFO>J* /!?^'C/[/O_0 ^('_AN=4_^,T?\/&?V??^@!\0/_#<
MZI_\9KWJB@#P7_AXS^S[_P! #X@?^&YU3_XS1_P\9_9]_P"@!\0/_#<ZI_\
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M !FO>J* /!?^'C/[/O\ T /B!_X;G5/_ (S1_P /&?V??^@!\0/_  W.J?\
MQFO>J* /!?\ AXS^S[_T /B!_P"&YU3_ .,T?\/&?V??^@!\0/\ PW.J?_&:
M]ZHH \%_X>,_L^_] #X@?^&YU3_XS1_P\9_9]_Z 'Q _\-SJG_QFO>J* /!?
M^'C/[/O_ $ /B!_X;G5/_C-'_#QG]GW_ * 'Q _\-SJG_P 9KWJB@#P7_AXS
M^S]VT#X@?^&YU3_XS4'_  3=O)]7^!_B;Q.^C:A8P:U\7/&&I:?#JEA):SM;
M3ZW=21.T4@#+N1@P! X-?0) /6@"@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJGXCUNV\,^'K_P 1WD4DD.GV<MS,D6-S*B%B!D@9P/6@"Y17Y&:;_P 'B?[#
MFM&X;P]^QM^T)J4%K=/;S76G^&--FB61>HW+?G!P0<=<$>M?<7_!-K_@J?\
MLL?\%2?AKJ?Q#_9OU35(9]"O1:^(/#OB"R%OJ&FRD942(&92" <,K,.",YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_%[QY'K?AN/POJ%U-+;6ZM<DK<B>VA"/^^7A#(.#STR ?.G[+O_  5!^/\
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M_@UW.?VN?VUL?]%,M_\ T=>UM?\ !;C_ (*Z^/O@U_P4,\!_\$\/"O[6=O\
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M-\4/VA=)_:3_ &'OVI/#+6\>C-IGB+X+?&S[?>^#=34YQ<B&VWF*;!P2J9.
M0R\@\M_P1T_X(T_$C]@SX]_%#]L/]H/QEX#/CKXG(EO)X1^$FC36/AK1+99/
M-98%F"R2,S[<%D7: >6+$T ?H91110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P %,HL>9X!^!ZY.!N\4ZL,_^2E 'OE%>"_VW_P4V_Z)[\$/_"HU;_Y$IO\
M;W_!33.W_A7_ ,#\XSC_ (2C5O\ Y$H ]\HKP./7_P#@IG*N^+P!\#V7U7Q3
MJQ_]M*<=;_X*;#_FGGP1_P#"HU;_ .1* />J*\%_MO\ X*;?]$]^"'_A4:M_
M\B4V7Q#_ ,%,81NF\!? Y1ZMXIU8?^VE 'OE%>!IKW_!3.1=\?@#X'LOJOBC
M5C_[:4X:Y_P4V/\ S3SX(_\ A4:M_P#(E '4?%/]BG]EWXV?'CP;^TW\4OA%
M9:QX[^'N[_A#?$4UU<)+IF7WG8J2+&WS<_.K5ZE7@O\ ;?\ P4V_Z)[\$/\
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M;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\
M@IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_
M ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3
MWX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5
M&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\
MA4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_
MX5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)
M0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U1
M7@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O
M5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5
M%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\
M%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_
M *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!
M3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z
M)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ
M-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-
M6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"
MHU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y
M$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*
M;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\
M@IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_
M ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3
MWX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5
M&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\
MA4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_
MX5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)
M0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U1
M7@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O
M5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5
M%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\
M%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_
M *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!
M3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z
M)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ
M-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-
M6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"
MHU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y
M$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*
M;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\
M@IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_
M ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3
MWX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5
M&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\
MA4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_
MX5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)
M0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U1
M7@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O
M5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5
M%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\
M%-O^B>_!#_PJ-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_
M *)[\$/_  J-6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!
M3;_HGOP0_P#"HU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z
M)[\$/_"HU;_Y$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ
M-6_^1*/[;_X*;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-
M6_\ D2C^V_\ @IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"
MHU;_ .1*/[;_ ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y
M$H_MO_@IM_T3WX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*
M;?\ 1/?@A_X5&K?_ ")0![U17@O]M_\ !3;_ *)[\$/_  J-6_\ D2C^V_\
M@IM_T3WX(?\ A4:M_P#(E 'O5%>"_P!M_P#!3;_HGOP0_P#"HU;_ .1*/[;_
M ."FW_1/?@A_X5&K?_(E 'O5%>"_VW_P4V_Z)[\$/_"HU;_Y$H_MO_@IM_T3
MWX(?^%1JW_R)0![U17@O]M_\%-O^B>_!#_PJ-6_^1*/[;_X*;_\ 1//@A_X5
M&K?_ ")0![T#GM17D/[(7QN^*GQGT3QI9?&/PUH.EZ_X,\>W7AVZB\-W4TUI
M*([2TN%D5YE5R2+G!RH^[T[GUZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M);>$M<\(:'<0KI6KZ?;P>1;I,C(6Q&@CPJL!F)3CKD ^$?V.O^"F'Q3^!/\
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M(QL&7[Q!Q7VEI'_!,7X)6G_!-"V_X)>ZYX@U;5O!EMX+;PZNL7@B%]Y>6*W
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M'C3?VH/#7Q\^(/PI^(%IX;;P]J'B;X=ZI';3:II)=G^R3B1&4J&9L, &&>O
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_8@_Y&OX]?\ 9=K_ /\
M31I->]5X+^Q!_P C7\>O^R[7_P#Z:-)KWJ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!?@)_P G
MO?'G_KIX=_\ 37%7O5>"_ 3_ )/>^//_ %T\._\ IKBH ]ZHHHH ****  GB
MJ.H^(] TBZALM6UNSM9;AMMO%<7*HTI]%!//X5>/O7Y^_P#!3K_@F!^TY^V!
M^U%X3^,?PB^+5KINCZ79V]O<VMY>RQ/ISQRL[7$*J"&9@P!Z?<'-=V78;"XO
M$^SKU53C9OF:OJME\SHPU*E6J<M2?*NY^@0.1D451\-Z;<Z+X?L=(O;YKJ:U
MLXX9;A^LK*H!<^Y(S^-7JX7N<[W"O,?VQ_VH?"7[&G[./B3]HSQMI%UJ%CX>
MMXV^PV159+B:258HHPS$*@,CJ"S$*H))X%>G5X_^W>?&_P#PR_XCB\#_  #T
MOXGM(L$>K>!=4^[JNFM,@NXXP2 TP@,C1J2 7502,YH YWX>_M(_M<M\0?"N
M@_&']E#1T\.^+FDCM_%'PY\:R:]#H[B/S%_M /9VXA1@-HDC:5-V!GD&NWT[
M]LC]E?5_BM_PHW3/C[X7F\7?:FM?[!CU9#<&=028@,X+@ _*#GCI7P+X&^!W
MASPE^T!\/[K_ ()5GXU>$5O=7>/XA>%_%VEZM;>&]-TDV\@;,>I(J+,DGE[!
M;,X)!R<<UY3\)?V;OCU_PS!X)_8E\<:A\3D\;Z/\4=/O+[PWI/PHMK>.QO(-
M86[?6U\1R1-&T6U&E9Q(T\B,8MN7X /T]\;?M]?L7?#;QY=_"_Q[^TUX/TGQ
M%I^H0V-_H]YK")/;7,H0QQ2+_ S"2,@'&=XQ5K]HW]J[X7? +2Y=/U?XG^!]
M+\1MI\.H6.F^,O$C:=!)9-?6UF\[21PS.JB2YCC4B,AI9(T)4,67YA\#_L9Q
M?';XD?MQ>!_''@"YT]?B)XHTV'0==OM,:(7!BT2W$-Q!*R_.L5P!\R$@,I'6
MOE[QI\(_VKOVG/V#/C3^TO\ ''X'>*+?QZR^!_ 'A?PU)H<[WIT_1_$&FR7U
MW#"%+M'/<_:)RP&#'$C9P,T ?J?\2_VM_P!F7X-^,[7X=_%/XY^&]!UR]5&M
M]+U+4TCF97.U25)^4$\ G -5_&W[97[*GPX\>6WPP\=_'_PMI7B"[\KR-*O-
M6C64^81Y>><+NR,9(SFOD.Y&C_L_?M ?M1:#^TO^S!XJ^(#?%C7['4/!0TGP
MI<:A;^(]+&EV]LNEFYBC>.S,4\4V?.:-0)-X))-?-]_\ /CCX!\!?M"? ?XF
M^'_B%I5Y\3]2N9=#\$^&OA7;ZZNMV=S:)%:VT>M21O':/!Q'OF=!"8]Z@X&0
M#]BO$'B30/"N@W7BGQ)K%M8Z;8V[3WE]=3".*&)1EG9CP !SFO/_  !^VA^R
ME\4]*US7/AY\?O#.K6OAK39-0UZ:TU)2+&U169YY,](PJL2W3 -<K\8/@YX?
MU7_@GA>? SXV:)XN\2V7_"MX-)\16^@LEQK-YLM4CE>,@HLDY(+<8#-G YQ7
MQKX?\1?&RW\$?&'P)I6I:YX]^&]C^S?X@C'C[QU\+)/#NLZ1<I8S"'3/.EAA
M:\0IECM4JI7J<T ?>7PK_;5_9+^.'BX> _A%^T+X5\1:PUJUS'I^EZM'+))"
MH!9T /S@ C.W..]3>$_VQ/V6?'?Q+F^#G@[X]^%]2\403212:+::JCS^8GWT
M !^9E[@$D5^;_@71+S]K;]ES]C[X-?LA_ [Q-X-\5?#UK/6]?\27WA.?3[3P
M]IR:#>6]Q"MXZ+'=F\FN(5"PM('!WOMVUS?[/'[.WQTU?X)_ O\ 94UK5?B9
M:>,_ /BNTN-6T6V^$]KIMOX?NK=I#/?MKCQ%+J&0DD^7(TDPDPP!S0!^HUC^
MV!^S!JGQ4;X'Z7\=_"\_BY9G@_L"/5D-QYR*6:/'=P 25'(P>*^=_B+_ ,%=
MO"GA;Q9\%?A-X,G^&_B'Q5\7HY[I;RU\?W"Z'9V<1<>=#=BP:6X+LACC7R$#
M.&!*@9KRW]D:+P[\./V=/AW^QS\6OV)?%7B?XI>&OB=%=Z@LWA^XM[.SO$U!
MYF\2_P!K&/[/(J1DS!5D:63/E%/F..?_ ."=WP>^+GA6#]@M?$_PM\1Z:?#7
M@3QC#XC^WZ'<0_V5)+#.(DN=Z#R&<D;0^TMGC- 'VOH_[=7P T'X8Z?\1?C/
M\;_A[H\>I:I=V5G/H_BEKRTG>"4QNJ220PNSJ1AQY>$;(R<9/H.K?&7X=:?\
M'KKX[6?BNQO?"]OH<FK1ZQ:7*R6\UJL9?S%=<@@@=:_+C_@GOX.\;_LG_'#2
M_P!H#]I?X'^,IO"6H>&?$6BZ)=6_@J]U";1+X^(+NXD1[2&)YHUNH9(F68)M
M8)@L!BOT#_9>T72[C]C)-,\"?LXW?PMT^_L]8DT7P'>2AI[2*>YN7C=U'$+3
M[Q/Y.?W7G;/X<4 8?[-'_!3+]FGX]?LAZ'^U_P")/B!HGA30]5D>&ZCU+5E*
MV=P)700%R%W2%5#;5!^]WQFNVU3]M[]D71/ACIOQGU;]HKPG;^%=8U8Z7I>N
M3:Q&MO<WPCDD-LK9YEV12-L^]A#Q7YI>'OAE\=(O@+^RAXOATGQQX=T_X,ZA
MKNF>/HX_AG-J=UH>H3,_D7JZ?<19O(P,KYT*R;=X*YR:T-(_9C^('C+XM^$_
MB]/X/\>^(] \4_MK>&-?FN/$7@>/2X)X['P[?6\^LKID,0:P@>7R$>2X"F22
M$.0N\ @'Z%^(/^"B7[#GA.*&;Q+^U)X-L5N-/AOX1<:PBLUK*6$<V.H1BC88
MC'RFMWP+^V)^RU\3?B!_PJOX??'OPOK'B+[&]VFCZ?JT<DTD* %Y% /SA002
M1G&>:^8O''P+OM5_;\_:4\:S_"2YN;34OV<+'2M%U)M#9H;J4K>F2V@?9M=\
MLNY%);YAD<BO+_A-^SWXE\(?#[_@G/9VGP.UJU7PS;ZY%XRM['0)(IM-BG\%
M:G'(EU\J^09+@QI^]*[I2@SNQ0!]U?#O]LK]E?XM>.Y/AC\-OCWX8UKQ!'Y@
M_LK3]4225O+SOV@??VX.=N<5T7Q<^./PA^ GAN/Q=\9OB+I/AO399Q!#=:M=
M")9),$[%SRQP"< '@5^>_P"QKIWC[X+_ !L^$OP1_9EM/'/BKX=Z;=7%MJGA
MGXM?"=["]^'MAY3X-OJTD2I*P;$>R.27>#]XCFO7?^"H2_$!/VA/@?JMIH^L
MZ/X5T^;6I=5^)GACP3-K^I>'[IX(4A@BMX4D:$3KO4W'E.5V;<KN)(![_=?M
MT?L=V/PZTWXN7O[27A&'PSJ^J2:;INM2:Q&L%Q>(C2/;JQ/^M"(S%/O8'2G#
M]N+]D$_#:/XPM^T=X17PO)JRZ8FN2:Q&MO\ ;&5F6W+$\2%48A3@D*:_(G3(
M[CX7_$C2_$GQG^"OQ(U;P_<?MW6NN:3:^+O"LC:CJUG)X7PNI);A )MSQ-*8
MXP77 1E#@K7;?MPZ;#K?Q6U3]KF7X#>(C\*_$W[1'P[ATWPS?^&I;6ZU^YLH
M;O[5?)83*DAS\H =%:3RL8.1D _1[XG?M^_!/2_V3OB1^U'\!O%VA_$*'X=>
M';S4;S3=+U@*'EA@,H@D<*S0[P.&*'CD UH_"/\ ;$\ ^,_ 'B#XF>/_ !IX
M*T72_#ZV3ZDUGXH:X;2_M%I%<>5?>9#$+>8>9PBE]R[6R"=H^*?VD?!7C']H
M[Q+^U=^TA\!?@WXJT_P9K'[*\?@VWM[SPK=:?=>+/$44]_<"6&QDC6>3R+>:
M.W$C1@N9-J;@F:X#1?V>?CH/!OB_Q7J7P1\3:AH?AWX_>#?$7B+PVVB2B;5]
M)MM$MXY9(8G4?:A#+ABBAB3&1@D8H _2S1OVS_V4O$/PUU'XQ:/^T!X6N/"^
MDW2VVI:TFJIY-M,V-D;Y.0[;AA<9.>,UQ?QM_P""B7P3\&_L@^//VL_@;XGT
M/XA6?@6S66\LM-UH1H9#(B^7)($<Q'#[N4/ KY)_;0\:67QE\9Z3\4/V?OV-
M?$VA^'9OBEX8;QM\:+GX>7DVI11VMCJ?EWMKHDD2SRM:/+%!]H>%L?;-RHWD
MAAY+XC^&OQ6\4_#K]N*VTGX<_%CQ=8^+O 7AUO#MYXK\)3V]UXL:*1UF-O"(
MDP>=@C91(H&6 4@T ?H3XH_X*4?L]O\ LP?$;X\?![QWX=\9:U\._ACJ7B[4
M/">G:XHD;[+8R77DLX5BBLT?E^:$8#.<'I73G]N/]GGP?\)O _Q)^.GQ/\/^
M";CQQX;L]6LM+U35EW#S[>.5D4D NJ;]N_:!].E?G_\ MA^'-;_:K\#6FH_L
MO?LZ>--#A^'?[)_Q#T?QE]N\#W>F27<U_P"'Q;V.A0121*U[*+F,R@1!T!0;
M6+/BII?A;\>/@K^TIX>^-/CG6_&7AWP[KW[,_A;P_HM_HWPC'BAK6ZMH6-[I
M<UN8I)+-Y"\;;BJJQ!5V&T4 ?I%\6?VA?AM\)_V>M>_:6U#Q!:WGAG0_#DVL
M?;K6Y5HKF)(RZ!'&1\YPH/3+"O/?@G_P4;_9F^)O[(G@3]KOQC\3M \+Z/XT
MT2SN?)OM64K:WLL"2360<A3*\3,R,0O\.<"O/?V1?V?O'_@+_@DWK'P8DT'Q
M)'J^J^$?$7]DZ+XF^SK?0_:X[@P6Y2 ".'_6+MB'W 0I/%?/7[/]QJ_P_G_8
M\_:1^)WP:\;ZAX)^'G[/\W@7Q)9-X%U"6\\*>)Q::6IN7L/)^T2(RVUQ;>?%
M&Z@\@E6S0!^DOPW^)_P]^+_A&U\>?"[QGIVOZ/>9^RZEI=TLT,F#@@,.X/4=
M17Q_XK_X+9?!ZS^#WQN^*'@7P_I^L7'P9^*6G^%+K3)=>\G[=:W-YIMH=2+B
M)O*C$E[-A<-N^S')7=\O6?\ !+;P!XQT74?C5\6KSP!J7A/PG\0OBA-K'@;P
M[JUD;2>&S^SQQO<-;'!M_.E5I-C -W8 FOE/]HWX7^.==_9M_;(_9TU#X.>*
M[_6/$G[4&C>*--T^+PI>36^JZ)/J/AH?:(9EB,4Z@07&]$8LBQ.7"@9H _1C
MX<?M=?LQ_%Z+6I_AI\=/#6LIX=A\[76L]40_88N?WDF2-J<'YNGO4WP;_:M_
M9N_:$U*^T;X)?&KP]XFN]-C$E]:Z3J"RR1(3@.5Z[<\;AQGO7P/_ ,%:OV5/
MCE\7?C[XJT']G#X?:E%_:G[/;64TVD:7LM[[R-8MI?L'F8$1D,*R;(F89&1C
M!-=!^R'X%\8?$_\ ;E^%/Q5M?$'Q$U2T^'OP[U>PU:^U;X4P>$;&PCN8[>./
M2I@T*27["2(2IY1,41A+;COQ0!]0?M9?ME:G\!?B?X ^ 'PZ\!Z=K_CCXD37
MO]@P>(/$ TK38(;6+S)I)[GRI6!P0%2.-W8G@8!-:?P:_:+^+5[J/B_0?VJ/
M@;%\/6\(V<-[)XHM=<-]X>U&UD1F,EO>RPP-NCVD2(\:%<J>00:\N_X*5^&/
M WC;Q-X+\+?M'_LH7'CWX4S+=OJOBKP[87=UK7A75%"_9IXH[3]]Y3@R*SQ!
MF5MO!&:^+_B]^RK^TS\0/@'\;/A%^QMK?Q9\0?!5M-\-W^CZ-\2+:Y.HWMU;
M:JEQJ5GIZ:DL<\L+6D8_=S@+(X\L9!- 'Z9>%/VXOV0?''A+Q!X[\)_M%^$[
M[1_"MB;WQ'J$.K)Y>G6PSF:4G&V/@_/T]ZF^&7[9_P"RE\9O$]IX+^%?Q]\,
MZ]JU_%-+8V&G:DKR7"0A3*R#^(*'7)&<;A7YF_M*_"/XD_M):5XX^(7@ZZ^)
M_C1M$_9V\1:'/<7/PA3PO;R_:U@6'2#:^0EQJ$JM&9$\L&.+8<,V_%?3G[:7
MPK\8_"+]C[X,_M5? SX1ZAJGC#X$1Z3J*^%-#TMFOM2TV2SCM+^Q2%%WN^QU
M<)C.Z'IF@#Z27]JOX7ZW\=-)^"O@KXF^"=0O)+_6-.UW39/$C+JEO?6%O:W$
MEO!;+"RS-''=Q//ODC,2RQ$!]Y"VO"7[8'[+GCSXAW/PG\&_'KPOJ7B.S:47
M&D6NJQM,IC_U@QG!*]\$X[U\"_#[]CWX\>!?B#^RR]SX=U1?&7B+P9\6/$7Q
M'\11Z?(T5AXCUVTT^XQ<2@;8F$K&&,.02ML ,[3BOX4\*W'C+_@GGX'_ &&/
M"O[&GBK_ (75X9\(ZAI<FJ7V@W&GVOAG5OL4\4NJ#4G00W/GNW'E2.S^=E@,
M4 ?H!\._VQ/V6OBWXYN/AI\,_CWX8UO7K5)7FTK3]4228+&<2$ 'Y@O?;G'>
MF_#W]LK]E;XL>/)/AC\-OCYX8UK7X_,']E:?JB23-Y>=^T?Q[<'.W.*_-_X!
M?!7XB_$"Y_9I^%6I#XI7%_\ "G7%U#7-!C^$MKX>A\,PP:;<P74$NIM$HOHK
MCS3!Y5O(QF:19&9=F:[K]C73O'GP7^-OPD^"/[,MIXY\4_#O3;JXMM4\,?%K
MX3O87OP]T_RGPT&K21*DK!L1[(Y)=X/WB.: /OCXS_M,_L__ +.O]F_\+S^+
MV@^%3K G.DKK6H+"UYY(0R^6#RY42)D#)^85!X;_ &KOV;/&.A^'?$GA;XV^
M'+^Q\7:TVD>&;FVU-&74;]4=VM8^>90L;L4Z@*>*^5?^"HOC+P+\/?\ @H!^
MQ]XV^(OP\U+Q%INFZSXQE:/2M%DU&>QD_LVU"W8MXE:23RR>=BLRAMP!*UX1
MK/PT^)UK^T5>?MZ:#\$/%VG?"JX_:HT7Q-8Z'#X8N?[133X/#KZ9>ZS_ &:B
M&=%GNW5BOEB5EBWL@)H _2;Q5^U!^SQX&M?%5[XQ^,OA[3(? [6R^,);S4DC
M71S<%1 +@D_N]Y=-N>NX5R-S_P %&_V%;33+;6+C]JCP:MO>321VTC:LOSLA
M4/QUP"P^8\<]:_/_ /:(\,?$']I3X1?MO:_X?^ ?CC^R_&VL>#8_#-KJ?A&[
M@GURTBN+ 2RPP/&)&7:KEE*AE"G<%Q7M'[</PZ\)?#G]H8?&3X7Z[\2O ?CZ
M;X5V>C?:M#^%<GB3PYXFLX9KAX--FAABE\J5))'#;Q$I25/F;'R@'VUI_P :
M_A)JWBS2? FE_$72+C6->T1M8T73H+U6EO=/! -S& ?GC!91N''(KG=?_;&_
M99\+^"9?B/X@^/7AFUT.'7+G1I-2DU1/+_M"W=TGM1W,L;1N&4 E2ISTKXY\
M,>*_C)\+OV@?V=_VL/VE?V?M6\/6K_ _4=!\2Z;X&\)W%]%HNJ27$<L4!M;)
M)'A5XU&,+L1B5)&,U\^_";2OCOIMU\-?%/CCX0>./ASX>F^+'Q2U:\\<6_PW
MN=7UWP_->:F#:6R6J1R&WCNX2Y^U"-QB,*&4.20#]/KO]N']D*Q\!Z3\3[O]
MHWPC'X?UR]FL]'U:36(Q#=W$2EY(4.>9%4$E>H':O,OVC_\ @K1^R;\"OACX
M+^+.@_$K0O$^C^,/B=I?A!;W3]74161N+A([FYD(5CBWC;S&3 )^4< Y'P=^
MRM\"OB7K_P ?/"!\6_!3XA7&CV?[8.I>((KCQQX7E61K*704$6HS?NQ$BR2+
MG/ 5B%;#@BO0/VEOA1\2?#/QZ^*/Q#T[X1^)G\-:+^V!\,?%]TVD>&KFX\[3
M;6&R^W7MO%#&S7(C()D\I7;*MP2#0!]O?MV_MW?#/]A?]G1/VA_%PAU"QNM2
ML;/3;?[8(1<FYE50X<J<!48R'@G"UT7CS]MC]DSX7VNE7GQ#_:"\+Z/'KEFM
MWI1OM26/[1;M]V4 \A#_ 'C@5Y+_ ,%<M!\3?%/_ ()_ZE>?#OPCJ^L2C5M#
MU?\ L[3]+FDO#:Q7L$\A%N%\TNL8),87?QC&>*\KT7QYX:^"/[7OQL^-/QU^
M GC3Q9X=^+/A_2KGP%J>G_#Z]U)KVQCL_*DT>2%86>T?S-QVSK&A\S)(YH ^
MXO$_Q)\(>%OAO??%>]URV;0['1Y-2DU".8-"UNL9D\P,,@J5Y!'&*^0_ W_!
M;'X(^-OA[\$?BL+#2;#0/BQKFK:=K5_>^(-J^&VLXW==_P"ZQ,[A5^7*XW\%
MJ[[_ ()E_ [XP_ W_@EQ\/\ X(_&339K?Q9IW@RZBNM*FN!+)8+-+<2V]D6R
M03!#)%!P2!Y6 2,5\E_LU?"[Q)XJ\,?L1^!O%'P5\3&Z^%_CKQ-#XOM]:\(W
M<46E7/E7!BE9I8@A0[QLE!*,2-K$T ?>C_MC?!GQ5X=\'^,?A#\7? FM:3XH
M\>0^&5OKSQ,T"S7#132-;6OEPR>?>_NLK;OY890[%UV@-?L_VS?V5;_XI'X)
MV?Q]\+R>*Q>-:?V&FJ)Y_P!H'6''3>/[N<^U? 'Q$^"7Q3M_VTM8N=#^$7B$
M:&?^"@'@WQ!#)9Z#/]F-E_PA3Q76H*RIM\D3X22;.P2?*S!N*OZ5I'C;X%_&
MZP\'_L?:1X^URUU3XQ37VO?"?XG?"=Y+'2EN+QWO-4M-8:,Q1*"SRQD3.Q#!
M<#H #[;_ &W/VN]$_8S^$FF_$'4/"TFM:CXB\8:3X6\-:7]MCM8KC4]1N!!;
MB>XD^2W@!)9Y6SM53@,2%.?\+/C_ /M22_%G3OAO^T#^S%INEZ7K6E7%YI_C
M?P'XJEUK2+9H@&,%Y)-:6KV[LI.P[&1B" V:H_\ !2&SU#4_@'9Z+JG[+UG\
M7O!=]XGLX/B1X3DMS->1Z&V_S;VRB#+YMQ!((9 @(8H'V_,%!^-O!WPFUOX<
M?&:&?_@F%IOQ>U7P3<>$=<_X6%X(^)=MJUOH9_T)_L=O:C5$CF6=I]JA8<IM
M+98<4 ???@?]M#]E'XE_$7_A4?@#X_\ A?5O$W[P)HUEJB/-(8_O[1_'MP<[
M<XQ7G_[-'_!2+X/_ !5_8A\ ?MG?'?5]$^&MGXZLWDATW4]<$J12K/+'Y22E
M$,IQ%NX08STXS7Y__##PQ\3[SXG_ +(%W9Z-\6+ZY\+?$16\7Z'_ ,*PN-'T
M/P2DNF7D+6RY@#2(9'V><KR1X&7?+#-/X _ 3]I/X6?!O]B_XT^*+3QIX1T'
MP7\./$VD:X]I\-&UR]\-ZK=7P>">;3)(VE DA22/S5C+ID= Y- 'ZGZ]^V-^
MRUX9^&VG?&#7/CWX7M_#&KS&+2]:;5$,-U(.J(03N8=P!D=ZZWX:_%#X=_&/
MP=:_$'X5^,].U_1+W<+75-+N5EAD*L58!AW# @CJ".:_+SP5^S9H_A[P]'\>
M/&^O_'?PAJUU\4]8USP/XXTOX;QSK8^?;Q13RS:-:0N]K!<E RQM$SY#%BF[
M%?:/_!,+Q+\<_%O[.FJ7OQW\"6>C72^.-7AT'4+7PJ-#D\0:6)1Y.JSV. ;:
M:<F1F5@&. Q +8H KZ7^VM\=OCMXY\6Z+^QG^SSH?BKP_P""-<FT76/%GB[Q
MH^D6U[J4('GVMDL5I<M,T9(5G<1H&XW'!QH?"K_@I;^SMXD^%]_XX^-_B*U^
M%^J:#XUE\'^*- \7ZA%')I^NQPM/]C60$I-OA0S1LA(>/D=Q7DO['_C:[_X)
MR67C[]G7X_?#;QD]G/\ $?6O$?@[Q3X9\(7NL6NM6>HW+70B)LXI&AGC=VC8
M2A5("D-UQX3XY_94^,?Q$^(O@[]ICX@_ [6+6+XG?MV>%_%:^$YM--Q-HVA:
M?HU[:V]Y?I&'6 L\22.6.U#)&K'/% 'WUXT_;P_9&\"^$M)\8Z]^T#X6M[7Q
M#8R77AUKC5%3^T40E2R=]NX;=Q& :X[X%?\ !2_X!^.OV5_!?[3/QO\ &'A_
MX?1>-8IGTW3=0UU9@_ERLG[M]B&084-D( ,UY!\6K6W_ &=OV]?BU\4OC3\#
M?$7BSPS\1/A;INE>";WP_P"$9]6CBE@:Z^U:6Z6\;FW,S31R;W"QMSN8;:^2
M/V3O@K^T1\"M9^#?QV\8VGCGX=^&6^"<V@:;)9_"5O$-QX=O1JEQ-+93V)BD
MFMC+$\6)5CPVS:Q  H _5/QG^V[^R+\/-)\.Z[XU_:*\)Z?9^+K&2\\,7$^K
MQ[=4@C,8DD@P3YBJ98P<9QN&:[+Q?\5_AKX \!-\4?&WC?3=*\.I;QSMK%]=
M+'!Y;XV'<?[V1CN<U^9_[#G[)_C;P=^U?^SWXN\3?"OQC_8GVGXK:_9MXL\/
MPPC1DU*ZLWMU:&V3R=.6?]]-%:D[HQ*4Y*D#Z=_X*ZV?Q G^"'@BU\#?#^;4
MM/@^)>ES>(-8T_PR^L77AJSC$A_M&WL8P3/)&^U0-K[-V[82HP >T>#_ -LC
M]E?Q_P##WQ%\6/!OQZ\,ZAX<\(P--XHUBWU)/)TJ-4,A><G'EKL!;+8& 3VK
M&;_@H5^Q$GA7_A.#^U!X/_LG[9]D6^&K(8WFV[MB_P!X[>>,C%?G ?AW\4O%
MGBG]N271/"_Q8\4:7XU_9CTNU\.>(_&'@ZXM9?%-Y"-7CD6V@$*$,IF2-864
M38^;;M92?1_C%\#OBQ\&_P!HCX"_'33KGQ%X3\&:/\"8/#JZEX=^&*^(I-"U
M+RX2T<MB(GDB,B KYJQD@@JV : /TF\"^/?!?Q.\*6?CGX>>*+'6M'U&'S;'
M4M-N%EAG3U5E.#7F-A^VW\!_#WA>Y\4?&#XU_#_1;?\ X3'4] T^XT_Q0;B&
M:>S9M\#-+%$5ND52985#!"" []:\]_X)(?";Q+\*_P!G7Q!<Z_8^*+.'Q1\1
MM:U[2[/Q9IMO83QV]S<;@Z6=NH6RBD;=,MN?F02X// ^4?A;^SY\0M4\<_"F
M/Q?\%M<FL]/_ &WO'>MW2W_AV8QP6<GVDV]Z^Y,+"Y*E)3\C9&">* /T.T/]
MKW]E_P 2?"F^^..A_'?PS<>$=-N#!J'B"/5$^S6TH('ENQ/RODCY3R<CBJ^G
M?MH?LHZM\,KKXRZ?^T#X7D\+V-T+6\UH:J@AAG(!$39.0Y!!"XR0>*_/KX\_
M ?XK:;^V1X[^+D?P2\0:Q\._"O[4'A7Q;XFT'3]!DD75;!?#AMGO[>';B]^S
MW<D,KI&'8F(X!9 *Z;X\3^'?B5^UMX+_ &S_ (=_L7^+V^'/A/Q_:W/CW7&\
M+W45WXDE.F75O;ZBNDRQ+<R+8O)&I<Q;V\S*J1&#0!]KS?MR?L@6_P ,XOC)
M<?M'>$8_"\^K+I<6N2:Q&MNUZRLRV^XGB0JCD*>3M-9^M_\ !0_]A[PW;:?=
M>(/VH_!UFNK:2FIZ:L^K*K7-F\\UNMPB_>,9EMYTW8QNB8=J_/?XW_!'QQ^T
M+^U--^T/X$^ ?B:W^&?B3]HOX>2V>FZAX5N+5[Z33X+S[9J\EF\8DAAW-$IE
ME1,[03U%>R?'+XH?![X(?\%S+KQ+\2/@]K.MP/\ LG64%C?>'O",^K-8N_B+
M4R\9AMHWD03\KY@7;D88@,30!]C>.?VM_P!F3X:>"])^(GCOXY^&M-T/7HQ)
MHNI7&J)Y5\I&=T1!.\8[CI6=XO\ VX_V0? /A_PYXK\8_M&^$M/TWQ?;7%QX
M7O)]8CV:K% 8A,T&#^\$9FBW8R5WC-?GA^Q1\(?BA^Q;\=/#'[1/[4'P/\52
M>!=<\.>(8O".GZ;X:N-6F\$_:]7DNH;26TM4EDA,MNRC*(50_(2*F_9+_9A^
M*-O^WG\"OBUXM^ NMZ/X.U#XE_&;Q7X5TC4M%?9X6TW4;?2DL$N%"E+)YRMS
M*D3%2#*P W*0 #]"?''[<?[(7PTUBQT#Q]^T5X5TF\U.U@N;*WO-41&DAF ,
M3_[*N"""<9KDOAC_ ,%$_@I\3_VU_B!^Q;I6KV,>J>!?#NFZF;]M0!%]]H6=
MIT5-ORB!8XRS%N?-Z #)^#/VW/"_Q<U[4?VJ_"5]X&^(FAZEKT;0>#_!WPY^
M'4MQ#XSMETY$BNY]3\IX\JP9/)WQE1'A5);)T[#X/_M#^,_#?[07PA\)>$O%
MFC^+_C!^R'X9TOP#JEWH=W##/J%KI6H17%M+=&/9:3!Y$CVRLCYE! .#@ _1
MGX6_MA_LM_&WQ+=>#OA+\>O#'B#5+&)Y;FRTW5$DD6-#AG S\R@]2,@5Y;\2
M?^"H_P"SYHOQJ^&OP1^#WC'P[XVU3QS\0&\-ZK#IOB!1)HZBRNK@W&U4;SL-
M;>65!4#?G=Q@_#UK\ /C3^T=X<^%/PS^%^O?$RW\0>!?!NH6\-K>?"2V\*VO
MA1CI,EJ;&>\,*_;4=V$86W9U8@2%ABNMT*?3?%.M_L2_!_PO^R/XVTKQ/\+O
M'*Q>-M1N/ 5U!:^'E31KV&8->&(1RQSS;6$D;.A(7<06 (!]O?MH_MJ^'?V,
M[WX8S>,-)LFTGQ]\1(?#6HZMJ&J_98](B>TN;@W1^1O,Q]GV[,KG?G=Q@]5X
M:_:]_9?\7_#34_C%X;^/'AF\\+Z+,8M7UR/5$^SV<@Q\DC$C8W(X/)SQ7BW_
M  4T^%NI?%+XE_LPV\/@"ZU_3]'_ &AM/U'6%ATQ[F&S@CTZ_P 7$^%*QQJY
M0;WPH)49R17R+^W=^S#^T%XJ_:@^*WC#X9^!?$5OX7TOXJ>"/$FM+I/A87BZ
MC;064R37,%M*HBOWAD:-VB&XG;T) % 'Z2>$OVN_V8O'GPTU[XQ^#_CIX;U#
MPOX7MY)_$FMV^I(8-,BCC,CO.?\ EFH0%LM@8&:P3_P4*_8B'A1O'!_:?\'_
M -DB\%I]N75T,;3%=P1?[QV\\9&*^#?%'P>^)'Q;\+_M;_'#P[+\1O%T?B3]
MF>3PK#J&J?#=/#L/B/4$2]EBBM]+6%+F>X@24Q>>Z@,)UC0-LS6S\8/@7\6/
M@[\>?V>_CEIDWB+PGX-T+X$P^'6U#P[\,1XBDT'4O)MR4EL?+>2,NBLGFK&2
MI!5L F@#[QC_ &FOA[K_ (T^'VD>!/B)X+U+2_'MGJESIL[>)&6\OTM(8Y&:
MPA2)TN@F_,Q:2/REVD!R2!0^'G[>?[&?Q9\4:7X*^&O[2_@_6]4UN(2:/9:=
MK$<C7BXS^[P<.<=@<^U? W[)'[.?Q5\%?M7_ +/OCQ_ WCQM#U#Q=\6M;DN/
M$7AV.S73H;^QLA S6]L@CTZ.XD222*WD(8%V'4$";X*?LZ^-_!__  2D_9 \
M.:9\$-8T[Q)H/Q4T74-:L8_#LT=]I^[4;@W$\Z;!)$-C?,[@?*1DXQ0!]P?M
MP_MF:-^Q3X<\ ^+_ !-HEG<:7XP^*&F>%-2O[[5/LD6DP745Q(]ZS;&#^6+?
M[AVYW?>&.=WPU^VQ^R5XQT.W\3>&?VA?"MY877B"#0[>YBU5-K:E-_J;7GD2
M/_"IQN[9KP?_ (+1>';S6?AC\$]9/P7UOQYIGA[]H[PUK'B#0]!T1]0F6PMX
MKUI;AH5!W)'E6(/!("]6 /BWQC_9RU7]N[XM_M!_''X3>!];\+>$;KX1Z'8>
M&]6U[0;C1Y-8\6:7>W.H0Z@EM<)'-MMT,4/FR(I;<5&57- 'Z*6OQ/\ A[??
M$2Z^$EGXQT^3Q/8Z;'J%YH:W -S#:R,529DZA&96 /<@URNH_M??LQ:3\8Y/
MV>]1^.?AN+QQ#>06DWA=M27[9%--"D\2-'U4O%(CKG&0P(KYS_X(T7WC[]H'
MX>>*/^"@WQC\-RZ9XF^+5];QVME<8+6FF6$0MXXU(XVM*LTG']ZHOA'\!_&N
MI_MO_MS>*=.\&W6E:CXPA\(6?A'Q->Z8R1W9A\+H@:WF90)%BN&8,4)VN,'!
M% 'T/I'[;?[)&O\ C+4/A[HG[0_A6[UK2XYWO]-M]61I8A"I:7@=2@!) R1B
MO'?V,O\ @JQ\,OVJ? GC[X[^(M3\%^$_AWX1\0W&EV.KW'C!I;UQ%=S6PFNX
M&MHXK993$'B5)IF=6Y"D<_&7[,'P"^,NH_#C]GS]FGQ-=_$R/Q1\.O&5E>:Y
MH,'PGMM*M]!FMC(;FZ?6WAVW<,V6SY3O),)!NP0:N:[^S9^TA>_L%_!?7M/\
M)^*--L?A[^UIXD\3^-M(A\(_;KZ/3'U76EMM073KA1]M2*6XMYQ'M8LA$B!B
MBY /TAC_ &XOV0I?AA-\:$_:,\)KX5MM2CT^XUV35D6WANI#B.%F)^5V/13@
MGM3=<_;F_9!\,^!M)^)>O_M$^%[30M=DDCT?4IM254O&C.'$8ZMM/7 P*_-'
MXQ_L[_$;XV:WXL^,5AHOQ%\;:7X@^(OP_M;W4-8^'"Z';ZQ]CU)I9+I-,2!9
MP(4;:]Q,J@@@8PN:]W_;1^&GQ<^&'_!3C2_VE(_%'B3PYX(O/A*-!T;Q#X7^
M%Z^*%TN_6]DEN+9[5(Y)(//1XV$R)AMA5B !0!]>^,/VU?V2_ &C:'XA\9?M
M#>$]/L?$VFRZAX=N9]8CVZE:QE!)+#@GS%4R(#MS@L,U9O/VOOV7[#X36OQV
MN_COX93P??3>39^(#JB?9IY,D>6K9^9L@_*.1CI7Y\?L-?LG^-/!O[6'[/OB
MSQ3\*?%YT59/BCK]G)XM\/PQ?V(-1N[62W!AMT\G3A-^]FBMB=\8D*YRI SO
MAY\)OB/\&?VH]*^/_P 0/@IXHN_AGX/^/?CB2ZTZQ\+W-RVG-?1V_P!DU6*S
MCC,D\64F3?$CE3)D=2: /T1U3]L[]E/1?A;8_&O5/V@/"T/A74[IK;3]<;5D
M\BXF4D-$A!R7!!RN,C'(%=E\.?B;\/OB]X2M?'GPP\8Z?KVC7@/V74M+NEFB
MDP<$ CN#U'45^7_QC\%^+=;_ &PO ?[:7P@^!GC+X4_#&SU_Q=%=:U9_#LZU
M>76KWD&FA/$4FBO&TULEPMO/;!A%YJ^2)"JB8U]4_P#!)SX6>)O W@SXD>-]
M9C\6)9^-/B'<:MIO_"6:';Z2]PIC1'NH;"%%^QQRLN[RW&\D%B!G% 'L?CC]
MM7]DSX:_$$?"GQ]^T)X6TGQ$;B.!M)O=51)4EDQL1NRLVY< D'D>M.^*_P"V
MC^RA\"_$\_@KXO\ Q_\ #'AW5[6SANKC3-2U-8YXX)2PCE*=0C%&PV,?*:_*
MO]M'PE\;_&'[/G[4'@;4/ 'Q,TOQAKWC;6[C1_A7X!^&\[Z?K,'FJ8-7FU/R
MG6[+Q()F191("HC2,$ 5]C?"/X2ZGXB_X*._$'XI>*_A??36FH?LU>'=/L]9
MU30Y/+EF+W+36RO(F/,PPWQYW#/S"@#Z3^('[87[+WPK\/Z)XJ^(?QW\,Z3I
M_B6'SO#]U=:H@34(\ [XL$[UP1\PXYZUB?L)?M:0?MK? 3_A>=GX6M])MW\6
M:[I%K!:ZE]LCFBT_4[BR2X638F1*L DP!A=^,MC)_/\ _P"">?AGQC^R1XL\
M$_&K]J+X'>-+SPSJWP(A\,>'Y+?P5>:C/X?O+?5+V2XL);2*)YH!<Q30,KE
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MB&/S-#N;S5$"WR8!WQ8)W+@CYAP,]:Y_]A+]K6W_ &UO@-+\<;+PQ;Z3;_\
M"9>(-%M8;74_MD=Q%IVJ7-BERLFQ,B58!+M (7?C+8W'X1_8F^$?BG]@[XM^
M%_BO^TC\(_B%J_@_6O@W_8WAF:Z\+MK-]X<N?[3N[F73YK;3XG^SB>*>';A-
M@$>QF&W-?27_  1-\)^)/ O[ 7]E:E\'-5\#S/\ $;QI>:;X/US3VLY]/M9O
M$%_+;0E".%$31A67*E<%2002 >X7/[:G[)MG\48_@I=?M!^%H_%4U\+*/0VU
M1/.:Y/2$#IYG^SG/M7(_L5?\%!_A%^VUXO\ BMX.^'ES;)=?#'XA77AQXX[W
MS7O[>&"V<7X 4>7&\LLT:KDG]QDD9P/S+^+WA;XWZU\ 8-#NO 7Q2L_%]E\?
M--UC4?A?X2^&=S!H^BV\?B"&5]1:\\EOMV8QOWQRN^7)*JJG'WK_ ,$QK37O
M /QC_:>^&?C?P?KVEZGJ?[0FJ^*M+FO]#N([.^TF[TW2D@N(;ID\F7<\4JE%
M<NIC;<HXR ?7M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM&_'30/VBM0\+?#'XLZYK?A[Q)8> ['4M7AU@Z6LUG<QSM),C2#98M=,J!I
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MFDE:Q]&8QTHQCI117S9L% &.!110 4444 %&,\T44 %%%% !@8Q01G@T44
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MBB@ QCI1CO110 4$9X-%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@
MO[$'_(U_'K_LNU__ .FC2:]ZKP7]B#_D:_CU_P!EVO\ _P!-&DU[U0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7@OP$_Y/>^//\ UT\._P#IKBKWJO!?@)_R>]\>?^NGAW_TUQ4
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M[^4/84]M?O9].ZW_ ,$Y_P!I[Q)\2%^,&O\ QQ^"MWXH25)5URX_9]W7&]0
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M 7SY;6ZD*G$3'5OE4%00.<&NY^+7[ ?[6WQXFL[CXR?M"_!WQ))I^?L4FK_
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M\5^&/VROC'^Q_P"*]?OM6L]#33_%?A6\U"[>>:"PU$.'M2[DL5CGCD"Y)PI
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M  #ATFZU76-<\4RVTFK17FCPZB88(TA?$RAI%^8A,!"6!8@ 'V117P_\5?\
M@K9XATS1M'\3?#3P+X0T_3=4^'MCXIM[KXA>*)+-]2^TP^;]CLXK:*:221!\
MK.RJ@8@9-7/A+_P5,^)'[74_AG0_V-?@9I>K:E=?"/2_'WC!O%FO/9V^DP:B
M\Z6FGQM%'(TMS(UK<GD! J*21N% 'VI17P9H?_!9C6-7_9\^&_C#5_A+X?\
M#GC[XF^--9T'3_#_ (F\6I:Z9I/]G7$L<\]W>,HP%$7(122QPN>M2Z1_P63N
MM>U*7]G_ ,,_#?PWX@^,\GQ-L?!NE:-X=\6+=Z%>-=:?+J2ZD+Y%+"U2TMYV
M<;/,5X]FW)% 'W=17QC^PI\3_P!I7QE_P45_:"\'_M$V/]E3:%X;\+#3]#TW
MQ!/>Z2HD%Z6NK02!?+$F K916)BYS@5R'[>_BGXF_#_]L*Z\5?M*?#OXR>(O
M@.WA*S3PU/\ !K6+^V_LG4P\ANY=0CTR:*ZE+ Q>7AF0*IRN3F@#[]HK\]_
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M%X7\6+J>CZQHUY=_8GE22,^7)@-'<1LRB2-EVG&6! /LZBO!?^"@G[6_C_\
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MN@1>M?4G[+7[5GP3_;+^%?\ PNG]G_Q)-JWATZS?:6M[-8R6Y>XL[A[>8!9
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M?2M.6TAT_;+HT=IHO]F,Q<N1,7_U@^5=O3GK2:__ ,%#_@9\//B!XHLOB?\
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M.-%\ >%M9URPO/%%G)=^$;CQ%X:NM/M_$$"+O9[&6=%6Y&SY_D)RO/2H;/\
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MGA+XO^*=<_8ZTWX^WEM9KK5Y\,X?$$T,<+"W%T^GBY*A=V[R]YQC=G'&<\T
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M?'*MY+9O]L=WNI3YQ^RX? "-E=JIM.[0_;=_X)X']LCXEZ5XWN_B<-%L]/\
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MT:SSYEXT2%A&N 3SCL#Q7S+^S1^UO^UQ\=M&\#?%GX<?&'X(_$[1?$=]9_\
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M#3XM2NDM;.=K:1!(89)7P) "H"L2?E- 'EOC[_@D=XLUOXS:M\??"7QNT/\
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M %%%% !1110 4444 %>"_ 3_ )/>^//_ %T\._\ IKBKWJO!?@)_R>]\>?\
MKIX=_P#37%0![U1110 4444 %%%% !1110 5YE^U]I?[0FK? ;5H?V8/["F\
M712V\UMIOB2V62SU2W29&N+*3<"$\Z$21A\':S X.*]-HH _..X_8BN?BE^T
MI\/_ (J_LY?L):Y^SOK6EZZ]U\0O%IU*PM;?4;!H)$DLH[>PN95NR[NI#R)%
MMVYQGBNR_9"\$?M?? +X!_#O]A74?V.K+4)O!WB:&WU/XB:W?6DF@'2HKIY?
M[3ME64W1OS'@HC1*$F;<9"!S]U9K-\9^,/#GP^\(:IX[\8:I'8Z3HNGS7VI7
MLWW8+>)"\CGV"J3^% 'YRWW[+W[8>@_L3^.O^"8>G?LTW6I2>)_&FJ/I?Q47
M5[-=(&F7^JM?&\N TOVD74:2%-BQ,&9%(<"N'^#VE_M%^(O@S^V9^Q3\(?V7
M[KQ5<>-OB-XE\+:7XV;4K2'3+:6ZL([*2?41)()@(@WF#RHY2X 7Y3S7ZC^#
M_B3X,\=?#32_B_X;UE9O#VL:'!K%CJ,B&-7LY85F24A@"H,;!L$ CO7!?LC_
M !=_9L^.'A;6OB9^S'X1DLM'UK7);S4-:7P;/I,.O7;@;[Y))88Q>[\ &X4N
M&VXW'% 'P+IG_!-_]I#]E_Q+\5/ .C>%_BUX^TOQ[INDCP_JW@7XB6^E6%Q)
M!HMMILL&KQ32+(J;K<N)(A*3')MV@C)_0#]G_P" <WPN_8]\.?LX3;=+DTWP
M6NCR?8;Z6X%HQ@*'RY927?86X9CDX%>J8YYKR;QY^V]^S5\-_"7C[QOXJ^(/
MEZ;\,M8L]*\:36VGSSMI]W<O D,6V-"SDM<0YV@A=W.,' !\4:/^RU^V/XL_
M8&^%_P#P2RUW]F:XT2X\#ZQH-EKGQ275K-M$DTW2;Z*<7]HJRFZ:YGC@7]V\
M2;9)&RY R?J3_@FK\%_B=\$/AS\1-&^*?A271[K6OC/XBUK3(9IXY//L;F9&
MAF'ELP 8 \'##N!7T5%(DL:RQGY67*UEW/C"PM_&=OX&?2M6:YN;%[M+R/1Y
MVLD56VE'N0GE)(3R(RP8CD CF@#X=_X*-_L-_'GXW_MV?#/Q7\)?!_V[X??$
M#2]/\/\ QXO%NXHEL].T76[?6K%F1F#2^=NO[0[ Q F&<+S4GQ)_87^.&N_\
M%>M#^*>C>%-WP=U)[7Q?XHU#[5%L7Q%I]M+:VT9B+;R768-N"D#RAD@XK[T!
MS7*Z_P#&GX;>&?BOX?\ @EK/B6.'Q-XGLKN[T72_+8O<0VP!F?(&%"[AU(SG
MB@#X2USX!?MA?"7]FO\ :$_84\'_ ++EUXRD^+6N>*&\(_$!=8LH])2VUWS<
MRZGYL@N$DMO/;*QQ2[Q$H!&>,:;_ ()T_M%>$_V6?VOO@7I7@B\U6]\;>'?"
M^C>!]22\@27Q"MAX=L;&692TG[L^;#)_K"ISDC(Y/W]\!_CU\,?VE?AK:_%O
MX/:])J6@WMS<06]Y+9RV[-)#,T,@V2JK##HPY'.,CBMSPCXPL?&5K>75AI6K
M6JV.J3V,BZMH\]FTCQ/M:2-9D4R0L>4E7*..5)'- 'Q__P $T_V5/C#_ ,$\
M?'>L?LV6/@N\O_A#KVBP^)='\47>H0R3Z%K#(JW^G7;,_FS!GS+'( P W*6&
M%JC_ ,$SOBUHW@RU\1>.-8\/ZLUA^T[^TCXN\0_#FYM88C"=,2W2.VNI0TBN
ML=S;Z6]TC(C@K,I.-V:^VM;T71O$VC7GASQ%I5M?Z?J%K);7UC>0K)#<0NI5
MXW1@0RLI*E2"""0:\"\<_MJ?L6_"7QM<>!CH^H:A??#6,66H7/@_X=WVJ6OA
M)6@0F"6XL[>2.Q_<%"49DPA7(QB@"#_@I+\%OB?\;?"'PJT[X7>$Y=6F\/\
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MZXTW48;$2R (\3W9*K,8PPBP&Y!K],** /S9^(7[(7[7'[77BS]I_P 7:O\
M!&\\!Q>/_#?A4?#^T\1:K:N^H2:;+/*]O="VDD6$LQ"E064*ZD,WS 4_VK_A
M9^VQ^V%\0I=<L?V(=<\*V.F?LL_$#PDD^K:UIC2WFNZE8V\=O:Q"*X;]P[QD
M1R,5YW;P@P3^A?Q?^,WPP^ ?@*\^)OQ>\96>A:'8[?M%]>R;5W,<*BCJ[L>
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M<#\7/V6/V9/C]JMCKOQT_9X\$^,K[2UQIMYXI\*VFH2VHSG$;3QL4YYX(YH
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MI_PZ\<:M-XFT[1[BW2ZAM[[2)[-)U%Q+&CHDKJ7 ;<%)(#$8KZ<HH _*.?\
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M?>';K0/B9#IOA>]M=47:\6KQ%UN(@@=ED\E)"Z+\I4D8_5*B@#X<MO@-\?\
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MO0/".AW:_<OKC0;"2&_F3^\J7=U+:[O[UFX[5]8'/:LSP=X+\'_#SPW:^#O
M7A73M$TFR5EL]+TFR2WMX 6+$)'& JY8DG ZDF@#Y)OO"/[2'[)_[97Q>^-/
M@C]FC5OBEH?Q6T_3;C29M!U.RAGTV^M;<P&UNA=RQ[;9N&#Q^81EOD->>?\
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MC;7=-T^_\33:NTUPMG:O%J2K*[D,[ G:N%;R\!:_5OPO\)_ACX*TG6-!\(^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>[^%MOJ !MSJO]N[=7D@#<&Z6V.GYV_,L3G'!:L[_@I+^T-\#/V6KKQYXQ^
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M\5:MI4VI:;HC;O.N+2%@DDR\8VJS 'GO7YO:1\4_B]\1(_A-^S3\$M7^(WB
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MLR:YX^\3Z;/XHU+QI\1_"-GX'U'3[Z<J]E8V;ZX9H7C1@L*K;+<N\>&7<2*
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MI%+)E@9$R3M%>C_ /X-R?!/_ (+.ZIX97XW>*/&%O+\!XI88O%VM/J-YI_\
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M^R[^SS\0;+X4?%WXJQ:9XEU#1FU:ST2'2[N[N9+$2^2;C9;12$1B3Y-QP-Q
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MYTR?6$M)=)^RW.N)+ Q@=HHG-LMTUR(UQEB* /U]R,9H!!Z5^?O[/6N?%O\
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M%!=(O)M\+P2V* /T-HH' XHH **** "BBB@ HHHH \%_8@_Y&OX]?]EVO_\
MTT:37O5>"_L0?\C7\>O^R[7_ /Z:-)KWJ@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!?@)_R>]\
M>?\ KIX=_P#37%7O5>"_ 3_D][X\_P#73P[_ .FN*@#WJBBB@ HHHH #S111
M0 4444 %8WQ!^'G@7XL>"]2^'/Q,\(Z?KV@ZQ:M;:II&J6JS6]U"PP4=&!!%
M;-<3^T/^T)\,_P!E[X4:A\9/BSJ5Q;Z3I[PPB.RM6GN+NXFE6*"VAB7F2625
MTC11U9ATZT <?\+O^"?_ .RE\'?&6F^/_!GPZOYM6T2)D\/W'B/QAJNLIHZL
MNTBRBU"ZFCL\K\O[E4^7CIQ7-_LM?L:^(_A[^U)\5/VVOC9;^%C\0/B5;Z9I
M*Q^%1+);Z?I&GQ%(8S--'')++(YWR,4 Q'"@R(\G#A_X*Y_LVZ)XP\4> OC)
MX&\?_#G5/!_@T>)]>M_&WA^*(0V#2B*+8UM/,LTDCD*J1ECDA3M;BNQ^#G[?
MWPP^*WQ#C^$NO_#;QQX#\27WA>;Q'X=T?QYHT-K)KNEPLBS7%HT,\R,8S+%O
MA=DF02H6C .0 =)+^Q=^S+/\)]>^!LOPOA;PKXG\27&O:[I/]I76VZU&>Y%U
M+.7\WS%+3*'VJP48P !Q61J7_!/3]D'5?BU'\;[SX2M_PD4?BBQ\2+<1>(M1
MCMO[7LXC#;WQM$N!;F=8SL+F/+K@/NP,>>_!3_@KO^SQ\<;+P%XHT?X8_$C1
M?"GQ+U#^SO"'C;Q%X=@M],N[[YQ]E++<O*C;HW4.T8B9E(60UI:=_P %5_V<
M-3UFUO(O#'C2/P-?>,$\+6?Q9FT.-?#<NJO<?9HX//\ .\]4:X(A%PT(@,C
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M5/!G_!.[]CKP'IWAC1]#^#RS6?@S2=3TKPS9ZSKVH:E%I]AJ$445U:*MW<2
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M ,5,=-,FJC5;R'S#82M-9EHXIEC8Q.[$$J2<D'(XK>O?V7O@1J.L_$+Q#>>
M(WO/BMIL.G^/YOMUP/[6MHK0VD<; 28BQ Q3,00G.22>:\F_X*G_ +6OC?\
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M\-_VE[/]I'XN^%O!UFVB^ K[PKIOA[0_$6L:_'=V]X\)F,\^L$ND"I (X[-
M84$LG7=7M?PU_P"";G[%WPDU3^UO WP9$,D6DW.EZ;#?>(-1O8-(LKA-DUO8
M0W-Q)'IT;H=I6V6(;>.G%</H7_!4+PU'X1MX+G]G3XI>(?$VB^"]/UWXA:/X
M;T73II?#D=Q;^<AN";Y8V=XP95AMWFDV%25!(%>S']H7PSXP_9:_X:A^"T5Q
MXIT?4_!7_"1>&5T]$$FH026WGP[5F>-02I7*NRXY!P10!#;?LB?LZ6G@_P
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MO@#I<_@/P?XDMM>\,^&9KRY:#3]0@E:6&6,F7=M5V;$98Q[6*E2ORU2\$?\
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MW);B>>8-'L5U 9=F9#M8A?FH ]2O_P!C[]FK6+#XB:5K?PDT^^M?BOJ4=_\
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M_%+P%X\\(Z[X&?0VU[P3XAT6WCU;[+JVHQ:=97L*QW+P3V[7$H5GCF;9L<,
MP"FC_P %&O\ @HO;_LE>!_&W@[X=^"]:UCXA:1\,[KQ7I,=O96[V<=O%.D!D
MD::>/.UY%8J 25'&3Q0!U4?_  2[_8<L] T7PSX<^#EUX?M_#^B_V/IK^%/&
M6KZ/.-.WM(+.6:RNXI;B ,[D12LZ#<<  FNFTC]AC]E'PYXG\)>+O"OP<L]&
MO/ _AUM!\-KHE[<V4$&ED@FRE@@E2*ZAW -Y<Z2+N^;&XDUTW[._Q%U_XL?
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M%E\17EO\%_B%'X,\36=OIL1N+[5);B&U@%DIE GCEGF$2.63<R., #) ._\
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M(Y-/G\4V7B2]FO=:OKF]OM5M)5EMKNXO)IVN;EXW12/-D<8&"".*^??VR?\
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MYTV]UC3[.PU.\OO$6H:E+/;6J%+>(O>3RD+&A*@ CC Z 51\ ?L$_L??"_\
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M$-[X9\4:# FH7VEF9(3=6H@N)8IPKNH=!()$S\R X% 'M/Q5_9S^#7QM\/\
MAKPI\4?!,>K:;X1\3:;X@\/V4E[/'';ZA8/OM)F$;KYPC<!A')O0LJEE)4$3
M?'+X _"']I+P2GP[^-?@V/7-'BU2UU&&U>ZF@,=U;2B6"59(71U9'4,,,.G.
M1Q7C.F?\%4_V>+2ZU>'XM>#O''PYATOX=7OCJUNO'&A16\>JZ#9A#<W=MY$\
MS%HQ)%NAD6.;$BG8<U4\;_\ !1OPRGP2\5_$#Q'\'OC%\.;/2_!_]OV/B'5?
M!=G<+<69>,"2!DN)[;S2)%(@N6BD*DG9P< 'IK_L2_LOO^S[>?LKO\*XF\ Z
MAJ'VZ\\/G5+O;+<?;%O?,,OF^;G[0BR8#@9&,;<BNEN?@+\)+OXP3?'JX\(1
MMXNN/";>&9M8^US;FTHSB<VVS?Y>/- ;=MW]MV.*^3=(_P""GOC/PG^VE\4_
M@QK7PS\>>/O#?A?P+X:\0:1:^"?"5M-=:?;7=CYUQ<7+--$&+-RL,9>0[6"(
MV*Z#PM_P4I\&^(/VJM>UZ/XL:3)\"[7]F71_B/I^M+9@<W.I7L3SE\>9@P0Q
MKY1&58$$!LB@#TJ]_P""9_[%ESHFBZ%I_P )[[1X_#^G2Z?I=UX;\9:OI5VM
MG),\SVTES9W<4T\)D=V\N5W3+'C%>J> OA%\-/A=\,K'X,_#OP78Z+X6TW3?
ML%CHNGQ^7##;X(*#'/()RV=Q)))))->4_!#_ (*$_"GXS_$+1?AE?_#?QUX)
MU+Q5H\FJ^"_^$ZT.*SC\0V:!2\EJT4\N&"NC&*41RA6!V8S7G'_!1/\ :W_:
M-^%/[3GP'_9=^ OA/Q-;1_$[7-2.M>+-#TG2+UUM[/3[BY:UMX]0N8U$@\I9
M)6= !"?W;/)^[H ]'^"7_!,7]AO]G;7M#\1?"'X%QZ7+X9WMX;M+CQ#J-Y9Z
M5(XVO-;6MS<2003,,AID19&R<L<FKFG?\$Y?V,-+^)</Q7LO@C;QZE;>(CK]
MKI_]LWQTFWU;);^T(]+,_P!A2Z#$L)U@$@8[@P/-<G?_ /!5/]G?1;ZZO)_"
M_CB[\%Z5XF_X1S5_BM;^'XSX>M=3$H@:-Y?.$VU9B(VF6 PJYP7&*Z3X%?M_
M?#?]HWXV>*?@S\+/A5X\O(_!?BJ_\.>)?&$VD6T>C6>HVJ;VB\TW/FR!UVE&
M2)E^=0Q0G% %_5O^">W['FN?%.?XQZG\&H7UB[UB/5KZW76+U--N]13&R]FT
MY9Q9S7 VKB9X6DR =V0*@^)7_!.?]B_XO^/[_P"(_P 0_@A;WVH:Q<P7.OVB
MZQ?0:=K4T)'E27^GQ3K:7[+M7#7$4A^4>E<A\7OVA/CI\4_VU)/V'/V<?%=C
MX3;P_P""X?$WCCQI=:7'?36\5Q.\-K:VL,N8O,<QR,S2!@JKP,FO._VMOCO_
M ,%#OV,_V8/BGXQ\6^+/#^O)X?U#PQ_P@7Q"72H(KB[CO=:L[.\MKNQ4>4'2
M.9PLB !O,!P"M 'TSJO[(_[.^MK\1EU/X;0R+\6HX(_B&OV^Y7^UUAM%M(@=
ML@\K; BI^ZV9 R<GFK3_ ++OP$E\3^&_&-S\.+6;4/"/A6?PWX?DN+B:1+;2
MIEB26U,;.4E5EAC!,BLV%Z\G/C_B[_@H]\%/A!\8?B3\//%?B+QAKVMZ!XRT
M/P[H_@O3?#=L\]SJ-]IB7D5KIQ1U:YW1DRR/<,@C(8;@BYJ]KW_!4C]G+P9\
M"_B%\<?B)H'C#PY_PJNXM8?'GA'5M%C&LZ7]IEBCA<PQS/',C><K!XI74J&P
M2PVT =!\-_\ @F]^Q7\)?$-OXF\%_!"$36-C=66CV>J:U?ZC9:/;7"[)X;"T
MNYY+>P21/D9;>.,%3MQCBK7PD_X)]?LD_ _QGIOC[X=_#"XAU'1()(?#HU3Q
M1J>HVVB1N,,EA;7ES+#8J1\N+=(QCCIQ7DOQP_X*L:5X3^&'C^U\+_ /XAZ%
MX_T/X7WGC+PCH/B[1+.W.MZ?"RQ->08O&0I#)+$TL,K1SJK@^6<XJ7X+?MK_
M !8T+X%-^V9^U?H^J^&?A[)\-/#UY;Z;>:?8O>7.L7*()7MTLY)&*3221A$=
MQC>O"?-@ ^NZ*\Q^ O[32?'+6M4\-:A\!_B-X&U#2[.WN_)\;^'XH8;NWF+A
M'@N;6:>VD8;#NB\T2H"I9 &!/IU !1110 4444 %%%% '@O[$'_(U_'K_LNU
M_P#^FC2:]ZKP7]B#_D:_CU_V7:__ /31I->]4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+\!/^
M3WOCS_UT\._^FN*O>J\%^ G_ ">]\>?^NGAW_P!-<5 'O5%%% !1110 4444
M %%%% !7S+_P5B\!IXK_ &7K'Q=;^,M"T74O _C[P_XGT5O$VH"UT^]O+/48
M9([.:5OEC$Q_=*S<*[J3P*^FJIZ_X?T'Q5H]QX?\3Z)9ZEI]U'LNK&_M4FAF
M7^ZR."K#V(H _)?]H+X6?''_ (*Q?M8_$7P=9>!+#P>VG_!33H])\OQA#=_Z
M='JZ7:P75YI<CK#YGE%5,4ID12'^4@"OH+]FW]AWXE3_ +3?ACXX>-/V<?$W
MA.'P+X(UBQL[_P")G[0WB'QKJ,NJ7\44#KID=QK5U:6=H8HV,KS1^;(?("I'
MY>ZOIGP!X^_9T^&/Q]F_8_\ AC\/+/P[KA\,CQ+-::%H$%G8M;&;R=Q,6W,F
M[MMZ=Z]9H _/SP[_ ,$__P!HV/\ X)R_LT_LTZOX/MX/$?P^\9:7>^,K6'6+
M?%E:Q37#3.D@?9(P612 A))/&:\N\#_\$C_C1H7PITW]CSQ5\!_$/B#3K7QM
M;S7WCC7/VD/$_P#PA]QH\>I+>>=_PCMKK<'^F!47RX! D"SA)"Y5=I_4S5K]
M]-TRYU&+3[B[:WMWE6UM%4RS%5)V(&(!8XP,D#)Y(ZU#X:UJ;Q%X?L]=N=!O
MM+DNK=97T[4T1;BW)'W) C,H8=\,1[F@#XQ\(?L@_MB>"_V(OVAOA9\,]2A\
M)^/O'7QB\8^(O!M_:ZM&CR6-_J)F@<3QEOLTLD/ 8_/&2"0"*^<_&O\ P3"_
M:,\3>/\ _A+?A+^Q%_PA=O<? 'QKX2UC4/$WQ-MM8UW5=:U'31%;R3W4EW.7
MMVE7:K&4E2S,R1K7ZI0>)[J;QK<>#SX1U:.&#3H[I=<DCB^Q2LSLOD*PD\SS
M5QN(*!=K##$Y UJ /SG^&?[!/B;P%\!OVF/#7[7,.F>&?#/Q!\"^"[+2]7GU
MBVD6*XTSPA8Z=/)E7/EO%>V[*A."Q4,F00:]._X(C_#;XN6O[*;_ +2/[1LJ
MW'Q!^*UY'JFLW2JPW6<$*6MF '^8!HHO-Y_Y[9XKZV\7^#/!OQ T-_#/CSPE
MIFN:;-(CRZ?J]A'<P.R,&5C'(I4E6 8''! (K0MK:WLK>.SL[=(H8D"111J%
M5% P  .@ [4 ?G;^UQ^PW^TW\9?CQ\:-4^(/[/,WQBT[Q9I]M!\%[G5_B0+/
MPUX2A^P+%+#>Z2UPBR2?:M\QG6WN7D5E7*;<5#\6O^"?G[9TW_!.K]G_ $+X
M%Z%8:/\ &_X8>&(/#>I07&L6ZQQZ?=V?V'41]H5]C[$(F0*QRR#'-?HX/7%
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M$'[OR!/AV;=Y:;!G[+H'%% !1110 4444 %%%% '@O[$'_(U_'K_ ++M?_\
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M'&J?_&Z />J*\%_MC_@IA_T)/P7_ /!QJG_QNC^V/^"F'_0D_!?_ ,'&J?\
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MX(8D$=:K^+?@!^U#X^TK2]!\=_LD_LPZU8Z'$(M%L]6TVXN8M/0=%@22V*Q
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M[&[\8::ES<7DEK#*9$MIO/MV%Q;Y>53"_P NV:3&TL30!Y9^S7X#_97^%?\
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M$U.'28[*"6^U5E@'FW$DD"11B-456D9FYK_@D-\0]<^)/QS_ &:]4UWQJOB
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MR/"6A8CJR$$U%I_PZ_;8TG2=$T'2OV>OV=K6Q\,S^=X<L[=;Q(M*DPPWVR"
M"!L,PR@4_,?4T ?FA\6?'EPWPZ\-_MH>%+OP/X;U34/VBM+MM'\2>)O$EQJW
MQ%U '7HX+BUFE@2UM[&V\GS%-J4G18<*PW-N'L'AGX47_P 9_@K\0/#VD?&3
MX>Z/>V_[>'Q O8? _P 4KN6+0O'82[N-VEW/DL)" &\]<)*H:!2T; <?6MW^
MSC^TG?ZUJ'B2^_8]_9<FU'5G5]5U";29VFO65UD4RN;;=(0Z*PW$X90>H%7]
M:^#G[7GB3PS?^"O$7[,/[-=_HVJ:I+J6J:3>VMU+:WEY(VZ2YEB:W*23,W+2
M,"S'DDF@"C_P2G^*?P]UCX=^-/AEH/P/L_AK=^#_ !U-I6J:+H_CB77-!GO&
MB60MI-Q*(PL&"/W"11"-LC9G)KZTKY=TKX3?MBZ#H^D>'=#_ &:?V;[/3_#]
MW]JT&QM;>[CATV?!'FP(MN%A?!(W( <$\UU']L?\%,/^A)^"_P#X.-4_^-T
M>]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U1
M7@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;
M'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\
M!3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2
M?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$G
MX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C
M5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/
M_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_
M;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\
M%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H
M2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"
M_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#
MC5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_
M^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0
M![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45
MX+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]
ML?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3
M#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_
M *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_
M .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^
M#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\
MXW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C='
M]L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!
M3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^
MA)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O
M_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X
M.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_
M (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T
M>]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U1
M7@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;
M'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\
M!3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2
M?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$G
MX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C
M5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/
M_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_
M;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\
M%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H
M2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"
M_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#
MC5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_
M^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0
M![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45
MX+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]
ML?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3
M#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_
M *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_
M .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^
M#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\
MXW1_;'_!3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C='
M]L?\%,/^A)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!
M3#_H2?@O_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^
MA)^"_P#X.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O
M_P"#C5/_ (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X
M.-4_^-T >]45X+_;'_!3#_H2?@O_ .#C5/\ XW1_;'_!3#_H2?@O_P"#C5/_
M (W0![U17@O]L?\ !3#_ *$GX+_^#C5/_C=']L?\%,/^A)^"_P#X.-4_^-T
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M -NS]J'4O@;^P+\3_P!JCX#ZYH>L:AX3\$WVK:#=-(+RQEGAC++N\IQO7(Y
M8?6@#W2BOF;_ (([?M;_ !5_;L_X)M?"_P#:P^-=OI,7BCQA87\VK1Z'9M;V
MH:'4KJV3RXW=V4;(4SECDY/?%?!'_!5?_@H;_P '%G_!/>U\;?M#+\,/@?'\
M&]*\1BU\/:E<V[W6H/;2N1 98DO%;<<<_*,>E '[(45^<?\ P2;^/_\ P7Q_
M:&\?^$?BI^W!\-O@_I_P5\5>$6U:UU+PBQ74F::!9+/Y#=2%0=PW KD>U??&
MM?&+X1^&_$T7@OQ%\4O#EAK$^!#I-YKEO%=29Z;8F<.<]L"@#I**P_$GQ/\
MAIX-U:ST#Q?\0]#TJ^U"-Y+"RU+5H8)KE5&6:-'8,X !)(!P!S6;9_'_ .!-
M_#9W%C\;/",\>HW36VGR0^)+5ENIEQNBC(D^=QD95<D9% '745S&E?&OX-Z_
M_:']@_%OPQ>?V2A?5?LNO6\GV)1U,NUSY8'JV*O>#OB'X ^(NF2:U\/O'6CZ
M[9Q2;)+O1M3BNHD8?PEHV8 ^V: -FBN5TKXY?!77?$Y\%:)\8/"MYK <H=)M
M?$%M)=!AU'E*Y;(],5U6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** #F@#' HHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_@@S^Q9^RS\;/#WQ]7QE\4/B-K_ (+LS:> _P#A:GCA]8MO"T.,;+"(QHL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO _^& ](_P"CM_CY_P"'6N_\*/\ A@/2/^CM_CY_X=:[_P * /?,<YHKP/\
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MC_H[?X^?^'6N_P#"@#WRBO _^& ](_Z.W^/G_AUKO_"C_A@/2/\ H[?X^?\
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M^?\ AUKO_"@#WRBO _\ A@/2/^CM_CY_X=:[_P */^& ](_Z.W^/G_AUKO\
MPH ]\HKP/_A@/2/^CM_CY_X=:[_PH_X8#TC_ *.W^/G_ (=:[_PH ]\HKP/_
M (8#TC_H[?X^?^'6N_\ "C_A@/2/^CM_CY_X=:[_ ,* /?**\#_X8#TC_H[?
MX^?^'6N_\*/^& ](_P"CM_CY_P"'6N_\* /?**\#_P"& ](_Z.W^/G_AUKO_
M  H_X8#TC_H[?X^?^'6N_P#"@#WRBO _^& ](_Z.W^/G_AUKO_"C_A@/2/\
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MO_"C_A@/2/\ H[?X^?\ AUKO_"@#WRBO _\ A@/2/^CM_CY_X=:[_P */^&
M](_Z.W^/G_AUKO\ PH ]\HKP/_A@/2/^CM_CY_X=:[_PH_X8#TC_ *.W^/G_
M (=:[_PH ]\HKP/_ (8#TC_H[?X^?^'6N_\ "C_A@/2/^CM_CY_X=:[_ ,*
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MQMK#ZMXPTEO#EN;?6;Y@JM<W,93;-*0B@NP+84<\4 ?E_P#\$A_BA\,_CO\
M"?\ :+_8N_:$_:5^(FBZ#X;?3[C4-8U#XN6][;Z!;S1\FQ\21.&(=L$^8V5P
M0,8-?KMX$TW1=&\$:-I'AO6)-1TZUTJWAL-0FO/M#W4*Q*J2M+D^:64!B^?F
M)SWKSSP]^PE^Q?X1^$&K?L_^%OV5_ 6G^!]>_P"0UX3L_"]M'I]]_P!=8%39
M)^(->G:)HFD>&M&M/#OA_3(;*PL+6.WLK.VC"1P0HH5(T4<*JJ  !P * /D7
M]D7_ )3%?MC?]BO\,?\ T@U:OCOX>_#-_A+^P%XK_;!\%?$/Q78^--'_ &G+
MLZ;-;^)+F.TBM9?%$=M+:FU5Q"\;QRN&W(6).01BOUJT3X8_#GPUXZU[XG^'
M_!&EV/B+Q1#9P^(M<M;)$NM3CM5=;99Y -T@B620(&)VAVQC)K(/[./P$;P#
M<_"L_!SPW_PC=YJQU2ZT(Z1%]EFO3.+@W#1[=ID\Y1)NQG> W6@#\Y?BWXS^
M.7QY_;0_:4T7Q_H&IW>G_#.RTB#P6L'QF_X16+PU82Z3'=-JXA"'[5YD[RDS
M/NC7R/+VY!S]:_!B[\9_'S_@D]I=]^T1KMKKVM:]\)Y)->U;0[R>&+47%LY6
MXCD412#S J.2 N2QXP:]6^*O[)7[,'QR\06/BKXR? 'PEXFU/38A%87^MZ%#
M<301@Y"JSJ2%![=*[J30]%FT1O#<FE6[:>]J;9K+R1Y1A*[3'MZ;=O&.F* /
MR+_X);_#/P3\1-3^&G[,WQ5\:>(M"\#VO[,^B^+/#OAVU\:7UG'KFJ75Q<17
M]]YJSB0_9TAMU$*,(T\S<4^;-9/P1^)_CSXG?&'11XN\:WGBC2_#7@7XV>'O
M!/BK4)?-FUG0K.>"*TN&E'$^ &C\T??$6<DDFOU(\6_L:_LF>/O ^@_#/QG^
MSEX-U3P_X7@$/AS1[WP_!);Z;&!@) A7$:X X7 XK8'[.OP&1]+EC^#OAM6T
M/0[G1='*Z/$/L6G7"A9[2+"_)%(%4,@P&P,@T ?G'^Q+%!\>_%WP9_9E^._C
M[6='\"Z7^S'I6N>%]!TWQ!/I::YJ$D\L=U<-- \<DAMT2(! V%\S<0<UY/HO
M[8GQS_9ST*\^/U[\7_$7BKP7>>(/B1\'/ >MW^I23IJT=I>&X\/7H(.R:;=%
M>68N0,R!$RQZU^L'C/\ 9 _97^(G@?1?AKX[_9Z\'ZMH'AR%8M T>_T&"2WT
MY ,!84*XC7 Z+@5IZW^SA\ ?$O@C1/AKXA^#/AF\\/\ AN\M[OP_HMQHT+VN
MG3P',,L,97;&Z'E64 @]* /R4^&/CW]I&Y^&?B#]B/QQ\8?%5QXF_9A^&/CK
M5O&^O+K5P+B_FDTV2/2FEF#AI/OW$BY)P44CE17L/[/_ (%U']J']L3X<_#[
MXM_%#QI<>'(OV$/"^NW6BV'BZ]M([W59-5O(OMLK0RJ[2A,_-N!;Y=VX*!7Z
M'O\ L^? R36_%7B1_A'X=.H>.=/^P>,KTZ3%YNMVOEM'Y-TVW,R;&9=K9&&(
M[U+X9^!?P;\%>([;QAX0^%V@Z;JMGX7@\-VFHV6F1QS0Z/#(TD5@KJ,BW1V9
MEC'R@L2!S0!^8_[$_C?QE^U3\2_A[^SK^U+\9/$J^#M%\(^*'T5E\33V$WB&
M\LM=GLT,]S"Z22O;VJ(<;N?O,#7TQ_P1&\27.N_LP^-BWQ;U;QQ8Z=\:/%EE
MH_B36-4:\FNK.'4I4A(D8G*A   . .@KL?VE/^">-G\5;+0?#WP?N/ACX>\.
M:--=W$G@WQE\';;7]*EN[B4RO>QK'<V<\%QO9R2LQ1BY+(QYKO\ ]BC]D?PE
M^Q5\#(/@SX5UIM3:35K[5M6U1K&.U6[OKRX>XG=(8_EACWN0D8)V(%7)QD@'
MY<_M)?''XJZC\+?''[:_@#QKJ%G#IOQQETGP_P",O$WQ$N+:^9H-66T;3+;1
M[=Q;K"H5HP)E:1UR[8W"K_[8,6@?M$?\$WOVQ_V@/VD/CAKVD^//#5[K^D:5
MI,?BF:UMM+M8XPECIXLPXBE2[0J"S(S/YV588&/TX\0_L%?L4^+/$>K>+_$_
M[*O@+4-4UR0R:S?7GA>VDDO7)!+2$I\[$@')YR*F^)'[#G[''QBUB3Q#\5?V
M8/ OB*^FTTZ?-=:QX;M[AY+4QF,PL70[DV$K@\8XH _/CXA:?X<_:!^'O[7&
MO_M-?&[Q!X:U#X8:-9Z9X%TRU\4S6%OI&C'P[:7$-ZL"NL=Q]JN);@,TBN/D
MV#!6O&?BJ+[Q[^PM^T)X+\5ZYJMUH^@_LP_#O4-)TO\ M>XCM[2<VJ;Y$1'"
MC()+#&&ZD' Q^N_Q,_8Y_92^,VM6?B'XL_LZ>#?$=]860L[.\UGP_!<216X&
M!$"ZD[ "1MZ5>L_V7_V<]/TW5M&L?@=X6AL]>T&#1-:MH]%A"7VFPQF.&TE&
MW#PHA*JAR . * /SW_;#^*/Q4_9=^-_Q.TC]F?Q)K,-KX3_88TV_\/Z>NK7%
M['8W'_"0W\4E\JS._F3)$/OMEB(PI)  JO\ M4W&G_LM6GPZN/V2OV@/$^O3
M?$?X5>*)/&4=QXQN-2^WV<6A2W$>L@/(WV:19]N)(MBY?&,@5^BG@K]FG]GO
MX<WD-[X#^"OAG2)K?PROAV&:PT>*-DTE9I)UL00O_'N)99)/+^[N=CC)-9?@
M?]C#]DOX:#6A\/OV</!>B_\ "164MGKO]F^'H(OM]O*I62*7:OSHP8@J>"":
M /S_ /!T.K?LL^#?V)OVA]'^+?CB]UCXC7,NF_$ZZU7Q)=:@FN6LOA/4M0+-
M;2NT8DCGM(GC,:J1C!)R:\S^'OQA^,?AZ[_9E_:=TOQC=64?Q2^)EI$NM:]\
M2;B\U;Q9I]TTS/Y^FQO]CMD"X/EQKF,!1G(-?K7/\!_@O<Z?X4TJ?X5Z"UKX
M%N%G\&6[:7$4T246\EL'M1C$)$$LD65Q\DC+T)KCM*_8$_8CT#6!K^B_LH^
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M?2K"XTO3OV4_ ,-O>6,5E=PQ^%[8+-;Q7*W4<3_)\R+.BR@'@.H8<B@#R/\
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M^,/#=G8ZI>:0MU?:;I&K1W\"2%-Q6&X3Y)5/\+#@@BOC+P;_ ,%D_$%Y\8?
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M)[?Q)-)JL?FZN-+COXXC$(VB$SQDH6#[22!Q4OQ:_P""JO[1VF_ ?XB?MA?
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M_B3=:CXQUZ:U%A)_:5Y87&F.L,;EI$FM"JL."0Y.  3J_#;_ ()C_M4_L_\
MQ"U;Q]^SW^V=H>D-KWPYT#PIJ-KK'P]:]6'^S;3[.+^#%ZFR=N64-O1> ROC
M-=A^S-_P2W\)?LJ?$2SU_P"&_P 0IGT+3O@#:?#:UTR^L=]Q)+'J-Y?RZG+.
M' 9I9+QRT810&R0V"% !QO[/G_!4GXY?%.+X'_$;X@_LZZ/X?\$_'+5Y]&T5
MH/$+W&IZ?>Q0S/OFC\L1F%VMY57:Q8?*2!FN*\!_\%8-1\'_ +.OP-O/#GPU
MT#PLOQ3_ .$C;^W_ (A>,-0FT/1FT^\$8MYM0D669I[@R;HU<A0(Y!D!0*]D
M\ ?\$T=1\%_"']G?X7O\88;AO@3XLEUJ:]_L,J-9#QW:>4J^<?(Q]JSN)?[G
M3GBK\,/^">WQ\^!?[+O@?]G'X9?M!>#=0M?#$>J1ZW8^./AFNIZ7K/VJZ>>.
M4PK=1SPR0AV0;9]C!F+(?EV@&!\5O^"H/Q0^&NI?#SP+K7@SX;^']6\:Z+?7
M[>*/$7C9V\,,8)Q''!;W]O&ZO)*I#J'V[1G/(IG[5O\ P4?TK]F"Z^#/Q@^/
MOPRACCU+P'XV\0ZQ-X<\:2W,%D-,TR"X,4"V["WU#S]X1&E!\LD%=I)-:7PX
M_P""9OQE^!OP6M?@U\*?CUX*U#2[K4-4U#Q%H/CSX7QZGI+W5[-YC-9P1W,,
MMI'&/D2+SG0#J">:Y[6/^"'GPZ\5?"+X6_ ?QC\6KS4/#'@7PKXUT;7K=M."
MS:F/$-JD+O;L'VV8MW4O&FV0 !%XVY(!W_A3]N+]HOP5\3?A;X9_:M^ FA>&
MM'^,5S]A\,77A_7Y+RXTO4&MS<1V=\CQJNYD5ANB+*&&*\U\%_\ !5W]I#5?
MA!I?[4WB_P#9N\,Z?\-I_BM%X*U)K?Q)-)JL?FZL-,COXXC$(VB$KQDH6#X)
MP#BO3?!/[!?QV\0?$CX9>*_VJ_VG;#QMI?P?F-UX/T_2/!_]F37E\+<V\=[J
M$IN)1/*D;-@1+"A8[BO:LY?^"7VI+^PU#^QS_P +G@\V'XG6OBW_ (2#^P6V
ME8=>BU;[-Y/G]2(_*W[^"=VTXVT >:_&+]N+XX?#W]M'7/%'PD\'+XNT_7?B
MCH7P7\*Z/J.ORVFG6U^FFW.JZEJ150RLRS7-O:NVW<!:2*#D8,WB/_@JE^U_
MX,\)_&CQ7XE_9=\'_9_V>]42+XA36OBR<IJ-NT:3%].!A#%UA?<1,$!88!KU
M'0/^":NHZ5X'^#>A7_Q@ANM8^'/QDO\ XC>*M9_L,K_PDFHWLNH372A?.)MP
M9;\[26DVI$JX/!"?$?\ X)J:CX^^&O[3G@!/C!#:M^T1-YEO='0RXT+_ $-+
M;#+YP^T?=W<&/KCWH XWXH_\%<+U?C/\0/AC\$].^&XM_A;IMA+XDF^(7C^+
M2+C5;VYLUO?L6G1')D9(7C#2/M3>^T'(-/\ $G_!8SP;XP7X4:-\ (_!]OJ'
MQ1\#-XM74/B9XJ32-.TJQ4A#'))RTDYE)0*@(^4GI6GXG_X);>,= ^*GC3XD
M_L__ !=\(Z/_ ,+)T_3U\7V_B_X;Q:T]KJ%K9)9?VAILAGB-M*\,46Y)!-&7
MC#;<DYT_B!_P3!D_X23X=_$WX._$[24\7>!/!K>&+F\^(WA-->L]=LF*N7N8
M5E@83>8"X>-UP6(P1Q0!X+%_P47_ &@/VK_VM/V7X/@9>^&]*LF^)GC7PU\1
M-"7Q)-/97NH:;HURTH$ULC)<VPA(N+=L\RM'N  W#I_@_P#\%)OC;XJ^/$?[
M,G[/O[.FBS:EX@\?>/K>34O$WC>_FM[4Z-J$4)G<R+)(B3"0D0Q82,X5%"UZ
M58_\$R_B/X:U/X0_$?PO^T;9R^-OAGXZUOQ%>:CK'A(/IVHIJUC-975I#:6\
M\/V2..*4"##L$\M=PDYS)^S?_P $NM2^ ?[45K^T9-\:8-4CMO$7C;4_[)30
M3"S#7[V*Y6/S//;_ %'E;2=O[S.<)C% &=I7_!4SQAK/P9T".P^"EG)\6/$?
MQ=O/AQ8>$UU@_P!GC5+3SWN;IKC;N^RI!;R2D[=^-JXR:[G]EG]K[X_?$K]K
MGXD?LC_'_P"#&A>'-2\ ^%]&UB'6?#^M2W5OJZ7TMTH>(21HR1K]GV_,-V\/
MQ@ GQW]H#]AZ_P#V??A'_P )[HNO^,M:\46/[0UU\0/"NO> _AZ^LS>'9+WS
MTD%WIL<_VB^L_)EDAE%L&F/FJR1C:2NM_P $V/AY^T=XK_;+^-7[8GQMN-:N
M-*\6>'?#NA>&[S6_ %WX6^T?8S>23BVTN_8WMO;(9XP&N?GDD>4C*A: .G_;
M0_X**^._V<_BIJWPW\+>&/!-I'HOAV/5%OO'7B26V;6G96;[-8P6L<LK,H7!
M=U5-S 9/->8_LQ_MI_M"?M:?\%)/A9XZ\$2Z;8?"_P <?LGIXO\ ^$8OM3N?
M-MS/JEHDLQC6/RWNDE_<J2=OD[CD%BI]2^*W_!.?XH:[^T9\0OCE\(OCQH.B
M)\3]#MM-U[_A(/ XU34-)$,+0^9IER;A%MB58G;)'*H?Y@.U9G[)/_!,#XB?
MLF^,O@OXS\/?M Z7JDWPW^#<GPW\3QWGA-U&MZ;]OBO(I[?;=?Z).&B"L6\Y
M6#'"J<8 -CXT^-?&>G?\%@_@CX$L/%NJ0:'J7PM\47&H:-#J$BVEU-');>7)
M)$&V.Z@G:Q!(R<8S1J'C;QHO_!<W1_APGB[5!X=?]D_4M2DT$7\GV)KT>)K&
M);DP;O+,PC9D$F-P4D9P2*] _:@_9*\0_&/XF^"/VA/A#\3(?"/Q!^'_ -KB
MT?5+_1_M]E=V=TH6>TN8!)$SQMM5@4D1@1UK-^#G[(7Q0\-?'SQ-^U_\:?B]
MHWB;XF:OX)B\*:%-I?AF2PT?1-,CN'NO*CM6N99I#)<,LDC/.681HJE * /.
M_P#@J3-^T%I/B_X<^)M#\!^/O%7PAL9KT_$S0/A;JTEGK,CF,?99=\+QS- C
M;BZ1.KDXY(XJQ_P3"^+?P#^(_B?Q]9? +]H?QYJFFVK6+S?"SXF07?\ :WA&
M4HX=O,OF:ZDBGP" Y8*4;:QS@>@?&/\ 96^.'CWQIX(^/W@#X_6/AGXE^%-'
MFT[4KB/P_+<>']9AGVF:.73VNA(J[T#(PG\Q.F\Y.<WX8?L<?&7P5\5/'7[5
M?BGXP^%]7^+GBSPS::%INH1>#9K;0M,M+:222-#9+>&XGR\KLS-=;C\H#*!B
M@#<_X*:^)/$7@_\ X)]?&+Q1X2UZ\TO4[#P!J,]CJ.G73P3VTJPDJZ2(0R,#
MT(((KY]_8@T3]GJ^\&_#WQ[KOP,_:.TW5K;PC9:OJ'B[Q?XP\2MI#31V2S2S
MR";5)(9$<AF"M&5;(&W%?6'[5'P+U']I?]E[QI^SW+XIATFZ\8>%[C2GUA;$
MRQVSRQ[3*(MX+ $YV[P<<9[UM?#;X667@KX'^'_@MK=S'JEOI'A2UT2\F,/E
MK=I%;+ S;,G:'"D[<G&<9/6@#Y.T7_@J5\:U^"'@W]M[QI^SQI.F_ _QOK5C
M;Z?>1Z\[Z]8Z??7*V]EJ4]OY?E>6[21.41RZI("1D&MSQM_P4-^/^K+\5OB'
M^SW^SYHOB'P+\&=2NK/Q->:MK\EM?ZM):0B:\%A&L;(?+0G'F,NYA@5E:!_P
M2H^)T'P@\(_L<>,OVHH-6^!?@G7;.\T?PW_PB?EZW<V5E<BYLM-NM0^T&.2W
MB=(ERENDC)& 7ZD[7CK_ ()P_&6&X^*?@?X"?M0VOA+P%\9;ZXN_&&BWGA'[
M=?6,MS"(;QM.N?M$:0>=&.?-BFVL<C% ''^)?^"DGQH_:K^'?Q0UW]ACX0Z9
MK7A7P/X/MI-6U[6->EL;Z\OKS24U 6VGK&C#S8;>X@):1D&]\ \9KVC_ ()\
M?$'Q'-_P3&^$_P 4?%=UJ?B+5%^$.F:E?2W%T9KS49A8+(V9)6R\CD?>9N2<
MDUYL/^"67Q!^#=CXV\$?L5?M&V?@#PE\1_#MCIWBC2=7\)G5)K.XM=.CTY;[
M3Y1<1""9[:&%7\U)D+1!@H).?8OAY^QY;^%/V =)_87USQ[<W$=C\-8_"5SX
MDTR VLKA;3[.;F-"S>6?X@I9L=,F@#YZ^$/_  6"\0>*OVB/AA\(/'WA3P.M
MK\5-4O-,LK7PKXEFO]1\/WD5C/>)%?\ [H6Y++;O&?*D8JY'49(K? O_ (*S
M?M#^-?@5\(?VM/B]^SGX9\/_  Y^*GB&#1?] \2S7&I:;+--) ERT9B$;0&2
M,\;MX4@D5I^$/^"4/QRTKQ9\!=2\1?M+^$5T?X"^)!?Z5HWAOX9_V?\ VW";
M"XLF:\D^V.3<^7-\LB;8P3)F)BP*]1X9_P""6MUH?[#?P9_8VO?C%;W7_"J?
M$^FZK=:V=!*IJR6MW)<-"(?./E;P^W<7?&,X/2@#PK]K_P#;I_:V^.G[*_AO
MX[?"KX;6_AOX::]\;O"^F:9X@TSQ5/!K?V$>([6!KB:-%5/L\^UHC&')*R@,
M"":][_X+=>*/%GA'_@G1XHU;P;XOU?0[Y];T.W_M'0M5GLKI(Y=3MHY%6:!T
MD3<C,I*L#@FN/\8?\$F?CMJ'PLTC]F'P1^U_8:7\*?#_ ,2--\5Z/H=SX(-Q
MJ8CM=5BU :;)=BZ5'M]R,%(B5U.PEG"E6][_ ."@_P"R9K7[;'[*^M?L\^'O
MB!:^&;W4KS3[JUUF\TEKZ*%[6[BN &A66)G#&/;PZGGK0!X%^W-\+K;_ ()Y
M>"_"G[5/[-'C_P ;6,FE_$+1-,\3>'->\?:IK5CK6F7UY':31&/4;B<I*OFA
MT>,J05P<@U9TW_@IE^TMK7PU_:(^/>F_L_>%(?!/P'\1>+M%5[OQ%<?;M:N-
M'@:6.546(I'$Y,:/EMRL6V@@<^A^-OV,OVD?VEO$OA6+]L3X_>$-6\(^$_$M
MKX@A\)^ ? MSI,>IW]JV^V-U+=7]V[1QR8D")L!95R2!BK_@;_@GOI&C?L__
M !W_ &?/&/C^34-,^-_CCQ5KEU<65A]GDTVWUG@VXR[B1HAG]Y\H;^Z* ,3X
M_P#_  4LL_V=HOA7XA\:^![?^P_'/@/4_$NNW4=XWF:<EIIJ7IBB7;B0L6V#
M)'8URMC_ ,%#_P!KWP_\1O@#I_Q4_9>\-:;X6^/GBO\ LS3M2L/$TLUUH49T
MR[OXTN8S$%:=TMQ@(Q0 29.0H.+XV_X):_&GX@KX0UG]IG]H6T\<^'_AO\.M
M8\-6OA#PAX%&GW.M6EQIXM@WF3WKK]MVH,-E(BQ^ZGWAY/\ "/X;_M;_ !\_
M:2_9>\,7FK_$"^\&_!'Q1=ZQKG_"9_ _4/";6%M'HMY96ZW=W>NT.J7QDN(H
ME^P9A"--(Q^Z: /L;_@IW^T['^R?^QGXK^(MEKUMI^M:A%'HGAFXNKI8534;
MUQ;PN78@*$+[RV>-N:^8_P!A3]NWP7^R-\)?CW\(/C9^T.?B9'\!]%/C&V\2
MP^)DU>ZU31;BU-QY0G\Q_,D2X2:  GY?D!P"*^L/VD/V01^TM\<?A?XZ\:>*
M[.3P?\.]3N]6N_!=UI F75]0:$Q6TKR,^U4AW.VPQMN8@Y&.?._VL_\ @E-\
M*/VEOB7HWB[0+W3?!^CW'@G7_!WQ%T71]!2/_A(]%U*W"K$'C9!!-!<*D\<I
M5\$$8YR #Q7XW?M1?MT6/[2G[-?BSXQ?##3_  CH.N-KVLMI?AKQ=<2K-Y?A
M^[N(]-U)"J*\@(#@KO0-&Q'(%:_P_P#^"JW[9WC+PW\"_%<_[)?A&&W_ &@C
M<6O@^VC\7S&;3+J*!IS)>YAV^08XY&'EEGX QDUU^I_\$U_VJOB+XY^&.O?&
M[]M+2=>TOX5Z;J5CH]C9^ #:SZH+K2YK 75[+]K</<JL@;=&D<;?./+!8,O6
M^!?^"<&H^#?"W[,_AM_BY#<']GNZN)KB8:(5_MWS;&6UPH\X_9\>9NY,F<8[
MYH \^A_X*)>)_&^K>#?!OQ4^#%K:^+-#_:W3X6^((=%\67D=E;W(T=]0CU"%
MH_+-U$T$\0^SSKLW,VY<HIJII7_!5?\ :3G^&.M_M)ZS^S;X9M_ASX9^+EQX
M*U:5?$LS:I+&FJ"P%]#%Y7EE SHQ1F#?>QG%=K)_P2XU.3XMW7Q-'QIA"W'[
M5D/QC^Q_V V5CCT&'2?[,W>?]XF+S?/QC#;?+XW58G_X)BZE-^QCXL_9-'QE
M@$GB;XGW'BY==_L%MMNLNL)J/V;RO.^8@)Y>_>,YW;?X: /.];_X*A2?!GX?
M>-O%^@?"6WMMW[4&I^ )-:\0>);^XTG3@D3RG5KZ5A*]E;MY8C$,*B-9)4"@
M FLG]H;]K+]L_P <Z[^SOJ?P^U+X<6MMKWQOBTR^O/"OCJ:^TS7K46K2)\\$
M9=8C\^Z.0!@R+P0:]J\&?L%?&GX1^#O'6C_"3]H;08+SQK\8]3\:WEOXB\!Q
MZCIMQ:7B!3IES TZR.%95<30RPL64#[N5/GWA_\ X(_^+/"=Q!\1_"_QS\/Z
M9XXC^+EGX[VZ?X)>'P[!+!:FV-K!IRW>^)71F9G\\L7(8Y Q0!;'_!2K]J"Z
M/QP\9Z3^S3X;O/"?P7\;7OABXD7Q4T-[JMQ&(A'<+YJ+##;J\R&5I'!5%=@&
MP ?)?CO_ ,%9OC)XW^&7Q>^!G@B^\ CQ=8?!V_\ %7AOQ?X'\07MQ90QPRQP
MSQ&22W1A<*)59&3<A(Y(XKW'X@_\$IKKXC_L_P#QB^#.L?&]8;KXH?%A/'=G
MJ5OH.8+"XCNK:ZCM)[=Y6%W 7M@LBED#HY'!YK!\8?\ !)[XP?&'XLZQ\5/C
M)^TGX;5=:^$>J^!6\/\ @WX>G3+"QANWBD6Z@5[N5Q('CRX=G#@*%\O!R 9F
MA_MYWW[/%SX1US]ISPQ#<76B_LHOXYU[Q!HOB:_E66*!D'D"UE*Q2S2<$S.N
M\,VT-MKLKS_@H7^T?\(IOAUXD_:@_9XT'0?#?Q8D:R\,S:)X@DNKO2=3>SEN
M[6TU!&C51YJPLA>(LJO@'K23_P#!*W4OB;<V$?[2/Q=TSQ!8+\ ;KX7:Q9:!
MX;DT_P"U6TLF5NXVDN9C$ZH!\OS9<;@0/EJ5?^"</QV^)4OP]T+]J#]JG3_%
MGAWX4L]UX/L=+\&G3[J]U%;.6TMKW4YC<R+</#',[!84@5G^9@<8H YOX"?\
M%0?VB_''@OX'_&WXO_L[>&]!\#_&W6(](TTZ7XCEN-2TVZDCF:*26-HEC:)S
M"P&UMPR"17K'_!33XR>-OAM\%_"OPR^&.N3:3XF^,'Q,T7P!HVM6[8DTO[>[
MO=7:'M)%9V]TZ>CJM8&@_P#!-G4=$_9M^ 'P";XOPR2?!'Q18:O-J@T,@:P+
M>.=/+$?G?N"WG9W%GQMZ'/'1_P#!2_X*>._BK\$?#?Q ^$V@S:OXN^$GQ'T7
MQ_X<T.W_ -9JLFGRL+BR3_;FLYKJ).GSR)0!S/Q[_8>U+3==US]H/0_CCJD4
M.A: MQ9:)=6LD\BBQTRYAB'VIKC>7#2^:)"I8.,G<3D?.O\ P3 T'X0?&+]F
MSX.^(?B;\%OVF=8\5ZYHMA-JWCFX\;>)_P"R;FZ8Y-VSKJHB\@GD_N]NW^''
M%?HIXCTZ'XN_".^TJQ-UIT?BCPW+%"VHZ?)#/:BYMR!YL$@5T==_S1L%8$%3
M@@URO[&/[/5Q^R;^RIX!_9KNO%::Y)X*\-6^E/K$=F;=;LQ+CS!$7?9G^[N;
M'K0!\C_L)?LV^%/VL]1_:+\8?&#XB_$J;6=)_:4\5:)H>H:;\5M=M%TRRA2T
M:&&&WBNUMU6-I'(4Q$<X((XKC]4_X*!_%GP7_P $N/''A/QG\6H4^)"?%*\^
M$'A'QOJ=W':^9<SWGV6'4I9<JJO!;,\[OP-T&>]>]_"3]B/]MC]G?5_BC8_
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M=!USXG6'A&Z\.6_B:6X\2Z6MYJ"V,-[<111M;(H>2-VB,H<(V,;N*Y/]N/\
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M_@E!J'C[PW\=-'C^.,-I<?%Z^\*7VEW'_"/EUT:XT33K6U3S%\\?:$D>V$A
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M%_$#2M%U[X;>)7U;2[;Q+X=.K:3?%X'A:.YM1-"S8#[E99%96 (]* /FU?\
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M"FOP6_:%NKZ'X5_"/XN7T.F:M>:7J5])\,K^.WM+ZU0M-;22,H"R# 7;W9E
MY->_^'=:3Q'H5GKT6G7EHMY;),MKJ%JT,\6X9VR1MRC#NIY!K\_OV,KZ]TS_
M ()U_M>:EIMW+;W%O\1OB5);SPR%'C=;4E65AR"" 01R#7GO[//PNT_]I[]J
MCX8^#/C)XH\1:GH%M^P;H>L3:&OB"YA@NM2;5KB-;R41N"\J(7 8G.6R<X&
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MVU71]:DT66*V$(;;ME=@!%(3G"-R0":]$!SVK\;_ -GCXH?&'X:_!#X ZO\
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M/_!4KPYXJ\?^.?A%XY^&MCI/BGP7\/[GQ?\ V?H/CBTUJ&[LH V^(S0*OD3
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MAQX/U";X=^/O@[J6O:BGB+Q7#)?.ZSQ)]HG80#S7BS@*NT/O)XQR ?7GB?\
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M*G_9]^ ]QX3U[P%/\$_",FA^*+R2\\2Z*_ANU-IJUQ(5\R:ZA,>RXD;:NYI
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M@^!?P1\6W<E]XJ^#GA74IIO#SZ!--J'A^VF>32F.6L&+H2;8GDPG]V3U6F>
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M_@#P/?:E>?&^&:YM]/6[19-"M[> O=2W''S"*7]R0 ,N>U 'T=17YJ?LG_\
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MT^4!Y;=4E5O,+IN .T''.G\1_P#@H/KUA\7_ !Y\)?@'^S7K7Q#;X56-K/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KP7X"?\GO?'G_ *Z>'?\ TUQ5[U7@OP$_Y/>^//\ UT\._P#I
MKBH ]ZHHHH **** "OB__@H!_P $'/V"_P#@I-^T)X9_:7_:)TOQ,GB/PW:P
MVLBZ!K26]OJUK%(TD<%TCQ.6169_]6T;8<@L:^T*,CUH JZ)H^F^'=&L_#^C
M6JP6=C:QV]K"N<1QHH55'L  *M444 %>$?\ !0W]F;XD?MA? VQ_9X\':UHU
MCX?\0>+-,7XD/JMQ,DD_AR.=9;VVMA'$XDFF5!#MD*(4D<E@0 ?=ZY7XO?&C
MX=? GPJ/&OQ/U>ZL=-:Y6W$UII%U>MYC9P/+MHY'QP>=N!W- 'S)\>?^"4'P
MM\/^*/AW\:_^"??P;^&/PS^('@3QE;7C:A#H2Z?;ZAH[JT5[92FSA+ONC;<B
M$;=Z+DK]X<M:?\$XOVA/&/[4WP^^/7B?X<? _P"&^K>#?&?]M>)_B1\(K[4X
M=6\9VJQS*=,N-.DM8XX()FD0RF6\O" A" $[A[I\.?\ @IM^Q+\7-2DTGX;?
M&"YUB:&XN()_L?A'5BD,T"%Y8G<VH5'55.4)#9P,9(!]N\.Z_I7BK0K/Q+H<
M[R6=];I/:R20/&S1L,@E' 93CLP!'<4 ?#_Q6_X)Q_M#?&OX_P"B_$G6?AU\
M#?!NJ:+X\BUA_C/\/;S4[+Q+?Z;%,7%C+8&V,9:2/;%+(]_*C?,RQ+D*.7UK
M_@F7^W='\ _#_P"QKX5\6_"E? 7A7XV:5XTM/%%YJVI?VMJNG6WB"+5#826:
MV9AM954-B99YED:-$*1!VD3]%,]Z <C- 'P[XC_X)G?'/6/V1OB9\ K;Q=X3
M76/&?[1FH^/],NI+VZ^S1:;<:TE^D,K"WW"X$2E2JJR;^ Y'S5-^VS_P2D\4
M?ME?%3XL^(]7\9^']/T?QMX!\-Z=X;-Y:R7CV^K:3J4M\K7=JR+'+:2%DC91
M(69&D&%."?J+PO\ M*?!+QNVWP?XZCU/;XOO?"TC6-G/(L6KVC,ES:N5CQ&T
M;(REF(3(P&.17=9XR* /A/X0?\$V/C)X-^(=S\8M#_9Z_99^&.K:3X(O=(T'
M1O!O@UM8MM8U"YV*]W?WDEE8W5M;>6C(+.V8Y\YC)+*%5:Z3]CC_ ()^_$SX
M,?M97O[2FJ_#CX8_"C2;CPJVEW_@+X/Z]?7NGZ]>-*'_ +1NEGLK*.%T *HB
M1.WS'=*U?9&><4<^E 'QQ^U/^P?\</B-^VVW[57@_P '_"OXC:5<?#J#PYIG
MAOXM:E>6Z>$+V.ZFF?4K!8+.ZCG,RRHLL;"!S]G3$X4E1Z#_ ,$R_P!E;XN_
ML:_LBV7P#^+_ (I\.:MX@L=>UB\;5O#<,PL[A;J]EN$?R9%1HC^]YB#,%Q@2
M-]ZOH8FC.: /A"Z_X)O?M">/?VH/ GQQ\1_#OX'_  [U7PCXV_MOQ%\3/A-?
M:G;:QXPLU29?[+N-.DMDCAAG+IYS2WEV0%;8H)!&C^Q3_P $T_CC^S=J_P"S
M;J'C?Q=X3NT^#GPS\0^'?$HTJ]N7-U=7]S'+$]MYENF^-50AB_EL#C"MUK[>
M)Q0#F@#\Y?CU^R;XB_94^&2_';QG\6/"^A^)-#_:;O?'?@?4[RSU&ZT?RK])
MX&LM5F@MF>PCDMY95:ZV/'#)Y9R^=I\RT+]G_P#:;_X*@_&_XZ?%)->^'K:-
MJJ_#FRT/6/#NIWUSX?:/2M4N-0O+.UU&2TC?49$1]S3K;Q1^9=+%@>6SG]9Q
MG-&,T ?FKX>_X(B>(_!T5S\'M$^#'[.=_P"&[CQP^L1_%KQ#X/2_\50:=)>?
M:I+$V%S82VLTW6);M[GY5.[R2R@U]?\ [=/[*.J_M8?LZ?\ "J_!WB^V\/\
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MK\6Z!\&?A9X6O/A;<^&])\+?#.:[NSHVH"[M[N"]\R2QM$O%:2!0R&.#RU4
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MAFA@<8@F0YD0EAMD'Z%44 ? >A?\$S?VOM<^#^N:+\5_'WP]F\5^(/VEM/\
MB1=S:/=7JV,.GPF+=:H9+?>9E6/8N0%?:&+)N*K+X/\ ^"9W[4&B_#[X9_!S
M5M=\ G1OAC^U,/B/8ZQ;ZU>FYU31WEU6:6)X#9!8+M6OXT6,2R1N$9C*APE?
M>]% 'P7J?_!.']L;2_@'XS_8!\"^.?AVOP;\9>+-1U"/Q=J%U?#Q#I&EW]^U
M]=::E@MN;>X<222I'<M=1X5ANB8CG:G_ ."9?Q8L?V-/VIOV9/#WBKPTMY\:
M;C7!X'N;B\N/)LX+O3UM;<7K"WW(RE<OY:R #IN/%?;5% 'YS_$?_@E)^U+?
M^*?BU=>&K#X,^*+KXG:%8V6@_$'X@7%_+JW@=(=*BLI+*TM%LY([BV\R-YD9
M;BV8&9MZ.0"?8OV7_P!A#XS?!SXV_"/XH>-?$'AB6U\!? %/ NL6^EWUQ))-
MJ"W*R>=#YEN@:#:OWF*/GC9CFOK:B@#P/X[?"+]L+3?VA;7]H#]F?Q[X?U_2
M;KPHNA>)OA'\1M>O;'1IWCN'FAU.SN+:"Z^R7>)'BES;2K-&(P=AC!/B,W_!
M)#Q7\4=#^)WQ ^)OBCPKX*^(/CSQ1HWB+P_;_#^UFNM(\-:EI1W6D[&9+=]0
MD=B1-(8H-Z':%&,U]U44 ?+/B/X2_P#!33X\ZCX1\(_%GXA_#[X;^&?#OB"S
MU;Q1J_PK\4:K<ZMXN^RN)$L )[2V72K6:0+YX62Z=HPT2LH<M7+_  $_X(\?
ML_:M\+O$VJ?MV_ GX:^/OBE\0/$6KZOXR\3KHB7_ )1NIG%O;6MS=0)-Y5O;
M"&--RKM9"0.Y^SJ* /"_V&/V?_CK\ ?V/M+_ &</C5X\TN]UCP];WFE:+XA\
M.W,TK#30[K92,9XD(N$A,>X89=Z\,PKXU\%_\$>?VO\ PK\,_A3\*K30_@-9
M7/PW\?:9KWB;XC6M]J4NN?$%;:Z,K3W9DL ;*X<'S''G7:O(-H:-3E?T^HH
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M_P C7\>O^R[7_P#Z:-)KWJO!?V(/^1K^/7_9=K__ --&DU[U0 4444 %%%%
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M?""#Q5XZ\!R-\#H/$6@V7B;XM?\ "4:QHVH?VK;V_P!J%PNX6N]'8&%)I8R
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M71_"?PEB\86/CJ;P?K%WISAXY)C-)+#"(FM5B57#)(/.^98V+# YKPK^S_\
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MQXL&J_%W1_!6NZ>O@77/MNC-<W$:W GLA:"YAN%A?=%!)&KS,RB-9/NGM_\
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MGPS^,^D17&C^%M,6-RL6EZFZ&9F23:L<4=Q<1;?0 5[A_P %&_A1X.\;^(/
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MQW\.M4DA)M[SQ#J/AVQT8V" <>9#+'JEUCJ#>(>IS75Z-^RE\>4_X)Y_L?\
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ME619/+$,,-S-&=V"H4<<SKG[.WQZO?A)XH^!=U^S_P"+)M0M_P!LZT\9K/\
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MV5QX+_86L/@+XA!B\3?#+QEXB\,>++63B2.]AU6YE$C>HF@F@N%;^);A3WH
MY+X8_M7_ /!13XF_M(K^RC::7\/?"/B#1_A=:>*_$TWCCPU<7\ZW-S?2P_9$
M73M2CA5$55PX=RPP3AB0.M_:^_:;_;)_9+^#?PW^WWWPSUSQQ\1/CEX?\#0Z
MA#X:U&WTFQMM3E>(7#6QOVFDDC9<X$RJPXP.M<OXU_8.^&O[1?\ P5L\7_$G
M]I[]D?PQX\\#Q_!G2[/P_JGCKP7::K81ZBM](94@-U$ZI+Y9&[;@[>O%2?\
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M@<=]X?\ ^"CW[%OBKXDVGPLT#XWV]QJ&H:[)HFEZC_8]\ND7^IQLRO8V^J-
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M&-TD!-L\.^-<&,QL!M/'ENN_!#]H_3_VR+']MO3_ ()_$[X-^%_$W@^]T?\
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MQS^U[^R[\.K?XJ_$+2=%B_9-:[OFT7XA:G#J%XSO;,(CJ/GF\CB5F)$<<J
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MM\:77PWO[C2XHWN;"UD:PLIP5N((>$5I4,<K ,08RW !^JW>D'LOYU^96O\
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M?QGLY->NM8DTFS_XE]TME=:B@8O917QB%K+<C:W[E)3)E2-N17L SW%?G/\
M\%(6\!^%?@U\)?VC?@+XM\ ZG\"_A_\ &_PSK%S\-? .BQVM]K>K'6HX(Y;6
M_BF>-C#=SI</9I;(TWDR*TX!(KZB_P""BGAG]I+QA^S;<:)^RSXNBTOQ*^LV
M+SP?\))_8UQJ=BLZFYLK>_"L;2>6/<B2@ J3PRGY@ >J?$7XJ?#WX0Z78ZU\
M2?%EKI%KJ>M6>D:?-=,?](OKJ58;>!< DN\C!1^9P 371<8YK\=_VD]0\"_%
M;P;HGP \9W7[0_A;Q1X6_:0^'[:YX%^(?Q:N[]M&@OKU8Q+8ZM9W;SW,;A69
M));F22%_FB$)->E:]^T5\6/!W_!+[]K?Q*?CWXHAUSP?^T%XST+PKK5YXLNI
M-0TRTBU2..RM8;B24S(JQ,H10WW6XZT ?IQJ%_::78S:G?S>7!;PM+-(03M1
M1DGCT K!^$WQ9^'GQU^&VC_%SX3^)H]9\.>(+%+O1]4AAD1;F%ONN%D56&?<
M U\1^(I/&G[5G[1_QH^'_P 4OVEO'/@/2/AE\.=*E\(V/A?Q=/I*&2YL7FFU
M>Z$3*+]0XV>5<"2'"L"A)S7SI^RI^UIXS_X)O?LV? GXY^./'NM:O\+_ (E?
MLP3:78Z3<ZC)):V7C+1H9+VS^SQL3'!)J%I)<QE8P/-ELXL@G% '[%T$J.2>
MG6OF/1=4_:*_9,_X)4WGC;QGX@U/Q9\4O#OPSO-<U:ZUFYDO)7UAX9+J2/\
M>%B8H9',:)T$<2J !7S;XCN/'OP@\!_LO_%OPI^UU\2/&VK?';QMIOA3XD:3
MJ/Q O9K37--U;3[I[N\L8(Y1_9$UD46:.:P^SF,1D,3D$ 'WA\$OVGO@C^T9
M<ZY#\%O&$FN0^'M2DL-2U"'1[N*S-Q'(\4B0W,L2PW.R2-T8PNX5E()!J_K_
M ,>?@[X7^+VA_ +7/B#I]OXS\2Z?<WVB>'#(6N;FVM]OFS;5!V(I=1N; )R!
MD@X^7/\ @@7\-/#W@3_@G#X;U31-2\03RZOXF\3-=+K/BJ_U&-##XBU.%?)2
MZGD6WRJ@N(@@D?,C[G8L<'XD_LU?!KX-_P#!9WX)_$_P+X5>+Q'XX\/>-;OQ
M1KE]?SW5U>,J:=Y<>^9V,<* G9"FV-,G"C)H ^C_ !9^WU^R)X'^*L_P6\4_
M&NQM=>L]2M]/U!?L-T]G87DX4PVMQ>+$;:WG<.A6*657(=>.16C\=OVS?V:?
MV:M6M_#_ ,9?B8NFZA=63WJZ?9Z3=W]Q':(</<RQVD4K0P*>LT@5!W:ORY^)
MOAKXN^/_ -F+]J7X\^!?&GA_2/@@_P"T5K.K^+OACJ]N9/$VHS:9?16VI-;Z
MKD)IWVJ6S\R&UDM;EU5E"SQAP%]I\$:#\</CM_P47_: OO"G[2,GPGMY/AQX
M9U#0[J3PSIM_>36,ED[)%<#4H9XQ9*Q;S4C5)&8M^^3B@#[!\>_\%#_V0_AS
MXHT'P3JWQ.O=3U7Q-X57Q-H-CX2\(ZKKKWFCF01"^7^S;6?$)D95WG RR_WA
MEVC_ /!1#]CC6OAUXP^*4/QDCM=*^']LMQXTCU70[^RO='B;[KS65Q ERJGL
M?*Y[9K\[?V+/CC\?_B9^VS\#?BQ^SQ^S1\.(=:U']AW4%NO!]YXBN/"^CVUO
M'XKM8S-9?9M.OBJR/&CQPF-5$<V3)E0'I_&[6?%'Q[^"7[9G[3WQXM]%\%_%
M"Q^'-KX-UKX/Z3=2W+Z'9V]V)HKR:ZDCB^V^?OW)+'&L83@?-NP ?J1XQ_:F
M^ '@#]GQOVJ_%?Q-L;?X>KIMOJ'_  E$<<LT!MIW1(I0(T9R&:1 ,*3\W..:
MU/!/QP^%7Q%^(/B[X5^"O%\-]X@\"W-K!XLTV."56T^2YA\Z!69E"MOC^;Y"
MP'?!XK\XO^"HC']G3_@ES\1O@5>?NO"?CCPCI.L?#^1O]79WPOK"34-)'IWN
MX5SRC7"* MMS]"_L'$_\/(_VS/\ L:/"'_IE- 'V)M'I7G\/[4_[/US%#/#\
M4=/,=UXW?P?9S;9 ESK:/Y;V43%<2NL@9&9"55T=2P*,!7_;'^(7B[X1_LB?
M%7XK_#Z/?KWAGX<:YJVBH$W%KRVT^>:$8[_O$7BO@#XJ?L]_#9OV+?\ @GSX
M;M-=\1+9+XX\&&34-%\9:CISWLEY8_:+F\D>TGB+SRS,\OG$[U:5]K+O;(!^
MC_P^^,_PR^*NM^)O#?@#Q9%J5]X/UIM(\2V\<,B&RO0BN8274!CM93E21SUK
MISRO2OR:\0_"WQ7H'@_]O3]I?P-^T/\ $CPUX@^'_C74M5\&P^&_&5U9V=M=
M6>EQ3A[BWC<1ZAYA0*ZW0E4J3A0>:D3]HW]JG]J[XY?'*Y\0:/\ &[[/\.=(
MT&T\$Q_"CXG:-X:T[07N-"MM1DU6_BO=6LGU%I9[AB//CGM5BA"!2V^@#]2/
MB)X\\.?"SP'K'Q'\77$D6EZ'ILU]?R11EW\N-"S!5'+,0,!1U) KQO7?^"F/
M[)7A+^S8O&'BG7M/NM<\07NB>']/A\&ZC?W>K7MG:QW-W';P6,$\CB!'(D;:
M K12]0A-:W[(FL^*/VF/V&?!.J_M0Z#X<US5/%7@R!?&%G;2VFH:9J3.FV1@
M86DMYHY0-Q"%D^<@<#%?+O[>GPT7X&_\%$/V,HOV0O@5X$M]<O\ QQX^OO[#
MNKT^']/U"Y;PG+'+/<7%G973K)Y*<-Y$A<QHA*@[U /K3X,?ML?LU?'SQO<_
M##X=^/KK_A);6Q^VS>'?$'AK4=&OC;;MOG);ZA;P22(#P652!W->K Y[5^8?
MB_XU_'_Q;^VCXX^.WQ\\#>%_AW\4/V??A#K\WP_^&NA:Q/K#>*8+N#/]K"^E
MMK59[9&BV^0D0=6!\S&5KE?@O\>?VS? N@_ +]H7P[I?Q?U+6/'6KQQ^/)/B
M;\8_#USX?\8VMS87$[QZ7IL>L3/:7,4B1R0QVEM$QCCD60-TH _64'Y:4'M7
MY*VWBGXO7?[%_P"R_P#MO2?MU_$J3QY\6/B#X7N?'6DQ^.KE=*U(7]PKW&E0
M:<'\BSBMBQCVP(C,L++*9-S9](^*W[1_Q8\,?L=?M_>*;GXW:_8ZIX)\3:]!
MX-OV\031SZ&O]GQFW2T?>&MQYC901E<,<CF@#[Z\'_&KX8>/_B'XP^%'A#Q9
M#>^(? -U9VWB[34AD5M.EN[5+NW5F90K;X)$<;"P ;!P<BKGQ(^)'@;X0^!-
M4^)WQ+\2VVCZ!HEFUUJNJ7C$1V\*]6; )_($D\"ORUO_ ([^(OA/XA_; \4:
M=\3O$VA^(/$?BSX3Z1I^I>&=/BO-6O;J]\+Z5$;>!KB:*.&:;>R"YD<"$OYF
M&*X/FG[8/B#XVVWA']H_]EGXHW'CC0O#J? >U\3VOA'7OCUJ7BB_L;Y;\1^;
M)>&3S(DD3[UKYTT#8!VC % '[5V-Y:ZE8PZC93"2&XB62&1>C*PR#^1J4G)Q
M7P+X/\.:K\8?VTY/V*/$?[0/Q&\)_#WX<? 'P_KOAO2]"^).IV>I>(;Z_N+R
M.XU"XU03_;KJ.U6UBC6%IS'NF)D5_E \0_9>^(?[0W[9/[4OPW^ _P 5_P!J
MGXD?\(OHMG\0-*N-4\)>,KK1;CQ;!I6J16]A?W$U@T1>55)5I$VB0HV<AF!
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M_$UJGB7P/\9_$46M7GAMKJS26&&TU)9)Y+RTD56E5IKFXD#,PRBE4 !]3=.
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M\?KW1[SQEJ_PRFE\07_A_4+6[L[VX6"1#=12VCO PE"B7]TQ0&0@8 P/%_\
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M<.N>#],\;02>+O"]D=/O)FLH==U;4$E1+^2U5HVFF26(13K%(V]50 _3R@G
MYK\AOBW\4_VP]*U2X_9OL?B=\4/ /A>;X\>";'2O[>^+6GZIXNTNSOTN1?Z=
M/=Z?J-Y/]GD5 T;7,K2#.0?E7'O?B'X(^)?$7_!4J3]D?_AJ'XSV?PY\/?LO
MV>O)HMA\6-7BNKS5)/$6I1+=37ZW'VMW2/Y,^:"ZQPK(72-5H ^Z+GQIH5EX
MRM/ 4WVW^T;RRDNH=FDW#6_EH0&W7"QF%&R>$9P[#D @&M8^]?DC\'/VL_VG
M/$UAH=AXD^/7BJ\FTO\ 9_\ B@DEX=8EC>^NM+U"XM[._G$957NTCC3$V V1
MG.2373>&O&'Q\_9E^&_['O[1NA_M#_$WQQXF^*K7.F_$+1O%GC2[U#3_ !!Y
MGA74M1B\NRE<P6<L=S9P[)+=(V(+"0R;CD ^[(?V$/V0[?XCR?%J'X$Z,-<E
MU1M3DN/WOE->,VYKDP;_ "?-+?,7V;L\YSS7>?$3XJ?#SX36&FZK\1O%EKI-
MOK&O66BZ7)=$_P"E:A=S+#;6Z8!)=Y&"CMW. "1^7\.O?%>+]ES]E7]L5?VZ
M_B5<>-/BQ\0O#T_CO2!X[N?[+U47K&2?3H=/W^39Q6S'R]D"(66(B4ODU]%_
M\%M/AKX>^(OPX^!EKXAU3Q!:Q_\ #3G@FT9M!\6:AI3".XU)(W;?9SQ-Y@'^
MKESYD3?-&R,2: /JWX6_&?X8_&NTUR^^%WBR'5HO#?BB_P##NM20PR)]EU.R
ME\JZMCYBKDQO\I9<J>Q(K2T_QKH.J>+-0\$6GV[^T-+@AEN_-TJXC@VR E-D
M[1B*4\<JCL5_B K\EO"GP_\ &?P?_9#_ &IOVM/AO^T3\2-'\1>"OVIO&4_A
M>QT_QM=QZ7%%#K**\5Q9[_)OS-E_,DNEE<@C:RD9/I_[17BG]M[XQ_M>?%#X
M>?L^_%/56L]-T[P+J=]X%A^($V@MJ5A-:SO>66FWN3_9]Q*_EL9(_+9Q&09$
MSF@#]+9X(KF![:==R2*5<=,@C!KE/A#\"_A+\!-#N_#OP@\#6NAVFH:A)?WZ
M6Y=FN;E_O2R.[,SL< 9)/  '%>"?\$Q_B]X:\6/\3?@TDWQDTOQ-X%\2V:^)
MO WQF\21:W=^&C=V:2PQ6FI*\TEY:2JC2JTUS/(&9QE%*H/DS]IG4_C]?>%_
MVW/V@-(_:X^*FCZQ\(_&-K_PK'3]'\<7=OINBE;2TD=6LT<0W<;LQS#.LD8!
M.%!)- 'ZN#CBJ^I:G8:/IUQJVJ726]K:PM-<3RMA8XU&68GL  37YM_$WXO^
M/?V$_CKJUM<?M8_$&3P]KG['/B'QQKVJ>+KZ?Q-_9WB"PO\ 3(8=3M+*>54C
M)6_E#6<#06[E8QM3&ZO,;KQC^T?X3^*OP]^&/CJ^^*&AZ!\6/A;XB'B*R\;_
M ![N]8U+7#%I1GCU!;.WF>/17WX.VSN$4;S&4(H _4#1/VE_@1XBM? UWHGQ
M-T^XC^)33+X%*,V=9\JWDN9#$-N<+#$[DG P/4@'NAGUK\@_V=_V=/AW)IW_
M  37E?Q5X\'VY=?GN-OQ4UY0DB>'[FY"QXO<0H74*8X]J-%F)@8F*%K_ +2G
M[:?Q0^&WQ<_:ML;?XQ:?XR\+_%S6]+\+ZM'\6- TGP3X?L].U)K6#3;W2KO5
MX?-#QQYFFGM'F9I=T3!=E 'Z_=*YY_BK\/(_BG%\$7\5VO\ PEDV@2:W'H>3
MYQT])T@:XQC 02R(G)R2>,X./CK_ ()L:7\2?C=^T;\;OC7\8_C?X^OKGPS\
M5)M/\-^$XO'EZ=#TNV:PA:2W%FDOV>X022,RLZOMPI0J.O.?M)>'H/ O_!9#
MQ!\=?#4GB:[\0:%^R#J.MZ7IL'C+4X[2>\@U>**.,VB7 @>(KAF@,9B:3$K(
M9,/0!^A/4T5^9&A^/?BU\)?V>?V:?VT_#'[6OCKQ?XW^*GC;0;#QMH&L>+)[
MS1]:M]35S=0P:8S&WLOLO5&MDC91$0Y;)K]-QGO0!X+^Q!_R-?QZ_P"R[7__
M *:-)KWJO!?V(/\ D:_CU_V7:_\ _31I->]4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+\!/\
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MV/?V;_@OK.A^(OAM\,8-/O\ PWH<NC:'>-?W,\EG82.)'MU,TCG9N48!S@
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M[GPKK^[2?LT?VRVNYGGE:.]>YD%V%C: "([$@;S5@9@'[C]I+X_^.=(_:/\
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M6$>GZ!<7,VBFQOKJUN+-KB0R3B.XAE68+([%F3?M)/2O9** /,=<_8T_9?\
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M[.6C7^A_!GP);Z/'JU]]LU:?[1-<7-]<;%023W$[O+,P154%W.  !@50UO\
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M#)=37&@W<-HZRC*B&ZDB$%PPQ\RQ2.4/#A3Q0!K4444 %%%% !1110 4444
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M>'?_ $UQ5[U7@OP$_P"3WOCS_P!=/#O_ *:XJ />J*** "BBB@ (SP:_'_\
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M%;3W.GKJEVTL\?G#S8HY79WC:8%2,#'C?Q__ &N_C'^S'\.O''P%\%Z/\:O
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M6)D"_-MV[VS^H_PB^!/PC^ OP[A^$GP@\"V>A>&[;<+?1K3<88U88*J')PN
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M(M4_:8E_;2U;XW_M*>-/!DGPGD_L7P/H.B^,KC3;'3M,_L*WNQ?SVD;K#?\
MVJ:XF&;E)5"QA%"E2:](\>R?%#P__P $1O 'Q;^#WBC6M-USX=>!?#7B]8M$
MU"6W;4+33U@N+RSE\M@98I;59U:,Y5CMR.!7TM\8_P!B/]D[]H+Q,WC+XS?
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M[:WX+_:6_:2^#_Q&\=B#X5ZI=6VA^+[CXJ7'AK2_#]Y:1H196^D6LSIJI,F
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MX$U'2;KQ%XLU#==)=V]\7>XL_-6W9OW8VKY06$[_ "ECWMFQ\5_@SX)^-/\
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M:>#-3;3KJ^^+\GB[PIXO>S6":XO8Q<22R6$RJ=R+&MM%ME92KG:!]>3?L?\
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M">?COQ[\&F^(6J:[\/;SQ)I,VE?$Z_CU#5['5K)I&:Q>YC!%W'$S*B2EI69
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M?37Q-_99_9Y^,GAS0_"7Q-^$.C:QIOALC^P;.XM]J6*A FR/:1A"@"E/ND
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MW-WO?YE23S;= NTJ>:I?LAZE^T-^VY^T5X,\.?M/?M(>,(8?^&/=*UW6-/\
MAG\1[K3=/U;5_P"W]3M8]66;3)HP7D@C1V\IE1R55@R1JH_0/XN_L9_LM_'?
M5K/7/BU\$=%UB\L;,6=O=2Q-&XMQT@8QLN^/_8;*^U=!H/P'^#GA7QLOQ(\-
M_#C2['7(_"L'AJ/4+.U$;II$,KRQ62@<+$CR.P4#@L: /S#_ &)(-2^/'[;/
M[-_Q*^,WC[Q9K/B#3_A[XULFU>7QIJ-N;W^S]7%M;M-'#.D4K&,#S%*;92 T
MBN0"/UJ'3BO+[3]B[]EG3I?#4^G_  3T6WD\'ZA<WOAF2WB:-M/N+B0RS.A5
M@?G<EF4Y!/:O4!GO0!X+^Q!_R-?QZ_[+M?\ _IHTFO>J\%_8@_Y&OX]?]EVO
M_P#TT:37O5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>"_ 3_D][X\_]=/#O_IKBKWJO!?@)_P G
MO?'G_KIX=_\ 37%0![U1110 4444 %%%% !1110 5P/[3'[2/PV_91^$MY\8
MOBE/>?V?;W5O:6MGIMJT]U?WEQ*L-O;01KR\LDKJBCU/) R:[ZO"_P#@H1^S
M#XR_:E^!UCX>^&>N6=AXJ\*^,=(\5>%Y-34FUFO=.NX[E(9L<[)-A0D=-V>U
M 'AG[9'_  5D\9_"7]G?XHP>%/V=/&7@_P"+7AGP%+X@T'P]XNCTQM]D3Y?]
MI(Z7;P3QPN1OA#F4$@&,C(KZ#_9EUWXUZ7^Q_IOC3XJR^,O$WC)] FU&XM/%
M7]@PZE<3%6D2 ?V4(;!5/"Q\C"E?,?=N-?+G[67[!O[9?[<X\>?%#XD>$_"G
MA'76^#6H>"_ WABS\1M>1SW%Y*DDUS<W7E*$3Y JJ$)').:^Z_"_AZ^TSX<:
M?X4OF1;BVT6&TE*G*B180AP>XR* /S/_ &3?^"LW[:GQ&\=? 2/Q_P#!SQ;K
MC?$#P;XPO-0\*Z#I^AAM:N++5#%;W,<OGA;2*&+,)$LT6YD)(?(8_6R_\%2O
M@,_[.^F_'?\ X1+Q7_:&L^.F\%:7\/UTU&URY\1K-)"VFK$)#'Y@:*1B_F>4
M$0N7"C->,?L&_P#!/_\ :I^ OQJ^$VI_%+0/#D&@?"OPGXLT)=3T[7C/-J8U
M'5#>6\XA\I?*^1MK*6)!'4YK(^(O_!)OXQ^._A/(=0@T.\\0>&_VFM7^(_A_
M0YM=N;>UUG3;M[B,VDMS;[);65H;@L'4G8Z '()H ^MOV=_VOO#7QX\=>)O@
MYKGPZ\1>!O'7A&WM;K7/!WBI;8W*6=SO\BZCDM9IH)X6:.1=T<C;60JV#Q7@
M'PD_X*<>,?"_C3]I?Q+^U9X"UC1/!/PG\=6VE>';R*/3YF;S8;=(;".*UGDG
MN+F::967*E?WJKE2"H[']A#]C7Q-\%OC1XS^/?C#X/>&_!,FO:+9:/I&BZ;X
MDO=<OTMX7>61KC4+J0[U:1ALB1%5-I.26->:_%[_ ()Q_M%?$35/CYX6TB70
M;.S\<_$?0_B%X \33ZBS^3JNFM:21V5U:A,^4SVI!D#GA^F10!TW[2/_  5.
M\1_#OX3^.- @_9O\;^"?B?:?#?4/%'@30_%L>F,NL6ULJB:XADCNW@9K?S(Y
M);=Y%F"G_5GI72>!_P#@HEXCTOX*?"O_ (33]GOQIKOQ$\;> ;;7;SP_ILVD
MPLL(@C\R\EN7NX[*%)';<D?G!\-C8""!Y]\?/V*/VO?VZO',?Q$^.GAGPMX#
M_P"$3^%7B7P[X3T?2M>;4FU#5-8MXK>6ZFE$<8B@2.+"QX+9DR3\M8>N_L/_
M +8'BS4?A-X@^*7P7\,^,M$\&?"^'PS??#2]^(4UM86NIP+&BZH'CB"W0=$P
M8W7*C@&@#M/!W_!1S4?VCOVL_P!F:S^!?B&_TOP-\1-+^(\/C;PSJFFVWVG^
MTM#_ +/ACAEDP[1M!/)<C]S($D# DNNTC3_X*;_M;_$3]G'XB_#;PK>?%/5O
MA=\-?$TEZ/&'Q:T;PO!JD^E7$: VUH!=07%O;"4EB9YH9% 7& 3FO)_V#/\
M@F+^U-^SU\8/@IXO^)>F>#;73_AYXE^*MYK,?AN^80B#Q#/936 MX2@PH\F5
M60GY J\MGCZF_:<\#_M8_P#"T/#WQ/\ @'?Z3XF\.VVEW.G^+/A;XDNEMK/5
M5D*M'=1SF-]DT>"N&4JRL>,T >7_  C_ &U-(^"GP-^(7[27Q?\ VW/"_P 9
MOA)H;V!\(>+M!L[9O$,UQ.X@.G74&FP0VLLKW+P) 88T9S*59%VACZ!X._X*
M%>%K_P 3:Q\/?BS\#?&WP[\4:;X+NO%>G^'?%4=DTVKZ9;KF:2VDM;B:(R(2
MH:)W61"Z[E YKY7^+?\ P1K\??M(Z1\8/'$O@KP;\)]4\<1>%Y_#_@/PQ>O+
MICW^B:E_:"W5]);K"#)<<6[-$J,B?-DL :[[X4_\$\_B3/\ $'Q!\4-:^ 'A
M'P'-'\,=7\/:':KXXU'Q#>W-]>PF-I1=73E;6WP #&J%FR"3\HH ]$_9L_X*
MM?#_ /:+\9?#CP[)^SU\0O!^F?%S1+W4OAYXE\56]A'9ZN+9(Y)( (+J26.7
MRW9U61%W+&Q!QC-?PG_P4R^#GQ._::TOP#HVI>.M)TRUU7QOI(NFL]+_ +!U
MMO#XM5OKQY&#W?EQ32R11-$\2L\4_F*RB,UR7Q/_ &!_VD&_X)E_"GX6?!V\
MT&Q^.7P9&DZKX,O+J\(L!J5L##<0/,$SY,MM-<1D[>=RY'%5-)_X)2>(O"LW
M[/OPWT#5+.3PO\.?@[XL\+^--7DNBMW=ZGJ]M:^9>HF/WAEN5N9G)((+]\T
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M@VZ\;>(/#OPA\=>*O _PSNC!\1/B-X=L;:72]#9$#SDJ\ZW%RL*-OE:WBE"
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M<D+"+=YK#TOP]^W[\;;+_@H/XO\ A#\6O@WK'A7X<^&?@W;>*-3N-2O-'?\
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M;QKX@L;%+-]09G1;>1([IYT!>-T$IC\IF'#FO(_@!_P2X^*_A_Q1\)=$\>_
M;P3I-G\+M4CU'4O%[>.-4UB36;BUMI8K5[*QGE\O3Y#(ZNTAWE5#(HPYKK/
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M)$:2W8C)C8QLR$@\$JQ''!(YKX0_:C_X)W_M)?$CXL_%+XK> +70;EM9\?\
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M\-OV=?AU\.]&U;]GWQ-X'AT6R\627EX^J7K6LD5S<W319FC8PE!WC"D_-OX
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M67EEX@UTZ?-9_P!G7$DMM?AA&XF5A,X>,;3\HP>: -3PS_P6!^''Q#\6^#?
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M!>11S,ADC-^-R[E((!'!P>AKY._X*"_#YOV=?VA?C'\)_P!F/PW>^$_ >I^
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MP4+\#)<0I\??C+I-W<3,;B)H/AQ87L=A9+)Y ,R02VT<MW)L&=E\YH _2_\
M:1_:F^&?[,?P%U[]HGQ<+S6-#\/-:K?0>'/)N+AC/=16R! \B)P\RDY<?*#C
M)P"[]I3]J#X7_LI? ;4OVB?BO/>1Z#ID=N\T=G"LEQ(TTB1QHBEE!8LZ]6
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MW]FKQI%?>.K74/"__">:NW@]M#M+Q;+3-.W?ZBQ>['F3VR/O\IPNTK@*, 4
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M[X23LW[84WC305\53LSGQ8^N&_0:W'J.?WQM OVD%9?W B"[>-M 'Z&_#?\
MX*7? SXH:YX!T'0?"/BR&;XB>+O$'AW16O+&U58+K2"1<O/MN&VQMC]V5#L?
MXE2O?5\1>'WU$Z.FN6;7@ZVJW2>8/^ YS^E?DS^RO?/IGC/]F74DM);@V_QP
M^+$JP0#+R;=YVK[G&![UXI_PG7ABV^&OP1_:.\/^*_ >@>+-4^/FAS26-O')
MJ'CNVCGUK;=)KFI-LDB4H[H\3H(3O6)1C% '[H1>)/#TT[VT.O6;21JS21K=
M(60#J2,\8[^E/TS6]&UI&DT?5K6[5&P[6MPL@4^AVDXK\N?V;_V5?V?O%?\
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M+_P3#^%GQB?2/#_A_5?$'A91X@\67[Q03WS/=R>7'-<2$%P#M1%)P  % Z4
M?<E%(CI(@DC8,K#*LIX-+0 4444 %%%% '@O[$'_ "-?QZ_[+M?_ /IHTFO>
MJ\%_8A_Y&KX]?]EVO_\ TT:37O5 !1110 4444 %%%% !1110 4444 %%%%
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MO]Q_.K>F_M$?M2:-;?8](_X)B>,+6'>S^5;^.O"T:[B<DX74 ,D\GUKZ"HH
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MXU4>E>F:3\;OVB] TN30]"_X)7>)K*RF),UG:>,O"D<3Y&#E%OP#D>U?1E%
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M_!++Q1#-9VY@M)8O&GA56@B/5$(O\JIP/E&!Q7GG[2^B?&G]I[X:)\+?%/\
MP36\?:1I_P#PE>G^(+B30_'7A*.2YNK2Y2X7S-]ZRL'9 ')&XCN#S7V910!\
MZZ/\<?VCO#UE+IN@?\$K_$]C;SL3-;V?C3PK$DA/4LJWX!S[U!IWQ>^/FCV-
MUIFD?\$G_$%K;7PQ>6]MXN\)QQS_ .^JWX#?CFOI&B@#YZE^/_[3<\EO-/\
M\$O/%DCVL;1VS-XW\+$Q(1@JO_$P^4$#! XQ5;0?C+^T%X5N)KSPO_P2E\1Z
M;-<?\?$MAXP\*0M)_O%+\$_C7T=10!\XV?QH_:%T_6I/$MA_P2H\20:C-GSK
M^'QCX469\^KB_P!Q_.FV7QA^/^F:Q)XBTO\ X)1^(K74)0PDU"W\7^$TF;/7
M+B_W'/UKZ0HH ^5?@;XT_:,^ /@!?A[X._X)M?$"6U.JZAJ,]Q>?$+PL9)KF
M\NY;N=SMOPHS),^   JX &!6QJ'Q;^/.K:C+K&J?\$G?$%Q>31F.:ZN/%WA-
MY)$(P5+&_P D$$@@G&*^DJ* /G:#XZ?M(6NIQZW;?\$L?%$=Y#;"WAO(_&GA
M42QPCI&&%_D)_L@XIFO?&O\ :(\4R0R^)_\ @E5XEU)K=LV[7_C+PI,8SZKO
MOSC\*^C** /GQ/VA?VH8]1_MB/\ X)@^+ENOLPM_M2^.?"WF>2"6$>[^T,[0
M23MSC)S4$WQP_:,N='?P]<?\$KO$TFGR,S26+^,_"AA9B<DE/M^TDDDGCK7T
M510!\]Z/^T#^T[X=L$TK0/\ @E]XNL;6/_5V]GXX\+11K]%74 !3?^%_?M-?
MZ9C_ ()=^+/^)A_Q_P#_ !6_A;_2?EV_O/\ B8?/\O'.>.*^AJ* /F^]^,7[
M0&I36ESJ/_!*/Q%<26"A;&2;Q?X39K8#H(R;_P"3'MBK&F_';]I/1W232/\
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MVAIO_!)S7K>X^T>?Y\'BWPFCF3:R[\B_SNVLPSUPQ'<U;/QU_:1;1H_#K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<?\7OV@/@G\ ;/
M2=0^-?Q2T7PO#KNK1Z7H\FM7R0"\O) 2D$>X_,Y / ]* .PHK OOBI\.=,^(
M]A\(-0\::?#XHU339M1TW09+@"ZN;6)@LDR)U9%9@">Q(IFK?%OX9:%\3-'^
M#.K^.=-M_%>OZ?=7^B^'Y+I1=7EK;E!/,D?4HADC#-T!<"@#HJ* <T4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P 4OBQ\-?@EX)O/B1\7/&^F^'=!T_;]LU;5;D0PQ;F"J"Q[EB !W)K#U_\
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M\P2_\(K;VK11B?=N^T>8C"7S]WS>=O\ ,)YW9KB_!W_!$O\ X)B^ /@#XO\
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MO$MUX+_9SL=-N[?QC)H-F-2N];DL#,VE6Y";(8!<>=&P +8BC&06-7_VQ_\
M@J!^W=JOPA^&'PG^&OQI\<V?C'PS\$;7QI\:KOP#I-A;W,?VB RVTTM[?/Y,
M<90 M&$+,3QR0*_4;5?^"4W[!^M_#SXH?"O5/@I--HGQF\:-XK^)5N?%6IB3
M6=5:83&9I1<^9$F\ ^3$R1 94)M)!Q?VA/\ @B[_ ,$S/VJ/&5CX_P#CM^RU
MINMZOIWAN/0;>\76+^U)T^.+RHHG6"=%E*)PCN&=#@JP(!H _)7QIXY_;!_X
M*<^"O^">'PD^-'[5OBC1=>^)G_"0^*?%L&BPV\<:VFB7$UQ8ZQ(I7$EPUJ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6GAW3+JY4B5)9?/#RL")?+M@I(8L:[CX/^&/%/Q>\/?%SX3ZG^TYKGACX/\
MPJ^-4L%UJ]UKLHN[O18;&&:?3O[1=_-CB2=SF0N7V_+NKW3XC?L<?M!^)?BK
MX9_::\ _M&>&?#/Q1L? -QX/\6:M%\/9;G2-6TZ6Y2Z4P64FH^;:30S*S1,;
MF51YKAUD! 7S#XP_\$BO'?B/X=_#_P"$/PC_ &E-(LO"OAG7+KQ!XXT+QYX(
MN-8A\=:U/)YK7FH?9-2L2RB0EA#DID*,84"@#EOV7_ 7Q:_:/^#/Q4L?AK\?
M_%_@KX%W_P 4-/NO ?B+7M1F?5+CPK;00-JR6UW<L9H;:YG280SN2Z1,[ X*
MD=__ ,$R=;O/%'QM^+6N_ [Q%XDU/X!QMI]IX$OO$FK7-\M[JL?FC4)[">Y9
MI9+,_N5#%F4NK%#BK_[6?[!O[7G[67P-\&_!;Q!^U=\/M#T_1?$7V[QEHVB_
M"?4(=&\5V$07[+ID]LNNB>.W5@6E1;DK,0@*JJE6]_\ V=_ _P 7/ASX#C\(
M?%GQ/X'U%K$K#H\?@'P3<Z#96MJJ@+%]GGU"])(QU5U&.-O>@#O:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH-PW7#&>2VBR $'F-\Q( /TYGG%?+&@?#OQUX\_X+"^(OC)K_@G5K/PW\/\
MX*V/A_PWK%YILL=GJ%YJ-])=WAMY64)*T:06J/L)VD@'!XKZG Q0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 48YSBBB@ HHHH ,<YHHHH *,8HHH ,=Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gz4fxfn2r2w0000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 2Y!AT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 449YQB@Y[4 %%!8#J:3<OK0 M%)N7UI<\<4 %%%% !11D9QFCGO0
M4444 %%%% !1110 4444 %%!.!TI-R^M "T4FY?6C<OK0 M%)N7UI0<]* "B
MBB@ HHH)QUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_\ -N)5CCW6AQN)P.]?-/B&S\?>-;"[^*?B&.22V:X$;7DK;5:0_P "#O\
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M[Y_]I+,X_G7+_"'X$O\ $\?\+5^+LDMU-J#^;:V)?:H3/!.#T/8>G6O9-/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWT'YU[G96%EIT(M[&SBA1>BQ1A0/RJ8$=!7FY#X1Y;@_93S>O/%RII*,9O\
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M&55\TWUDTK)OY#YFPHHHKO$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYW)=W,B(&^;YQGC%>8_"W]O']E7_ (+'_MSS?M8?\%AOVQ-#^'WPI^'^K_\
M%N?@G(+MUN\897E\F)EV8V^9(3O=LH-J@Y /Z"/^">?Q5^*'QQ_8<^%7Q=^-
M-IY/BKQ%X'L+W7,P^699GB!,I7@*7&),  #?P .*]DKE_@G\2_A7\8OA-X?^
M)?P/UZSU3PCJ^FQS>'K[3X6C@EM0-J&-652J@+@# QBNHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OA/_@H[\:_^"LEG\4M2^#7[-/\
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M^U5%M=&\0?%30KNWB"C:H5)+H@8' QVK];J* /R-^"GQ5_X+D?LW>'+CP?\
M #_@W ^$7@S2KS_CZT_PU\4M!LXIN,?,L5T >/6G? _XK_\ !<K]F>WUBU_9
MZ_X-P_A)X*C\0:@;_7(_#/Q5T*S%_=$8,TOE70WOC^(Y-?KA10!^9+?M[?\
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M[OV>O",?@'X%?\&[WPM\'Z)&Q:/2O#GQ:T.SMU8]]D=T!FOUAHH _&S7(/\
M@KMXF^+:_'KQ%_P:^_ F^\:K<+.OBJZ^(7AY[X2#H_G&YW;AZYKU/5OVV_\
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M ?5-%OI;'1_A]X5UNUOK&UT],&)XWM7>- Q+?(#QCIS7T)110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !110"#TH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 <^E?(_Q5_X*0?&
M_2/VL?'W[*W[/?[#/B#XC77PYT_1;KQ#K-CXFL[*%/[3MY)H$59CN)Q#(#_N
M^]?7%?(/[(?_ "EV_;&_[ ?PS_\ 39J= !_PW5_P4)_Z1*^*O_"_TS_&C_AN
MK_@H3_TB5\5?^%_IG^-?7U'>@#Y!_P"&ZO\ @H3_ -(E?%7_ (7^F?XT?\-U
M?\%"?^D2OBK_ ,+_ $S_ !KZ]#9/%+0!\@_\-U?\%"?^D2OBK_PO],_QH_X;
MJ_X*$_\ 2)7Q5_X7^F?XU]?44 ?(/_#=7_!0G_I$KXJ_\+_3/\:/^&ZO^"A/
M_2)7Q5_X7^F?XU]?<^E% 'R#_P -U?\ !0G_ *1*^*O_  O],_QH_P"&ZO\
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MA/\ TB5\5?\ A?Z9_C7U]10!\@_\-U?\%"?^D2OBK_PO],_QH_X;J_X*$_\
M2)7Q5_X7^F?XU]?44 ?(/_#=7_!0G_I$KXJ_\+_3/\:/^&ZO^"A/_2)7Q5_X
M7^F?XU]?44 ?(/\ PW5_P4)_Z1*^*O\ PO\ 3/\ &C_ANK_@H3_TB5\5?^%_
MIG^-?7U% 'R#_P -U?\ !0G_ *1*^*O_  O],_QH_P"&ZO\ @H3_ -(E?%7_
M (7^F?XU]?44 ?(/_#=7_!0G_I$KXJ_\+_3/\:/^&ZO^"A/_ $B5\5?^%_IG
M^-?7U% 'R#_PW5_P4)_Z1*^*O_"_TS_&C_ANK_@H3_TB5\5?^%_IG^-?7U%
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M+')021API]QFOGC_ (+(_P#*+OXV_P#8CW'_ *&E>Y?!;_DCGA/_ +%FP_\
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M  6__P"B1_ +_P *74?_ (U1_P )5_P6_P#^B1_ +_PI=1_^-5]?44 ?(/\
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M (2K_@M__P!$C^ 7_A2ZC_\ &J^OJ* /D'_A*O\ @M__ -$C^ 7_ (4NH_\
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M_0:]]^$O_)*O#/\ V+]E_P"B$H Z"BBB@ HHHH **** "BBB@ HHHH ****
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M(GA7X_7WC'3O _B[29M+N=;M8VN8C$B7:QYW)<>8A;"OY> ?F!H _1KX)?\
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M?\G(_M:_]EPC_P#3195]?4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP_XMT]6\7WGA^VNHVE-Q;Q_,9%'S+&1YAV284C9GU#]JGX>?M7?&#5/V._\
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M)K_\$\_ GA']F_QS?:QX+\?>'[CQ9H^G>#[V6ZT*%)(#))=Q)$6M57!+-(%
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MVU8:)8>(/VD?C)\/1H<TDD<OPC^(4V@O=[P!BX,:-YH&. >AKX"_X(Z?#O\
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M.G[&%]^SU<1_$SQ=\2)=3\.^%_\ A(--+7EJ=6@G$@F%SY"?ND9L/(K<8QG
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MR#X7^('A/Q9/J]EX3^,#>.[6SM],T[4E:.4W=I+B=Y%C<X\M3@_WJUOV@_\
M@B?^T[\)OV4?V%/V7/@!X1;QY_PI'XJ-KOQ&U>VU&UM8[5;BZ%W<SJMS+&SQ
MB:24*J!GVJ.* /I3]F3_ (+!_'[Q/_P40MO^"=_[:/[&*_"[Q'X@\-2:YX1O
MK#Q4FJ175NHSLF*HHCDQG(4L 1@FOOROSU_:!_8K_:;\:_\ !?OX0_ME>&?A
M=+=?#7PS\/;S3=<\3#5+15M;IR=L9A:43-G/58R/>OT*H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /F+_@L[_RBS^./_8@7O\
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M*\Q_9+\1_M8^*OA.NL?ME_#OPCX7\8-J$P_LGP7JTU[9I:\>4QEF56,AR=P
MP".*].H **** "BBB@ HHHH **** "BBB@ HHHH ^0?@W_RFN^-/_9&?#/\
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M\#OCW\&OVE?AS8_%SX"_$?2O%7AO4L_8]7T>Y$D3X."/56!ZJP!'<4 >9?\
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M<^&M/7Q!;&?5H0"3+;1[]TZ *QW(&&%/H: .JHKQ'_@HO^U7KW[$O[&GC?\
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M^U7,U_) Z2QD#8$41'.3GD8H ^&?VBOVP]<_:O\ A5^S?I7Q<T>/1/BM\/\
M]IC2_#GQ5\-KQ]DU6%'!GC& 3;W"XFB; !5\#.,UP'[7G_!>'Q[KG[8'Q0^$
M_A'_ (*4^$_V;]!^%_B>;0-'TF^^ >K>,KSQ7<6X'G7-Q/!;20V=NTF40(WF
M@*2R=&;[#_;L_P"".DW[3/[<?PM_;6^#OQ'L_"M]X8\1V=Y\0=(N8Y#!XC@M
M23;OA 0+B/<5#MC*G!/ JGXR_P""</\ P4"^ O[0_P 0OBM_P35_:W\$^%?#
M7Q6\0-K_ (M\'_$;PM/J$-CJTB*D]U9/ ZE3)M4E6^4$#CN0#S;]G?\ X*_?
M'_X]?"G]F?\ :IO=3T[3_"GB3XH7_P //C!8:?HY2PNKPJ4L]4MWNXENK>%W
M\EUC.Q@9]KJ=M4/@%_P6K^,%O^TM^U%K'Q[O;63X5>$?!>L^*?@FHL8(6N[/
M1KB>SO4,B*'E9[A854.S'+C'!%?3'[0__!/'XU?M&_\ !-35?V0?BC^T_<>)
MOB1=QK?6/Q*U338[5;35XYQ/;S)#;(-D43 *H +8&2237@7QO_X-_=1^+/P
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ME^(CK?CKQ1!9?9[>2;8(XX+>(\QPQHH50>>I[T ?-W_!'CX#?"[]CS_@H/\
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MQP!DDD\FN@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /D'X-_\IKOC3_V1GPS_ .E%Q7U]7R#\&_\ E-=\:?\ LC/AG_THN*^O
MJ /D'_@FA_R<C^UK_P!EPC_]-%E7U]7R#_P30_Y.1_:U_P"RX1_^FBRKZ^H
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M!^+FC_\ !/#]NS1?A]\./C9KDFJ^*-+U;0[B75-%N)G+32:;<0L/+<[GP3C
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M7XU\&_';X6:?H7Q ;PIXNM=233?%&"T9N/)D8QR-,?+ . 3,/2OTT_X*E?\
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M?U[X'_%[]M3X3^.O!6L:@QM?&7C?X3PMXRTNS+@B&WNK9$BC*@8#  G)R1G
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M@I)^SE\)O@CX=T3P+<6<UK=^%[734-I=0RJ4E696SYV]20Q<L6!Y)KP32?\
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MEC>VL>C_ !&\2:/H\4'AWP!I)D5IHD2)5B>\901';Q@;6.YMN*O?#GP+X?\
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M*=(K&9$%N9$8F,(&VCD$8!H _H HK\S[_P"#OQR_;'_X+0?'SX2:M^VW\7/
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M95+?5KJ'2+%)6MK*3&();AR69TPR  C(W*W/_M3ZW^U-_P $P?'_ ,0/V/\
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M7_!9W_E%G\<?^Q O?_0:]]^$O_)*O#/_ &+]E_Z(2@#H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KY!_9#_Y2[?MC?]@/X9_^FS4Z^OJ^0?V0
M_P#E+M^V-_V _AG_ .FS4Z /KZO!/V\O^">7P;_;\\->&[;Q_KVO>&_$O@G5
MFU/P/XX\)WYM=3T.Z=0DC0R<@JZA0R,"K;5R.*][)QVJC'XF\-S:[+X7B\06
M+:E##YTVG+=(9XX^/G:/.X+R.2,<CUH ^1_V=_\ @COX-^%WQYT3]I/]H#]J
MCXG?&[Q9X460>#[OXC:I%)#HS.NUI88841/,V\;R"0*D_:1_X(]^!?BW\>=7
M_:;^ ?[3GQ*^"'C;Q+'&OBK5/AOJT<46LLB[5DF@F1XS)C@N%W'N:^KK7QSX
M+OK"[U2R\7:7-:V#E;ZXBU"-H[9AU$C!L(1[XINA^// _B=9W\->,M)U!;6,
M/=-8ZC%-Y*D$AFVL=H.#R?0T ?'EE_P1 ^"L'P#^('PFU?X\^/\ 6?$OQ5^R
M0_$#XF:[J$=UK&JV4$@?[%EU\N*!@"I5%'WB1SS7V%X=\#^&O"_@2Q^'&G:7
M'_9%AI4>G0V;1@H;=(Q&$(Z$%1@T1_$#P)-H#>*XO&NDMI:/L?4EU*(VZMZ&
M3=M!]LTMAX]\#:KI=SKFE^,])N;&SS]LO+?48GB@P,G>X;"\<\D<4 >4_L _
ML4>&/^"?7[.EM^S'X ^(.M^(/#FE:UJ%WX>77?+,FF6MS.TXL8RBC=%&[OM+
M9;#8)X%>V5DR^._!%OHMOXCG\8Z5'I]VX2UOWU"(0S,20 K[MK'((P#VJ]J6
MK:7HVGR:OJ^I6]K:PKNFNKF98XT7U+,0 /K0!8HK'MOB#X"O+^#2K/QOH\UU
M=1++;6T>I1-)+&PR&50V6!'((X(J?1_%_A/Q%<S67A_Q1IU]-;-BXAL[V.5H
MCZ,%)*_C0!HT5E7_ (Z\$Z5JZ>']4\8Z7;7\F/+L;C4(TF?/3"%MQS]*GUWQ
M/X;\+6RWOB;Q!8Z="S;5FOKM(5+>F7(&: +V<45\;_"7_@JSJ_QC_P""A/QL
M_8-\+_ >S:3X3^#8]:TOQ+_PEZ[-=ED0%("C6X2V4D@>:9' ')&*]R_9'^-W
MQ?\ C'\ K/XI_M)?!_1?AOX@DN;A;[P_I?CRU\06MK%'(523[?;JD3[E^8J
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M&+8;\,T ;-%(KHZAT8,K#*L.AI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Y!^#?_ "FN^-/_ &1GPS_Z47%?7U?(/P;_ .4U
MWQI_[(SX9_\ 2BXKZ^H ^0?^":'_ "<C^UK_ -EPC_\ 3195]?5\@_\ !-#_
M ).1_:U_[+A'_P"FBRKZ^H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#VN_LYZ9=:3X;\3:4]LMQJNEW#Q&6QNU,91HRD*1DJ VW/.37M'P#_86\"_
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MMU> ?V]O$^J:I#XD\!V+6\6CVY3[%J;@L8)K@$;F>'>^S! &XU@_M;?\$F?
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M?LO_ $0E>!?\%G?^46?QQ_[$"]_]!KWWX2_\DJ\,_P#8OV7_ *(2@#H****
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M8_#_ .(VN#5_%7ABS\4:E';S708L&AVW :T0$\1P&-  !MP !>_:'_X)"?\
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MJ'X3ZY\3/A'K,<.G^"?B%-J?A3Q1;V@6X>::U:0R),&C5DF.T=5&<UF?LR_
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MZA^&G[-GP;^$/Q*\:_%[X?\ A1K'Q!\0M0AO?%U\VH3RB]GBB$2,$D=DBP@
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M10 4444 %%%% !1110 4444 %%%% !1110!\Q?\ !9W_ )19_''_ +$"]_\
M0:]]^$O_ "2KPS_V+]E_Z(2O O\ @L[_ ,HL_CC_ -B!>_\ H->^_"7_ ))5
MX9_[%^R_]$)0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@
M_LA_\I=OVQO^P'\,_P#TV:G7U]7R#^R'_P I=OVQO^P'\,__ $V:G0!]?5S?
MQA^*GA/X&?"CQ)\9_'LMQ'H?A70[K5M6DM83)(MM;Q-+(50?>;:IP.YKI*^)
M?^"R7[ OQ1_:L^!WC;XA_#3]K;XX>&;K2?A?J5G:_##X:ZPBZ;XGN%CN)%CN
M+3[/)+<23%Q"51@60*H&>: /K#P5\9/!/C[X):1^T%X?GN6\.:UX5M_$-C)+
M:L)C8S6RW*$QC)#^6P^7DYXKX[_9$_X*H_&/]K+_ (*AZI^S2GP-U+P;\,8_
M@S-XK\,77BK3&M]5UN1=6BLA>;&.8(#F95C9=QVACCI71?\ !(;]@GXE?LJ_
M KP;XQ^)?[6OQL\77.M?"_1;>[^'7Q-UB.2P\+S_ &6%WM[:U^SQR6[1',&Q
MR2JIM/(-9<BK'_P<<VZ*, ?L7G '_8U&@#[3\1:G>:-X?OM9T_1YM0N+2SEF
MAL;?'F7#JA81KGC<Q&T9[FOS,^-_[8__  76_9\^ .M?\%"_BC\-?A-H_P /
M/#@_M/6O@W?0SKX@M])$P4[KT.8A<!"&V!3SQFOTR\1^(=%\):!?>*O$FIQV
M>FZ;:275]>3-A((8U+.['T"@G\*_)O7OV_OV/?\ @KG\0/\ C)+]O#X._#+]
MFWPWX@#V/PWU[XJ:19:Y\0KBUFREQJ<4ERKVFGB1 R6Q&Z7 +_+@$ ^C/^"H
M'_!6GQ;^R?\ LV2>+?V;?@3X@\6>,M2^'J^+;>:XTEQI?A_3&3<;N^F)"@KS
MB '>Q!Z#FO7?C7^T'^U7H_["_A?XN?LU?!*/QY\2_%FDZ(MGI2R""RLY[V&-
MI;V<ELK;0[F9@"3C YKFO^"Q-_X=UK_@C_\ '37_  I?6=YIMY\(KZ73[[3Y
M4DAN+=K?=&\;H2KQE2"I!((.1P:G^)?[='P9_P""=W_!,;P=^TK\;;P_8;#P
M'H5KI>F0W$<4NJ7\ME$(;5'D(1"Q!)=B%1%9CP,$ \@^'W[6?_!4/]E+]LKX
M2_L_?\%"Y?ACXP\-_&Z^OM,\/ZU\.=/N+*XT/4K>V-P(YHIG;SHRHVF1<!>M
M>_?\%._VT?$/[#'[,+_%#P#X)C\1^+==\1Z?X:\&:-<S>7#/JE]-Y,'FM_#&
M#R?I7S#^P/\ $K]FG]I7]JW1?VQOVN?^"AGP+\9?&Z_LYM-^%GPA\"_%;2=0
ML_ MI<K^\MK2.*X:2^U"5 !-<A3D#9&-@RWN7_!:_P -? GQ!^P)X@N_VBCX
MRL_#^D:QINH1^)O =C'<:AX9O([E?(U8(\B Q0.0[X);;G"DXH \U^%O[87_
M  4E_95_:?\ A3\$O^"F5M\-]:T#XX:E<:/X6\2?#VUGM6T+6DMVN([&YCE9
MO.6159!*I'S@<8S4GQU_X*U_%2P_X*"_"7]E3X*? _58/!>O_$Z7PKXR\?\
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M,55Y-@)P$;."I  /T:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^0?@W_P IKOC3_P!D9\,_^E%Q7U]7R#\&
M_P#E-=\:?^R,^&?_ $HN*^OJ /D'_@FA_P G(_M:_P#9<(__ $T65?7U?(/_
M  30_P"3D?VM?^RX1_\ IHLJ^OJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MH- 'R[^UM^UU\6O@O^W;^SQ^SOX,&F?\(]\3M2U6#Q-]LLS)/LM[8R1^4^X;
M#NZ\'(IO_!6W]KSXN?L7?L[^%?B?\&?[+_M+6/BWX9\.7G]K61GC^Q7UZ(9]
MJAEP^P_*V>#V->-?\%DO'&C?LT_M:?LJ_MI?$_S[3X>^#?'-_I_C+Q!':O+#
MHR7EHT<-Q-L!*QF3"EN@ZG@&O/O^"MO[;W[*'[>>G_ O]BK]BWX^>%?BIXW\
M8?'WPOJ<UAX!UJ+55TG2;&X:YN[Z[DMF=+=(T4$JY#X+$*0K8 /L[XY_\%1?
M^"?/[,_B76/!GQY_:N\)^%]6\/W%O!J^FZI=.L]O)/&9(@4"DL&0$Y4$#N14
M/C;]K7PKXP\7_ O7O@3^T_X!7PI\1O$5Y L-Y;2W<WBN%+*246^G2Q?+#,C+
MYCF3C8K+C-?-_P"RU^S[\%OBI_P6J_:R\:_$KX9Z-KVH:;H_A>QL9M6T^.X\
MB&:R8R*H<$#=M&2.<5\D_L<:/IWACQU^R7X.T*V6VTW2?VQ_B1:Z;9Q\1VT(
MM+[$:#^%1G@"@#[V_8*_X+'_  $_;7_:P^-7[.N@_$;PVW_" ZTD7A%;*:7S
M=6TV*V5KR]<NH55CG9HR,C&S/.:]5^&7_!4S_@GA\9?C,_[/7PN_:\\%ZUXR
M69H5T*SU3,DDB]41B DC<'A6)/:OS@\:RZ4LW_!3SX&? S4=%L?BU>:A'>>&
M?#>FM#'K4^GG0[<S2VD (E:/DY9!MRPR1D9^=?A]\//A'\7OV>_A!X9D_P""
M]?P7L_*US0W\*^ _"?[,MBWBS3-6CEC,5OY6G7!U))!*-CRE K9)8X8T ?M9
M^T-_P4J_8C_9O\?-\#OBG^U%X/\ #_CR[LFDTWP[J6H@3&1HRT0<#B/=P0'*
MY!!Z$&JG_!+']IGXD_MA?L,^"OVAOBTVG_V_KZWAOCI5J88#Y5W-$NU"S8^5
M%[G)K\[OV8OB[_P3C^!&I_MG?##_ (*=ZWX,TSXN:E\:/$=]J-M\0;5!J'B+
MP_<0QMI!TU95,EQ"8C^[A@W.F<E0&4G[&_X-\DL(_P#@D?\ "6/2K&XM;5;.
M_%O;7:D2PQ_;[C:C@\[@, YYR* ,?]L7]M+]MSQ7^WU!_P $X_V"3\/?#?B"
MP^'L7B[Q#XS^):RS0M#-<M!';6EI$RM<,"A9V!PO3L:Q]3_;Z_;[_85^%WQ0
MU_\ X*6_#SP7-IWA#PB=5\(_%+PCYUOHVM7S96/3987+2P3%P,'D$'J*YW_@
MH=\6_P#@F'\3_P!N"Z_9/_X*H_"ZP^&TVE^&;/4OA#\;-8\53:5%K]O+G[=;
M1:C$L(L'MYPBF)YV$F0_R\!OG&?XE^&+7Q/\;?V2?V+OVPM;_:'^!J?L_P"N
M:MXFFUG6%\16?@[5(XB+2&TU(!EE$HW9C#N5VY)R1@ _0;]FG_@K-^R-\3?V
M#/#/[;7Q2_:"\):'HMY:Q6_B#4)+QHK:TU79F:S3> SNAR,*"< FNL^%_P#P
M5"_8)^.OPO\ %GQ<^"'[4/A7Q-HW@G2Y+_Q'<Z?=/_H,*@GS)$*APF>-P4C)
MK\U_B)^VW^S[X,_8:_8N\#_"#1_V>=1OO$MG<06_Q6^+5Q')X8\":E9:=$;H
M7#0<17\F_P H+*R8;A^&)7)_X);_ !)T?XJ_\%J/B98WO[2?PI^*]Q<_L^SV
M>J:E\(_!\>G:$TJWBN+6-E9EU!E4[C,"PPP7)*D  ^]O^"9G_!7CX#?MR_LI
M:]^T3XI^)OA;1Y/">I7B^+H8KQH[?1K43,+=Y9)0HR\05O<MCKQ7K7[,_P#P
M4?\ V%_VQ]<U+PS^S)^T_P"%?&&HZ3&TFH6.EWQ$T48."^R0*64=V4$#N:_%
MWXD:OX:\6?\ !!KPUX<^$'Q)T'2XO!W[2<+_ !NFTG18=8F\.Z8-4N@MSJ>F
MHP:>WC<PN8)<"10H&17IWP9^&GPE^(/[9_PD\8:S_P %T_A/\4-7T6UU":P\
M+_!/]GVVAO[G2C9.MY;7-SH4TQLX_().VZ4 ,HPI8 4 ?I]X3_X*K_\ !.CQ
MU\;_ /AF_P (_M@^"K[QM]L:T70(=2_>/< X,2L1L9\C&T,23P*^@J_GE\,_
M$WX>?L=:#X!T_P#9T_;,_9I_:A^&-IX_T^/PK\(?%7A&.R^(-E+)? (8HEC%
MX;J)FW>9<K'@C)7M7]"FG3/<V$-S);M"TD*LT+=4R,[3].E 'S;_ ,%D?^47
M?QM_[$>X_P#0TKW+X+?\D<\)_P#8LV'_ *3I7AO_  61_P"47?QM_P"Q'N/_
M $-*]R^"W_)'/"?_ &+-A_Z3I0!\S_\ !4'_ )+7^RC_ -G#:?\ ^DMQ7U]7
MR#_P5!_Y+7^RC_V<-I__ *2W%?7U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S%_P %G?\ E%G\<?\ L0+W
M_P!!KWWX2_\ )*O#/_8OV7_HA*\"_P""SO\ RBS^./\ V(%[_P"@U[[\)?\
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M-=6T?7_&7@31M7OO#M\;WP_>ZII<5Q-IESM*>?;NZEH9-I*[T(;!(S@UM44
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MHH **** "BBB@ KY!_9#_P"4NW[8W_8#^&?_ *;-3KZ^KY!_9#_Y2[?MC?\
M8#^&?_ILU.@#Z^HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /D'X-_\ *:[XT_\ 9&?#/_I1<5]?5\@_!O\ Y37?&G_L
MC/AG_P!*+BOKZ@#Y!_X)H?\ )R/[6O\ V7"/_P!-%E7U]7R#_P $T/\ DY']
MK7_LN$?_ *:+*OKZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /F+_@L[_RBS^./_8@7O\
MZ#7OOPE_Y)5X9_[%^R_]$)7@7_!9W_E%G\<?^Q O?_0:]]^$O_)*O#/_ &+]
ME_Z(2@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY!_9#_Y2
M[?MC?]@/X9_^FS4Z^OJ^0?V0_P#E+M^V-_V _AG_ .FS4Z /KZBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_!,[]L?XI_MG_\ !0'6M,^#]U9Z+\8?@[_9'P[UZ]N(DM=6OA$2(5(8LN6
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M-9WGQ</BVS@O'@BF\J6\BTDQF22!6#9?S0%VD,58%1]!?L._L<^/-1_X(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YB_P""SO\ RBS^./\ V(%[
M_P"@U[[\)?\ DE7AG_L7[+_T0E>!?\%G?^46?QQ_[$"]_P#0:]]^$O\ R2KP
MS_V+]E_Z(2@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY!_
M9#_Y2[?MC?\ 8#^&?_ILU.OKZOD']D/_ )2[?MC?]@/X9_\ ILU.@#Z^HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D
M'X-_\IKOC3_V1GPS_P"E%Q7U]7R#\&_^4UWQI_[(SX9_]*+BOKZ@#Y!_X)H?
M\G(_M:_]EPC_ /3195]?5\@_\$T/^3D?VM?^RX1_^FBRKZ^H **** "BBB@
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M?^"K7_!,'Q'K%IX>\/\ _!1/X'WVH7]U';V-C9_%329)KB9V"I&B+<$LS,0
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M^$<G@GP?=:M_;/A^\ANHM2\36MC>SI+/:,)"EL%BC"X?<6>-SP"!70?MW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Q?\
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M6='EN9(TNKP/*B95\!0#@$GC+T7]@_\ X*Y_'7]I#]G_ ..7[:'Q2^#Z:?\
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MU_9[^'WQOEFUO4K^2RT:]O-#NK?3=5N$)!BM;R1!#._!P$8YQQ7UE0!\S_\
M!9'_ )1=_&W_ +$>X_\ 0TKW+X+?\D<\)_\ 8LV'_I.E>&_\%D?^47?QM_[$
M>X_]#2O<O@M_R1SPG_V+-A_Z3I0!\S_\%0?^2U_LH_\ 9PVG_P#I+<5]?5\@
M_P#!4'_DM?[*/_9PVG_^DMQ7U]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\Q?\%G?^46?QQ_[$"]_]!KWW
MX2_\DJ\,_P#8OV7_ *(2O O^"SO_ "BS^./_ &(%[_Z#7OOPE_Y)5X9_[%^R
M_P#1"4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(/[(?\
MREV_;&_[ ?PS_P#39J=?7U?(/[(?_*7;]L;_ + ?PS_]-FIT ?7U%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\@_!O_
M )37?&G_ +(SX9_]*+BOKZOD'X-_\IKOC3_V1GPS_P"E%Q7U]0!\@_\ !-#_
M ).1_:U_[+A'_P"FBRKZ^KY!_P"":'_)R/[6O_9<(_\ TT65?7U !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1C-%% 'QK_P6E_X*6>'O^"=?[/^AVR^
M.;'POXF^)FMGP_X;\6:Q937%CX>7:#<ZI/'"CR2^1&P9(E4EY"@.%W$?"?\
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MKFHZIK'PYTGP/I<EXDE\[/<Q1ZN_^D+$[,04VX*G:<Y- 'SG\.]%^/W[;_\
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M_0TKW+X+?\D<\)_]BS8?^DZ4 ?,__!4'_DM?[*/_ &<-I_\ Z2W%?7U?(/\
MP5!_Y+7^RC_V<-I__I+<5]?4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?,7_!9W_E%G\<?^Q O?_0:]]^$O
M_)*O#/\ V+]E_P"B$KP+_@L[_P HL_CC_P!B!>_^@U[[\)?^25>&?^Q?LO\
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MD?VM?^RX1_\ IHLJ^OJ^0?\ @FA_R<C^UK_V7"/_ --%E7U]0 4444 %%%%
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MVG_^DMQ7U]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\9/#F@7GA76OA#I[:9X2?PK<+:1'2S$(SIMPFQA-:[5&(S@@C((R<^#>./\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'R#\&_^4UWQI_[(SX9_]*+BOKZOD'X-_P#*:[XT
M_P#9&?#/_I1<5]?4 ?(/_!-#_DY']K7_ ++A'_Z:+*OKZOD'_@FA_P G(_M:
M_P#9<(__ $T65?7U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#*/=6!'X]17FW[/?_!.?]A7]E#Q1-XV_9Q_95\%^#]8N$9)-2T71DCGVGJ
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M:^'M%M;;5K+3YM%@DN!:")!*D3,SR,L>%9SDY)S7@/PT_9&\2:_\!?@_X_\
M G[4O[!?@.:UUO1;[PKXN\)^']5L_&']H"2,B":Y61Y9II&W1R)*K(VYA@ C
M'[PVO[(?[,EC\>M1_:ALO@AX=B^(6KZ;]@U3Q:FGJ+R[MM@3RI&_C7:H7D=
M*Y'P/_P3'_X)\_#3XM_\+X\!?L?^ ]*\8?:#<+K]GH,:SI*3G>IQA6SW &*
M/S9_9G^'?_!-?XC:O^V=XC_X*A:7X'U#XPVWQH\11:G=?$!HQJ-AH$<,0T<Z
M8TI$D4'DC]V\&'. ,D!0/LO_ (-\1IZ?\$COA*NDRW$EJ+._%K)=9\UH_M]Q
MM+YYW8QG/>O<OB_^P)^Q9\?OB?I_QI^-/[,G@[Q+XKTM5%CKVK:-'+<QA?N_
M,1\V.V[.!Q7>?"KX3?#;X'^!K/X9_"/P98^'] T\R&QTG38?+AAWNTC[5[9=
MF8^YH ^#?VVS_P $Y/VD_P#@H1>? ']I7Q-XR^!_Q?\ !WA&QG\!_&+0/&A\
M.7/B+2KDM)-;6EVC[9HX)QMDBG4X9B5X+9^>OB]\2/&NFZE\9/\ @GQJ_P"U
M?9_M3?#.3X#ZUXD?5_$VE65]>^#=0MHS]FBGNH5,=P9.61F'F*R9!%?JC^T5
M^Q_^R[^UOHEOX=_:7^ _AGQM9V;$VL7B#2TG,.>NUB-R@^@.*K_!/]BK]DS]
MF_P-J/PT^!/[/7A7PKH.L0M#JFFZ/I*1QW<;*59).,NI!(P21S0!^57Q"\?_
M +%O@O\ 8+_8S^!/@S]C_P"$_P 1-<\<V\U_X=MO%&N0Z/X2T_5;?3HVO;O4
MQ'_H]U<LLA54N(W8L6^ZS9.%_P $Q-%\)ZK_ ,%A_BQ\+=>\#_ "UL]4_9YF
M@\1^#?@?8J_A]F%XI$5S&5\B:?;RVQ,;2N>:_4JY_P""7W_!/:\^#?\ PSU=
M_LA>!Y?!/]K2:FOAN31U:U2\D^_,J_PLV!D@C.*UO@K_ ,$^_P!BC]G+Q38^
M-_@3^S)X1\*:MINGSV-CJ&B:4L$L=O,09(LC[RL5&<YZ4 ?B;X[T#PCX<_X(
M(>&-)^ %CX"\/PZM^T=;Z?\ &:^_LT1VRZ6NIW2QKK0L=EPUDK+ '!(8(H"D
M<5ZG\#/V2_%?@O\ ;/\ A1\1I/VL/V)_ \D-G?PSZ?\ L[Z#?Z9J?B'1I+1U
MN8I8T9XIPJ8E#2@,K(&W"OUJ\$?L+_L>_#>R\8Z9X&_9Q\)Z;:_$&8S>-K6W
MTE/*UF0YRTZ'*N>3VZUG_L^_\$[/V&?V4_$5YXN_9T_98\&>$-4U"-H[S4-'
MT=(Y9$;[R[CD@'N!C(H _$KPKX&\ _L)Z7X!\8ZQ\-_V6?VC/AKI_P 0-/D\
M-^/_  1J!TGXAM<27P\FXFEBD6XO9U=LM&?D;&&R*_H6T^X%W80W81E$L*N%
M?[RY&<'WKPWPU_P2^_X)Z>#?C#_PO_PK^QYX#L?&0NS=+X@M]!C%PLQ.?,'8
M-GG('6O>!P,4 ?,__!9'_E%W\;?^Q'N/_0TKW+X+?\D<\)_]BS8?^DZ5X;_P
M61_Y1=_&W_L1[C_T-*]R^"W_ "1SPG_V+-A_Z3I0!\S_ /!4'_DM?[*/_9PV
MG_\ I+<5]?5\@_\ !4'_ )+7^RC_ -G#:?\ ^DMQ7U]0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\Q?\%G?
M^46?QQ_[$"]_]!KWWX2_\DJ\,_\ 8OV7_HA*\"_X+._\HL_CC_V(%[_Z#7OO
MPE_Y)5X9_P"Q?LO_ $0E '04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7R#^R'_P I=OVQO^P'\,__ $V:G7U]7R#^R'_REV_;&_[ ?PS_ /39
MJ= 'U]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?(/P;_Y37?&G_LC/AG_THN*^OJ^0?@W_ ,IKOC3_ -D9\,_^E%Q7
MU]0!\@_\$T/^3D?VM?\ LN$?_IHLJ^OJ^0?^":'_ "<C^UK_ -EPC_\ 3195
M]?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S/_P %D?\ E%W\;?\ L1[C_P!#2O<O@M_R1SPG
M_P!BS8?^DZ5X;_P61_Y1=_&W_L1[C_T-*]R^"W_)'/"?_8LV'_I.E 'S/_P5
M!_Y+7^RC_P!G#:?_ .DMQ7U]7R#_ ,%0?^2U_LH_]G#:?_Z2W%?7U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'S%_P6=_Y19_''_L0+W_T&O??A+_R2KPS_ -B_9?\ HA*\"_X+._\ *+/X
MX_\ 8@7O_H->^_"7_DE7AG_L7[+_ -$)0!T%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5\@_LA_P#*7;]L;_L!_#/_ --FIU]?5\@_LA_\I=OV
MQO\ L!_#/_TV:G0!]?4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'R#\&_\ E-=\:?\ LC/AG_THN*^OJ^0?@W_RFN^-
M/_9&?#/_ *47%?7U 'R#_P $T/\ DY']K7_LN$?_ *:+*OKZOD'_ ()H?\G(
M_M:_]EPC_P#3195]?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'S/_ ,%D?^47?QM_[$>X_P#0
MTKW+X+?\D<\)_P#8LV'_ *3I7AO_  61_P"47?QM_P"Q'N/_ $-*]R^"W_)'
M/"?_ &+-A_Z3I0!\S_\ !4'_ )+7^RC_ -G#:?\ ^DMQ7U]7R#_P5!_Y+7^R
MC_V<-I__ *2W%?7U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'S%_P %G?\ E%G\<?\ L0+W_P!!KWWX2_\
M)*O#/_8OV7_HA*\"_P""SO\ RBS^./\ V(%[_P"@U[[\)?\ DE7AG_L7[+_T
M0E '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#^R'_REV_;
M&_[ ?PS_ /39J=?7QZ5\1^,_@;_P4=^"7[>_QB_:5_96^'7PW\4>'?BKI/A>
M!H?%OB:XL;BRDTJTN(3@10N&#FX8\XQM'KP ?;E%?(/_  LO_@MO_P!&N? S
M_P .)>__ ")1_P ++_X+;_\ 1KGP,_\ #B7O_P B4 ?7U%?(/_"R_P#@MO\
M]&N? S_PXE[_ /(E'_"R_P#@MO\ ]&N? S_PXE[_ /(E 'U]17R#_P ++_X+
M;_\ 1KGP,_\ #B7O_P B4?\ "R_^"V__ $:Y\#/_  XE[_\ (E 'U]17R#_P
MLO\ X+;_ /1KGP,_\.)>_P#R)1_PLO\ X+;_ /1KGP,_\.)>_P#R)0!]?45\
M@_\ "R_^"V__ $:Y\#/_  XE[_\ (E'_  LO_@MO_P!&N? S_P .)>__ ")0
M!]?45\@_\++_ ."V_P#T:Y\#/_#B7O\ \B4?\++_ ."V_P#T:Y\#/_#B7O\
M\B4 ?7U%?(/_  LO_@MO_P!&N? S_P .)>__ ")1_P ++_X+;_\ 1KGP,_\
M#B7O_P B4 ?7U%?(/_"R_P#@MO\ ]&N? S_PXE[_ /(E'_"R_P#@MO\ ]&N?
M S_PXE[_ /(E 'U]17R#_P ++_X+;_\ 1KGP,_\ #B7O_P B4?\ "R_^"V__
M $:Y\#/_  XE[_\ (E 'U]17R#_PLO\ X+;_ /1KGP,_\.)>_P#R)1_PLO\
MX+;_ /1KGP,_\.)>_P#R)0!]?45\@_\ "R_^"V__ $:Y\#/_  XE[_\ (E'_
M  LO_@MO_P!&N? S_P .)>__ ")0!]?45\@_\++_ ."V_P#T:Y\#/_#B7O\
M\B4?\++_ ."V_P#T:Y\#/_#B7O\ \B4 ?7U%?(/_  LO_@MO_P!&N? S_P .
M)>__ ")1_P ++_X+;_\ 1KGP,_\ #B7O_P B4 ?7U%?(/_"R_P#@MO\ ]&N?
M S_PXE[_ /(E'_"R_P#@MO\ ]&N? S_PXE[_ /(E 'U]17R#_P ++_X+;_\
M1KGP,_\ #B7O_P B4?\ "R_^"V__ $:Y\#/_  XE[_\ (E 'U]17R#_PLO\
MX+;_ /1KGP,_\.)>_P#R)1_PLO\ X+;_ /1KGP,_\.)>_P#R)0!]?45\@_\
M"R_^"V__ $:Y\#/_  XE[_\ (E'_  LO_@MO_P!&N? S_P .)>__ ")0!]?4
M5\@_\++_ ."V_P#T:Y\#/_#B7O\ \B4?\++_ ."V_P#T:Y\#/_#B7O\ \B4
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M17R#_P ++_X+;_\ 1KGP,_\ #B7O_P B4?\ "R_^"V__ $:Y\#/_  XE[_\
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M/_#B7O\ \B4 ?7U%?(/_  LO_@MO_P!&N? S_P .)>__ ")1_P ++_X+;_\
M1KGP,_\ #B7O_P B4 ?7U%?(/_"R_P#@MO\ ]&N? S_PXE[_ /(E'_"R_P#@
MMO\ ]&N? S_PXE[_ /(E 'U]17R#_P ++_X+;_\ 1KGP,_\ #B7O_P B4?\
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M_/PK_P##2S__ ";1_P *!_X++?\ 1_/PK_\ #2S_ /R;0!]?45\@_P#"@?\
M@LM_T?S\*_\ PTL__P FT?\ "@?^"RW_ $?S\*__  TL_P#\FT ?7U%?(/\
MPH'_ (++?]'\_"O_ ,-+/_\ )M'_  H'_@LM_P!'\_"O_P -+/\ _)M 'U]1
M7R#_ ,*!_P""RW_1_/PK_P##2S__ ";1_P *!_X++?\ 1_/PK_\ #2S_ /R;
M0!]?45\@_P#"@?\ @LM_T?S\*_\ PTL__P FT?\ "@?^"RW_ $?S\*__  TL
M_P#\FT ?7U%?(/\ PH'_ (++?]'\_"O_ ,-+/_\ )M'_  H'_@LM_P!'\_"O
M_P -+/\ _)M 'U]17R#_ ,*!_P""RW_1_/PK_P##2S__ ";1_P *!_X++?\
M1_/PK_\ #2S_ /R;0!]?45\@_P#"@?\ @LM_T?S\*_\ PTL__P FT?\ "@?^
M"RW_ $?S\*__  TL_P#\FT ?7U%?(/\ PH'_ (++?]'\_"O_ ,-+/_\ )M'_
M  H'_@LM_P!'\_"O_P -+/\ _)M 'U]17R#_ ,*!_P""RW_1_/PK_P##2S__
M ";1_P *!_X++?\ 1_/PK_\ #2S_ /R;0!]?45\@_P#"@?\ @LM_T?S\*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_A%/^"E'_18?A'_ .$C?_\ R31_PBG_  4H_P"BP_"/_P )&_\ _DFO>J*
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M<=:,T >"_P#"*?\ !2C_ *+#\(__  D;_P#^2:/^$4_X*4?]%A^$?_A(W_\
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M$C?_ /R37O5% '@O_"*?\%*/^BP_"/\ \)&__P#DFC_A%/\ @I1_T6'X1_\
MA(W_ /\ )->]44 >"_\ "*?\%*/^BP_"/_PD;_\ ^2:/^$4_X*4?]%A^$?\
MX2-__P#)->]44 >"_P#"*?\ !2C_ *+#\(__  D;_P#^2:/^$4_X*4?]%A^$
M?_A(W_\ \DU[UG-% '@O_"*?\%*/^BP_"/\ \)&__P#DFC_A%/\ @I1_T6'X
M1_\ A(W_ /\ )->]$X[44 >"_P#"*?\ !2C_ *+#\(__  D;_P#^2:/^$4_X
M*4?]%A^$?_A(W_\ \DU[U10!X+_PBG_!2C_HL/PC_P#"1O\ _P"2:/\ A%/^
M"E'_ $6'X1_^$C?_ /R37O5% '@O_"*?\%*/^BP_"/\ \)&__P#DFC_A%/\
M@I1_T6'X1_\ A(W_ /\ )->]$@=Z,^U '@O_  BG_!2C_HL/PC_\)&__ /DF
MC_A%/^"E'_18?A'_ .$C?_\ R37O5% '@O\ PBG_  4H_P"BP_"/_P )&_\
M_DFC_A%/^"E'_18?A'_X2-__ /)->]44 >"_\(I_P4H_Z+#\(_\ PD;_ /\
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M"E'_ $6'X1_^$C?_ /R31_PBG_!2C_HL/PC_ /"1O_\ Y)KWJC/.,4 >"_\
M"*?\%*/^BP_"/_PD;_\ ^2:/^$4_X*4?]%A^$?\ X2-__P#)->]9HSSB@#P7
M_A%/^"E'_18?A'_X2-__ /)-'_"*?\%*/^BP_"/_ ,)&_P#_ ))KWJB@#P7_
M (13_@I1_P!%A^$?_A(W_P#\DT?\(I_P4H_Z+#\(_P#PD;__ .2:]ZHH \%_
MX13_ (*4?]%A^$?_ (2-_P#_ "31_P (I_P4H_Z+#\(__"1O_P#Y)KWJB@#P
M7_A%/^"E'_18?A'_ .$C?_\ R31_PBG_  4H_P"BP_"/_P )&_\ _DFO>J*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!X+^PQ_Q^?&#_ ++3KW_H
M^O>J\%_88_X_/C!_V6G7O_1]>]4 %%%% !1110 4444 %%%% !1110 4444
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MPG.H?$J#7?MY9&2=+F.XD#,/O#"[6VCYL"OT6_X*E_ '2U_;1^$/Q<A_;O\
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M(VKU64@\5^2G@36_@7<?\&Y_@30_#-]X7;QY;_M$VK>)+>S-O_:JVIO%\DW
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MI[**^TM*U;3-<TVWUG1M0ANK2ZA66UNK>0/'+&PR&5AP01R"*_*#]AO]B_\
M9=^,OP6_;0^)WQ8^"&@^(-<O_B=XOM?[0US3H[B:UBAMRR+$S ^20QW90@Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >"_L,?\ 'Y\8/^RTZ]_Z/KWJO!?V&/\ C\^,'_9:
M=>_]'U[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!POQP_9B_9Q_:8TB#0/VB?@1X1\=6-J^ZVM/%GAVWU".)O5
M5F1@#]*L?![]G7X!_L]^&I/!GP(^"WA;P;I$S9ETSPSH,%C YQCE(553^5=E
M10!XK/\ \$WO^"?=S::_87'[$OPJ>#Q4R-XFA;P'8%=59)EF0W \K]Z5E1)!
MNSAE!ZBNN\&_LN_LV_#OXAR?%OP%\!?"&B^*9='ATF3Q%I?AZW@O7L85"16I
MF1 YB15553.T   5WE% 'EL/[#_[&MM\7U_:"M_V5OAZGCI9_.7Q@O@^S&I"
M3^_]I\OS-WONS6K\<?V6/V:?VFM/M]*_:+^ /@[QU;6;$VL'BWPY;:@D)/4J
M)T;'X5WM% '-_"GX-_"7X%>$8? /P6^&>@^$]#MR3!I'AW28K.VC)ZD1Q*JC
M\JO>./ /@?XF>&;KP9\1?!^F:[I%]&4O-+U>Q2XMYU/9D<%6'U%:U% 'E_P7
M_8C_ &.?V<=9G\1_L_\ [+/P_P#!.H72D7%]X6\(V=C+*#V9X8U)_.MZV_9W
M^ MG\:[C]I*T^#/A>/XA7FEC3+KQO'H< U6:R&W%NUUM\UHAL3Y"VWY1QQ79
M44 >>_&;]DG]EO\ :+U33=;^/O[.W@GQI>:.V[2KKQ1X9M;Z2S;.<QM,C%.?
M3%6OAG^S/^SQ\%W\02?"+X'>$_##>++LW7B@Z#X?M[7^UIB"#)<^6@\YL$C+
MY.#7<44 >8_";]BO]D#X"^,[SXB_!']E_P  ^$=>U!6%]K7AOPG:6=U< G)W
MRQ1JS9/J:W?"?[/7P(\!_$S7OC3X)^#?AG2?%_BI47Q+XHTW1((;_553.P7$
MZJ'F"Y.-Q.,UV-% %#Q/X6\-^-O#M[X0\8:#::II6I6KV^H:;J%NLT%S"PPT
M<B,"K*1P01@UX!_PY[_X)1?](W/@?_X:_2__ (Q7T=10!Y7/^PQ^Q?<_##PW
M\$[C]E+X>2>#_!VJ-J?A/PNW@^S.GZ->L\DAN;:#R_+@E+S2L70!LR.<_,:Z
M/Q-^SU\"/&GQ4T3XY^+_ (-^&-4\:>&H7A\/>*[_ $."74=-C?[Z07#*9(@<
M\A2,UV-% 'F?QE_8P_9%_:+\0V7BWX_?LQ^ O&FJZ: -/U+Q1X3M+Z>WP<C8
M\T;,N#SP:Z/Q]\#_ (-_%7P WPI^)GPL\/>(/##0K$?#VL:/#<67EJ,*ODNI
M3 '08XKJ:* .-^"_[.WP$_9R\-R>#O@!\%_"_@G299/,DTWPKH4%A [_ -XI
M"BJ3^%<'-_P35_X)Z7#ZD\W[$'PH8ZQJ,=_JV[P#8?Z9=(^])Y?W7SR*WS!C
MD@\BO;J* ..^+_[/7P(_:!\ +\*?CI\&_#'C#PQ'-%*OA_Q-H<%]9J\8(C80
MRJR94$@''&>*Z./PQX<B\.+X/CT&S728[,6J::+=?(6 +M$03&W8%XVXQCBK
MU% 'F?P?_8Q_9&_9\\47WC;X$?LR> _!NLZD"-0U7PSX3M+&XN03D[Y(8U9N
M?4UV'Q(^&?P\^,?@?4OAE\6? ^D^)O#NL6_D:MH6N:?'=6EY%D'9+%("KKD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /!?V&/^/SXP?\ 9:=>_P#1]>]5X+^P
MQ_Q^?&#_ ++3KW_H^O>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *I^(-<L/#.@WWB35G9;73[.2
MYN65<D1QJ68@=^ :N5D^/=6.A>"-8UK_ (1R;6!9Z7<3-I-NJF2]"QL?)7=P
M6?&T \9- 'XXS?\ !P-_P6&_:!TGQM^TI^P=_P $N/#?B?X&>!]2O8=0U[6M
M:+:G<06A;SI4B6\A=B%4L5B@FV]#D@U^A'[$W_!5']G#]K/]@OPS^WEXV\3:
M5\,=!U82VVN6_C;78+.'2-0AE:&:W:XF,:,N]=R/\I='0E5)*C\1=.\9_P#!
M+S48O''[27[&O_!3+XJ?L8^/(M:OKG6/@_KMY)-!-?(S$J(('V.K,.%(D*],
M=JT=;_X*7?&W]O7]D']D_P )?MD_!GX?ZMXV\7_%#7--\/\ Q7^+5K<IX>AM
MK,62+J4UC#+%;W,KFZDB/F*T?^CN0H#L* /WUTW]K3X&_%+X*^*OB[^S3\:?
M!?CZV\/Z+>72W?A?Q';ZG:B:*!Y%21[:1@,E1D;@<5X5_P $<_\ @I)XS_;[
M_P""?4?[9/[2=CX1\(W$?B'5[/46TEY+73K:VM)R@E9KJ:0I\HRS%\?2OS$_
MX(YZ#H_PR_X*3?MC?#/P?\8?"_BW3X_@],;K4O N@V^E:/<7"PR[A;6MMB((
MA)4,HY[U\Z^+M1^+-K_P:^?"W3O!=XUOX6OOVHM0A\?32)*UJ++SKEH1=B,A
MC;?:!&6'&66,=<4 ?TG?!C]J+]FO]HZWO+O]GO\ :#\$>.HM/;;J$G@_Q5::
MDMLWHYMY'V'ZXK'T7]NG]B;Q'\3Q\$O#_P"U_P##"^\9&Y^SCPE9^/-/DU+S
MLX\O[,LQEW9_AVYK\0_@/\!X](_X*5:+!I_[77[/_A[[5\&M7B\60_LS^!=3
ML[ ^'YK-U^UW<BEX5GCRKJ7*N=ISEN:\7M= ^$'_  3V^ FA^)/BM\+OV8_V
MI/@SI_C6*32/&G@C7FT?QTEP]RVR0S0/'>3&-LG:V$!49;@$ ']/ .>U?E-^
MT9_P7<_;F^,7[7OB[]CO_@C+^PAI_P 8+[X=S?9_&/B_Q/J'V?3([@$JT:,;
MBVC0!E959YP7*MM3 )K]0_!/B.T\;^!M'\8:=:75K#J^DV]Y!!>(5FA26)7"
MN#R' ;!!Y!!K\.?^",_[;G[/_P#P1^_:L_:4_8R_X*&>)E^'NN:Y\3KCQ#HG
MB?7+=UM=0M9,JJB4*>, ,IZ'><=#0!]B?\$S?^"WWQ/^/O[3FO?\$^_^"C'[
M+Y^"/QNT/2I-3MK$71;3=7M8T\R1H6=GV[8PT@99)8W1'(<%<'["\'_MV_L1
M_$'Q!I/A/P'^V%\+];U37KF:WT/3=)\?:?<3ZC-"2)8X(XYBTKH00RJ"5(.<
M5^/^I_'[P-_P5H_X.%-!_:"_8TBNM8^'WP8^$.H6?BCQY#:/';74GE7KB-&(
M&Y&:X2-<\DF0@8&:D_X(.?LJ?#Z\_P""4'QY_:C^'WPATC4/C/::IXS_ .$'
M\5MIB3:IIUY'9W$<"V<Q!>%B6X"$98\YH _1K_@HG_P55^#/[+?[,?Q8\9?
M+XX?"_Q5\4OASX=FU#_A ;KQ1!=7,<D; ,+FTM[A;A5&>?ND>M=Q^R]^W#X0
M\;_L%?#[]LG]J/QSX-\ Q>*O#%KJ.L7NH:LFG:7:S2C[BR74ORKZ!G)]S7X*
M^$O!'_!+=_\ @V UWQMXPT[P:W[0+:IJ7]IZA<F/_A)UUS^UI%BBR?WPA-IY
M6Y!^[*%F8;B36]^US:_%CQ/IW_!.OP1JNO>!]-\"77PU5M/G^+&G37?A/^U^
M0#?Q1LN\[<!03CD9XH _H,L?VL/V7-5^#MY^T1I?[2'@.X\ :>F^_P#'$'BZ
MS?2+9=P7,EX)/)0;F5<EAR0.].^&/[5O[+_QK\3S>"?@W^T;X%\6:S;Z;#J$
M^D^&_%EG?7,=G*JO%<-%#(S")U=65R-K!@02"*_GGN/AEKG@#]FO_@HF_AGX
M\?#37M!/P_TJ'Q9X7^#/A34-/\+Z?K@U*S$,MFT^8"3"+D.L3GEEX"A0/V$_
MX(5?LF?L[_ O_@G?\'OB3\,_@_X?TGQ1XF^&>GS^(O$UGI<::AJ1G43L)YP/
M,E4.1@,2%"@# % 'F7_!:K_@JW^W;^PY^TM\%_V7OV%/@/X$\=^)OBXMS#8Z
M;XP::-I+M)52...47MM%&""<F1L>XIG['?[4_P#P<M>./VCO"_A?]LO_ ()I
M_"?P;\-;S4-GBKQ-H/BNSGN[&WP?GC1-=G9CG'2)_I7RG_P=2:;X:UC_ (*%
M?LFZ7XQ_:)OOA+I<_P!N2^^)6FSO'<>'(_M"9O$:-T967U#*>>M=9_P2UT;]
MCWX4?MN>#M?T/_@Y5\:?';4KR:;3=+^%_B+7KZ:VUBYN(FCC&R6[E4NI.Y<J
M>0.G6@#]1M?_ &_OV$_"EIJE_P"*/VT/A3IL&B:N=*UF:^^(6FPK87P&3:S%
MI@(IL$'RVPV#TKOG^*?PRC^'R_%N3XAZ&OA5K#[</$S:M"+ VN-WG_:-WE^7
MCG?NQCO7X<_\$V/V+?V8/VE_C)_P4(\8_'OX,:'XLOM+\1:Q::/-KEBMQ_9H
M-M-(9;??GR9=P4^8F'&T8(KYQUK7_B5J?_!K)\$]&EU75)/ ]K^TE<6/CQ;>
M1RL6A"\O)!')CI"+EHSCH&*T ?K?^V1_P6FT[X;_ +3/[._PK_8\\:?"WXD^
M%?BYXVDT/Q-KVFZT-4^P!<<02V5R(TDYY$@?Z5]$_P#!3S]JCQS^Q'^P3\3?
MVJ_AKH.DZGKG@GPZVH:;8ZY'*]I-()$7;((I(W*X8_=93[U^/W[?/@O_ ()F
M^#?^"L'[$L'_  3[TOP19O-X@M6UE/ GE>1);9'V>2X\KY3.1G+-^\(^]FOT
MS_X.!R?^'-?Q^R/^9'?_ -'Q4 ?!N@?\%S_^#AOPY^SKI7[<OQ-_X)4?#?5O
M@O=:;'JMQKGA/66^U-IY;!F$2ZI<30CK\TEOA>I %?J1^SM_P4,_9D^/_P"Q
MEX9_;HF^)&C^$_ WB'2X[J;4O%FK064.G2D[7MYII66-720%#S@D<5^8_P '
M?^"TG_!-[X,?\$"=%^!&N?M&:#JOCV/X,W&A-X'L"\UZ+Z:&6)8V3;@8+@DY
MXQ7S+]@U?]F?_@D?^P_^R5\;_@+X.O-?^)_Q,U+5-!U_XN27O]@>$A/?1O#<
MW=I#+&ERQCNU;9/N15#C:0S @'[\>#OVT?V0/B+\.];^+GPY_:C^'OB+POX;
MMFN/$'B#0/&-E>V>G1JI8M--#*R1C _B(KRG_@GC_P %<_V1/^"EA\7CX ^-
MK)9O"NLSVHTO4=6MEU"\M(R%_M$6JN9([9VR$D;A@,\=*_*'_@DM\+_!'A?_
M (+<_'SX#P_$CP#\1-&U#X)S0>(4\$>$;/3_  [>W&(6>VBLH%\B1(S@9P2S
M9SS7EO[*]KHW@_\ X("?M<W7[/.BZ#8_%.'QMJ%EJTVAV<$>NP^'/[2@6XB#
M(!,+81%U*_<"%^!0!_07\,OVP_V2?C5XTO/AQ\'/VH/A[XL\0Z;N_M#0?#?C
M*QOKRUVG#>9##*SI@]<@8K9\(_'WX%_$#XB^(/A#X$^,WA76O%GA/9_PE'AG
M2?$%M<:AH^_[GVJWC<R6^[MO5<]J_G&^"/P4OEN/V+_%'PT_:3_9J\/^([S5
MM*N/!4?P<\!:K_PE=XPAC^TVVM30L^\_,5E>8!=X;!"9!_=?]FWP[_P3>T[]
MMCXR:S^S7<: WQMO&M?^%S)I^J74MXI'^H\^*1S%%[>6JY[T ?2%%%% '@__
M  4D_;>L?^"?'[)VM?M&O\/KGQ9J<.H6&D^&_#-K=K;_ -I:G?7,=M;1/,X*
MPQ[Y SR$'"J< D@'YY7]J_\ X+N? F_T7XB_M._L,?"7QGX%U+5K:VU;1_@7
MKFKW_B70X9W"^>\$\9CNUBSE_)R, D$#FO8O^"M_Q:_9K^$_[(,X_;(^!M]X
MY^%?B?Q/IF@>.H[2(-'H=E<S<:M<?,'6&WE2)B\9\Q&*,O3(^%_VC]5^'_\
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M]HKX ?%SP!<_%CX4_''PAXF\+64<DEYXDT#Q):WEA D:EI&>>)VC4*H)8EL
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M !7@O[.7_)X_Q\_Z^/#O_I'/7O5>"_LY?\GC_'S_ *^/#O\ Z1ST >]4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/.?^/':N\HH **** *7B/PYX?\7Z%=>%_%>B6NI:;?0M#>V-];K+#/&>JNC
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M?V;O^"<W["_['WBN\\<_LO\ [+/@_P #:QJ%G]DO=1\.Z4L$LT&X-Y;$=5R
M<5-X?_X)Y_L.>%?CA-^TIX;_ &5? ]EX\GN&N)/%5OH,2W9E;K)NQPQ]0,U[
M)10!\V_$[_@CY_P3!^-'C[5?BE\5OV'OA[K_ (BURZ-SJVLZGH:R7%W,0 7=
MB>3@"M*__P""5/\ P3EU7X*6'[.&H_L;^!9O >EZ[)K6G^%)-'7[%;ZA)&8W
MN5CS@2%"5+>AKZ HH ^>_@I_P2@_X)N_LX_$6P^+GP*_8P\!^%?$VEECI^N:
M/HJQ7%ON&#M8=,@XKZ$HHH **** "BBB@ HHHH *\%_9R_Y/'^/G_7QX=_\
M2.>O>J\%_9R_Y/'^/G_7QX=_](YZ />J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#Y+/9WSBZMWLH;GS'A#!;A"4.1'N=R^A_P &V7_!.3]CW]I;]C;XI?$?XV?
M[0/$'B35_B)X@T>W\1:GIL<][IELZ20,+61P3 2LK$[,9."<D"@#]C+KX]?
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M\0?AOJ_CCQ!\0--T36O#^O>+8(I-#L9B&FO+J-)1);JL1W*T@5"2O7->4_\
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MF$F,,&53N.%'(H _6:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\%_9R_Y/'^/G_7QX=_](YZ]ZKP7
M]G+_ )/'^/G_ %\>'?\ TCGH ]ZHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ#^RW^S3X9\&:AJR[=0OM+MF,TJYSMWR,S*N?X5('M7M6:* "BBC- !1110
M449HH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7@O[.7_)X_Q\_Z^/#O_I'/7O5>"_LY?\GC_'S_ *^/#O\ Z1ST >]4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?/\ KX\._P#I'/0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X+^PQ
M_P ?GQ@_[+3KW_H^O>J\%_88_P"/SXP?]EIU[_T?7O5 !1110 4444 %%%%
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MQS^W-I?_  4(TOQ9\0/"OCZQM[6WOX_!_BLV.G:S#!CRX;R 1GSH^ "@95;
MR"1FOJ:B@#X6^.7_  ;S?L!_&KXI^*OBCIFK_$SP"OCZX\_X@^&/AQX\FTK1
M_$[EBS&\M%5ED#%F)52JY9B "23[#\7/^"57[#/QG_8\TW]A3Q-\%+6T^'>A
M1QCP]I^DS-;W&E31Y*W$$XRZS9))<EMQ)W9KZ(HH ^2?V0_^"+G['/[(7Q-U
M+XV6>H>.?B1XSU+P\V@CQ5\7?%CZ]>6FEL-K64!D55CB9?E(VD[<J"%9@?,Y
M/^#:G_@FR?$;"WD^)D/@>37/[7E^#\/Q"N%\)/=[MV\V&/4#C?TXZ<5^@5%
M'SQ\9/\ @F1^S5\;/VE_@[^U-KQUW2]<^!R/'X'TO0[R&#3EC92NR:(PLSJ
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M0PZAJ4FI:]K.M:B][J6LWS@![J[N'^:60@ 9X     XKV"BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KP7]G+_D\?X^?]?'AW_P!(YZ]ZKP7]G+_D\?X^
M?]?'AW_TCGH ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_$"Q^+?C1KK2?%WVZUCG>PLX)946*4&0J@CR3CIF@#]+],_:1^"&M_'>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_88_X_/C!_P!EIU[_ -'U
M[U7@O[#'_'Y\8/\ LM.O?^CZ]ZH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (
MSWKYS_8\_P""97P)_8F_:(^-7[2_PL\7^+=0UWX[>((-7\6V?B"^M9;2SGBD
MNI%6T6&WB=$)NY,B1Y3A5Y&"3]&44 ?/?@+_ ()M_!#X=_\ !0/QA_P4@T7Q
M9XJE\;^-/#4&B:II-U>VS:5%;Q! K11K;B8/^[&2TS#KP*\@^,G_  ;^_L3_
M !E_:-\8_M%3^//BMX9/Q(*_\+*\%^#?'CZ;HGBP<[EO8HX_.=6R<JDJ*23P
M,FON.B@#X%^'O_!NQ^QQ\./A;\'_ (0Z7\8_BM>:5\$?B!=>+O!K7^L:8TKW
M5PR.]O<%-/4/!O0L%4(^7;+D8 ]S\9_\$TO@3X[_ &_]#_X*-:YXF\4?\)GH
M/A.;P]:Z+'>6O]D36LHPS21-;F9GP>HF"_[)KZ'HH _/?QI_P;=_L;>*QKGA
M+1OVB_V@/#?P[\2:H]_KGPA\/_%!H_#-Y([!F5[:6"23:2HX$HP  " !CT7]
MJ+_@B!^QC^TQI'PQMM.U'QO\,]4^#VGC3_A_XG^%OB3^S=2TRT QY FDCER#
MU+$;\DG=DFOL.B@#XA_9Z_X( _L*_L[>*_BMK>F:EXZ\5:7\:?",>@?$+PQX
MX\11ZC9ZBJLKM>&1H!="Z>0/(9//*AY6**F$V9?P&_X-XOV*/@?\1_"/CC4O
MBA\7O'FE_#V^:\^'O@;XA>//[0T+PW-G(:UM5ACQM[;V<=SD\U]Y44 ?*7B7
M_@D'^SWJW_!0J/\ X*4>%/BK\3/"?CB9;5/$.C^%?%$=MH_B&.W"[(KZW,#/
M+&=B;D61%8J"1GFH/V=O^"+W[&O[/?P$^*W[-$D/B+QKX/\ C%XFN]<\7:;X
MTO;>;$]Q]Y(&MH(#&BGE2=SJ1G?7UI10!\$?"+_@W5_8?^&/Q&\)^-/%/Q-^
M,'Q"T?X?WPO/ /@'XB^/CJ6@^'9E8,C6UJ(4/R$ @2.XR 2"0#7M/[/7_!,3
MX#?LV?M5?&C]KSP-XN\6W7B3XZ-$WBRPU2^M7L;/RPP7[(D=LDD?WCGS))/P
MKZ.HH \"_P""?7_!.KX+?\$W?ASXB^&/P0\5>*-6L/$OBJZU^^F\57EM--'<
MW#;G2,V]O"HC!Z J6]6->A_M-_L_^#_VK/V>/&W[-/Q"U/4K+0_'GAF]T+5[
MO1IHX[N&WN86BD:%I4D19 K$@LC 'J#TKNJ* /GWX3?!_P $?\$H_P#@G[I_
MPB^"?@3XB?$K0_A?HLRZ3H6EV]MJ'B+5T>Y>9DC1%MXII=TS8 "?*O<CGX,_
MX('?\$W/B+X:_;J^//\ P5"^-'[+>L_".W\<:G=6?PQ\"^*81'J.FV-S<>?=
M2RQ=8BQ2%%X!XEQE6!/ZZ\]J.>U 'X]_%'_@EQX]_:R_X.%OBA\2/B3X7^+/
M@OP7)\,; >$_BYX%NKK2'M=22*)&6UOU0Q-)MWJT9#@C.5K[8_9M_P"",W[#
M?[-?[-'C?]EK3_!FJ>+M$^)C2O\ $35_'&JF]U3Q#(X_UEQ<(L>&4X93&J;6
M&X8;FOJSFB@#X3_9M_X-[OV+?V<?BWX-^*;_ !-^+7CRW^&\TDOPU\'_ !%\
M;+J.B^%)&.=]E;+!&4*X&-[/@@'J :]P^ '_  3P^$G[.G[7?Q7_ &S/"/C[
MQEJ'B+XOM;'Q!H^M:G;RZ98>3]W['$D"219[[Y),^U>^44 %%%% 'GO[4?[+
M7P-_;,^"6L?L]?M%>!X?$'A;6U3[59R2O%)'(C!XYHI4(>&5' 99$(92.#7R
MKX8_X( _LUVVMZ5_PMK]JS]HCXG^%=#O(KK2OAS\1OBJ]]H$$D3!HO\ 1DAC
M9U0@85W8<<@U]V44 ?+O[1G_  27_9R_::UKXK:UXT\6^,--;XO?#W3O!WB&
MWT*^M(HK+3[*4R1/:"2U?RY<G!+F1<=$7K7H7[0?[%/PN_:2\-?#OPMXW\0^
M(+2W^&?B[3/$6AOI-U CW%U8J1$DYDA<-&<_,$",>S+7L%% 'X[_ /!27X!S
MR_ML>.O%S?\ !/C]LC39_$L4-LWBC]E7QU;MHWQ M_+VC^VHVC0V#9S&VTN=
MOS%CTKWS_@E'_P $@8O@=^RW^SGJ_P"T)!K'AOQ[\'=?\4^)--\+Z7K$-Q:V
MDFN23@V=W(\;M<-#;21*6C=/WJL=SKC/Z&44 ?$_QB_X(4?LR_$SXO\ B3XN
M^ /V@/C?\*F\;71NO''AOX4?$5M)TG7YF&'DN+<PR?,X^]Y;)G)/4DU]6? [
MX)?#C]G/X4:'\%/A+H1TWP]X=L4M-+M6N'F98U[O(Y+.Y.2S,22223S7644
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MHH *\%_9R_Y/'^/G_7QX=_\ 2.>O>J\%_9R_Y/'^/G_7QX=_](YZ />J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /!?V&/\ C\^,'_9:=>_]'U[U7@O[
M#'_'Y\8/^RTZ]_Z/KWJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)_:.^/'A
M']F'X%>*OV@O'NF:G>:-X1T>74M2M=%@26ZEBC'*Q)(Z*S>@+*/>OS!;_@]
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M#[=\-;S5K738Y?&LIAU1I+.<BYOU"C[5/&0"DA(*'D5Q_@3_ (*7?MH_"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX\U[4?V;-)N],\(KJOV/;J%M,)U5+G9""?+28JNPKPBYSSG[FHH ^4?V[_\
M@D;\$?VX?BSX9_:,C^)OC/X:_$[PE:-9Z/\ $#X>ZDEKJ"VK$DP/O5D=<LV,
MJ2-S8ZFL?X=?\$0/V,O W[%7C[]BC6(-=\1Z7\4+IKWQYXJUS4/,U?5K[>LB
M7;S ##H\:,H "C;C&":^QJ* /S9LO^#:OX&F[^&>M>*OVTOC3XBU3X1:U9W7
M@&]U[6[:X32K*V^YI\<+0^6L)*QY;;YF(E&[&0?JK]G_ /8)\/? #]KOXK_M
M=:=\:?&6N7GQ6:V-YX7UJ_233-&\GI]CC"@IN[Y)S7OE% !1110!SGQ=^$GP
MY^/'PRUSX.?%WPC9Z]X9\1Z?)9:SI&H0AX;F%QRK _F#U! (Y%?$L?\ P0/\
M+:-I_P#PKWP-_P %#/VB- ^'7W%^'.G^. ;%(/\ G@LKQF=4QP,29 Z5]^T4
M ?,/A_\ X).?LP?#_P#X4?I_PDAU+POI7P)\3:AKOAW2[&99%U*[O;62"=[M
MY0SNS>8TA8,&+\DD<5S_ (]_X(P?LR?$[P9\4O"/C7Q/XFN)/B7\6I/B+#K%
MK>);WOAO6FBBB22PEC4% @BXW;B=S D@XKZ^HH ^2OV1_P#@D9\-/V:?CDO[
M3'Q%_:"^(_Q@\?6>EOINA^)/B9K274FDVCD;X[=(T1$W8 +8W$<9KR:U_P"#
M=CX':7X6NOAQX=_:^^-&D^$=?UB_U'QYX1TGQ+';V'BB2ZO);AA<QI&-FU)!
M!F(H6CB3=DY)_0ZB@#YOTW_@E]^SEI/Q5UKQ_817T.DZU\((?AQ-X/A\M+"'
M1X]P&PA?,$A5RN=V.^,\U\S^+O\ @VJ^#7Q ^$O_  SYXZ_;K^/&K?#W3[?R
M_"O@F[\40G3]"*?Z@Q1B$>8(C@JLN]>!D'%?I110!\5_&3_@C-I_Q(\:W7C3
MP#^WC\<?AZVN:7:6?B[3?!_BB..TUPP6ZV_FR121NL+.BC=Y6P$DG%;GQ@_X
M(Z?L]?$+]DSX=?LG?#OQ[XO^'MK\*_$=MKW@GQ7X3U)5U6QU")9 ;CS)5=7=
M_-=F+*<DYKZXHH ^-/VB/^",_@#XU_%A/C_X _:I^*WPO\>7_AVST?QEXJ\
M:Y%:S>*8;>(1I)>HT;1M+M&"ZJ#C@8  K5^'?_!&_P#9B^$VD?"/2?A[K?B&
MQ_X5/XXN_%L=Y-=I<7'B#4[FW>&:6^EE4LY8.6^4J00!TXKZVHH \CTG]C_P
M5I'[<FM?MWP^*-4;Q#K7PSL_!4^CMY?V..TM[Z:\6=?EW^:7F93EMNT# SS7
MC?BO_@C%^SMXU_9P\6_LY:]X]\6?9_$WQ4N/B#8^(+2\B@O]$UB2;SDDMG1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P7]AC_C\^,'_
M &6G7O\ T?7O5>"_L,?\?GQ@_P"RTZ]_Z/KWJ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LKQQXV\+_#;P;JGQ \
M;:LMAH^BV,M[J=])&S+!!&I9W(4%B  3P":U:\A_;]_Y,@^+7_9/=6_])9*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /!?V&/^/SXP?\ 9:=>_P#1]>]5X+^P
MQ_Q^?&#_ ++3KW_H^O>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *XO]H[X6WWQO^ 7C+X.Z9JL-C<>)_#5YID-Y
M<1EHX&FA:,.P') +9P*[2B@#YE_X)%?L(^*O^";O[#OAO]D[QGX]T_Q-J&AW
M5U++J^EVLD,,HEDW !7)88KE/^"L/_!,SQO_ ,%%/$WP)UWP=\3]*\-K\(_B
MA!XJU"/4[*68ZA"ACS#'L(VL=G5N.:^Q0,=!10!\<_';_@F1XQ^,/_!6/X:_
M\%$;;XG:7:Z'X&\(7>C7WAF6SE-U=M-N^=) =J@9[\U\G77_  ;H_M=>%_@C
M\9/V,_@[^WYH^B_!GXIZQ?:VVCW'@\R:J+V0!XH)KD-C[,9(XO,"C>44@$9K
M]=Z* /SD@_X)/_\ !1#X?_LX_"GX/?!;]NSPE&O@7P'!X;\0>#?&?@*/5_"^
MJF$NL=XD$@$RRF,H&!<KE<@52_9C_P"#=_X?^ OV.OCA^S;^T'\6(]>U+X\7
MRWOB*\\+Z.NG:?I%Q&RR0/96O1 DBJV#U V]*_2BB@#\W_V<?^"0'[?GAKQA
M\)/"O[3_ /P4?N/$'PN^"7EKX3\,>#+"YTF\U>.!%CMH=4G20"YCC1%7;C!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZM_X;>U_^2*]ZHH \%_X9V_;+_Z/U;_PV]K_ /)%'_#.W[9?_1^K?^&WM?\
MY(KWJB@#P7_AG;]LO_H_5O\ PV]K_P#)%'_#.W[9?_1^K?\ AM[7_P"2*]ZH
MH \%_P"&=OVR_P#H_5O_  V]K_\ )%'_  SM^V7_ -'ZM_X;>U_^2*]ZHH \
M%_X9V_;+_P"C]6_\-O:__)%'_#.W[9?_ $?JW_AM[7_Y(KWJB@#P7_AG;]LO
M_H_5O_#;VO\ \D4?\,[?ME_]'ZM_X;>U_P#DBO>J* /!?^&=OVR_^C]6_P##
M;VO_ ,D4?\,[?ME_]'ZM_P"&WM?_ )(KWJB@#P7_ (9V_;+_ .C]6_\ #;VO
M_P D4?\ #.W[9?\ T?JW_AM[7_Y(KWJB@#P7_AG;]LO_ */U;_PV]K_\D4?\
M,[?ME_\ 1^K?^&WM?_DBO>J* /!?^&=OVR_^C]6_\-O:_P#R11_PSM^V7_T?
MJW_AM[7_ .2*]ZHH \%_X9V_;+_Z/U;_ ,-O:_\ R11_PSM^V7_T?JW_ (;>
MU_\ DBO>J* /!?\ AG;]LO\ Z/U;_P -O:__ "11_P ,[?ME_P#1^K?^&WM?
M_DBO>J* /!?^&=OVR_\ H_5O_#;VO_R11_PSM^V7_P!'ZM_X;>U_^2*]ZHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\UE_;'_ &5X
M/VCH_P!D*;X^^%U^*$UOY\7@,ZM'_:;1^0;C>(,[L>2#)_NC--T/]LK]E3Q+
M^T'??LH>'_C_ .%KSXE:7"9=1\$VVK1OJ-L@C64L\(.Y0$96Y[$4 >F445R?
MQH^._P &_P!G7P6?B-\=?B7H_A/0EO(+0ZMKEZL$'GS2".*/<W&YW8*!W)H
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M:SH.8RRD$ ]0: .PHHSZT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ,*H'8 "@"Q1110 44 Y[44 %%%% !11GC.*,T %%&3Z49]J "BBB@ HHHH
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M9W?B34IEM=8N+A;F:XD+W)-T&E128IS)'@;0@7BNSL/^"<_[&%EH/Q1\,3?
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M_P""-_CO0M-\<?&+XSZ3\/?&VL:7-(WAWPSJ0CD#W,4)1;99 D3_ #1%D+2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'Q1_P6PU;Q?XI\ _!O]F;X<^&X-<USXC?&
M[12WA^ZU+[)%J.GZ6S:K=1/-L?RU(M8P6*L!GI6=^UWX;_: ^(=]X+_:8_:E
M\(^$?A+X'^ NKS>-9+JQ\0/KM_?7L%I-#;PAHX(-D&Z;<Z %I-JJ,9KZU\<?
ML_?"7XC_ !4\'_&KQIX6:]\2> 6O6\)WS7TZK8-=QK%<,(E<1NS(H7<ZL5&=
MN,G.O\3/AKX$^,?@#5_A;\3O#-MK/A_7K"2RU?2[Q28[F!UVLC8YP1Z$$=J
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M[510JJ.P%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\O\
M]A7]JCQ]JG_!6[X]?%7XH_$W4A\-?&$OBO3O!=C?:I(VG6<?@^?2--N)H(V;
MRX_,>6]D9E WE23FOT^F$QB9;=U63:=C.I8 XX)&1D?B*^(O!_\ P1ETCP_\
M#_@]\&]9^.DE^WP^D\0KXRU:/P_Y,GBR'7+F2ZU*/ N";7S99,[MTI &/0@
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M[+<Z1JVG2W*72F"RDU'S;2:&96:)C<RJ/-<.L@("^8?&'_@D5X[\1_#OX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 !SV-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7G:_M9_LWM\%&_:,'Q@T?_A!X[Z>S;Q)
MYQ^S_:(;Q[*2+IN+K<QO"5QG>I%>B5^9'[)O[+_QX\8?M5^-/V>/C!\*/$&A
M_ _X*_'/Q1\0-%N=2T>9+7QA=ZK?/J.F06?R_P"E6]F]Q=2OY>X&;R$Y8$4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQSG%%% !1110 8YS1110 48
MQ110 8[T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gz4fxfn2r2w0000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 2Y!AT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1/ACX&L_B-^SY#=&6^\&ZS)J'AO7_+%P$FMW\PN8B\'42'>KJ05.17A_@?\
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M"65NJDB@#]\/$/B#1_"F@WGB?Q%?I:Z?I]K)<WMU)G;%$BEF<X[  FOD"/\
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M'Q=_9A4W>K?#75'6&ZNHI;F*:2)<G'FJUK#A<\J[=Q5G]L'P-_P4\_X*(_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117QG^V?\1?VS?%G_!0+X?_
M +(_[,?[0VG_  ]TS6OAKJGB+5[^Z\*PZE)--;W<<2(HE(VC#\_2@#[,HKY!
M_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9
M/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\
M^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBOD'_AD_\ X*N_
M])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!_P"&3_\ @J[_
M -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9/_X*N_\ 24/3
M/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\ ^"KO_24/3/\
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M['_&@#Z^HKY!_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\
M&@#Z^HKY!_X9/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#
MZ^HKY!_X9/\ ^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBO
MD'_AD_\ X*N_])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!
M_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9
M/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\
M^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBOD'_AD_\ X*N_
M])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!_P"&3_\ @J[_
M -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9/_X*N_\ 24/3
M/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\ ^"KO_24/3/\
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M['_&@#Z^HKY!_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\
M&@#Z^HKY!_X9/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#
MZ^HKY!_X9/\ ^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBO
MD'_AD_\ X*N_])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!
M_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9
M/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\
M^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBOD'_AD_\ X*N_
M])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!_P"&3_\ @J[_
M -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9/_X*N_\ 24/3
M/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\ ^"KO_24/3/\
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M['_&@#Z^HKY!_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\
M&@#Z^HKY!_X9/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#
MZ^HKY!_X9/\ ^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBO
MD'_AD_\ X*N_])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!
M_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9
M/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\
M^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBOD'_AD_\ X*N_
M])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!_P"&3_\ @J[_
M -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9/_X*N_\ 24/3
M/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\ ^"KO_24/3/\
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M['_&@#Z^HKY!_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\
M&@#Z^HKY!_X9/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#
MZ^HKY!_X9/\ ^"KO_24/3/\ PT]C_C1_PR?_ ,%7?^DH>F?^&GL?\: /KZBO
MD'_AD_\ X*N_])0],_\ #3V/^-'_  R?_P %7?\ I*'IG_AI['_&@#Z^HKY!
M_P"&3_\ @J[_ -)0],_\-/8_XT?\,G_\%7?^DH>F?^&GL?\ &@#Z^HKY!_X9
M/_X*N_\ 24/3/_#3V/\ C1_PR?\ \%7?^DH>F?\ AI['_&@#Z^HKY!_X9/\
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M*:IJ<FB:9XGT^XO(<^=9V][&\L>.N5!R/Q%:%?SO?\&^OQK\._L0?L*_$_\
MX*V_M0?!?1]2LK.ZO[*U^):^)KFX\2:]J<DMLHTR2WD/E+$2^Y9<EBS'/%?;
M-U_P77_;'_9WLOAQ\>/V_OV#-,\!_!;XH:I;66C^+-%\4M>7NC&Y7? ]_ RA
M4!3+G:2=JL>V* /U(HK\W_VC_P#@L1^V5X>_X*I>(O\ @F+^R7^R-X6\;ZM9
M^![/7M'UC6O$LMC&/,ABGE-R0K!8PC,J[06+E!T)KE[G_@M3_P %$O%'[9?Q
M-_89^"_["'@_Q)XR^'?ABSU2ZGD\7S6]I"[0+)<1RN4);YF*1[!\Q'.* /U(
MS17XY^'/^#DK]LKXF?L2:Q^WA\+/^">6CS>"/AOJJZ7\5K[5?&#1M'>>;&KI
MIT:INF5$F@9F<C'F8&<&OJ[]K;_@JO\ %'X<_LL?"O\ :,_9G^ >BZU;?$[2
M+;4FUCQ]XRMM%T?0(98%E"W4[N'=\MM"Q*Q."<4 ?;U5-7U_0_#UNMWK^M6E
MC$\@1)+RX6-68]%!8CGVK\:+[_@XF_:I_:-_8D_:4F^ _P *_ ND_$_X)Z/%
M>ZEK^B>)I+[1_P"R9EG26^L9'C#33PO&NU& 5]^<\<\KXI_;0^,\?_!#;X*_
M&O\ X*'?LI^!_BM'KGCW1HO"LFM^*;R274(YIG(U2Y,6PQ7*R9Q&"4P!]* /
MW+5U=0Z,&5N0P[TM?!'[4O\ P5G^*G@7]J3PI_P3M_8,_9JT_P"(GQ8OO!L.
MOZQ9ZUK;6&D^']/,2%#-,H9^0Z8P#]]?7BA^SE_P6Q\6?$?PK^T!\*/CI^SU
M%X%^._[/GAVXU;Q%X'DU,W%CJ%NL0DBN()P-QB;S(>2,[9D8=<  _0:C-?CC
M'_P<=_MVV?[$7A?_ (*-ZY_P3M\/Q_"6XU2+3O%&I1^,)/M@E:0HTMI 5YAX
MP&<Y+=L5^GT?[1>M:OXT^%^E>"?@MKVM^&OB-H]YJ-[XSM)(EL_#J16L<\"W
M*L=[&X,A1-@.&0YXH ]0HI ><4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>QV=I)?7*QB:XD.U(DR?F=CP%')H _&'X*?\$AO^"E?B?QO^VPOQC_9P\%^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5O$5YXN\7?#=[_QEI3:@Y>6VAN^8WC3<5CWYVCD!237D-I^PK^VE^RY^U?\
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M#GXS7N@^"8X]/BA:TTU-,M+B.-RBCS6#S.=SY8YQG %?GQ^UC\5?VY?VX/\
M@G5^RS\>V_:9TG0=<UCXX+97TC>!;6X5[]-4N(+*[VAD4+"D8S$!B3N17UUX
MJ_X)K?\ !13X8?M-_%CQC^Q1^V+X)\,?#OXY:XFM>-+'Q9X4FO=7T;4&MDM[
MBXTYHV6%GD5%/[[Y00HV\$ME7/\ P1O_ &@_#7_!+[X9_L<?"[XX>%[;X@?"
MGQZOB7P_XBUNUN;G3;IX[^>XC2X"JLIRDJAB /F#8[&@#F?VEO\ @IM\>OV#
M/BY^TE<>/'T7QU>?"_X-^!Y?#\4/AVWL'U?Q#JMV]BKRO$/-\AIY(G,1<A$5
MPA!.:]<_9[T/_@N7\(OC3X*U?]IOXC_#_P"+G@GQ9.;?QOHOA7P[;:+/X%+1
MEEN(9Y)5;484<>6PVF0@@A.I&+\8_P#@CQXW_:X\8_'+6/VHOB1H,5M\:/A+
MX6\/R3>$8IUFTK6](F>Z6^C68#]TMR(71=^YE0JV,YK6^!G[&/\ P5KU_P"+
MO@O4_P!MK]OCPWJ'@OX?W?VNST[X6:7>Z3?^*YEC*1G5Y&<(\?.]HD7RW;JO
M>@#XVA_X+,?MF^,?VG/%'@K6O^"A/P9^"_C#0?&]QING?L\_&+X<W>FVEY91
MW.R)IO$3(1&TT7SKL!.6 QWK]J;.66:TBEF5 [1JS>6^Y<D<X; R/? S7YI_
MM?\ _!*/_@IQ^V)9Z]\ OB_^U#\#?%OPRUR\F2W\6>+OA.)_&6C6,DF[R[62
M)4M4E1?E20!6X!)SS7U1\(-6^._PV_;(L_V3M(MM-N_@UX3^!>GR:?J4VGW+
M:K#K$5VMI$D]TS>3*DMM%(P15WAH69B R@@'E'_!Q[_RA:^./_8'T[_TZV=<
M=^U[^T-_P4>U#_@H-\*?V$?V'_BKX2\)Z?XN^ ]QXAUO7/%/AE-1&D26][%'
M]MBC^5II-NV$0LXC/G%B,J"/HS_@JC^R!XU_;U_8'^(7[)?P\\4:7HVL>,+&
MU@L=2UKS/LL!BO()R7\I6;!6(@8!Y(JA-^Q5XZD_X*3>!OVU1XMTG^PO"WP-
MO?!%WI/[W[7-=S7\%RLZ?+L\H+$0<L&R1QB@#XZ;_@JW^WU^S)\,?C)\ /CK
M-X/^(7QE\%?$KP_X-\!^*+'23IMAJTVM+^XN;JVC)$0BY+*A[=3W^COV5M$_
MX+,_!S]H[P_X5_:\^(?@KXQ?#GQ9H]X^M>)?"_AZUT&X\#:A%&)((VB,VZ_M
MYCNA#(K2*^UF"("6Y+X]?\$:_$G[0GCKX^>+-=^,%GH4_P 1O$WAWQ'\.]7T
MF%Y+KP_JFDQ_N9IT=0CKYG\*L05//I75_LQ?LD?\%1+[]HGPS\9OV^OVUO#>
MK:)X#L;R+P_X+^$UC?:79:[<W$/D_:]8$KXNC&F62'!C60AP 5Y /LP#%%<%
M\ +']I2PT;Q G[3>N^#]0OW\77[^%W\&6=S#%%H98?8X[D7#$M=JN[S&3"$X
MV@5WH.>U !1110 4449H **,T YH ***,T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\@_\ !8#_ )%?X!?]G.>%O_0+ROKZOD'_ (+
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MMJ.R9A;M,JYA5=X88R5KV/XP>+O&?_!:GQ7;_L]_ '3)=,_9P\.^)H+CQ_\
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MH\LCR([,9, @*N/5O@=\+?"W_!9']J[2O@Q_P4/^(GB36/"?@G]GWPGK6@^
M;7Q;=Z7!K>H7UOFZU2X-K)')<2!E&#N^4DYR#B@#]E,T9YQ7X8?%MM?^%/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_\%@/^17^
M7_9SGA;_ - O*^OJ^0?^"P'_ "*_P"_[.<\+?^@7E 'U]1110 4444 %%%%
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MVU@\32QZCJ)N9I9P"D;2")71W61.%92A]C_8S_;E_;P\7_M$?$/]@?\ ;/\
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MX6_] O*^OJ^0?^"P'_(K_ +_ +.<\+?^@7E 'U]1110 4444 %%%% !1110
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ML9_M-H_"%J#<Y.X[ODYY - 'RGJ?AGX Z7_P7ZTW7?$GA7P3!XBUK]GB&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_
M\%@/^17^ 7_9SGA;_P! O*^OJ^0?^"P'_(K_  "_[.<\+?\ H%Y0!]?4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?(/Q,_Y3>_"_P#[('K_ /Z<;>OKZOD'XF?\IO?A?_V0/7__ $XV] 'U
M]1110 4444 %%%% !1110  8&**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%!KRK]LO\ :Y^'G[$GP/F^.OQ-T[4+S3H];TS28;73(U:62ZOKR*T@'S$
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MOJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OD'XF?\IO?A?_ -D#U_\ ].-O7U]7R#\3/^4WOPO_ .R!Z_\
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M"/BRXTRS\0J !B]AA($X( !!(#8YR>: /SE_X(F?L$? #_@HA_P1G\2?L_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(/\
MP6 _Y%?X!?\ 9SGA;_T"\KZ^KY!_X+ ?\BO\ O\ LYSPM_Z!>4 ?7U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7R#\3/^4WOPO_ .R!Z_\ ^G&WKZ^KY!^)G_*;WX7_ /9 ]?\ _3C;T ?7
MU%%% !1110 =>HHHHH **** "BBB@ HQ[444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 8]J*** "C\*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY!_X+ ?\BO\ O\ LYSPM_Z!>5]?
M5\@_\%@/^17^ 7_9SGA;_P! O* /KZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY!^)G_*;[X7_ /9 ]?\
M_3C;U]?5\7_MH>#/VP? W_!0OX>_M:_LY_LQM\2M'T?X9ZIX>U>RA\3VFG2P
M3W%W'*C#[0P##:ASCUH ^T**^0?^&T?^"FG_ $B7U3_PZ&D?_'*/^&T?^"FG
M_2)?5/\ PZ&D?_'* /KZBOD'_AM'_@II_P!(E]4_\.AI'_QRC_AM'_@II_TB
M7U3_ ,.AI'_QR@#Z^HKY!_X;1_X*:?\ 2)?5/_#H:1_\<H_X;1_X*:?](E]4
M_P##H:1_\<H ^OJ*^0?^&T?^"FG_ $B7U3_PZ&D?_'*/^&T?^"FG_2)?5/\
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M_P!(E]4_\.AI'_QRC_AM'_@II_TB7U3_ ,.AI'_QR@#Z^HKY!_X;1_X*:?\
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MR@#Z^HKY!_X;1_X*:?\ 2)?5/_#H:1_\<H_X;1_X*:?](E]4_P##H:1_\<H
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M_P##H:1_\<H ^OJ*^0?^&T?^"FG_ $B7U3_PZ&D?_'*/^&T?^"FG_2)?5/\
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M_P!(E]4_\.AI'_QRC_AM'_@II_TB7U3_ ,.AI'_QR@#Z^HKY!_X;1_X*:?\
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MR@#Z^HKY!_X;1_X*:?\ 2)?5/_#H:1_\<H_X;1_X*:?](E]4_P##H:1_\<H
M^OJ*^0?^&T?^"FG_ $B7U3_PZ&D?_'*/^&T?^"FG_2)?5/\ PZ&D?_'* /KZ
MBOD'_AM'_@II_P!(E]4_\.AI'_QRC_AM'_@II_TB7U3_ ,.AI'_QR@#Z^HKY
M!_X;1_X*:?\ 2)?5/_#H:1_\<H_X;1_X*:?](E]4_P##H:1_\<H ^OJ*^0?^
M&T?^"FG_ $B7U3_PZ&D?_'*/^&T?^"FG_2)?5/\ PZ&D?_'* /KZBOD'_AM'
M_@II_P!(E]4_\.AI'_QRC_AM'_@II_TB7U3_ ,.AI'_QR@#Z^HKY!_X;1_X*
M:?\ 2)?5/_#H:1_\<H_X;1_X*:?](E]4_P##H:1_\<H ^OJ*^0?^&T?^"FG_
M $B7U3_PZ&D?_'*/^&T?^"FG_2)?5/\ PZ&D?_'* /KZBOD'_AM'_@II_P!(
ME]4_\.AI'_QRC_AM'_@II_TB7U3_ ,.AI'_QR@#Z^KY!_P""OY_XI?X!?]G.
M>%O_ $"\H_X;1_X*:?\ 2)?5/_#H:1_\<KS7]H6]_P""C?[:'BGX2^"_%'_!
M/:Z\#Z/X5^,6C>*-9\07GC[3;M8K6T$X=1%$Y9F/FC&/2@#]"**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,\9Q0 44 Y[44 %%
M%% !1110 4444 %%&?:@'/2@ HHHH **** "BBB@ HHHS0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX;(-?IG_ ,%P/V1/'G[<?_!+[XJ?LZ_"^T^U>(M1TF&_T.Q#!3=W5E<Q7<<
M)X!=H0@SQEJ /SF_8^_X)??\%8/^"HW[/NG?MY?'W_@K7\1/A_KOC:&35/"7
MA7PG<S06-K;EV\H2QQ2QJJG'"A6.W&237M7_  1&_P""H?[2>F^.OC]_P3\_
MX*1>*#KWCC]G6QN=5/BVW@#3ZKH]M)Y<[.% $C(3"R-@%UG /*Y/FO\ P2R_
MX.6?V"OV9?V$_#?[-W[;^H^*O /Q*^%VE-HFH>&YO!M]<2:DUNS!1$8HF6*3
M&%9)VBPPZXY' _\ !)SP/\6_VNOBE^W%_P %I?%OPXU'PKX.^)'P[U_0? -K
MJD)22_MY-MQ)(N?OK$EG;1F0?*SO( <QL  ?HK^RY_P7L_8&_;(\9^&? _P"
MG\>:Q<>)IWABO/\ A![E;/3I%W';>7',=N2$+#<W3![UPW[2W_!?C_@GIJ7A
M7XJ_!+X>_%GQ%/J^C^&=6TU_&>C^';MM&T_4VM94AC;48QLAD,I558D?,1@]
MZ\6_X-H/AK>:W_P0$\2Z/\/=-CC\1>)+SQ3'9SQJ%DDO'M!%#\W7(.T YXKY
MD_X)6?MB?L-_LR?\$-/V@/V2/VHO$NAZ1\6H&\5:5KGP]UJ(+K?B+4+J&6&T
MCM[9AYMRQ=HX]R@B,KN8J!NH ^L_^#?W]O7PQ\'/^"'$'[57[<O[0NI36>F^
M,]6BO/$GBW6)[ZZE >,1P(TK-)(V3A4!/7BOJ[]D3_@M!^PO^VC\58O@A\,O
M%?B'1O%EY8M>Z/H?C;PS<:3/JML!DS6HG \Y,<Y7J.1P#7X!ZOX ^+/B+_@V
MK^"?C[P9)=1^&_"?[1U_?>,+RWT\W<>G0%0D=W-#TEC21AE3P21GUKZH\(H?
MVK/^"JG[+?D?\%;+;X_>+/#,T.M:/_PJ#X Z39V6B:3&0UQ:ZK>6^K1FS#1A
MHRK12LAD V98*0#]*OBI_P %_/\ @GU\(_CYXW_9CUZ_\<ZAXW\ ZHEAK6@^
M'_!-S?332%=Q:!8<F5$7EWP H(S7U;K'BZ#Q7\#[OQWH*WEK%J7A62^LQ<Q-
M#<1*]L9$W+U1P",CJ#7Y,?\ !)GPUHFI?\'-'[;WB"_TV&:ZLM/\JUEDC#&-
M9+BRWXSTR% ^E?KK\30J_#/Q"JK@#0KL #M^Y:@#^;K_ (),?LS>)_\ @HK\
M%?&?QB_:(_X+U?$[X0ZOHWQ)OM#L?#=U\5'C-Q:1VUK.MR!<W\;8+W$D?"E?
MW7!SD#]D_P!F:]^ /_!';_@GS-XM_:'_ ."@>K?%+PDNN7&I6OQ)\6:M]ON;
MWS]B):6[K--YP5HF"JK'EFZ<U^5G_!N+_P $4?\ @G=_P4E_9+^(WQK_ &NO
MA!J/B#Q%I'QIU/1+&\L_%=_8JEE'8:?.L9CMID4D27$IW$9.[&< 8]J_X.7O
MV-T_9<_8+_9S\ _LR:=?^'_A/\)_B/%_:4K03:NFAP2.7CNKB.5F:Y1)&<['
M8AONY - 'Z(?L>?\%DOV'_VV_BH?@=\+/%/B#1_&$FGM?Z?X;\;^&;C2+O4K
M0 DSVR3@><@ W97L"1P"1F?M3_\ !;_]@7]D?XQWWP$\?>,/$6N>*-'M5N/$
M6G^"?"]QJW]BQ$ [[MH01 ,$$YZ \XK\POAK:3?M4_\ !9+]F/4+7_@K)!^T
M%XR\'QIK=G>?"'X#:59Z7I&BH2]S9ZK?6VK(;7=$&BVF*9D,ZKLW2!&\D^!V
MJ_&3]F#_ (*%_MI>"?B__P %,?"/[->MZMXPU+5;J/XA?"VQUQ_&.DRW%U+$
M+*:^GBP6AEBV01DF0.. 8\  _=OQ/_P4R_8D\(_L=Q_MY:O\=M+_ .%7S0HU
MKXAA8OY\C':L"(/F,Q8%?+QD$'. ":\]_9A_X+<_L*_M4_&S3_V>/"NK>+_"
M_B[6K=I_#^E?$#P=<Z,VKHHR3;&< 2\<C'7MD\5^37A/]G_]E_1/^#</Q%>_
MM"ZY\?/%'PN\1?%X:_X9\4^'_A5I^F7^@S$21)?G3WU>9&TYY&E&_P Q<^>H
M"*2K5R/@#XP_''X#_M]_LT^']!_;N^$G[<NDZEXDA@\)PQZ7'J'B/PM;LT.9
M"Q\V;2Y NTA3-E3$0R84T ?NK\)_^"CG[-/QH_;(\<_L)^"-2UE_'WP\M$N?
M$EO<Z2T=JD;8QY<V<.>1VKWBO$/A=^V5^Q-\2OVN?&G[*_PP\8Z?<_%KP?:I
M-XSTN'PM=V\UO$V-I:[>W6&;J.$E<U[?0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'G/Q)_8^_9*^,OBE/'/Q?_9;^'/BO6HPHCUCQ)X)L+ZZ4*,*
M!+/$SC';GBNPN_ 7@:^\'-\.[WP9I,WA^2T^ROH<NFQ-9M!C'E&$KL*8_AQC
MVK6HH \I3]A+]B%/"\/@@?L<?"K^Q;;5%U.VT?\ X5YIOV6*]52JW2Q>1L68
M*S 2 ;@"1GFNK3X$? ^+XK-\=XO@WX57QPUG]D;QDOAVV&K&WQCR3=[/.,>"
M1MW8]JZNB@#S_7_V3OV6O%GQ&A^,7BK]FKX?ZGXNMYEEM_%6H>#;&;4HI%^Z
MZW+Q&4,.Q#9%=1X\^'G@#XI^&;CP5\3O VC^(]&NQBZTG7M,BO+68>CQ2JR-
M^(-;%% ''_"3]GOX!? "PN-*^!'P/\'^";6[8-=6WA'PS:Z;',PZ%UMXT#'Z
MUV&.<T44 ><_$/\ 8]_9)^+GBM?'?Q7_ &6_ASXGUR/:8]8\1>"+"]NE(Z$3
M31,XQVYKMYO"OABX\-/X+G\-V$FCR69M)-)>S0VS6Y7:83%C:4*_+MQC'&,5
M?HH YWX7?"#X3? [PG'X"^"OPN\.^#]"BF:6+1?"^B0:?:)(WWG$,"*@8X&3
MC)QS6+JW[+7[,FO?$=OC%KG[.?@.\\7/&8W\57?A"RDU)E*[2IN6B,N"I(QN
MZ'%=Y10!R?@7X"_ WX7_  ]E^$GPR^#'A/PYX5F:0S>&=!\.VUGI\AD_UA-O
M$BQG=_%E>>^:J?"C]F?]G'X"W5Y?? S]G_P3X+GU+G4)O"?A2STYKKG/[PV\
M:%^?[V:[>B@#E/"WP(^!W@7XA:U\6_!/P9\*:/XK\2#'B+Q-I?AVVM]0U09!
M_P!)N8T$D_*J?G8]!Z5T]Q;6]Y;26=Y DT,J%)8Y%#*ZD8((/!!':I** .5^
M$OP,^"7P"T&Z\+? GX.^%?!6EWVH-?7NF^$O#]MIMO<73*J-.\=NB*TA5$4N
M06(103@"N@UW0=#\4:/<^'O$VC6NHZ?>0F*\L;ZW6:&>,]4='!5E/H015JB@
M#B?A)^S9^SK\ 9+Z7X$_ /P5X*;4F#:BWA+PK:::;HCH9/L\:;_^!9IGQ5_9
MA_9L^.VHV>K_ !Q_9Z\#^,[O3_\ D'W7BOPE9ZC);<Y_=M<1N4YYX(KN:* *
M+>%_#+^'#X.?P[8G2&M?LK:6;-/LQ@V[?*\O&W9MXVXQCC%<9\+?V2_V5?@=
MX@G\6?!3]F;X?>#]5NE9;G4_"W@RQT^XE4]0TD$2,P/?)YKT&B@#E/#_ ,"/
M@?X3^(^J?&/PM\&_"NF^+M<C$>M>*M/\.VT.I:@HZ+/<H@EE P.&8UU=%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%)DTM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M >"_\,":!_T=9\>O_#N7_P#C1_PP)H'_ $=9\>O_  [E_P#XU[T.E% '@O\
MPP)H'_1UGQZ_\.Y?_P"-'_# F@?]'6?'K_P[E_\ XU[U10!X+_PP)H'_ $=9
M\>O_  [E_P#XT?\ # F@?]'6?'K_ ,.Y?_XU[UWSFB@#P7_A@30/^CK/CU_X
M=R__ ,:/^&!- _Z.L^/7_AW+_P#QKWJB@#P7_A@30/\ HZSX]?\ AW+_ /QH
M_P"&!- _Z.L^/7_AW+__ !KWH^M% '@O_# F@?\ 1UGQZ_\ #N7_ /C1_P ,
M":!_T=9\>O\ P[E__C7O7/I1SWH \%_X8$T#_HZSX]?^'<O_ /&C_A@30/\
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MR_\ \:]ZZT<^E '@O_# F@?]'6?'K_P[E_\ XT?\,":!_P!'6?'K_P .Y?\
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MES7M6M]?^(__  B'B#PF?$D276E7"D>9+!+'#*EZ-IRB@1^8>,KG-=_\#?\
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MI/!_[*MG\/O%D&L>)O&6A>7;7.K+&ZLR$1*@D+;2OW2WS'+8XH ^\?C_ /\
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M\*?^GBVH ^OJ9<7$%I ]U=3+''&I:221L*J@9))/04^O#/\ @IGHGQ&\2?\
M!/OXQ:#\)!='Q)=?#W4X])6Q)$S2FW;Y8\<[B,@>] %-_P#@J#^PZNIQVK?&
M6X&GRZH--C\6?\(CJW_".M=E_+$(UG[+_9^_?\N/M'WN.O%=TO[5GP0N?%'C
M;P3H_B#5-6UCX=W6E6_B_2]!\*ZEJ%Q9/J44<UGM2VMW:X5XI4D9X1(L2;FD
M*!6(\:\+_&;]AWP[_P $JO#WB[XCR^'[[X3V_P .-/MM1T7R$G2=5MXU-D+<
M<R3^:-OE ;R_;-?'/[3/Q&USP9%^V]X^^#FKZUX9F'B[X*?V5)I]Q+8W=M;R
MQ:/&8<HP=-T3M&RYY5F4Y!(H _7"BOQOLOC?^U]X^^$/Q!_:LFNO%.E^/-%^
M,&H:=I7B34/C-;V&A:-#;:I]F@TJ;13+M=7A !+0M*[2!E8#%?0,?PR\3?M.
M?ML?M/:7\3_C=\0M/L/"?@?PM<>&=%\*^/+_ $VUTC4+C0S+-=1+;2IN;S%4
MA&S&2"61BQ- 'W2OQA^&LOQ>;X"1>+(&\7Q^'_[<DT15<R)I_G+!YY.-H4R,
M% )R3G (!(Z:ORO_ ."7+M\>_P!N'X3_ +3/Q8UW6+_QEX@_8NT'6=4OV\27
ML<5YJ#7D,,DK6RS"$AA\QCV>7O;?MW?-7O'_  4+^'?[0WBK]HS2?%/@NZO?
M&G@O2_!<@U;X8^%_BQ-X6UBTNO/9O[51H)HC<@IA DK^6"AX.30!]56_QU^%
MEU\=+O\ 9KM_%&[QM8^%8/$EUHOV&?Y-+FN9+:.X\[9Y)S-#(NP.7&W)4 @G
MKJ_*7]F31?A5^W]^W/H'Q(T3XH_%+_A%Y?V,=):UDNO%,^F:Q>3Q>(M4MO,O
M;FQ,+RO&\4G*%4D.'(8$9P_@W\>?C9^TUI/PO^ %WXR\9^--:T?PKKUSK.FM
MX]E\,VT]M;:M-:0:A>ZG;2QW4\JI$%\J/Y3@N^2: /U"^,?[0GPA^ )\,CXM
M^+?[)_X3#Q-'X?\ #O\ Q+[BX^UZE)!/<)!^YC?R\Q6TS;WVH-F"P)4&Y\%_
MC+\-_P!H7X5Z'\:OA!XC_M?PSXCL5O-&U+['-;_:(22 WES(DB<@\,H/M7Y/
M>"OC'\0OC3^PS^S)K'Q)\<GQ)?:+^VKJNAVNL-JCWQGL[2#Q)#;C[2X#W 6)
M402L-SJJELDDU]6_L(ZIJ>A_\$#O#>MZ)J-Q9WEG\"M3GM+NUF:.6"5+6Z97
M1E(*LI (((((R* /MRBOS'^"%E\0/@9IG[#7QHTOX[?$#7->^+6N#1?B0/$O
MC*\O[36[>X\-:C>@FUFD:&%XY[6)D>)$;@ABV37-ZQ\0O&_B7]A#XK?M_P#B
M/]I?QCI?QF\*_$S7+71]"MO%UQ#8Z4]GK#VMGHITL.+>82P)&27C:1S-N##B
M@#](+#]I;X.ZSXBU7PIX<\07VL:AH/BN'PWKEOH?A^^OO[.U&6$3+'<&WA<0
M1B-E+3N5ACW .ZD@57\ ?M5_ _XI_&/Q1\!_AYXDU+5O$'@NX^S>*&M/#&HG
M3M/NO+BD-J^HF#[&;D)-$QMUF,JA\E!@X_*WX=VFH?#GXX:MX^\*^)?%.@Z]
MXD_;G\(:;XBM(?&FIF.>SN-%,\]K+!)<,CH96YW*20JJ3M50.N^&G[.NO^ /
M@9^V!\8/V8O$_C+3_&7PZ_:HU+4])A3QUJURFH6FG66C7<EG-%-<NDYE0RHS
MR*SLI568JB@ 'ZT5Y7\$?VUOV9/VC?BY\0O@3\&_B<NK^+/A5J<>G^/-';2;
MRV;3;AWE10'GA1+A=T$J[X6D0%<%AD9\4_X)N?'35_VW/BM\1OVV-"\5ZI)\
M/]073_#W@#2&OI/L9CMX1+=W:Q9V>8T\IC+[<XCQG KY&^"/Q%T7]CC]J;XJ
M_MU:W.MKX?E_:P^(/@#QY<G[OV6\LM,O-,E?_KGJ%HL*GM_:+^M 'Z6_#_\
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M;B",7%UJ<,L=PJPM+D00G+E\M@)@@'VK17XW_LW_ !*^-O[0?C7X-? +QO\
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M2*N9^(GQB^&GPGO/#^G_ !#\6V^ES>*M>AT7P_%,KLU[?2Y\N! H/)P3DX
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MK_RE\_9S_P"Q&\6_RM* /KZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDT?\-@?&;_HPCXG?]_-._P#DF@#WJBO!?^&P/C-_T81\3O\ OYIW_P DT?\
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M5_#/AO0;R&]TG?#<21W27,ETZRY^SG="8EVAAAV(J_-_P47_ &S-#_9#\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*OA#XW?#'0_BQX$U!;C2]?TNWOK1ED1FC66)9 C["0'4, RY.#Q7YT_M"?\
M!QOIW[/'_!6K3_\ @F=XJ_9:232;SQ%IVDS_ !$_X30J;>2\ $3&S^QD']XR
MICSQUSGC% 'Z=45^8/\ P6 _X./]._X)<?M>Z#^R9X8_9:C^(UUJ'ANRU36]
M5_X30Z:NEM=7,D4<!06<^\[$63)9>)5&.]?I5KWC;P;X5DCB\3^+=+TUI?\
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M4(M-T'P[HZK]IU.]E.$B4MPH[ECG ['I7QC\"/\ @Y8\97/[0W@7X)_MV?\
M!-3Q[\!M+^)FJ0Z?X*\6ZYJ+W-K=3RNJ1>8LMK;E$9G12Z&0*7!.%RP /U6H
MK/U[Q=X5\+"-O$_B;3]-69L0M?WL<.\^@WD9HO\ Q9X6TJ"UNM4\2Z?;17LB
MI9R7%XB+.QZ*A)^8GL!F@#0HK%B^)7PYG,0A\?Z*_GW!MX=NJPGS)AC,:_-R
MW(^4<\BCQEXTTSPK831+?Z>VK26DLFDZ5>:G';-?2JA*QJ7/ )&"V"%SD]*
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M\,=:NM.\:?%:P\5VMK(3:-MO9[#3Y$+WT,.'RX=!\C9P!F@#]#J*^3_VJ/\
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M HHHH **** "O!?V/?\ DL'QX_[*=_[86U>]5X+^Q[_R6#X\?]E._P#;"VH
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M(2P6!Y7PC948J<)P[G6.P\:]"BY1E>SNE>S4>KO\4E&_=I;L)5:<96;/K8G
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M)DU+PGX7^'/P>\6^+?$'BSP7#XJAT'26L()[33I3A7D:[NHHV?<"/+C=W..
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M=,DWC[P_X>6W,>H3"(0O-%+(ADM)'B4(SQ$$XSUYKT/3/"WQ=\$_&[P3X'\
MW#1_"W1_ =];ZXE[Y<TDFH)+:)8A96S,6\K[67).TX3J3QYY_P /.?A)HWA#
MQ9J?Q#^'GBSPWXA\(^(+'1+[P7J%I!-J5S?7J[K2*#[--)#+YHS@B3 VG<5P
M:R?B'_P5@^%'P7^'_C;Q3\:?@[XX\,ZYX$L])OM6\%WEI:2ZC/8ZC?1V,%W;
MF"X>&>,3.0P60LNQ@5W;5,QX:SV<XPC0DW)I*W5OEM;NO>CJM/>6NH_;4^Y]
M6#/>BN1^$_Q+UWXA^"O^$N\6?"_7/!<WFN/[(\126K7 C !$O^C32IM8'INW
M#!! (Q7E/P4_X* :%\?/%%C#X ^!'CJZ\+:EJUQIUEXXBM+66Q\Z$N&:6**X
M:ZMXRT;*))H40DKSR*X89;CJD:DHPNJ>DG=63LW:^S;2=K/6SL5SQTUW/H3-
M<S\7O &K?$_P!?>#-#^(FM>%+RZV-:Z]X?F6.ZM71PP*[@58'&&4@AE)!ZUY
M+>?\%#_A1:? /XC?M#2^$/$)TGX:^-M5\,:Q9K#!]HN;JPN_LLLD(\W:8V?E
M2S*VWJ >*Y'6?^"KG@'3M=\?6^E_L]?$C5-%^%]^+?QYXFT_3;5K/3(_*68S
MX-P)9D6-M[+$CNJJ25 KLH\.YUB(RE"B[1=GLK.\5;5[WE%6ZMHEUJ<>IJ:-
M_P $R_ NM^*OB!\1?V@?BEK'C_Q)\1?AU_P@VL:M>:?:Z>(M$,DDC0)%:HB%
MV>3<96!;Y5&<"N>TG_@DMX:U;QAX/\1_&_\ :1\7^/;'P5X1U#POI&AZQ:VD
M-L^E7=J+9XI1#&I>01@#S2=Q[UJZI_P5-\ WOQ-\:_#;X7? 3X@>./\ A7^E
MZ;JGB76?#-E:/9Q6%]8QWD%Q&TMPC39C<_ND5I28V(0C!.I<?\%+/A?XHN;6
MR_9\^&GBWXH2-X7MO$.H#P?:V^-/L+A2T32&ZFA!D8!L0H6E^4_+52X:SV*3
ME0:5D];:)I-<VONW337-:]] ]M2[G+:K_P $G-.\6?#'_A2?Q!_:O^(&M>$=
M-\&ZQX>\(Z),]O"NDPW^GS:>9I&C0&^>*WGD$?VC<%)#8) ->IWW[%?@S4/$
M?P5\2OXOU19/@G:-;Z+&(X]NH*; 669^.#L&[Y<<^U<;XH_X*@?".*+X3Q_"
MKX=>+/'MW\9K/59O!MCX;M;=)-VGQQ27,4YNIH5@95D;.\@ Q.I(.T-YQ\"/
M^"A'QY\8?LU_'GXN?%'X=:CH-YX+\;:II/A%M0_L_;$X2&*VLF2WFE9Y8Y9%
M9V8%6\S"LP&%VCPKG?U5UYT^57BDI-*3<IRIZ1>ME.,D]-&GV)]O3YK)_P!6
MO^1]PYHKX0^%W[=7[3'P[_:@^)/P3^)7@;QI\41X/\%^&]3FM?"NAZ;$=-:>
MP$MY*S,UOYK/+N*PJ9'^4A$QQ5[X_?\ !1S1?$?PQ\?>._V7OBMXB^V0_L_V
M?C?PO</I>G/I,,5Q=2QQSJLL)N3=Y0H\4I:%0H 0/N-;?ZH9U]8A2C%-34&I
M)WC:=G&_6-T^J76U[!]8I\M_ZT/N'(]:I>)-%A\2^'K_ ,.W,S1QZA92VTDD
M?WE5T*DC/<9KX6^"7[>'Q%NM-U>[^-_Q-\33*WQXTKPIX?;PSI&E*PCN+-9!
M;W'G08-LS[R[IB<?*$<#(KT:_P#^"L?PWL8/''B6+X"?$*X\*_#7QU>>%O''
MC"*QL_L>F75M<"%Y=IN1-/%\RONAC<JK#>%.0,:G"N=PQ$J,*?.U:[3TU<4D
MKVNVY))+6^@*O3:O<Z*P_P"";7PRLOV?O@[^SO+XZUB?2_@WKMIJ>EW4L,)D
MU)H$F01SC;M"L)FSM / KE]-_P""3'@.T\-Z3\$]2^//BZ^^#N@^*(-=TOX4
M7"V_V-9(+H7<%L]P$\^6UCG5'6!FV_(HZ#%:WQE_X*B?#?X56_CCQ%H/P7\=
M>,O#?PWA/_"9>)O"MC;26MC-Y0E\@"6=))G"LNXQHRIN!9E&2/?_  +\0]%\
M=_#K2_B7I\4UO8ZKI,6H0Q7*CS(XGC#@,%)&0#S@D9KS\5D^9X&A&M7I.,9.
MR;[V4K-;IV:=G;1I]2XU(2=DSYVU/_@ECX*U.S\3>&E^-?B.+P]XB^+EK\1(
M]#6TMBMCJD<L<LBI(4WM'*T:Y5B=O.W%6_&'_!,O0M9UKQMIG@G]H;QIX3\%
M?$C7&U?QQX)T&2&..]N9"IN##=;?/M!-M^<1,N=S8QFD\,_\%1_A9K?BWPM9
M:K\+/%NB^&_&^L-IOA7QCJJ64=K?3?-L)@%R;J%'V$J\L**1@YY%>8_M5_\
M!4?Q9=?#/P[XJ_9N\ ^,M+T77/B]X=\.Z?\ $F?1[*;2]2ADUNWMKV)4D>2:
M-)(?/19WA12?]6X8J:]+!\)9]C,1"BJ7+S.R<G:-[M:OO>+NE=Z/30B6(I1C
M>YZ1+_P2^T/3)?$7@[X>_M'>-O#'PZ\6>*IO$&N_#[1I(4A>\GF$]R(;K;]H
MMXII<N\<;@$NW3)KZBLK6#3[.&QM5VQ0QK'&I8G"@8 R?:OA[]M3_@J#XDT#
MX&^-O$?[-'@+QCY'AWQ,GAY?B=:Z393Z5#J27:07$0CF=I9%1]\33>08@P8;
M\C(]/\"?\%(_!'BCQ/XXT"Z^%?BRUT/X77%S;>/O'U]'9QZ5I\EO:_:7?_7^
M=(I3D%(C@G#;:4N$\^C@(XOV7NMM6NKJW)NNC;G%);W=K!]8I<W+?^OZ1]+4
M9STKYI\(?\%-/AOJ=YX=NOB+\)/&O@?0_&EA-=^"/$/BBQMUM]:2.W:YV*L,
M\DMO(\"-(D=PD3N%. 3Q6U^SO^W9IO[1$^FZKH/P%\<:9X8US3Y+W0_&%]:V
MDUA<PH,Y?[-<2R6I93E5N$C)],\5Q5LASC#TY3J46DMWI:^NB?5^Z[I:JS[%
M*K3>S/?,C/6OE?4/^"5GPXU'0?&?A63XN^)(M.\1_$0^.?#Z6\<"3>&==+(S
M75M,$WN&9.4DW+@D=#72?L__ +?^B_M':OHM]X"^ GCIO"/B.ZF@T7QU]EM)
MK"0QASOFCAN'N;1&\LA7GAC4DJ,Y89^A  .E<>,P.+R^M[+$QY9=G:ZLVFGV
M::U3U1491DKH\2_9_P#V,K+X0_&37/VC?B+\6]<^('Q UW0K?1'\2:Y;P6_V
M32X)'E2T@@MU6.-3*[2,0,NV"3P*]M QP**Q?B3XYTOX8_#O7OB1KB,UGH&C
MW.HW2Q_>:.&)I& ]R%XKE*-JBOBWX'I_P40_:^_9CL?VO/"/[8/_  @NO>*]
M)?6/ _PYM/!>E77A^"!LM:VVHR7%N]_,SJ%$LD%S!MWDJOR@'C_C;^WS\>O@
MI^U!-X$_:#\6:UX8TNW^"W@?5=6\._#FSTF]:R\2:EXBGT^Y\JXU"V8RVS;4
MB;=@B)2T820[J /I[]MK]CKP_P#MK_#?0?AYKWQ%USPK)X=\::?XFTS5_#K1
MBXCO+/S#$,NI&W<^3QSMQT)KSC7/^"4GPQ^)EGXVUW]H/XK^)O''C7QI8Z39
MGQQ=+#9W>CV^F7+7=A'91P*L<'E73M.2!EW.6STK1^)__!4+X9?#[Q-XYM-!
M^#'CSQ9X<^%TXA^)7C7PWI]M)I_A]P@DE#B6=)[@Q1G?(+>*4HN2<8K+\1_\
M%9OAU'\1?B)\/?A5^SQ\1O'Z_"W2=)U;Q9K7A6UL#91:=J&G1ZA;W,4EQ=Q&
M?,+M^Z0&4F)B$*X8@'I'P-_9-\0?#;XGW'QF^*'[17BOXA>(6T9=*L9M86&U
MM;.U#;CMMK95C,C'&Z5@6..M>S5\=?L^_P#!0/XE_M _\%#KKX3>"? &J7GP
MGU#X.Z3XI\/ZXITY$S>2;ENY,W'VG:RD1",)N5@Q9 ,-7V+0 49HKYU^)G_!
M1'PYX.^,_BKX(?#O]GSQ]\0M4\"6MK/XR;P;;V+MIPGB\Z-$@N+J*XO'\LAM
MEM'*W.,9XH ]L^)O@J\^(G@/4_!NF>-=7\.7&H6QCAUS0K@17=FW:2-B",CW
M&#7S/XT_X)+>!/C;=^*/$'[3/QO\1^.=<\1>"_\ A&+?6GL+33I=.LQ<I=*Z
M+:QJKRB>**3>^3E .F:Q?B;^WI\;/AG_ ,%,]:^ ?A[X7^-/'GA=?@)IOBJQ
M\'^&=(T^&:SNFU*[BGNI9[QX&0F*.)/)>7[PPL>XFNT@_P""H_PH\6^$O!NN
M_!GX2^-/&VH^--!GUBUT'2X+.SFT^U@F,$INIK^XM[>%UE5H_+,I9BIV@CF@
M!W@C_@G%<Z7^T)9?M,_%+]IWQ=XT\2Z?\.=3\%VO]I6-I;VR:?=R6\FX101J
MHE5H,EQR^_YL[5QS?P%_X)(^&?@[X9^'/PR\6?M*>-/&G@?X67Z:AX1\(Z]#
M:K#%?)N\N>62*,23!"[LB,=JD\#@5R\W_!2G6_CQ\;O@3J_[.WBJ^TGP;XY\
M&?$R7Q1X?U32;4W4>K:$+.".*5F61HWM[@W(Q%)Y<@()\Q=IKW;_ ()J_&'X
MB_'_ /8/^%OQF^+?B+^UO$OB+PK#>:SJ7V2&W^T3,S OY<*)&G0<*H'M0!RO
MAS_@F'\,_#G[//PJ_9UM_B-KLFG_  G^*=AXYTK4'CA\Z]NK6]GNUMY1MVB-
MFG925 ; &#FE^+/_  3'^&GQ:^(WC#XCZM\1M<M;GQEXN\+^(+RWMXX3'!-H
MAD,,:97.V3S#OSSQQBOIFO,OVK?VJ/ '[(WPXMOB)X]TS4M0_M+6K71]'TK2
M8XS<7U]</LBA4RND:9/5I'5 .I% 'C5Q_P $IO"Z?"*Z^#FB?'[Q-8Z?9_%J
MU^(?@F9+"TDD\-ZM#J!U ;-R$7$9F9LK+N^4XK8\7?\ !..>]\;^+O&GPR_:
M?\9>"6^)%K:K\1[30H+4IK5S#;+;&\0NA-G.\2*K/"5SM'<5H>-_^"B&B_";
M]G3Q5^T3\9/V;OB-X4M_"6M:7IU[HFJ65D\]V;^]M;.&:UGAN7M+F(/=H6:.
M8[0CC&X!3R7_  4Z_P""@%S^S'\.?'OPV^&TFK:9X^T_X/ZIXTT+Q##I]M<V
MMK'9W$$+*4FW[Y29P0IB92 <G. 0#6\4?\$P_#$.L:IJ?P/^/OC+X?Q^)O"M
MKX?\90Z1)%=-K-K!#Y$<K27*N\5QY1VF="'(ZGBO8/V4/V>_#_[)O[-/@7]F
M;PIK][JFF^!/#%GHECJ6I*@N+F*WB$:R2; %W$#)P ,UX)X-_P""K?A#P_\
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M%% !1110 4444 %%%% !1110 4444 %%%% '@W_!+7_E&O\  /\ [)!X=_\
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MI?\ !K?XXU'XF)-XAU#X4_&2YL? NI:I=22S:5;O?I"RHQ;H4^7!R .F*_H
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MX=/L+RYN6E*VT>I2[$5F).P _*,\+@=J]_\ VR_V2/A1_P $\OVL?V$_CO\
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M4KMS^%P7NP=HMQ>CYKW7*K/=6#ZN_+OU/E+5_C3HOP%_:)^)_P 4OV<OC_\
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M2:UJ$UN+?S -R^1"%W-L.YLD#/%<CX*\.?#/0OV//V?O@C??M3_![^VOAO\
M&;3?$WB0)\2+ PBQ@U"YGD,3;_G?9*F%P,G//%?<^G_LV?LLZM#]HTOX,>"[
MF/./,M]'MG7/U HO_P!FG]ES2[?[5J?P6\&V\0.#)<:/;HOYD5S_ .MF%C3C
M2ASQA%IJ*C"R:]IM[U]75FWKNUV0_8RO?3\?+_)'P/\ M/?"'X'?'CXF_%+X
M@Q?M8_"(KJGC'PSX@\)V<_Q+MH5OO[/@ECGMYWAF5X-_F85U8D'GVKD_B3\%
M?@_\4? 'C[5-!^)OP-\(ZSKEGX:TW0]+N/C,FK7)@L]?M-2O'FOKBX;;&4@/
MEPJ@ 9<DY<U^D7_#.'[*ALEU$?!WP5]G<X6X_LFVV-]&QBFP_L[?LGW%HVH6
M_P (O \ENC!7G32K8HK$X )Q@') _&NF'&\:<:24JG[KEY=(:**@K6Y[._)&
M]T^NUQ?5]]M=_P"OF>=_$[Q__P $W?B_KFG^+O'?[2/@6ZU/2H56QDM_BP+2
M-2"&&Z.WO$1_F'\0/''2OEBPM/A?+^T9X4^(W@3XH?!7X5SZ7XT&I^+O$W@W
MXT0-:^(=/'F;[5M,,@0/-E0SMDJ<D'-?6_[0.D_L3_LY_ SQ1^T!XK^!/AW5
M-&\)6!N]4MO#^A64]RR!E7:BNR(6RPX9U^M:W@[X4_LS>+[NY)_98T73=-AT
MRSO;76M1TO2_L]VEQ$)-J)'.\T;1Y"MYL<:D_<+CFO(P&>9?E\91IRJM235G
MRM6::>G/9[O=-7U+E3E+L?"_Q9@OH_@U\:?V7/A=^T-\#;[0_B1\3=3\6Z9X
MJU#XJV,+PPW]TEW-9O;[B=ZOYB+(&VXP2*ROAU^T)JFM:G^TY\"_ 'Q?^#L>
MB>//%<^F6WB;7OB%:6WV".?3H[>:Y2(M_IB!2Q7:P&X8)K]'K7]F_P#96O+(
MZC9_!OP5+;KG=/'H]LR#'7Y@,5Y_^TDG[#O[+_P'U_\ :)\8? ?P[JVA^'?L
MPU"W\-Z#8SW+&>ZBMDVAWC0X>92<N,*#C)P#[M'C7+8X&IAZE*4N:S3Y8*TE
M*F^9^]J_W:5M$KMVU:,OJ\^9-/\ K7_,^(/V>?CE9_L__M&_M"?![X"?%OX2
MZQX;FT/P?H>D:YXD^(EI8A);?PY!;&Y5MS"ZC 7#(A!5TQGDUV'[..G^$_\
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M!EK:>5+_ !_ZS=T3N.XKJK_2OA7<?L7_ +1WP*B_:J^#_P#;OQ0^)GB;7?#
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M;R7"AVS[$YJ:F'Q%.$)R@TI)M.VZ3:;7HTUZH.:+ZGQ=^PI^Q%^TQ^RG\:/
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M\$>"_BIXRU32_$$Q^#LFFQ>,M+LX+62Y66\$6R.'_2!'*4\U0[!P@(.UGXR
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M1QXK-XT>J7%Y:3K++*(54PL(3T&5V8.=W'Z,)*DJ++%(K*PRK*<@UX3\1O\
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M[AD ^=_@K_P3?_:#\+?M1_ ;XQVO[-G@7P3IGPY^UQ^-;R'QI-JVJZS+-8M
M;H7$J;F3?EC$QR2^<\5UG_!/#_@G9^T1^S+^TEI'Q3^)D>AC2[+P#K>CS?V?
MJAFD^TW7B&XOXL+L&5\B1<G/#9'/6O7/%/\ P5(^!OA3QAK5A)\-O'M[X/\
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M5&9?9OVL[3QQX3_X+W_M&W/Q]_;A\#_ >+5/!]K/X.U_XJ?#.Q\0V&M:.+6
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MHH *\%_8]_Y+!\>/^RG?^V%M7O5>"_L>_P#)8/CQ_P!E._\ ;"VH ]ZHHHH
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MT0W3Z)X*TFS^W*RWIM=-BC^T ]0^U1O!]\T@/RU/P#^#?PC_ &#_ -CV^O/
MEKIOPP\3^+/#\O[0FJVENR_VO;#2+UK%]6D7YIK0ZB]MYID)7!0-\F17C'[1
M%O\ #G2?C'^T9IW[ DFEP_#V37OAW'XV_L.XG32(M/,UY]L6)K0$I8XV>9Y
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M _V1])\6Z0=1\.Z[^U-XWN9]-O(WC2[@:\U:0131G!*D$;HV&#T([5F_'?\
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M[P/J%M8RR0M<NJQ'>C-;F4C@$C)%>'?%FW_9J\._!WXC2_\ !,ZZOH_B-<?
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MS16R*RP*<K$"!G8"20O09Z4 ?D1\&]+^%G[,_P#P3+^ G[>_P?\ #>CV>I?
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MGDCO7"_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5%>*_\/)?^"=?_ $?Q\%?_  Z>D?\ R11_P\E_X)U_]'\?!7_PZ>D?_)%
M'M5>._\ !07_ ),C^*7_ &)=]_Z+-5_^'DO_  3K_P"C^/@K_P"'3TC_ .2*
M\K_;?_;_ /V$/&?[(/Q&\*>#_P!M?X1ZMJFH>$KR"PTW3?B1I<]Q<RM&0L<<
M:3EG8GHH!)H ^IOAY_R(&A_]@>U_]%+6Q7@/@C_@HU_P3VT_P9H^GW_[=WP9
M@N(=+MXYH9OBAI*O&ZQJ"K W&00>"#R#6I_P\E_X)U_]'\?!7_PZ>D?_ "10
M![517BO_  \E_P""=?\ T?Q\%?\ PZ>D?_)%'_#R7_@G7_T?Q\%?_#IZ1_\
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MI'_R11_P\E_X)U_]'\?!7_PZ>D?_ "10![517BO_  \E_P""=?\ T?Q\%?\
MPZ>D?_)%'_#R7_@G7_T?Q\%?_#IZ1_\ )% 'M5%>*_\ #R7_ ()U_P#1_'P5
M_P##IZ1_\D4?\/)?^"=?_1_'P5_\.GI'_P D4 >U45XK_P /)?\ @G7_ -'\
M?!7_ ,.GI'_R11_P\E_X)U_]'\?!7_PZ>D?_ "10![517BO_  \E_P""=?\
MT?Q\%?\ PZ>D?_)%'_#R7_@G7_T?Q\%?_#IZ1_\ )% 'M5>"_L>_\E@^/'_9
M3O\ VPMJT/\ AY+_ ,$Z_P#H_CX*_P#AT](_^2*YG]@3Q]X%^)_C;XV^.OAI
MXTTGQ%H>H?$KS+#6-#U**[M;E/L-N-T<L3,CC/<$T ?2%%%% !1110 4444
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MP]IUOXF\6W=]!:Z5=Q"*:S2.5BHBV@ +_#VJ?P__ ,$K/V7/"WC+P'\28O\
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MV<_!O[+]IX/O+/PY\/\ R7\'W5EJTT6HZ7<1[L7,=VI\P3L6<M)G+EV)SDT
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M_P"A7T[_ , 8_P#"M&B@#._X1#PG_P!"OIW_ ( Q_P"%'_"(>$_^A7T[_P
M8_\ "M&B@#._X1#PG_T*^G?^ ,?^%'_"(>$_^A7T[_P!C_PK1HH SO\ A$/"
M?_0KZ=_X Q_X4?\ "(>$_P#H5]._\ 8_\*MZGJ5EH^FW&KZE.(K>UA>:XE8$
MA$4$LW'H :^+=2_X.+_^"+.D:C<:3J/[>/A^*XM9FBN(SH.J_(ZG##BT[$4
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M_P"A7T[_ , 8_P#"M&B@#._X1#PG_P!"OIW_ ( Q_P"%'_"(>$_^A7T[_P
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M$_\ !1O]I[2?B7XZ\':,^F^ ]-\+Z VG:9I"."'F".S,92&;/.,L30!\8?\
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M^VM^UAXP\'Z?^V7^V7\._$7AWPCXEM]5_P"$GT'X8QV/BW4_)D#JEQ?)A3G
M!V@ =0,BOU;TRQBTO3K?38&9DMX5B1G;+$*  2>YXH GHHHH **** "BBB@
MHHHH **** "O'?\ @H+_ ,F1_%+_ +$N^_\ 19KV*O'?^"@O_)D?Q2_[$N^_
M]%F@#TKX>?\ (@:'_P!@>U_]%+6Q6/\ #S_D0-#_ .P/:_\ HI:V* "BBB@
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M^"=W[5&B_#?Q/X^T2RTSXC:/XK\.MJ6FZM]D0QVUXJHRLEQ'$?+!SC:!QUH
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MB*SU?PWX5L?"YMM4U5K%MUC%J-R6*R1Q$*<*!NV@'/8 ^C/^"L'CSQ7\/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\@_M*_\ *7S]G/\ [$;Q;_*T
MKZ^KY!_:5_Y2^?LY_P#8C>+?Y6E 'U]1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >#?\$M?^4:_P#_[
M)!X=_P#3=#7O-?$'_!.SX<?MR:C^P3\&=0\ ?M0>"]+T.;X8:&^CZ;J'PSDN
M9[6V-C$8XI)1?H)75< N%7<1G Z5[+_PJO\ X*)_]'>_#_\ \--+_P#+*@#W
MJBO!?^%5_P#!1/\ Z.]^'_\ X::7_P"65'_"J_\ @HG_ -'>_#__ ,--+_\
M+*@#WJBO!?\ A5?_  43_P"CO?A__P"&FE_^65'_  JO_@HG_P!'>_#_ /\
M#32__+*@#WJBO!?^%5_\%$_^CO?A_P#^&FE_^65'_"J_^"B?_1WOP_\ _#32
M_P#RRH ]ZHKP7_A5?_!1/_H[WX?_ /AII?\ Y94?\*K_ ."B?_1WOP__ /#3
M2_\ RRH ]ZHKP7_A5?\ P43_ .CO?A__ .&FE_\ EE1_PJO_ (*)_P#1WOP_
M_P##32__ "RH ]ZHKP7_ (57_P %$_\ H[WX?_\ AII?_EE1_P *K_X*)_\
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M1/\ Z.]^'_\ X::7_P"65'_"J_\ @HG_ -'>_#__ ,--+_\ +*@#WJBO!?\
MA5?_  43_P"CO?A__P"&FE_^65'_  JO_@HG_P!'>_#_ /\ #32__+*@#WJB
MO!?^%5_\%$_^CO?A_P#^&FE_^65'_"J_^"B?_1WOP_\ _#32_P#RRH ]ZKQW
M_@H+_P F1_%+_L2[[_T6:Q_^%5_\%$_^CO?A_P#^&FE_^65>7_ML?#;]NRP_
M9)^(E[XS_:D\$:CI,?A2[;4+&S^&,EO+/%Y9W(DAOV"$C^+:<>AH ^LOAY_R
M(&A_]@>U_P#12UL5\X^"OA?_ ,%")?!NDR6'[6G@&*!M,MS#%)\*969$\M<
MM_:(R0.^!FM3_A5?_!1/_H[WX?\ _AII?_EE0![U17@O_"J_^"B?_1WOP_\
M_#32_P#RRH_X57_P43_Z.]^'_P#X::7_ .65 'O5%>"_\*K_ ."B?_1WOP__
M /#32_\ RRH_X57_ ,%$_P#H[WX?_P#AII?_ )94 >]45X+_ ,*K_P""B?\
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M /X::7_Y94?\*K_X*)_]'>_#_P#\--+_ /+*@#WJBO!?^%5_\%$_^CO?A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFM5^+>HZ7X3TOQ(N@QW.K^&;RUGU+4#&LBPV<$D8DNRR,K Q*P(/6M+X(?\
M!8?]@G]H7X:^-OBA\./BQ=M;_#O2FU+Q=H^IZ#=6>J6%HJY\YK.9%F*GL0O-
M 'U!17PM8_\ !Q[_ ,$DK]/#-Z/VAKZ'3_%+1)8ZO<>%;Z.RMI)#Q%<SF+R[
M=QU*N00.37NG[9G_  4C_8__ &"-&T75?VDOBDNFS^))&7P_I&F6,M_?ZC@
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MBEK8K'^'G_(@:'_V![7_ -%+6Q0 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0/\ H!V?_@*G^%'_  CV@?\ 0#L__ 5/\* /'?\ AXW^Q=_T6V#_ ,$M]_\
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MW_QBO8O^$>T#_H!V?_@*G^%'_"/:!_T [/\ \!4_PH \=_X>-_L7?]%M@_\
M!+??_&*/^'C?[%W_ $6V#_P2WW_QBO8O^$>T#_H!V?\ X"I_A1_PCV@?] .S
M_P# 5/\ "@#QW_AXW^Q=_P!%M@_\$M]_\8H_X>-_L7?]%M@_\$M]_P#&*]B_
MX1[0/^@'9_\ @*G^%'_"/:!_T [/_P !4_PH \=_X>-_L7?]%M@_\$M]_P#&
M*\Q_;0_;H_96^(O[*'Q"\">"?BJNH:OJWA6[MM.L8='O=\\SQD*@S"!DGU-?
M6'_"/:!_T [/_P !4_PH_P"$>T$<C0[/_P !5_PH \*\%_\ !0W]CC3/!VDZ
M9?\ QGACN+?3;>.:-M&OLHZQJ"/]1V(K3_X>-_L7?]%M@_\ !+??_&*]B_X1
M[0.^AV?_ ("I_A1_PCV@?] .S_\  5/\* /'?^'C?[%W_1;8/_!+??\ QBC_
M (>-_L7?]%M@_P#!+??_ !BO8O\ A'M _P"@'9_^ J?X4?\ "/:!_P! .S_\
M!4_PH \=_P"'C?[%W_1;8/\ P2WW_P 8H_X>-_L7?]%M@_\ !+??_&*]B_X1
M[0/^@'9_^ J?X4?\(]H'_0#L_P#P%3_"@#QW_AXW^Q=_T6V#_P $M]_\8H_X
M>-_L7?\ 1;8/_!+??_&*]B_X1[0/^@'9_P#@*G^%'_"/:!_T [/_ ,!4_P *
M /'?^'C?[%W_ $6V#_P2WW_QBC_AXW^Q=_T6V#_P2WW_ ,8KV+_A'M _Z =G
M_P" J?X4?\(]H'_0#L__  %3_"@#QW_AXW^Q=_T6V#_P2WW_ ,8H_P"'C?[%
MW_1;8/\ P2WW_P 8KV+_ (1[0/\ H!V?_@*G^%'_  CV@?\ 0#L__ 5/\* /
M'?\ AXW^Q=_T6V#_ ,$M]_\ &*/^'C?[%W_1;8/_  2WW_QBO8O^$>T#_H!V
M?_@*G^%'_"/:!_T [/\ \!4_PH \=_X>-_L7?]%M@_\ !+??_&*/^'C?[%W_
M $6V#_P2WW_QBO8O^$>T#_H!V?\ X"I_A1_PCV@?] .S_P# 5/\ "@#QW_AX
MW^Q=_P!%M@_\$M]_\8H_X>-_L7?]%M@_\$M]_P#&*]B_X1[0/^@'9_\ @*G^
M%'_"/:!_T [/_P !4_PH \=_X>-_L7?]%M@_\$M]_P#&*/\ AXW^Q=_T6V#_
M ,$M]_\ &*]B_P"$>T#_ * =G_X"I_A1_P (]H'_ $ [/_P%3_"@#QW_ (>-
M_L7?]%M@_P#!+??_ !BC_AXW^Q=_T6V#_P $M]_\8KV+_A'M _Z =G_X"I_A
M1_PCV@?] .S_ / 5/\* /'?^'C?[%W_1;8/_  2WW_QBC_AXW^Q=_P!%M@_\
M$M]_\8KV+_A'M _Z =G_ . J?X4?\(]H'_0#L_\ P%3_  H \=_X>-_L7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7R#^TK_RE\_9S_P"Q&\6_RM*^OJ^0?VE?^4OG[.?_ &(WBW^5
MI0!]?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_P#!
M;[_DQ^+_ +*9X4_]/%M7U]7R#_P6^_Y,?B_[*9X4_P#3Q;4 ?7U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?(/[2O_*7S]G/_L1O%O\ *TKZ
M^KY!_:5_Y2^?LY_]B-XM_E:4 ?7U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?(/_  6^_P"3'XO^RF>%/_3Q;5]?5\@_\%OO^3'XO^RF
M>%/_ $\6U 'U]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#
M^TK_ ,I?/V<_^Q&\6_RM*^OJ^0?VE?\ E+Y^SG_V(WBW^5I0!]?4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_\%OO^3'XO^RF>%/\
MT\6U?7U?(/\ P6^_Y,?B_P"RF>%/_3Q;4 ?7U%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?(/[2O_ "E\_9S_ .Q&\6_RM*^OJ^0?VE?^4OG[
M.?\ V(WBW^5I0!]?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\@_\%OO^3'XO^RF>%/_ $\6U?7U?(/_  6^_P"3'XO^RF>%/_3Q;4 ?
M7U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(/[2O_*7S]G/_
M +$;Q;_*TKZ^KY!_:5_Y2^?LY_\ 8C>+?Y6E 'U]1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7R#_ ,%OO^3'XO\ LIGA3_T\6U?7U?(/
M_!;[_DQ^+_LIGA3_ -/%M0!]?4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\@_M*_\I?/V<_^Q&\6_P K2OKZOD']I7_E+Y^SG_V(WBW^5I0!
M]?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_\ !;[_
M ),?B_[*9X4_]/%M7U]7R#_P6^_Y,?B_[*9X4_\ 3Q;4 ?7U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?(/[2O\ RE\_9S_[$;Q;_*TKZ^KY
M!_:5_P"4OG[.?_8C>+?Y6E 'U]1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7R#_P6^_Y,?B_[*9X4_P#3Q;5]?5\@_P#!;[_DQ^+_ +*9
MX4_]/%M0!]?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_M
M*_\ *7S]G/\ [$;Q;_*TKZ^KY!_:5_Y2^?LY_P#8C>+?Y6E 'U]1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#_P6^_Y,?B_[*9X4_\
M3Q;5]?5\@_\ !;[_ ),?B_[*9X4_]/%M0!]?4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\@_M*_\I?/V<_\ L1O%O\K2OKZOD']I7_E+Y^SG
M_P!B-XM_E:4 ?7U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?(/\ P6^_Y,?B_P"RF>%/_3Q;5]?5\@_\%OO^3'XO^RF>%/\ T\6U 'U]
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#^TK_RE\_9S_[$
M;Q;_ "M*^OJ^0?VE?^4OG[.?_8C>+?Y6E 'U]1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7R#_P %OO\ DQ^+_LIGA3_T\6U?7U?(/_!;
M[_DQ^+_LIGA3_P!/%M0!]?4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\@_M*_P#*7S]G/_L1O%O\K2OKZOD']I7_ )2^?LY_]B-XM_E:4 ?7
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(/_!;[_DQ^
M+_LIGA3_ -/%M7U]7R#_ ,%OO^3'XO\ LIGA3_T\6U 'U]1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7R#^TK_P I?/V<_P#L1O%O\K2OKZOD
M']I7_E+Y^SG_ -B-XM_E:4 ?7U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?(/_!;[_DQ^+_LIGA3_P!/%M7U]7R#_P %OO\ DQ^+_LIG
MA3_T\6U 'U]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#^T
MK_RE\_9S_P"Q&\6_RM*^OJ^0?VE?^4OG[.?_ &(WBW^5I0!]?4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5\@_P#!;[_DQ^+_ +*9X4_]
M/%M7U]7R#_P6^_Y,?B_[*9X4_P#3Q;4 ?7U%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?(/[2O_*7S]G/_L1O%O\ *TKZ^KY!_:5_Y2^?LY_]
MB-XM_E:4 ?7U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?(/_  6^_P"3'XO^RF>%/_3Q;5]?5\@_\%OO^3'XO^RF>%/_ $\6U 'U]111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R#^TK_ ,I?/V<_^Q&\
M6_RM*^OJ^0?VE?\ E+Y^SG_V(WBW^5I0!]?4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\@_\%OO^3'XO^RF>%/\ T\6U?7U?(/\ P6^_
MY,?B_P"RF>%/_3Q;4 ?7U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?(/[2O_ "E\_9S_ .Q&\6_RM*^OJ^0?VE?^4OG[.?\ V(WBW^5I0!]?
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0O\ AIC_ (*Z_P#2.+P=_P"'8C_^,4?\-,?\%=?^D<7@[_P[$?\ \8KZ]HH
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M/^"NO_2.+P=_X=B/_P",4?\ #3'_  5U_P"D<7@[_P .Q'_\8KZ]HH ^0O\
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M](XO!W_AV(__ (Q1_P -,?\ !77_ *1Q>#O_  [$?_QBOKVB@#Y"_P"&F/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?H__  21M_C/X1C\7:;K<-[)XH>.Z_LUU357O2H'E^;G8VW[OWO;FNN\7_\
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MQ\$_B=)\,?&WQNOKJU^(7CK1;41W$8LYC%*UMG_4EE5G^7'S$#@<5]*^$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Y/XE_'OX&?!=[>/XQ?&CPGX3:\4M9KXF\16
MM@9P#@E//==P!],URG_#>7[#G_1YGPH_\.)IG_Q^N/\ C%X:\.^)?^"@WPUM
M/$>@66H1+X%UHK%?6J2J#OBYPP->R_\ "H?A-_T2_P ._P#@D@_^(H XK_AO
M+]AS_H\SX4?^'$TS_P"/T?\ #>7[#G_1YGPH_P##B:9_\?KM?^%0_";_ *)?
MX=_\$D'_ ,11_P *A^$W_1+_  [_ ."2#_XB@#BO^&\OV'/^CS/A1_X<33/_
M (_1_P -Y?L.?]'F?"C_ ,.)IG_Q^NU_X5#\)O\ HE_AW_P20?\ Q%'_  J'
MX3?]$O\ #O\ X)(/_B* .*_X;R_8<_Z/,^%'_AQ-,_\ C]'_  WE^PY_T>9\
M*/\ PXFF?_'Z[7_A4/PF_P"B7^'?_!)!_P#$4?\ "H?A-_T2_P ._P#@D@_^
M(H XK_AO+]AS_H\SX4?^'$TS_P"/T?\ #>7[#G_1YGPH_P##B:9_\?KM?^%0
M_";_ *)?X=_\$D'_ ,11_P *A^$W_1+_  [_ ."2#_XB@#BO^&\OV'/^CS/A
M1_X<33/_ (_1_P -Y?L.?]'F?"C_ ,.)IG_Q^NU_X5#\)O\ HE_AW_P20?\
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MW_P20?\ Q%'_  J'X3?]$O\ #O\ X)(/_B* .*_X;R_8<_Z/,^%'_AQ-,_\
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M ,.)IG_Q^NU_X5#\)O\ HE_AW_P20?\ Q%'_  J'X3?]$O\ #O\ X)(/_B*
M.*_X;R_8<_Z/,^%'_AQ-,_\ C]'_  WE^PY_T>9\*/\ PXFF?_'Z[7_A4/PF
M_P"B7^'?_!)!_P#$4?\ "H?A-_T2_P ._P#@D@_^(H XK_AO+]AS_H\SX4?^
M'$TS_P"/T?\ #>7[#G_1YGPH_P##B:9_\?KM?^%0_";_ *)?X=_\$D'_ ,11
M_P *A^$W_1+_  [_ ."2#_XB@#BO^&\OV'/^CS/A1_X<33/_ (_1_P -Y?L.
M?]'F?"C_ ,.)IG_Q^NU_X5#\)O\ HE_AW_P20?\ Q%'_  J'X3?]$O\ #O\
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M$O\ #O\ X)(/_B* .*_X;R_8<_Z/,^%'_AQ-,_\ C]'_  WE^PY_T>9\*/\
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MAWW9&W .<\4 :/\ PWE^PY_T>9\*/_#B:9_\?H_X;R_8<_Z/,^%'_AQ-,_\
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M>^(7PBLO&<\BQP^$[K4=,CU*1V&546S$2$D=!MR: +W_  WE^PY_T>9\*/\
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M/[57PJ_X)DZ'XH^%-S=-]CFT#Q!!=^++JR6X,#7<6B1:<T;@$,_DB]\\H/\
M5[OEKZ&^*OC7]B?X#:+INO\ QXU?X:^![75F":?)XP:PTWSY, F-?M&W+C(R
MHY% "_\ #>7[#G_1YGPH_P##B:9_\?H_X;R_8<_Z/,^%'_AQ-,_^/UG?$+XP
M_P#!/?X26FFZA\4_B1\'_#=OK-A]NTB;7-4TRU6]ML@>=$96421Y8#<N1DCG
MFMC_ (2#]C/_ (030OBC_:GPU_X1GQ1>6=IX;\0>98?8M5N+MQ':Q6TWW)GF
M=E6-4)+L0%R30!!_PWE^PY_T>9\*/_#B:9_\?H_X;R_8<_Z/,^%'_AQ-,_\
MC]<[;?&']COPQX)U;Q_\:]<^!OAG2M.\6WVAKJD/BJQN+,26\I3R9YYX+=8+
MP8_>VN'\IOE\Q^M=)XE\6_L3^#/AC#\:O%^O_#'2_!]RB/;^*M0FT^'3I5?[
MI6X?$9![8;F@!O\ PWE^PY_T>9\*/_#B:9_\?H_X;R_8<_Z/,^%'_AQ-,_\
MC]5K_P")7[!FF?"B#X[ZCXV^$]OX(NFVVWC":^TU=,E.=N%N2?*)R".&ZUT'
MPWLOV7/C%X4M_'?PET_P'XGT2Z)%KK'A^WLKRUEQUVRQ!E./8T 9'_#>7[#G
M_1YGPH_\.)IG_P ?H_X;R_8<_P"CS/A1_P"'$TS_ ./UX-\+OC_\:_VBOB)\
M6?#7[/'_  3[^"5YHOPI^*=]X&O-4\:?%*YTJZU"[MK2SNFG2VMO#5XB1%+V
M(#,Q;<KY& "?9/%'Q#_9/^"'AS0W_:VN?@S\.=?UB,#^R[[Q!9?9GGS@QVT]
MW!:O<@<?-Y*'G[HH U?^&\OV'/\ H\SX4?\ AQ-,_P#C]'_#>7[#G_1YGPH_
M\.)IG_Q^F?%+QU^PW\#M!T_Q5\9_%'PM\)Z9JS!=+U#Q)=:=90WC$ @1/,56
M0X(/RD\&H?B'\3/V"_A)X6TOQQ\4_&WPG\-Z+KBJVBZMKE]IMI;7ZD9!ADE(
M60$$'Y2>* +/_#>7[#G_ $>9\*/_  XFF?\ Q^C_ (;R_8<_Z/,^%'_AQ-,_
M^/UT_AOP1\ _&6@6GBKPAX-\(ZIIE_"LUCJ&G:;:S07$;#(='12K*1T()!KQ
M+0?V@O@GXUT7QIXU\)_!SX9V'A?PO\1(_!^F^*/&FN0:59ZW>QS+!?>2PLIL
M>5<,UM$O/VB>*1,QJ%=P#T;_ (;R_8<_Z/,^%'_AQ-,_^/T?\-Y?L.?]'F?"
MC_PXFF?_ !^LCQ)\<_\ @G-X-\8?\*]\7?%?X-:7KQU3^S1HNH:OI4-U]L!
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M5M'<^+]0@TBQ87$R1@"Y%K/F5MW[N/9^]<JFY-VX #/^&\OV'/\ H\SX4?\
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M\0S>%9M.M9;Q+7[#+:Q:)?RI=*TB;T<)M(=3@KR >Z_\-Y?L.?\ 1YGPH_\
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MJO\ VQ9W/V2-KN**)O->*2*"0)%+QE55P#WW_AO+]AS_ */,^%'_ (<33/\
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M^B7^'?\ P20?_$4 <5_PWE^PY_T>9\*/_#B:9_\ 'Z/^&\OV'/\ H\SX4?\
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MCX66_P 0[V/7-0MM"M])T6XD:&WCDE%I=,U[+-'/&MN$"@V\N^2, $@'OO\
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M1_PWE:?]&@_'C_PV\G_QV@#WJBO!?^&\K3_HT'X\?^&WD_\ CM'_  WE:?\
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MVL3:1\*_"/PYFO;GQ.@B4V^JW&HW"S;T**)=L/EF)8]L85@*_3?_ (;RM/\
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MK[ _X;RM/^C0?CQ_X;>3_P".T?\ #>-IT_X9!^/'_AMY/_CM 'YQ? OX&_M
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M_P#CM'_#>-I_T:#\>/\ PV\G_P =H \S_9@LM;_:+_X*1>-_VU?#GAG5-/\
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M_HL#R/'$JF7"@/-(W Y+$FN@_P"&\K3_ *-!^/'_ (;>3_X[0!\5^%K+P_\
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M>(+'4=3O)]*D$"L48QZG&$)&UFB<9&!7VXG[=]E&H1/V/_CLJJ,*!\-Y./\
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M;S.%&<D]A7>?L*C'['OP[&?^97M^GTH ]8HHHH **** "BBB@ HHHH ****
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M#/C?3)?#?_"-?#GX,WWA74ETNW-GNOY[B.;=;VP4JD)(?C?D9 P>M<S\$?\
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MK#_:+_X)=?%?XO\ [2/PG\=>'/$NCV?@N7PQHVC?'S1Y)W$FM0Z+<QWNF^0
MF)#YWVB%RQ7]U-WQB@#NM1_X*P^%%T'Q%XY\,_LS?$'6O#?@2UAD^(^NZ?#:
MF/PY(8$GG@>-IA)<O!&^91 LFW!]*3XN?\%._P!GWX,_&N\N]<\8>+M0T?\
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M/)127+#<YV"N-_9T_P""2/Q*^',_PO\ AOXL^"?PRM]+^&NN6]W>?$!=<O\
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M!O\ A./^"GG_ $;!\!O_  ^VM?\ S+T?\)Q_P4\_Z-@^ W_A]M:_^9>O>:*
M/!O^$X_X*>?]&P? ;_P^VM?_ #+T?\)Q_P %//\ HV#X#?\ A]M:_P#F7KWF
MB@#P;_A./^"GG_1L'P&_\/MK7_S+T?\ "<?\%//^C8/@-_X?;6O_ )EZ]YHH
M \ ;Q1_P4M:X^UM^RG\ #+_ST/QRUG=^?_"+U-_PG'_!3S_HV#X#?^'VUK_Y
MEZ]YHH \&_X3C_@IY_T;!\!O_#[:U_\ ,O1_PG'_  4\_P"C8/@-_P"'VUK_
M .9>O>:* /!O^$X_X*>?]&P? ;_P^VM?_,O1_P )Q_P4\_Z-@^ W_A]M:_\
MF7KWFB@#P;_A./\ @IY_T;!\!O\ P^VM?_,O1_PG'_!3S_HV#X#?^'VUK_YE
MZ]YHH \&_P"$X_X*>?\ 1L'P&_\ #[:U_P#,O1_PG'_!3S_HV#X#?^'VUK_Y
MEZ]YHH \&_X3C_@IY_T;!\!O_#[:U_\ ,O1_PG'_  4\_P"C8/@-_P"'VUK_
M .9>O>:* /!O^$X_X*>?]&P? ;_P^VM?_,O1_P )Q_P4\_Z-@^ W_A]M:_\
MF7KWFB@#P;_A./\ @IY_T;!\!O\ P^VM?_,O1_PG'_!3S_HV#X#?^'VUK_YE
MZ]YHH \&_P"$X_X*>?\ 1L'P&_\ #[:U_P#,O2+XS_X*<([2)^RY\!0S?>8?
M';6LG_RUZ]ZHH \&_P"$X_X*>?\ 1L'P&_\ #[:U_P#,O1_PG'_!3S_HV#X#
M?^'VUK_YEZ]YHH \&_X3C_@IY_T;!\!O_#[:U_\ ,O1_PG'_  4\_P"C8/@-
M_P"'VUK_ .9>O>:* /!O^$X_X*>?]&P? ;_P^VM?_,O1_P )Q_P4\_Z-@^ W
M_A]M:_\ F7KWFB@#P;_A./\ @IY_T;!\!O\ P^VM?_,O1_PG'_!3S_HV#X#?
M^'VUK_YEZ]YHH \$?QE_P4WE*M)^RY\!&*ME=WQUUH[3ZC_BEZ=_PG'_  4\
M_P"C8/@-_P"'VUK_ .9>O>:* /!O^$X_X*>?]&P? ;_P^VM?_,O1_P )Q_P4
M\_Z-@^ W_A]M:_\ F7KWFB@#P;_A./\ @IY_T;!\!O\ P^VM?_,O1_PG'_!3
MS_HV#X#?^'VUK_YEZ]YHH \&_P"$X_X*>?\ 1L'P&_\ #[:U_P#,O4,7BC_@
MI;!,;B']E+X )(WWI%^.6LAC^/\ PB]>_P!?$_\ P7?_ &A_VP?V:_V.K'QS
M^R%:ZQ!//XLM+7QIXB\.Z)_:.H:%HK!O.O(+?!WNI"CH0 Q)X% 'K_\ PG'_
M  4\_P"C8/@-_P"'VUK_ .9>C_A-_P#@IY_T;!\!O_#[:U_\R]?&O_!%K]KC
MXR_&[]I37/"GAC_@H[I/[07PKD\+"[9O%T,6F>+]"U0.H,4EDD2!X,%@74D*
M0HSDTO\ P2V_;1_:D^-?_!&3XZ?M"_%3XRZKK7C3PSXK\96VA>(+I8O.LXK2
M"-K=%VH%Q&22,@]><T ?9/\ PF__  4\_P"C8/@-_P"'VUK_ .9>C_A./^"G
MG_1L/P&_\/OK7_S+U^/OQ0_X*9?M//\ !']A[4?C1_P4M\6?"#0_B=\/]5O?
MB9\1-/T^WN)YIXKN9(I7C,#@GY53Y5 Q7U?_ ,$,_P!MGXQ_'_\ ;3^,_P "
MM!_;?NOVB/@WX2\,:9>Z!\1]>TV&QU%=4F90]L(D2-GAV^;ES& &C49RU 'V
MG_PF_P#P4\Z?\,P? ;_P^VM?_,O3(/&'_!32V4I;?LL_ .,$Y*Q_'361SZ\>
M%Z^=?^"]'@[]KGX7_LO>//VXOV<?V_\ QY\.?^%?^#?M$?@?P_I]D]AJ,ZS*
M/,EDFC:120^/E./E%>>CX^_M1?\ !,#_ () ^,O^"D_QD_;(\8_&_7_$'@70
M[GPOX=\::?9PVNC:E=RK"IC-LB,Z;[I&</U6W &"30!]G_\ "<?\%//^C8?@
M-_X??6O_ )EZ/^$X_P""GG_1L'P&_P##[:U_\R]? GQV\-?\%F?V*OV(U_X*
M9^)/^"C=QXTUK0=#M?$OC3X5:AX;M8]#^Q.$DFMK9T42AD1]H8L02,BO//VI
MO%7[?B_&/]E/7_A'_P %7_BQI?AW]JWQ%<?:-)&DZ9M\,0?9H;A8K;,),@4R
ME!YAZ*#0!^GW_"<?\%//^C8?@-_X??6O_F7H_P"$X_X*>?\ 1L/P&_\ #[ZU
M_P#,O7BG[>7QG^,/_!+[_@E7<:++^T5X@^(_Q6U&\_X1KP7XU\0V=O'J6IZO
MJ5[)]F8Q0J(S]GCEX 7F.VR<G->=?\$X?VP/VJ+3]G#]I#]D_P#:W^+%UK?Q
MN^!.FZE.WB:=8UGO;673WGM;I0JA2$D!4-C!*T ?6'_"<?\ !3S_ *-@^ W_
M (?;6O\ YEZ/^$X_X*>?]&P? ;_P^VM?_,O7GW_!";X\?%[]IG_@EG\+_C;\
M>/'=YXF\5:U#J3:IK5^$\VY,>I742;MBJO"(J\ <"O%_^#D']K'XR?LI_!_X
M/ZE\*_VG=8^$MCXD^*$.E^+O%NBV\<LMKIK1$R/MDC?.W[V ,G% 'U&WBC_@
MI:UQ]K;]E/X &4?\M#\<M9W?G_PB]+<>*?\ @I==LK77[*?P!D*_=,GQRUEL
M?GX7KXW_ &3_ (ZZ)K'[+W[2'QQ_9Q_X+6^-OVC;OP7\']7GAM]9\/V]FGAS
M4!8W,]K>1D6T1:3= V =R_*<BOE/_@GU^W7X5^/OPW^&NN_';_@Y5^(V@?$K
MQ%-;C6?AK'X4MI(X[MKDHMGYOV(Y#J$&=W&_J* /UX'C?_@IVHPO[+_P%_\
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MQ^;.=H'>@#[^_P"$X_X*>?\ 1L'P&_\ #[:U_P#,O1_PG'_!3SI_PS!\!O\
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M ,31_P ,M_M,?]'\^*__  F=/_\ B: />:*\&_X9;_:8_P"C^?%?_A,Z?_\
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M /B: />:*\&_X9;_ &F/^C^?%?\ X3.G_P#Q-'_#+?[3'_1_/BO_ ,)G3_\
MXF@#WFBO!O\ AEO]IC_H_GQ7_P"$SI__ ,31_P ,M_M,?]'\^*__  F=/_\
MB: />:*\&_X9;_:8_P"C^?%?_A,Z?_\ $T?\,M_M,?\ 1_/BO_PF=/\ _B:
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MZ/Y\5_\ A,Z?_P#$T?\ #+?[3'_1_/BO_P )G3__ (F@#WFBO!O^&6_VF/\
MH_GQ7_X3.G__ !-'_#+?[3'_ $?SXK_\)G3_ /XF@#WFBO!O^&6_VF/^C^?%
M?_A,Z?\ _$T?\,M_M,?]'\^*_P#PF=/_ /B: />:*\&_X9;_ &F/^C^?%?\
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M/_\ B: />:*\&_X9;_:8_P"C^?%?_A,Z?_\ $T?\,M_M,?\ 1_/BO_PF=/\
M_B: />:*\&_X9;_:8_Z/Y\5_^$SI_P#\31_PRW^TQ_T?SXK_ /"9T_\ ^)H
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M /$T?\,M_M,?]'\^*_\ PF=/_P#B: />:*\&_P"&6_VF/^C^?%?_ (3.G_\
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M?P)XQ^%NM^%/B;X:\:>,]8O+B[GN;>1;6[MWF2Z+>6Y3<KR( I8J"< _8/\
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M#O@VW6TAU;6$\5S:K-!YS2,[2);QQM+\[8(11PN17VO_ ,,M_M,?]'\^*_\
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MMS9Z!:11,6,Y-R%DFF8GDLN>Y8YX]\UK_E*%X9_[('KG_I[TFG_\,M_M,?\
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M+4- UJ\^).FW?]DZ]%?.99YO]%#RQNDIR@VD,$7=CD'WG]@3]@;]KG_@G%\
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M/$%W=_MU^*+F&+1+MY;=_#=@JRJ(6)0D+D CCCUKO/V%2#^Q]\.\#_F5[?\
ME0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '@OQ&_Y2&_#7_L1=;_\ 0XJ]ZKP7XC_\I#OAK_V(NM_^AQ5[U0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9X0=R@(RMSV(H Y'_AVK^R-_T(VI?^%->_\ QVC_ (=J_LC?]"-J7_A37O\
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M@J[F. .23VH \%_X=J_LC?\ 0C:E_P"%->__ !VC_AVK^R-_T(VI?^%->_\
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M]"-J7_A37O\ \=H_X=J_LC?]"-J7_A37O_QVO>J* /!?^':O[(W_ $(VI?\
MA37O_P =H_X=J_LC?]"-J7_A37O_ ,=KWJB@#P7_ (=J_LC?]"-J7_A37O\
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M]"-J7_A37O\ \=H_X=J_LC?]"-J7_A37O_QVO>J* /!?^':O[(W_ $(VI?\
MA37O_P =H_X=J_LC?]"-J7_A37O_ ,=KWJB@#P7_ (=J_LC?]"-J7_A37O\
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M!>>8L;%2R!_-W;254E<X)4'M7OU% '@O_#M7]D;_ *$;4O\ PIKW_P".T?\
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M $(VI?\ A37O_P =H_X=J_LC?]"-J7_A37O_ ,=KWK--9T1#)(VU5&69NPH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQO\ 3_C1K+ZK\2[36+ZYODUFZ8$;R+B5_* !.U(MBI_"!0!^.?PX_P""H?\
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M !E^RAH/[$?B;]G"RO/AKX7N?M'A_0YM8OO.L)MQ8R1WGG_:@Y).6\W)'!)
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M%GBC1OA9\(=,U&W\3IIMK;W.G>(;T03"QM0B;8XGAE=0#E@".<KFOU&\)?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M OC;X^_%'P]9>*O#EJT!T^+2)T?4[U-.AV;H1!;VIC,N6W)(P;!=37TM<?\
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MM(F$2(."P=S\SDU]$4V**.")885VJBA54=@*=0 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1CG.*** "BBB@ QSFBBB@ HQBBB@ QWHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gz4fxfn2r2w0000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000006.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 2Y!AT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\
MQN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO
M!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^
MS9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A
M%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H
M_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-
MG_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7
M??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#
MWJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\
MAX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U
M-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_
M ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'
MCW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V
M?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\
MQN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO
M!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^
MS9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A
M%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H
M_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-
MG_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7
M??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#
MWJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\
MAX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U
M-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_
M ,;H_P"'CW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'
MCW[-G_4V?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V
M?^$7??\ QN@#WJBO!?\ AX]^S9_U-G_A%WW_ ,;H_P"'CW[-G_4V?^$7??\
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M9_X1=]_\;H ]ZHKP7_AX]^S9_P!39_X1=]_\;H_X>/?LV?\ 4V?^$7??_&Z
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M7_AX]^S9_P!39_X1=]_\;H_X>/?LV?\ 4V?^$7??_&Z />J*\%_X>/?LV?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \%?_ )2;'_LB,/\ Z=KBO>J\%?\
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M7CK7NO[6/BO]H_PW^S+XL\7?L8^!M#\6_$JWT?SO!.A:_<*EAJ%T67:DKF>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !03BB@\T >$_L V\MOX ^("RA?F^.'C-UV
MN&X.LW!'3^745[M7@O\ P3Z'_% ?$(_]5R\:?^GJYKWJ@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O!?A!_RD-^-G_8B^"__ $/6:]ZK
MP7X0?\I#?C9_V(O@O_T/6: />J^&_P#@Y"_Y0U?&;_L"P_\ H]*^Y*YOXM_!
M[X6?'KX?ZA\*?C3X TKQ1X;U:,1ZEH>M6:W%M<J#D!XV!##(!YH _%G]AO\
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MR?$"RT$Z':>,GT]#J$6FF1Y?LBS8W"+?([;,XRY/>@#\5_VE?#?Q8\7?'O\
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MH **** "BBB@ HHHH **** /!7_Y2;'_ +(C#_Z=KBO>J\%?_E)L?^R(P_\
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MSXD?##X4:%H/B#QU?1WOC+6-+TY(;C6;A-^R6X=1F5E\Q\%LXWGUH\+?L[_
MOP/\6-?^.W@_X3:#IOC+Q5!'#XD\366G)'>:G''C8LTH&Z0+@8STQ0!^(_\
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MHUP <@,44$C- 'Q+\.O^5H_XB_\ 9N>C_P#H^:OAO_@LYX6^+'C#]NW_ (*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X+\(/^4AOQL_[$7P7_Z'K->]5X+\(/\
ME(;\;/\ L1?!?_H>LT >]4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@K_\I-C_ -D1A_\
M3M<5[U7@K_\ *38_]D1A_P#3M<5[U0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1C-%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X+_P $^O\
MDG_Q"_[+EXT_]/5S7O5>"_\ !/K_ ))_\0O^RY>-/_3U<U[U0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7@OP@_Y2&_&S_L1?!?_ *'K
M->]5X+\(/^4AOQL_[$7P7_Z'K- 'O5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X*__ "DV
M/_9$8?\ T[7%>]5X*_\ RDV/_9$8?_3M<5[U0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"_\
M!/K_ ))_\0O^RY>-/_3U<U[U7@O_  3Z_P"2?_$+_LN7C3_T]7->]4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+\(/^4AOQL_[$7P7
M_P"AZS7O5>"_"#_E(;\;/^Q%\%_^AZS0![U1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"O
M_P I-C_V1&'_ -.UQ7O5>"O_ ,I-C_V1&'_T[7%>]4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'@O_  3Z_P"2?_$+_LN7C3_T]7->]5X+_P $^O\ DG_Q"_[+EXT_]/5S7O5
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_"#_E(;\;/
M^Q%\%_\ H>LU[U7@OP@_Y2&_&S_L1?!?_H>LT >]4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '@K_\ *38_]D1A_P#3M<5[U7@K_P#*38_]D1A_].UQ7O5 !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X+_P $^O\ DG_Q"_[+EXT_]/5S7O5>"_\ !/K_ ))_\0O^RY>-/_3U
M<U[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@OP@_Y
M2&_&S_L1?!?_ *'K->]5X+\(/^4AOQL_[$7P7_Z'K- 'O5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!X*__ "DV/_9$8?\ T[7%>]5X*_\ RDV/_9$8?_3M<5[U0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >"_\ !/K_ ))_\0O^RY>-/_3U<U[U7@O_  3Z_P"2?_$+_LN7
MC3_T]7->]4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X
M+\(/^4AOQL_[$7P7_P"AZS7O5>"_" _\;#?C9_V(O@O_ -#UF@#WJBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \%?\ Y2;'_LB,/_IVN*]ZKP5_^4FQ_P"R(P_^G:XKWJ@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \%_X)]?\D_^(7_9<O&G_IZN:]ZKP7_@GU_R3_XA?]ER
M\:?^GJYKWJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  Y
M[5X1\(_(/_!0?XT[ _F?\(-X,\S.-N-^LXQ^N?PKW<G':O!?A!_RD-^-G_8B
M^"__ $/6: />J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\%^$'_ "D-^-G_ &(O@O\ ]#UFO>J\%^$'_*0W
MXV?]B+X+_P#0]9H ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!7_ .4FQ_[(C#_Z=KBO
M>J\%?_E)L?\ LB,/_IVN*]ZH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!?^"?7_)/_B%_V7+Q
MI_Z>KFO>J\%_X)]?\D_^(7_9<O&G_IZN:]ZH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KPCX1B#_ (>#_&HH[>9_P@W@SS%*C:!OUG&#
MGGOG@?C7N]>#_"&"9/\ @H/\:IWA98W\"^# C%3AB'UG.#WQD?G0![Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >#OY?\ P\RSN;=_PI.'Y=O&/[6G[U[Q7@SQR?\ #S/S
M=C;?^%)0C=MXS_:T_%>\T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %!..M%!SVH \)_8 $ \ ?$#[.[
ML/\ A>'C/=O4##?VS<9'4\9[_H*]VKPC_@G_  3P> /B L\+(6^.'C1EW*1E
M3K-P0?H17N] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>#?"$G_AX;\;!G_F1?!?_H>LU[S7@OP@_P"4AOQL_P"Q%\%_^AZS0![U1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >"N3_P\U(_ZHC#_P"G:XKWJO!7_P"4FQ_[(C#_ .G:
MXKWJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \&_X)]DGX?_$+)_YKEXT_]/5S7O->"_\ !/K_
M ))_\0O^RY>-/_3U<U[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7@OP@_Y2&_&S_L1?!?_ *'K->]5X1\(IW?_ (*#_&J [=L?@7P8
M5PHSR^LYYZGIWZ4 >[T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '@K_ /*38_\ 9$8?_3M<
M5[U7@[R-_P /,O*XV_\ "DX3]T?]!:?O7O% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E '@O\
MP3Z_Y)_\0O\ LN7C3_T]7->]5X1_P3_GDG\ ?$!I=OR_'#QFHVH%X&LW [=_
M?J:]WH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPCX1+
M"/\ @H/\:F61C(? W@SS%V8"C?K.,'/.>>PQCOFO=Z\%^$'_ "D-^-G_ &(O
M@O\ ]#UF@#WJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \'<1_\/,MV]MW_  I.'Y=O&/[6
MGYS_ /6KWBO!7_Y2;'_LB,/_ *=KBO>J "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#P5_^4FQ_[(C#_P"G:XKWJO!W0_\
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MG_D+3]^M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '@O_!/K_DGWQ"_[+EXT_P#3U<U[U7A'
M[ $[S^ /B SJB[?CAXS7Y(PO36;@=NI]^I[U[O0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7@OP@_P"4AOQL_P"Q%\%_^AZS7O5>"_"#
M_E(;\;/^Q%\%_P#H>LT >]4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@K_ /*38_\ 9$8?
M_3M<5[U7@K_\I-C_ -D1A_\ 3M<5[U0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H \%_P""?7_)
M/_B%_P!ER\:?^GJYKWJO!?\ @GU_R3_XA?\ 9<O&G_IZN:]ZH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPCX1M"?^"@_P :E2)A(/ W
M@S>V[AAOUG'&.,<]SG/:O=Z\(^$<+I_P4'^-4Y*[9/ O@P+B0$\/K/49R.O?
MKVZ&@#W>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \'<I_P\RQL.[_A2</S;NW]K3\8KWBO
M!W1O^'F7FY7'_"DX1]X9_P"0M<=NM>\4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A/[ #0MX
M^(!@B91_PO#QF&W-NRW]LW&3T'4]NU>[5X3^P!!)!X ^("R%?F^.'C-AMD#<
M'6;@]CP?;J.]>[4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5X+\(/^4AOQL_[$7P7_Z'K->]5X+\(/\ E(;\;/\ L1?!?_H>LT >]444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% '@K_\I-C_ -D1A_\ 3M<5[U7@K_\ *38_]D1A_P#3
MM<5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_LN7C3_ -/5S7O5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>"_"#_E(;\;/^Q%\%_^AZS7O6<=:\(^$:1+_P %!_C3*LX9F\#># T8
M4Y4;]9P?3G^E 'N]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X*_P#RDV/_ &1&'_T[7%>]
M5X.ZK_P\RW^8-W_"DX1MP?\ H+7'->\4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!^M '@O_  3Z
M_P"2?_$+_LN7C3_T]7->]5X3^P!'''X ^( CG63/QP\9EMJD;2=9N,KSZ?E7
MNU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_"#_E(;
M\;/^Q%\%_P#H>LU[T<XXKPCX1W%P_P#P4'^--N\[M''X&\&&.,L=JDOK.2!V
MS@?E0![O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >"O_RDV/\ V1&'_P!.UQ7O5>#O++_P
M\Q\GS&V?\*3A;;GC/]K7'->\4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!H \%_X)]?\D_\ B%_V
M7+QI_P"GJYKWJO"?V +B>X\ ?$ W$[R;?CAXS1=[$X4:S< #Z 5[M0 4444
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MXC6VG"]M%*C4]547%N%Q9LQ7[.KN\Q4A2M?5U !1110 4444 %%%% !1110
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MP7_@GU_R3_XA?]ER\:?^GJYKWJ@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA/XM?\$_O^"7F@^+S\!O$7Q,^)6O7">)O&WAOPU)"NHZCJ^KWJS7DFZ9E4B
M3G))SY=O@9.!7L_[2?\ P3[_ &6/VN/B;X.^+/Q_^'\VOZIX$N//\/P3:K<)
M9K()!(K2VZ.(IRK@,/,5L$<5[/&B11K'&@557"JO8>E #J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!7_ .4F
MQ_[(C#_Z=KBO>J\%?_E)L?\ LB,/_IVN*]ZH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!?^"?
M7_)/_B%_V7+QI_Z>KFO>J\%_X)]?\D_^(7_9<O&G_IZN:]ZH **** "BBB@
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M_ASM5_\ D>@#[RHKX-_X7%_P<;?]&8_LQ_\ ASM5_P#D>G/\8?\ @XRX\O\
M8R_9C^[SGXFZKU_\!Z /O"C-?!Z_&'_@XSVMN_8R_9CSCY?^+FZKZ_\ 7O3?
M^%P_\'&W_1F/[,?_ (<[5?\ Y'H ^\J*^#?^%Q?\'&W_ $9C^S'_ .'.U7_Y
M'IQ^,/\ P<9;%V_L9?LQ[N=W_%S=5_\ D>@#[PHKX-_X7%_P<;?]&8_LQ_\
MASM5_P#D>C_A<7_!QM_T9C^S'_X<[5?_ )'H ^\LT5\'O\8?^#C(.?*_8R_9
MCV]L_$W5?_D>F_\ "XO^#C;_ *,Q_9C_ /#G:K_\CT ?>5%?!Z?&'_@XS+?O
M/V,OV8\8/3XFZKZ<?\N]-_X7%_P<;?\ 1F/[,?\ X<[5?_D>@#[RHKX-_P"%
MQ?\ !QM_T9C^S'_X<[5?_D>G#XP_\'&7EDG]C+]F/=N&T?\ "S=5QCG/_+O]
M* /O"BO@W_A<7_!QM_T9C^S'_P"'.U7_ .1Z/^%Q?\'&W_1F/[,?_ASM5_\
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M_L9?LQ[LC;_Q<W5?_D>F_P#"XO\ @XV_Z,Q_9C_\.=JO_P CT ?>5&:^#?\
MA<7_  <;?]&8_LQ_^'.U7_Y'IS_&'_@XRVKM_8R_9CSM^;/Q-U7@Y_Z]_3%
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MR_9CW?Q?\7-U7_Y'H ^\**^#?^%P_P#!QM_T9C^S'_X<[5?_ )'H_P"%Q?\
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M!O\ PN'_ (.-O^C,?V8__#G:K_\ (]'_  N+_@XV_P"C,?V8_P#PYVJ__(]
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M:?\ IZN:]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 8YS1110 4444 &.]%%% !1110 8Q1110 4444 %%%%
M!1110 8S1110 48[T44 &.]%%% !1110 4444 %%%% !1110 4444 %%%% !
MCG-%%% !1110 4444 %%%% !1110 48Q110 $9X-%%% !1110 4444 %%%%
M!1110 4444 %%%!/% '@O_!/K_DG_P 0O^RY>-/_ $]7->]5X3^P!]G_ .$
M^('V??C_ (7AXSW;\?>_MFXS^&:]VH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KPCX16]PG_  4'^-5P\+".3P-X,"2%3M8A]9R >^,C
M\Z]WKP7X0?\ *0WXV?\ 8B^"_P#T/6: />J*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P=X
MI/\ AYCYWEML_P"%)PKNV\9_M:XXS7O%>"O_ ,I-C_V1&'_T[7%>]4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %'UHH(SP: /"/^"?]O/;^ /B L\#1[OCAXS=0RD94ZS<$'Z$5[O7@
MO_!/GCX??$(?]5R\:?\ IZN:]ZH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\%^$'_ "D-^-G_ &(O@O\
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M ,<"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X+_P3Z_Y)_P#$+_LN7C3_ -/5S7O5>"_\$^O^2?\ Q"_[+EXT
M_P#3U<U[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@
MOP@_Y2&_&S_L1?!?_H>LU[U7@OP@_P"4AOQL_P"Q%\%_^AZS0![U1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >"O_RDV/\ V1&'_P!.UQ7O5>"O_P I-C_V1&'_ -.UQ7O5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!X+_P3Z_Y)_P#$+_LN7C3_ -/5S7O5>"_\$^O^2?\
MQ"_[+EXT_P#3U<U[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7@OP@_Y2&_&S_L1?!?_H>LU[U7@OP@_P"4AOQL_P"Q%\%_^AZS0![U
M1110 4444 %%%% !1110 4444 %%?/?[:GP,_P""A7Q<U[0KW]BK]N[0_@_8
M6=I,FNV.K?"NU\1-J,S,ICD5YIHS"%4,-HSNW9[5XC_PQ=_P7F_Z39>"_P#Q
M&73?_DN@#[RHKX-_X8N_X+S?])LO!?\ XC+IO_R73I/V+_\ @O&QRG_!:_P6
MHQT_X9FTT]O^ON@#[PS17P;_ ,,7?\%Y<?\ *;+P7_XC+IO_ ,ETZ/\ 8O\
M^"\:L"__  6O\%LO]W_AF;31_P"W= 'WA1FO@W_AB[_@O-_TFR\%_P#B,NF_
M_)=.;]B__@O&0H7_ (+7^# 0/F/_  S-IO)S_P!?= 'WA17P;_PQ=_P7F_Z3
M9>"__$9=-_\ DNE'[%W_  7ESS_P6R\%_P#B,NF__)= 'WCFBO@]_P!B_P#X
M+QEV*?\ !;#P6HSP/^&9=-X_\FZ;_P ,7?\ !>;_ *39>"__ !&73?\ Y+H
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MTW_Y+IQ_8O\ ^"\90 ?\%L/!F[N?^&9M-Y_\FZ /O"C-?!O_  Q=_P %YO\
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MC\L*/^"U_@S=N.6_X9FTWD<<?\??U_.F_P##%W_!>;_I-EX+_P#$9=-_^2Z
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M_I-EX+_\1ETW_P"2Z /O*C-?!O\ PQ=_P7F_Z39>"_\ Q&73?_DNG2?L7_\
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M_P $^O\ DG_Q"_[+EXT_]/5S7O5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>"_" _\ &P[XV#_J1?!7_H>M5[U7@_PB,1_X*%?&H*K;
MO^$%\%[B3Q]_6<8_6@#WBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHZT >"O_ ,I-C_V1&'_T
M[7%>]5X,^W_AYGT.[_A24/TQ_:UQ7O- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110W2@#P7_@GT?^
M+?\ Q"_[+EXT_P#3U<U[U7@__!/XQ'X?_$#RE;_DN'C3=N/\7]LW&?PS7O%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>#_"(1C_ (*%
M?&IE=MW_  @O@O<I7@?/K.,'/U[5[Q7@OP@_Y2&_&S_L1?!?_H>LT >]4444
M %%!..U% !11GG&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HY]*** /!GV_\/,^IW?\*2A[<8_M:XKWFO!7_P"4
MFQ_[(C#_ .G:XKWJ@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS_LC^'_VS/AU\ ?A1IWCC5K2WUB']I;5/VE[NVUF"^9UD+W,<H\B/Y\HUJ_
M!*$T ?T<2:EIT5]'IDM_"MS*I:*W:4"1U'4A<Y(%35Y3X&_9_P# /CGQ'\._
MVJ?BYX$TF\^+'A[P2-/C\26%Y)(EI]K@B-[% 5?RY(GD7ABIR "",UZM0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X+
M_P $^O\ DG_Q"_[+EXT_]/5S7O5>"_\ !/K_ ))_\0O^RY>-/_3U<U[U0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@OP@_Y2&_&S_L1
M?!?_ *'K->]5X+\(/^4AOQL_[$7P7_Z'K- 'O5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MX*__ "DV/_9$8?\ T[7%>]5X*_\ RDV/_9$8?_3M<5[U0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI^L?M+_LN_#_ .(%WI,,D.EW/C3P?9ZG)9QN072)KB-RBL5!(7 ) STK@?\
MAT/_ ,$J/^D;'P)_\-1I'_R/0!T'_#R/_@G;_P!'[_!;_P .EI'_ ,D4K?\
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M-1I'_P CTI_X)$_\$J2 #_P3:^!/R\#_ (M3I/'_ )+T ;__  \C_P""=O\
MT?O\%O\ PZ6D?_)% _X*1_\ !.T\#]O;X+?^'2TC_P"2*Y__ (=#_P#!*C_I
M&Q\"?_#4:1_\CT?\.A_^"5'_ $C9^!/_ (:C2/\ Y'H Z$_\%(O^"=ZL5;]O
M7X+@CCGXI:1_\D4G_#R/_@G;_P!'[_!;_P .EI'_ ,D5@-_P2)_X)4L=S?\
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M%8!_X)$_\$J2 I_X)M? GCI_Q:G2>/\ R7I/^'0__!*C_I&Q\"?_  U&D?\
MR/0!T'_#R/\ X)V_]'[_  6_\.EI'_R12M_P4B_X)WHVUOV]?@N".N?BEI''
M_DQ7/?\ #H?_ ()4?](V/@3_ .&HTC_Y'I6_X)$_\$J7;<__  3:^!1)ZD_"
MG2>?_)>@#H!_P4B_X)W[=W_#>OP7QT_Y*EI'_P D4G_#R/\ X)V_]'[_  6_
M\.EI'_R16!_PZ)_X)4[=G_#MKX%;<YQ_PJG2?_D>D_X=#_\ !*C_ *1L? G_
M ,-1I'_R/0!T'_#R/_@G;_T?O\%O_#I:1_\ )%*?^"D7_!.]?O?MZ_!<=_\
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M *1L? G_ ,-1I'_R/0!T+?\ !2+_ ()W*=K?MZ_!<'W^*6D?_)%)_P /(_\
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M_P"2*]1\!?$+P%\5?"-GX_\ AAXWT?Q)H.I*S:?K6@ZE%>6ETJN48QS1,R.
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MH_Z1L? G_P -1I'_ ,CTI_X)$_\ !*D@ _\ !-KX$_+P/^+4Z3Q_Y+T ;_\
MP\C_ ."=O_1^_P %O_#I:1_\D4#_ (*1_P#!.T\#]O;X+?\ ATM(_P#DBN?_
M .'0_P#P2H_Z1L? G_PU&D?_ "/0/^"0_P#P2H'(_P"";/P)_P##4:1_\CT
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M'[_!;_PZ6D?_ "16 ?\ @D3_ ,$J2 I_X)M? GCI_P 6ITGC_P EZ3_AT/\
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M3U)H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** /!?\ @GU_R3_XA?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >#.C_\ #S/S-C;?^%)0C=CC/]K3\5[S7@KEO^'FN,G'_"D8?_3M
M<5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >#_\ !/\ AFA\ ?$ 31,N[XX>-&7<N,J=9N"#
M]"*]XKP;_@GV7/P_^(&\G_DN/C0#/_8:N*]YH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KPCX13SO_P4(^-5N\S-''X%\&&.,L=JDOK.
M2!VS@?E7N]>"_"#_ )2&_&S_ +$7P7_Z'K- 'O5%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!X.\DG_#S+RM[;?^%)PG;GC/]K7'->\5X*__ "DV/_9$8?\ T[7%>]4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'A'_!/^>>X\ ?$!IYFDV_'#QFB[V)PHUFX 'T KW>O!?^"?
M7_)/_B%_V7+QI_Z>KFO>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /!7_ .4FQ_[(C#_Z=KBO>J\%?_E)L?\ LB,/_IVN*]ZH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /!?^"?7_)/_B%_V7+QI_Z>KFO>J\%_X)]?\D_^(7_9
M<O&G_IZN:]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGG%% !1106 .#0 44 Y&:* "B@D#K10 44$XYH!SR* "BBC/.* "BC.:,]Z
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M_@[]ASIQMUGQ?U_[\TW^U?\ @YM_Z$W]AO\ \'/B_P#^,U]Y44 ?!O\ :O\
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M#OV'/N\[M9\7]?\ OS7WA10!\'KJO_!S3M;?X-_8;S_#C6?%_K_UQIO]J_\
M!S;_ -"=^PW_ .#KQ?\ _&:^\J* /@W^U?\ @YM_Z$[]AO\ \'7B_P#^,TXZ
MK_P<T[!M\&_L-[OXO^)SXOQ_Z)K[PHH ^#?[5_X.;?\ H3OV&_\ P=>+_P#X
MS1_:O_!S;_T)O[#?_@Y\7_\ QFOO*B@#X/?5?^#FK>?+\'?L.;>V[6?%^?\
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MK_P<V_\ 0G?L-_\ @Z\7_P#QFC^U?^#FW_H3OV&__!UXO_\ C-?>5% 'P?\
MVK_P<T^6,>#OV'-VX[O^)SXOQCC'_+'ZTW^U?^#FW_H3OV&__!UXO_\ C-?>
M5% 'P:=4_P"#FT_\R=^PW_X.O%__ ,9KZ\_9SE_:+F^"VA2?M:6G@RW^(9AE
M_P"$EA^'LUW)HRR><_E_9FNP)BOD^7NW@'?NQQBNVHH **** "BBB@ HHHH
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MW[#F[^+_ (G/B_\ ^,TW^U?^#FW_ *$[]AO_ ,'7B_\ ^,U]Y44 ?!O]J_\
M!S;_ -"=^PW_ .#KQ?\ _&:=)JG_  <U>8WE^#OV'-N?EW:SXOSC_OS7WA10
M!\'_ -J?\'-/E_\ (G?L.;MW_09\7XQ_WYIO]J_\'-O_ $)W[#?_ (.O%_\
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M_P##J:1_\D4?\/2O^"9W_20SX(_^'4TC_P"2*]V\J+_GDO\ WS1Y47_/)?\
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M  3._P"DAGP1_P##J:1_\D4?\/2O^"9W_20SX(_^'4TC_P"2*]V\J+_GDO\
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M47_/)?\ OF@#PG_AZ5_P3._Z2&?!'_PZFD?_ "11_P /2O\ @F=_TD,^"/\
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MFD?_ "11_P /2O\ @F=_TD,^"/\ X=32/_DBO=O*B_YY+_WS1Y47_/)?^^:
M/"?^'I7_  3._P"DAGP1_P##J:1_\D4?\/2O^"9W_20SX(_^'4TC_P"2*]V\
MJ+_GDO\ WS1Y47_/)?\ OF@#PG_AZ5_P3._Z2&?!'_PZFD?_ "11_P /2O\
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M_P##J:1_\D4?\/2O^"9W_20SX(_^'4TC_P"2*]V\J+_GDO\ WS1Y47_/)?\
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M  3._P"DAGP1_P##J:1_\D4?\/2O^"9O_20SX(_^'4TC_P"2*]V\J+_GDO\
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MAGP1_P##J:1_\D5[MY47_/)?^^:/*B_YY+_WS0!X3_P]*_X)G?\ 20SX(_\
MAU-(_P#DBC_AZ5_P3._Z2&?!'_PZFD?_ "17NWE1?\\E_P"^:/*B_P">2_\
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M_P"^:/*B_P">2_\ ?- 'A/\ P]*_X)G?])#/@C_X=32/_DBC_AZ5_P $SO\
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MYTO6-'OH[FUNX6UFX*R12QDJZD=&4D&OHVD50@VJ*6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ-T?Q1;Z#KEQHVLS:+>K.MGJ$#;9K:0K]V1#PR]10!U]%%#,%7<QP!R2>U
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M]<.>PH **Y_XI?%CX:_!+P3>?$CXN>-]-\.Z#I^W[9JVJW(AABW,%4%CW+$
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M._!.I_MP>%+?_@IMXENO!?[.=CIMW;^,9-!LQJ5WK<E@9FTJW(39# +CSHV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA\)=!U6U\&^$_!WQ"U[Q-%)>W\*6SS+)K$4*Z7:0P><L5A:QE-UP6:0^6@H
M\7\7_MO?ME_&+0?BY^T/X*T[XL:2OA3Q]J/A[X96>AR:':^%Y3I]W]EQJ,EY
M>Q22/<3*ZD%5VADVY-?H#^T/\7XOA5^QMX@^*_Q*^(6G^ [J/P>!/XDU"UDN
MK71=1N8E@AED2 ,SQI<S1YV\8&<@9(RG_P""=/['LOQ.F^+,WPG=M0N==_MN
MXTUO$%^=(DU3C_3SI?G_ &(W.0#YWD^9D9W9YKU3XA_#OP-\6? >K_"_XE>%
M;+6_#VO:=+8:QH^HP"2"[MI5*/$ZG@J5)% 'P]^SW\+?B9_P3E_:+_9S_8K\
M(_M$^(/'&A^(/!.I67BC0]:\MH;86%HL@U*V55!MU,Y"LI+;C+R2QKU']HCX
MA_%GXR?MZ>&_V'/ ?Q/U7P1X?M/AY+XP\7ZYX?D2+4K_ '79M;:S@E=6\I 4
MDD=U!/W!QS7JGP#_ &)_V;_V:=?N?%WPJ\%7RZS=:='I[:YX@\2:AK-]'91G
M*6D=QJ$\TL5NIQB%&6,8&%X%3?'G]C?]G[]I+Q#IGC'XG^%M2&N:/9S6FG^(
M/#GBC4-%U".UE(,EL;K3YX)G@<@%HF8H3U6@#\UO$^L_$?\ ;?\ BO\ #_\
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M./PA\6?$_@?46L2L.CQ^ ?!-SH-E:VJJ L7V>?4+TDC'5748XV]Z .]HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1CG.*** "BBB@ QSFBBB@ HQBBB@ QWHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gz4fxfn2r2w0000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000005.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 2Y!AT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$C_@L+X/\/:M"JM-I>N:;HUI<1JPRI:.6Z5@".1D<U;\$P_$#XF3V]K\-_\
M@K7X9\0275Q)!:QZ)HND7;32QH'>-1%<MN94968#D*P)X(KR+_@JE^S=X(^"
M_P#P2RT7P->:-H^K:MHGB+PI9WWB :)'#)?S?VI;^=.02[)YKEW*[B!O(Z5M
M_P#!0;X8>(A^WK^R/X4^ &OZ;X O+[5O&37>M:;X?MI9((1I=MO:*&1#"TQ
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M\//BI\0/V=M=\/7%IJ.I:F;"[L9[ Z9:'4I($,=U"+6WW2"0Q$.RD@ ^S_\
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M@/ VM:3X@T'QCJF@KJ6N>";_ ,.R>(K*VFQ:ZLFGW\44]LMQ \;%&0!9!(
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M!9>/=2CC^(O@MOV8]>T?2/"]A<6TLJ7UAJ\VE01RQV\BQ)(9KF82I(70KMR
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MPOH?C#Q1I/B+7?%GQ,\+Z1'=22:3IL]O#;):V]Y#]GBO)C=1M,&CECB".$#
M@CQ_QG^W'^WCI_[05E^PEI7QPTN+Q)H?Q^TSPGJWQ(7PG:-)JN@ZCH4VI1,]
MJ5,$=["4VEHU6-BJ-L 8J0#ZZ_X9P_;!_P"C^+S_ ,-[9_\ QVC_ (9P_;!_
MZ/XO/_#>V?\ \=KXY^('[5?_  47^&GP>_:>^*$O[6EMJ"_LS^(6CT6WN/ F
MF*_BNW2&&Z>+4F2$*F8Y#$K6BP$$;B6Z5TGQI_:C_;QU_P")/[7FO?#']I.W
M\*^'O@+H7A[5/!>@Q>#]/N_MUQ=>'(-1GM[R6>)I#;F0L1Y924&9L2!45: /
MIS4_@'^U?HNFW&L:Q_P4(EM+.TA>:ZNKKP'91QPQJ"S.[-, J@ DDG  R:S]
M+^%?[1>N0276B?\ !2BVO(H;&*]FDM?!NGR*EM*&,4Y*SG$;A'*O]U@C8)P:
M^==?_:[_ &T/A;::#>_$+XV:?XFB^)W[,_B/QQ%IC>$K*"W\.ZI:::EU%';;
M4WS0?O@K)<M,6V9S@E:\)^"]M\<_BYH_[8GQ7UO]I_Q+9WNI_LN^!=3OK73=
M#T:*W>2YT+4YQ&J_8CY21;)8T"%25N'+%V6-D /T0T_X _M9:O8P:KI7_!06
M:ZM;J%9K:ZM_ 5D\<L;#*NK";#*0001P0:F_X9P_;!_Z/XO/_#>V?_QVOC7P
MA^V!\:/A!X+_ &:_V-]&^-GQ"T^UU3X"Z=XI\1>.O"OP7G\6ZTL7V6V2WL(+
M33-+N8HHE+X,\UNQVH 7+L6KIO@C^W9^W!^TO\5_ O[&%QJ>O?#?6KV\\5WN
MM?$_7/A;-H^H:[H>DRVD5G<6.F:S;*L$MRU]&TID@8(('"(,_* ?2ND?!G]I
MOQ%<7UEX=_X*-)?3:7=_9=2BL_!-A*UI/M5_*E"S$QOM96VM@X8'&"*Q/'NC
M_%+X5ZE;:-\3O^"K>@>'+N\YM+77O#^E6<DW./D66Y4M^&:Y'_@D#H?Q#\->
M-/VG]"^*OC.U\1:]:_M 3I>ZY9V*VRWJ_P!C:;Y<C1(2J2&/9O"X7?NVA1A1
MYYXX^&G[2_P]_:;^+_QV^ /[/OPI_:N\'>,->6/7-!?QQ:V/B7PO<06Z0RZ6
MC7,<EHT2!=PA9XI SD'&0: /I>T_9Z_:XOK:.^LO^"@-Q-#-&KPS1> +)E=2
M,A@1-@@CD&I/^&</VP?^C^+S_P -[9__ !VOB?P/_P %'? VG>%?@7^RC^Q/
M#\4OA;X/U+2?%%SXJ\KX7:IXT\4^%Y=*U'[+/HJV<-MJ)1DO)I$,LD<D44,<
M:)@,@7J_%G[>?[=]_P#LS:78Z'J&N>%_%$G[1^C^!M/\?>,/A/<Z))XAT&[$
MA-\-,U6VA:*8*,'$:+YD?"A25(!]6_\ #.'[8/\ T?Q>?^&]L_\ X[5&#X-?
MM-7?B&X\(VO_  4;CDU:SMTN+O2X_!-@UQ!$Y(21XQ-N56(.&(P<'%?/GQ-_
M;I_:>_8PG_:"_9S^,'Q/D\=>.M)T'0=;_9_UR^T&QM+C7(]9<:3%:O#:11PR
MO;ZO&=Y"9,=W&2,8 POV@/VX/VO?@/\ M;R?LHZ;X\T2]\2:YX<\#Z);^*;S
MPS:A;34KY[A;_42(T0R9$#&.!CY2LPPH&00#ZN'[.'[8/_1_%Y_X;VS_ /CM
M'_#.'[8/_1_%Y_X;VS_^.UXO^V-^T9^VW_P3E_9C^('C_P 8?$_1_B8UUK7A
MO1OA?KUWX98ZM:WVJ7T=C<&_T_2[9$N8H#(LT*VZF6<YA*9VLW"K^V;_ ,%!
M]&UWQ)\,?V>M(^)_QCGO?AW=:GH?B3XA_L\ZGX,DTG6H)(\VJF^T[3[6Z2:)
MI&BC.6#Q!7D8-R ?47_#.'[8/_1_%Y_X;VS_ /CM'_#.'[8/_1_%Y_X;VS_^
M.UYS_P $[?VJM8^+/Q+USX8?$#]I[Q?K'B6S\/VU]??#7XK?"%?"_B/1W+LL
MMQ&T4-O#=V9;:@:..8*PYG;<!6-^W1^UE\;/#7[4)_9]^#?Q7\3V;:?X!76I
M/#_PD^'L7B#Q ;J2>1$EU%]0MFT_3[#;'A"TR32N9,;%CRP!Z_\ \,X?M@_]
M'\7G_AO;/_X[1_PSA^V#_P!'\7G_ (;VS_\ CM?+7@C]N[]M#]H[X=?LF6GA
M'XDV?@?6/BYJOB/3OB#J2>&[.ZF"Z?#D2012>;%%-N3H"\8+MPX"BF:?^W9^
MV0/C%??\$^U^+UI<>,O^&CF\#V?Q:NO#5FMQ%H*^&8/$#3-:(@M&OPLC6RGR
MA$W#F/*D$ ^FK#X,_M-:KK5YX<TO_@HW'<ZAIH0ZA86_@FP>:UWC*>8@GW)N
M )&X#/:KW_#.'[8/_1_%Y_X;VS_^.UXW_P $Y_"7Q3\$_P#!0;]ISP_\7?B?
M'XQU*'_A&C;Z_P#V7!9S7%L;279Y\<"K$)1R"8T12,$**YS]L_\ ;2_:-TW]
MH'XH?#;X$_%KQ8S?#WP]:3Z=H'PC^&]MK7V6[>T:X<^(;_5X$LK,,=OEV]O<
MI+Y*^8S*7"J ?0__  SA^V#_ -'\7G_AO;/_ ..T?\,X?M@_]'\7G_AO;/\
M^.U\A:K_ ,%$?VQ?%G@GP#\>OB7XD\;?"GX:^*O@[HOB"T\>_#WX3Q>+-)CU
MJ>(O>IJR^3<75I:H=A78L0*LV9P1D;7Q[_;E_:7\'>-]0\:>-OVB_$G@3X3-
MX3TS4/A[\9/ OP7C\3>#]7+VJO<W6L-&EQ=V,0FW#8)+9%C /G]6 !]1_P##
M.'[8/_1_%Y_X;VS_ /CM'_#.'[8/_1_%Y_X;VS_^.UYK<_'7]HS]K+]KCQ1^
MSU^SS^T=I_@?PWX%^'.AZ]-XJT'P]9:C)XCO=5$[P-$+Q9XUL5C@W90&1S*
M)!C)\G_91_;Y_:X_X*!?$W1_V<O#_P 3+/X:ZAX9\+ZC>>//%GA_P_:7DVKW
MMOJ<VGQ"SBODFAB@;R&E?*.P+A59<9H ^DU^#7[33^*&\$)_P4:C;68[%;Z3
M21X)L/M2VK.46<Q>?O$9=64/C:64C.0:O2_LZ_M>0QM--^WY=(B*69F^']F
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M\QK?4+@Q_: [INBC>%XRH57<REB  ?4G_#.'[8/_ $?Q>?\ AO;/_P".T?\
M#.'[8/\ T?Q>?^&]L_\ X[7QG^T5_P %0/VF-:T'XC?%_P" 'Q#\52P^"?#5
MEJ^E^%_A[\-[;5-)L0]A'>20>(-4U2"&..?Y\&&RN-Z( >6;;7KG[+?[2'[6
M7[4G[8/Q&EU/]H&+PG\._A]X=\%ZU;>&+/P]I[K>MJ.CI>7L%S=3PM,D&02K
M1LDBES\^U0M 'N'_  SA^V#_ -'\7G_AO;/_ ..T?\,X?M@_]'\7G_AO;/\
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M-O$MYU +1.T5PP1P""5." 1QS7H'[3WAKQ@G[&?CKPWI_P 6M:M=:M_ =_\
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M/ER ?;"?LY_M?2()(_V^KIE895E^']G@C_O[1_PSA^V#_P!'\7G_ (;VS_\
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MLZ_M>S0K/#^WY=2(ZAE=?A_9D,#T(_?=*Y/_ (+8Z=KFI?\ !+CXQ?\ "/\
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M-X%L5DN75#(RQJ9LN0BLQ R0JD] :LC]G#]L$_\ -^]Y_P"&]L__ ([7R/\
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M4U]8:CI6I31Q7,5NJ0B>-E=2T:(K*5.T'.0#[0_X9P_;!_Z/XO/_  WMG_\
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M[6_OC=3QP(DUT8POG.% +[1TR><=LU/10 4444 %%%% !1110 4444 %%%%
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MQ#XJ^&VM>"?"P\-:+KW@/58H+EM'#!A8S"YAGBGC#Y=2\9969BK*2:\M\?\
M_!7F+X*:7XR\.?'OX Q^&O''A#Q%HFDOHX\:Q2Z1<#52XM+IM4DMXA!!NC=9
M&DA#*1@*^179ZQ^WW\3OA_8?#\_&3]EU-'F^('Q>TKP1I-YHOCVVU33;B.^M
M+BX74K>XCA226-/LY0QR0PDDY5B "0#5T/\ X)E_L[>"_P#A7EW\.M3\4^'=
M2^&^K:CJ.EZWIFKI)>:G<:@6;4'OI+B*3[0;EG9I&PKY/RLH  ]*_:&_9Q^'
MW[3?AG0O"GQ&GU&.U\/>--(\3V!TVY6)C?:==)=6X<LK9C,B#<H )&0".M>
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M=0TWPWX=\0QZP/$J:S>/8Z?%:2F&#$SWB&%T= J9W;F4$@ ]1\/?\$_/V?M
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MD&MV>C:9.BNVKV]Q#;C[9#"KJTL6R*1%#DCY3G2TS_@K_P"'_''A5?&WPA^
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MSXA_ C3?#VEG3[:]T'Q1X7\?6OB#2=7CE+[HXYDC@E66/:I8&'RR)!MD8A@
M#C+?_@F/\)-.\)^!='T'XQ_$?3=?^&^DMI/A/QU8ZY:IK%MI91$^P.QM3!-
M%C0!9(6/R@[MWS4X?\$N?V<-,\)>&]+\%ZUXN\.^)O"NNZAK.E_$;1];3^WV
MOK\8OYIIYHI([C[1A?,22)D.Q,*NQ<<U^TQ_P54\/?LQ:=\<SXM^#%]=:M\'
M]/TJ]T?1;?6%$WBR"_!$30?NCY)$J/&00_W<]\#Q+_@I7_P59\1/^R'KU[^S
M%I&N6>J1_#/PAX[G\3:#JJK<:;'J/BG3[.'3%78-TMS"+Y=Q=1M3&TA\@ ^Q
M/V1OV+_A;^QGI/BS3?AIX@\3:I+XV\52>(O$6H>*M6%Y<W&H20Q122;PBX#>
M4&*XP&8A=J[5&)XL_8 ^'^H?$WQ#\5_A;\8?B%\-=2\7SK<>+8? >M6T-KJ]
MP%"?:)8;JVG1)BH"F6(1NP R21FO(OCU_P %*/&'PMT'Q]\.?VD/V:=5\'ZU
MI?PQF\8:'%X8^(BS/J5C%<Q030B[CMXVL[J-IH\A5E3!.V1JZ[6?^"@OCS4?
M%FK_  T_9G_9=U+XC7G@?PAI^L>-GF\6)9-;FZM1<16-J6@E-]>F+#;6\I26
M4%P6X -^]_X)B_LUV?A'P3X>^&ESXF\#ZK\/IK^;PUXQ\*ZT%U=)+^0R7[33
M7*3+=&YE)DE\Y'W/AN"!BQ9?\$V/V=++X?:/X ,_B*9M+^)%KX[O-=NM6634
M-8UN$L5GNY6CQ(#NP454   7:!BOFOX:?\%$_P!J./\ :;_:=\4>$/V>O$_C
M'P3X1T_P=X@M]#\6Z_\ V#<^&[*[\,6MY/916DUO(_VPNTLDD#B(*X(9P2!7
MVYX.^/7A+Q[^SMI_[2OAC2]6OM%U+PFOB"TT_3]/>XOYH&M_/$,<$>6DF(^4
M1KDL_ SD4 <G\>/V%?V?_P!H_P#:$^%_[3/Q+TB^D\4?".\NKCPN]I=".&8S
M^4VRZ3:3.D<L$,\:Y&R6,-Z@Y/QH_P""<?[.7Q]^(WB;XJ_$*'7&UKQ-I>EV
MC75EJ@A;39-.E>6TNK0JFZ*='=CN)92."N,@^5^#_P#@KG$WQP\$_!?XO_!?
M1?#%Y\1K/4)/#6FV?Q*M=1UJPFMK&2]^SZMIBP1R:>S1Q.NY7F5),(Q!(-5_
MAO\ \%=/%/BS]D_PY^UOXP_9'O-&TOX@75GI_P ,O#]KXRBO-2UW4;B9H5@D
M3[/&EK&"COYI=_D7<5!PM 'IP_X)E?LYZYX)\=>%?B[J/BCX@7WQ&L[&T\3^
M*/%^L(^IO#8R>;8I#);10I;?9YB9HS$BD2G>2S<T:+_P3=^%5KJ6J>*O&7QA
M^)WBKQ-?^'O[$L?&.M>+1'JFC6/F+(8K*6SB@6$LZ(6?:SR;0'9AD'5_9]_;
M"\1_$;XZ^(/V6?CG\&?^$!^(6A^&[3Q'#I=KXB75K+4](N)9(%NK>Y$,+$I/
M$\4B-$I5MN"P8&OC_P#X*=?MD_MK_"/]H'XW>"_AJR:?X7\+_LZ1Z_I-YIGB
MIXKRVN3J<49O(H?LN&G)S"(S* $.[?D[* /LWX*?L4>!?@_\6KGX\ZS\2O&G
MCOQE-H*Z';>(O'&I6\TUEIHE\TVT*VUO!&JM)AF8HSL5&6.*S_C!^P#\,/BQ
M\:-2^/&G?$KQUX-U_P 0>&X=!\5OX,UJ&VBUW3X7D:**X66"4AD\V0+)$8Y
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M]I9NVTVZ4/<6KJ2)(6V9#LK*R_+G...M?//P+_X*5_$;]L/X%W7QJ^$?[/\
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M5U;XR:;X%U_Q8NG:>MS9Z#X7TU[J^U!G*K''%&HSR74LQPJ+N=L*I-?)U_\
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M66X90#(P&"V!P,GGBIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_&^CZUJVJ1M<?8[F&TUDW[I$3%OW-&=HW*HW=2!S7MW[;_[,GBW]I_PU\/\
M1?!^O:;I\GA'XK:+XIO6U)I LUM9M*9(DV*W[QMXVYPO!R17ME% 'P/\?_\
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M\4O!-QXD^*'Q^T/X@K/IL=W'9V-K9C3/,LOFC+LZBR>-'QAQL=O++,J_?%%
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MI2W!FM,#:\PDAC\N4G.47>H&,.<\;-%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 49]*\D_;#_9M_9^^/GPFU
MB]^-WP7\,^+)M#T&_FT>7Q#HL-VUE)Y#'?$9%.QL@<C!X%?F5JG[/'P5^&?_
M  ;@6O[1_P *O@7X7L_B1J/@_P /K<>)K+38K74-19_$E@3%+=JGF;79$#$D
M]!D'% '[(45\'_'C_@I;^T;^P+XP\0>'OVR-&^'_ (FLU^#^H>-?#=UX!T^]
MTOR+JRN;:WETRX^V7-R)D)NXBMVODY"MN@7C#?V5?^"K'BSQ_P#M&_#[X'?$
M?XO_  2\?K\3-'NKBU_X4W<7!N/"=]#"LWV.^$MW<BYC9"RK<J+?+QL/*P00
M ?>6:"<5\6?MZZG^T!:?\%-/V1],^&_Q7T+1=!O+[Q=)J&EZIX8NKW[0\&BR
M/*\ABU"W5P8&*1 IF&0F4F93Y->,ZA_P7=UI[#Q!\=-)^(_P13PGX?\ 'DVA
MI\(KK49V\:ZG80WHM)=0BF6[$4<F[=*EH;1RT:\RJ3P ?ISF@$]Q7P/H'_!0
M7]N'Q?\ ##]IO]I/1]-^%MGX+^!>H>,K'PWHEUX;U*74M<;3-.DN;2XFN!?K
M'"OF>5'+&L1,@60J\)*BH_#'[:?_  4_UKXK?!KX37^E_ ^WNOCI\/YO$FFW
MJ>']79/!YAMX;EX;A/M^=6)27:"C66&!Y8#) /OSGTHK\Z]7_P""MO[15K\'
M/ OB#Q1HW@?P*^I>-/$OAKX@?%35/"6JZSX:T*ZTFX\B+_0[:ZAFB%VVYD::
MZ1(A&P+R'%?9'[(WQ9\4?&KX#:5\1?&'C3X=^([RZEN%_M[X6ZM-=Z+J$23.
ML<T1F&^)F0*7A+RB-]RB60 ,0#TS-%?FW\1_^"RGQF^'OCM-;N-1^&-YH\'Q
M2L_"^K?#?0]"U+5]7L;*XU".R6]FUZRNWTZ"8&19/LLD P/W9E#FM;6/^"D?
M[?$?PH^.W[4NE^%OA-%X%^!OQAU_PQ)X<NM(U)]5\2:9IUXB/.EVMZ(;&<0R
M!1F"X662-CMA4@4 ?H=GG&**^/?B=^U=^U=\=OB]\1O@I^QWI/@.QTWX=^#;
M6]\07WCS3[VYFUF\O;9YH["V^S7,(LL1#FX<7 #,,1$ UJ?\$D_&+>&O^"2/
MPF\>>-9&!T_X<QWNIMYAD*^7&SR?,>6Q@\XYH ^KLT5\-^"_V^?VY&_9KT/_
M (*#^-O@_P"!-0^$>OZ#<Z_=>$=":>WU_P .:1Y#S6MU->W%T8+YW58P\,5M
M$4,ORM)M.=#0?VX?VT/AI-\$?BO^TQX1^',G@/XY^+=/\-VNC>$;*^BU?PE?
M:E#)+IQFN9[F2'4HV:,12E(;4QM(&4. 10!]J9HK\\[S_@I#^WM:_"OXL_M2
M_P#"+_">/P'\)?C9K7@^;PVVD:DVK:[IMEJ8M3=)=B]$-I,L;K\I@F61T8_N
M00!R/[?7[67[87[5G[ W[47Q _9_TCP'IOPS\':'KGAUK'6K2^;7=76WMB+R
M^ANXKA8;/RBS,D+6\QD\L@R1[@0 ?IUFC-?DG^V9\=?C%XA_9[_:8\"_"B/P
M;X,O/ ^K?#"VNO%%KX;N9-2U^WO=(T^9A>2Q7L.]T:18T;&! IC*DMYB^Q:1
M^WW\8?A7XJ^(OPJT3X5?#?4/B9JOQZL? VAZKH^A76D:?J=W)IRW$VJ:A&;J
MXE?RXU<B-90S *F\<O0!^A7/I1SZ5^>/[5/_  5!_;,_8O'Q%^"?Q)\$_#?Q
M5\2O#_A?PSXK\#:WH>FW^G:-KFE:CXCM]$NK>YM);N>:TN8))?E=;B5'$J/M
M&QHV]5TG]KW]L+X4_'KQ=^SO\=?!O@KQQKEK\)[KQKX._P"%;Z3>Z:UU+ _E
MOI<L=W=71D8N4"7"%-^3^Y4X% 'USSZ45\9?\$\_V_?BK^U7X_M=$\9_&KX*
MZFUQH$UWKO@'1='U;0?%?A6\5H]MO+:7T]Q]OB&YU>?;:;652J.&(7O_ -HS
M]IOX\C]JGPQ^Q5^RU9>$[/Q-J_A.\\3:]XL\<:?=7UCI.GP2QPHBV=M<6TEQ
M+++*%'[^-4"DG=P" ?1U (QG-?DS^T7\9OVC?V\OC_\ !']F?XES_#G1Y/#O
MQXUSPG\1O"^H>#K[6=#UJ_L=$N[R*[\O^TK8RVKP[&2VDRT,Q#F654\MOJ+_
M (+@7?Q4\,_\$\M7E^"WCC3_  U<6^O:+!<37&DSW&^V:^AC\J,0W5N8^2N<
ME@4#)M&X,H!]B$^E%?G7:W_[=NG?\%//CI9?!/QI\,_[4TGX1^&;S6M4\5>%
M]1EL;Z[2&<B"VLH-01[19"#F1[B8H"/EDYK)L?\ @N3J?Q>UCX?^!/!/Q!^#
MOP?U#7/@QIOCSQ9X@^,5U/=627%[++##I%A!%=V3S/NMYI'N&EVQQF/]T[,0
M #]*@<]* <]J\1_X)\?M?1?MM_LT:?\ &R70;/3[]-4O=)UB#2[PW-E)=6LS
M1/-:3$ RVT@"R1L1G:X'.,GX#_X(K_&JT_9*T+XB2_%3Q1<1^%/'&A^*/B1I
MMU>W#,L%UHNKW5AK$2;CVMAI,P4'J\AQU- 'ZU49YK\:_P!F+]K[QK_P3OM_
MVC_BI\1XK&7QQXZ\>>"96MO%VL-;Z=I&JZY9SW<BW,I^Y;V@F\LA=I*VZ@$$
MYKVZ_P#^"WOBGX<7?BSX57/B/X2_&7Q?_9NAO\._$7PHN;BST34-0U35(M*C
ML+Y)+F]>U:">:.5F$S&6$Y5(VP* /TFS1SZ5^=NJZM^UUX-_X*B6S?M07WP_
M\0&R_9A\47ND7G@_1KVPL+YEN[%I;:XLKJ[N6_=D*OF"?]ZDI^2(@@Y?[*O[
M<?[8'[87P$U#PQ^R9\-?A'X3T_P)\,[.X\1:=J.B7_V?4M1N[1YQING+!=I_
M9L21[1Y\@NOG;_5D F@#])J,\<5^:/[.G[:/Q(_9M_X)A_LC>'=!\7^ _#,W
MC3X;V_\ :GC+X@>=JBV306<3+!;Z1:W5O>ZG/,\F!Y4BI$L;M(V2BMR-Q^VY
M^U5^V;\0_P!GN^\/>.?"GA>_T']HK4_#.NM_P@>KK9ZRUOI[RQW?V.XU"WG@
MC>%R/L\I=D<JXD=1M8 _5R@$GM7YP?M>?\%@_CE^SWK/Q/\ $.AZQ\+6M_A=
MK$D,GPSCT#4]=UK6[&#9YMW-J6F7AMM":0&1DAN;>4QJ%,S)N(7[._:>TWXF
M_%;]D?Q9IOP"\;0^&?%7B#PC*/"^M7TWDK9W$T68V9QGRSSMW#E2<CI0!ZCF
MC-?E5\(-=_9Q^!WQ+^%'AO\ :B_8F^+7[+_Q'L_%VEVL?Q4T.6WO]!\8:DS>
M5_9U]K4!F6Z@O68JR74<;Y<;)(W 8;_BG_@NKK:GQ]\8?"7Q)^!]KX5\">/;
M[P_:_"?6M2G_ .$S\2VMC=_9;F^@F6Z6.V=W61H;9K28NB@M(A;  /TVH)Q7
MP?X(_;5_X*-_M$)\?O&7[.FB?">'1_A;JE]8^"=#U[PKJESJ/B21-.2[MUDE
MBU&*.!BSK$0(VW$Y!3&#A?M0_P#!5'6_B%\$-#UC]GOX<^#?%&@Z[^S;JWQ/
M^(&G^,M.FO+>TT_R$AL;!DCGB&^:]::.17W'99S@!3\P /T-HS7QAX9_:[_:
M\^.WCB_^#/['/A7X9Z.?A_\ #G1-6UZ;QAI5[<0:CJ%[9B>'2[..WNH/L484
M;?M$C3A-R_NVP2?,?&O_  6,^+=[\6/''PMA\8_ GX,:Q\+M%TQ?$GACXQ:\
MUY?:_KUQ8I>3Z=926E[!';00"1(3>$70>1CMBVKD@'Z.YHK\W]1_X+,_%+XA
M7?A/7?"VH_#GX+>'/%7P]T_7]!U;XW>'M4N;'7]0F9TN-,CU&UN+>"Q\AX]A
ME=9W8.K"#'!_0SP3K5]X@\&Z7K^JR:8UQ=Z?%-<-HM\US9EF0$F&5D0R1Y^Z
MQ521@X% &I17XT_%C]OWX1P?MW:]_P %$(/VD] CE^'_ ,7[/X=Z;X!_X2.-
M;N^\+1*]IJEXMKO^<-?7+R+)M)*6*D'%?;GBW]K_ /:X^,7QJ^)O@O\ 8KT?
MX<OHGPBTVU;4I_&UK>W$OBG49[07@LK62VN(EL$\IXU^TNESEG_U6!D@'UU0
M,]Q7YV_L?_\ !2?]O+]L?QU\,_"OAO2OA+X;L=>_9KT/XG^,M4U#PWJ=V4NK
MK4+JVFL;2)-0C\M&2%6221I#&5;(EW +R\G_  7AU>;2-0^/UG\1O@E_PB.F
M^/#HG_"GVU"=_&UUIRWPLWU%)EN_*$H),PM/LA)B4YF4T ?IU1D9Q7YD^-?^
M"ZNO21?$SXP?#_XE_ W3_#/PW\6W^CZ?\)_%&I3CQAXQ@L)/+NKFWF2[2.Q>
M1UE%M UI<&78NYTWC&U\0_\ @J1^W'=^%OV@/CY\%_!_PM_X0'X(W6F7-AI/
MB+1]2;5?$UE=6-M=M#YT=XD5C,JSD"4Q3*3@&(8+$ _1RBO@_P 6_P#!3W]H
M3]E+Q-KTW[8WA?P-JFBK^SGJOQ6T6/P#9WEK<67V"XM89=(GDNIYENF<WL&R
MZ5+<95]T(&#7%^!O^"SOQ%L=1\+V_C+XI_ 7QY<>//"^HW=KH7PJNKF6\\&Z
ME#I\EY#;7Y>\F%_ 2GDO<(EIA^B$$8 /TDHS7PA\!/V__P!MZ^L_V<?BI^T-
MX=^%Y\)_M!ZE_9*Z#X2TG4(=2\.W;Z=<WMO,UU/=R17<;_971XQ!$8]ZD/)@
MYW_^"0]W^T)J7BK]IBZ^,OQ7T'Q%:V?[2FOV%K#IWABZLY89HK:P#%9)M0N0
M+;RS$L=N$!C*,3*X<*@!]H9]*,^M?('QF_:<_:\^,?QD^+GP*_9%T?X?VNF_
M"KP[$OB"Z\;V-[<3Z]J%S:M,+&U:VN(5L0L>!]HD2X&YO]40":^;/V7_ -O?
MXO\ P-_8A_9M^#WAGQ]\.?",FH?L_P"FZY)KWC;2KWQ-?ZM>9\H:?::-IEY;
MWFU0A=[UR8QYD:(LC!PH!^J61G%&1ZU^7GP0_;)_:*_:Z_;*_9S^/X\9>'?"
M>AWWPU\6S^)O"\WA74+A#)8W0@NG0O?PLC.(PT9EA+P#<KK*>1)X8_X+T:QJ
M?A#1OVF;[XB?!&X\'ZQXUMM,F^#&EZA/)XYL-)GOULUU(SB[:*>>/>MS)9"S
M3;")/W^5Y /T_P ^E'.>E?EO^VY^U#^V9^U=^PMXP^/O@;2_ .F?"<?$R+0]
M/T>2UOAX@ELK+7([.34S>BX\A=\T3D6OV;.PC,P.17OW_!=*29/^"-OQ=:*>
M2-F\-:8I>.0JV#J-D#R.1D$T ?95%?G3_P %%?%OB?X?_L.>(OV8O&FOWDVN
M>"/&GA@:!K%Q<,9]:\/R:M MI<,Y.9)HE!M9V)+,\(E;:)U6NX\6_MX_MH^-
M/"'QD_:,_9P\&?#D_#_X+:MJ=I-X>\4VM])JWBU=,C,E^T%Y#<1PZ:<*ZQ![
M>YW,HW;0> #[>S1SZ5\>0_\ !4'_ (1[XEWVI_$32M+L?AOXG_9WM?BE\+=8
M-K+#>3I$N=3L+LM*R2RQK<6$J>6J$),X.\KN'B&C_P#!9'X^^(]?M_A5XO\
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M1QI<1R(RNLGEHQ!^9%(Q7J_[1?P0TC]HOX1:I\'_ !#XZ\1^'=-U9H/[2O\
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MFUWXT^%-+\/7.H:>ENL#>*O$$6F:;;&69(S<7$TKK^[C#F0QH?,D"[$!9@*
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MM:>*OL>AZK$_C*V5(KB0V:-?-_9+K!+@&5KT-(,81>: /T>)XSBBOSS^._\
MP6(\0:=^T%\5?A9\+/C'\"_!-G\(([*"XT_XM7T_]I>,]2EL8[Z6VLA%=VXL
M88TECA^T/'<EY2P$6U<F[\*?^"C_ .VI^V7\1->TK]E+P[\-/"OA_2OA+HOC
M*WN/B#H6HZA=R7-Y#*SZ<R6U[;*H#Q$"X_A'/E2=  ??_/I021SBO@OX&_\
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M_;9M/V#/V<6^+\>FZ3=:IJ.O6.B:&OB#4?LFGQ7=W,L2S74W\$$>3(^,$JI
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M94T:2\B@=TU:W@SFUN%0F)S"%2164N"RJU 'WA03CM7Y>>#O^"HLG[+GP/\
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MA\,ZU\/_  CH>I:E?^%H[BZ>"*2;Q);W<NEW4Z80R0I#&NXLB2L5R>G^)O\
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ME=YX=\1:=IDUYJ6DB9(6N+1K#4+F"1E=U#1/*DJYY2@#H++_ ()Z^%[/X<_
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MO &I:+J L[[1O'FBPP2,QC619(+BUFN+2\B(8#S+>>558,K%6!% 'SA\4/\
M@D-+XV\%Z]\$O!?[5WB+PO\ #/7?&O\ PE,G@NTT.WF^SWS7BWDL4=RS!A;/
M.&<P[>"YPV.*]R_;2_9-T/\ ;-_9+\4?LG>(/&-UH=CXHT^VM9M8L[59I8!#
M<0SA@C$ DF$#D]#7S%\??V]=6T?]NOQ?^S#\:/VW[+]FO2M'TW3YOAY=:MH.
MG"+QEYR,9[C[=JL$EOLBD"Q>1&8Y2<G=R,>RZ5^V#XZ^!'PJ\ ^&OVA]-M?B
M7\3_ !Q=WT'A?2?@LD4R>(K:V!E-\KWTMM;6JB Q-*99TB5Y51'?<N0#7_;U
M_8%\$_MW>$=!T#7O'&H>&=0T'7;6_M]7TNW21YX(IXYGM)%8@-%(T2$\\,BL
M.5%<=\1?^"8$WB1_B+X.^'/[3'B#P?X!^+5]/=>/O!VGZ3!,T[W">7=BTNG8
M-:"=,A\*_P!XD8-<SXM_X*6:A\3/'WP;TCX*PZUX3DU#X]S^!?BIX1\7:3:#
M4;!XM+FNVMG,<D\0R#;RK-;RNKJWRN>17:1_\%8?V?Y=5;5X_AS\0&^'J>,%
M\+R?&+^Q;;_A&DU5IQ;+$7-S]K$9N"L/VG[-]G#L 91UH G_ &PO^"7/P0_:
MY\"?"_X=7FLWWA?3/A;JL#:7%H\8/VO25M_LT^DR%CQ;S1!%;J?W:GM6E\3?
MV%-?O_C?K?Q]_9U_:$U+X:ZUXKT.WTKQ9%9Z%!?V]]% I6"9(Y&7R9T5BHD&
M1C&5.*;X1_X*/^!/B)X[OM!^&O[//Q6\3>%]-\<7'A'4/B/X?\.6MWI$&JV]
MP;:X0PQW9U$PQ3AHWNA9FW78S>9L&ZNU_;9_:<T_]CC]EKQE^T=J'AY]6?PW
MIJOI^DQR;#?7DLJ06\.[^$--(@)[+D]J .1^#?\ P3[\)_!CXXV?QLTSXJ>)
M-8N;3X+V_P /6C\0W+7EQ<Q1ZA/?&_EN9&+O,SSLI4_* !C'08G@?_@F;X0\
M%?!3X*?!BV^*>I7%O\%_&K>(]/OGT^-7U.0S7,ODR+NQ&N;DC()/RCUK \<Z
M'_P4L^&7[/-[^TU#^U+I'B+Q=I.AMKFH?#&3P790>'KN-(S-)I]O.B"_B<J"
MB3O<.-V&:,C*TWPA_P %E_@+XXU31]'\)_!KXB:PUY\+]*\?Z[J6EZ?8?V?X
M?T6]1B9[F>XO(2?)*.LBQH[G;E$<9P 9'PY_X(\-X3^&>E?LX^-?VK_$7B?X
M3V'C9?%%YX%N]"MX3?W2:A_:$=M)=*Q?[(MRL<AA"Y;8!NP<5U<?_!-#6?#L
MOB3P+\+/VKO%?A/X;^*_%UQXCU;P7H]G''<0W5S/]HNHK74%=9;:&68L[(JD
MC>P5@#7GOC7_ (*J>*O'?[0_[-?@SX3_  I^(7@WPG\5/'UY'+X@\9>%[)+'
MQ/H<6BZA<[[>1)YI;0^=%;2!9TMIF3E59=^/3O '_!5_X ?$+4/#NMV/PX^(
M%A\/_&/B(Z'X-^+FJ:);1^'=;O?,:)%A9;EKN.*21&6.>:VBAD.-LA!!(!Z1
M\+_V5=!^%_[2_P 0/VD=.\5WEU<>/M*T>QN-)N(1LLUT^ PHRR9+.7!R=W?U
MJ/\ :(_9M\;_ !:\9^&?BA\*_P!H37O /B/PO'=00O:0_;=-O[>X""2.ZL7=
M(YF!1623(9#G!PQ!P?@_^WWX/^.O[1'C#]GOX<_ KXC77_"!>*)_#_BSQE-I
MMA%HMA?1Q"4)O:\^T2AU*[6C@< L ^S-2?&K]O'PE\*/C3=?L^^#_@9\0_B1
MXKTKPQ!XA\1:7X!T^PD;2--FEEBAFE^VWEMYK2/!-MAM_.F(C)\OE<@'/Z'^
MS)\2OV2/@CJT/[.GB.X\4?$/QAX^L]7\7>)M=T^.1M3:>ZB2[E>,.JPHEJ'"
M!22NQ0-Q->A?M@_ +QW^TY^SWK7P0\"_'?5/AS>ZY''#<^*-#L4GN8K?>#+$
M@9UV^8H*%@0RJQP0<$>"_&7_ (*$?$_P#^WC\-OA5X*^%/CWQ3X=\;_!^\\0
M1^ M&\*VUOK!O$ND423G4I+46?EQG:R331C<<8+8KM-+_P""IWP)\6_#WP3X
MJ^&?PX\>^*O$7Q U+6-/T+X<Z7H]K#KD5SI,ABU1+D7EU!:VHM90(W>6X5"T
MD81GWKD V_@)^QWX]^%OPWF^ WCWXP^'O$/P[D\-S:-'X1T?X=1:0B02QF-\
MRI<R%LJS9R,L6))SS7)_#3_@F??^#?$/@.?QI^TQKGBK0_A&EU)\*= U+18(
MTT:[EM);2*[N)%;-])!;S2QQ[@@&\DY.".:U'_@I)>_%WXR? W1/@C_:_ARS
M\0?%'6O"OQ+\*^*-'MEU"SN+/3_/^S2%'F12&*.)()61U(P["O2_^"7?QZ^)
MW[3'[&'AOXQ?&'7(]2\0:C?:E'=WD-G%;JRPWTT48V1*JC"(HX'.,GF@#D/V
M4?\ @GM^T/\ LKWEY=:9^VM:^(IM<UQM3\9:QK?PQ@;5=?D9R<378N\@*I\N
M-50)&H 51SGV'XA?LP:/\0?VI/AY^U!<^*[JVO/A[HNM:=:Z3';JT5XNHBVW
MNSDY4I]F&  <[CGI7RM^S%_P5SU6TTKXFW_[2OPX\?ZEH'@WX\^(?"EY\2M)
M\*V::'H-G%J)M[*&X*S1W$H1"@DFBMY53>IE=<UZ[\1_^"K7P%^'VL^,9[#X
M:_$+Q1X/^&]TMO\ $CXD^%=#MKG1/#3[5>3SB]RES<"%&#RM:07 B7)<C!P
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M^PQX8U.Y^!-Q<>.;QE^!EN(M/B:S0C5U_LMM._>\_N\JV_Y<\\=*P5_X*C?
MWQ18^"X?@5\.O'?Q-UWQUX5;Q+IGA3P9I5JM_9Z2LGE/=79O[JU@M@)0T01I
M?,=T941]IJ27_@J%^S_KGA'P#K/PB\'>-O'VN_$JUO;CPSX%\+Z+%'K'EV4A
MBOC<I?3VT-G]FF!AD\^9,2#:NXD9 /CGXB_L6_M1?$?1=-_9$^&'AGXF^%_
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MAC7IOCM^TUXK\2>+M4U73=2T?Q);Q+9V_A^YL'+VSV5B'>*,[RQD)):0'!.
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MU\*^.=9M_&WQ+3X?V/AG1_#JMK-CXD*W6=/NK625/*D66TDA.&8!WC;)C)D
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M!$7(R 8NK_\ !-*?7M*L?%^M?M.^++SXH:7XW;Q3I7Q"NXUD6QNFM_LQMH+
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MJ/@_4?B+X:L9]-O97W-;@7-E=7=HZL\826$S)<1QR;MJ$JXZ/]FO]L+X?_M
M_L8^&_VSIXI-%T75O"9UC6+6XR[Z5)"K"\MVP,LT,T4T1P.3'P.: /!_BE_P
M1W/BSX1^/_V>?AA^UCXB\%>!?B=8LGBW0;'0;>X9[IK=8I9X)78&!92BM)$
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MK5H;[]O[4OAA/C1[;Y_#$-KJ,D=IG9PP:WB/G#]X=O+<F@#]!Z*** "BBB@
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M^QA\-O&&O>(OB/X3U3QIX6\+SZW;_#-O&5I::QJ4,4>_$<#%I<%>=XC8 <T
M?%'P3_X)._M%?L\Q^%?&VH_"35O&E]>?!G0/#?B#0_"_QNU/PO)H^K:=$Z;S
M+8WEO'=VS;^?O,I7*CFON[]A7]G"^_9=_93\._!34=+TG2=0LX)YM0M?#=Q=
MS6MO<SR/+)Y<E[-/-(0SG+NYW')P <5H?M0?M/V/[,_[*'B#]J:^\(2:M;Z#
MH<.I/H\=\(&F$CQKL\THP7'F9SM/3I1X,_;;_9)\;> M5^(FF?M-_#IM/\-V
M,5UXNN(?'-A)#X?#J#B]D$NVVP3MS)MYH ^4OC)^R?\ M=?'S]G*]_99_:K_
M &2O ?Q@\3QV=QINC_'#5M0TZV^0NWD:B\ 1;FUN44JS+;KMWH2IP:Y<_P#!
M+7XX? ;XMZWXXT'PGXD^+,?B?P9HUDU]I7QOU?PE/9:I8V:VS27(M+VW6Y@?
M:K!L/*HR,'BOT2U3Q]X$T'7M)\+:WXUTFSU37VD70]-NM2BCN-29$,CB"-F#
M3%4!8[ <*,GBN>^*/[3/[.'P/U2WT/XT_M >"/"%[>1I):6?BCQ79Z?+.CN8
MT9$GD4L&<%00""P('/% 'S#^P/\ \$]OB3^R1^TKH/BJ]\,^&['PSI/[->E^
M$)#X;NYS;QZTNNZAJ-W%!'=S37'D?Z6"KR2-NSVQM%/P#_P3H^,/AS_@ISJ'
MQ<U&?3_^%)Z=J=UXS\*Z;'=#SHO%5[;K:W)\G^%%1"X;NTK5]6:[^TO^SEX8
M^)]C\$?$OQ_\$Z=XTU-$?3?"%_XJLX=4NE894QVK2"5P1T*J<]J\8^"W_!3C
MX3?'_P#;)\>?LL?"[5/!=]9_#F''B37F^)%H;QIPFZ00:?'&[20Q'*2S-*@C
M<;2N: /!/V</V /VN?V5O#7[//QLT'P%I?B+Q?\ "WP]XO\ #7B_P./$$$/V
MO3]8U&.\CN+6Y<^2)8GM8=RL0&65AD%<&Q\8/V'_ -LGXO\ [1'AW]M3XO?#
M:'7M0CTG4=#NOAWX$^*.H^&;S3--DFCEM&_M"TO(%NIE*MYJEQ&=XV@E<G[/
M\&_M8_LL_$?PUX@\:?#S]I;X?Z]H_A.-Y/%.K:+XRL;JUT=55F9KJ6.5EMP%
M5B3(5 "DGH:98_M=_LH:KX*UCXDZ5^T[\/+GP[X=N!;^(-?M_&E@]EIDI&1'
M<3B7RX6Q_"[ T ?*7AW_ ()]>(O#/[(-U\.?'G[%7@GQU-XH^)]QXI\2>";C
MQYJ$EY8[PPANH=5U"XFDEU*,",-.)H0=TA4CHWK'_!-C]G[]H/X":+XZMOB[
MJ^N6OAO6/$<-Q\/?!/B3QB_B"]\-6*VZI)"]^[.TH>7+*GF.(U  /)KV"+]I
M[]FN?X?Z;\5X/VA? \GA;6KHVVC^)4\669T^_G$<DABAN/,\N5PD,K[58G;$
MYQA21+X%_:0_9X^*7@.\^*?PR^//@SQ%X7TUI!J'B30?%%I>6%J4&7$EQ%(T
M:;1R=S#'>@#\\_AYH_[8'Q:F_;5_9I^"?PBT'4-*\??%37M!A\8ZEKT5O'H?
MVRR2WN)KBW8>9.$20N@C#;CA3@<U[A^S5_P3B\6_"V7]HWX5^(+M8?"?Q#\-
M^%?#_@W6ENE>YGM=.\*6ND232HO,;"6%N#U'(X-?1W@/]H']E+Q)X UGXR_#
M'XV_#V_\*VMQ)-XA\5:#XDL9=/AE4#>]Q=12&-6 QDNV1QFMSX4?&GX.?'CP
MJ/'/P-^+/AGQGHAF:%=8\)Z];ZC:F1<;D\VW=TW#(R,Y&: /BS1_V1_VU_BI
M\,/@?^R1\7OAGX?\/^&?@_XLT?5M8\=6/B"*X&N1Z2K"T2UM4_>1-*=AD\P*
M% 8#.:?\#_\ @FQ\;O 7[=7C?QAXC?39/@]X5_X276O@7IL5XOFVVL^)T@;5
M%>+_ )9);R1WBQ$\%=3DQT-?7&I?M >"/"WCKQ-X=\>^./!.BZ9X9L+&XO+Z
M\\;0+=6WVEMB?:[9T3[)&SE5CD:1A*6P #P>1^(?_!0W]CKP7\&/'WQKT/\
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ML\8-??=M^W%^Q5>2ZU#:?M?_  ME?PY9K>>(5C^(&FL=+MR5 FN )OW$9+*
MSX!+#GD5O7G[2/[.^G_"F/X[W_QZ\%P>!YHP\7C*;Q3:+I+J3@,+LR>203QG
M=0!\,>+/^"9GQN\4_LD_&K1?#?P?TWP_XM^*'CSP??V.B:E\0=1UR_.FZ/JF
MGS9U#4]1O+A9IA##<E5B*HJ>7'ER 1^@'Q*\-W7C'X=:_P"$+"58YM6T6ZLX
M9)/NJTL+("?8%JQ-+_:3_9UUOX3S?'O1OC[X*N_ MO&SW'C2U\56DFDQ*&VE
MFO%D,*@,0"2W!.*X/]GO]O+X3?M*_&_Q]\+OAAJ6CZMH?@?1]+U&/QOHOB2"
M^T_4X[Q9R?+>(%%$?D'+;V!SVQ0!\^_LR?L8_M3>%_$/[(\OQ%^&UAI-O\!]
M'\4Z-XGN(_$%O<?:$NK"W@M;F$(<E9&C?*G#(/O 9K!\>?\ !._]J+6/VH-:
M^+6D>!_#^HZ3=_M,)XUM[;5-8C6*YTD>%8M-/FJ S#=<(R%-I;;\V"*^W_A3
M^T7^SY\=[C4K7X'?'?P9XRDT>81:Q'X4\46FHM8R'(V3"WD?RFX/#8/!I/B_
M^T;^SU^SU;6=[\?/CQX+\#PZC*8]/F\8>*+33%N7&,K&;B1 Y&1P,GF@#X__
M &6/V)?CO\*_VJO"/Q!^%_P0N?@;X(TRUU#_ (6%X1TWXEMJVA>(998P(%LM
M/\QTL]DF9/,"0G V[>37TQ^USX:_:CU3P]X<\3?LJ>)]/35/#_B2*]USPKJ_
MEI:^*--\MXYM/>9T8V['>LB2+CYXP&.TFO4M'UC1_$>E6^O>']6MK^QO(5FM
M+RSN%EAFC895T=2592.002#7"^"_VO?V3?B5XRM?AS\.OVG_ (=^(/$%]9_:
M[+0=%\;6%U>7%OC/G)#%*SNF 3N (QWH ^.?%_[ 'Q]^+WQXOOVE/@G\ O#/
M[-WBJU^'6N:/'J^AZA9RWFOZC>0A;>2Y%@#$8X7&\229D#'@<5P'AG_@F?\
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MC-XHO-%UKQQK'[3Q^)WQ8N+&Z\NTTVV_LN>QM[.T\S#3);PBVB!P&=M[X (
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M!GB#6/M:E["_U&UL([9UC^]*@>W<MM[+C^(5)9?";_@H)\8_VDOV<_%7Q?\
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M[,7A7XH6_P #_%'[1W@/3?&EX5%IX0U#Q?90ZI.6&5"6CRB9LCIA3F@#SO\
M8E_9Z^(_P.^(7QS\2>/M-M;>W\>?%R]\0>'WM[I9&ELI(8D1G"_<;*'Y3R*\
MW_X*#?LG^*?CM\4E\6^'OV/(?$>K6OA<6?A7XG^$?B8_AOQ!H]R7D8Q32(\+
M26JL5D50TH):3,8SS]A7]]9:793:EJ=W%;VUO$TMQ<3R!(XHU&69F/   ))/
M %<G\*?VB/V?_COIFH:U\#_CGX.\96>DS>3JEWX3\36FHQ6<F"=DK6\CB-L
M\,0>#0!\Y?L__LB_M2^#/VHOA%\8/C?XJM?%$WA3X$W'AGQ=XH:\7SKK5I+Q
M9A\F SC8,&3 R5R>37A4'_!.;]L/0=6T,>,_A])XV^'\7Q2^(NN>(_A;H_Q"
M_L@:D=6U;[5I.H32I+&MPD4)E#6SOA6FSM8C ^]O!G[5G[+OQ&AUZ?X>_M)>
M =>C\*PR3>*)-%\8V5T-'CC!+O=&.5OLZJ%8DR;0 IST-9]G^VM^QWJEQKFG
MZ)^U9\-]0N_#.CR:KX@L['QUI\LVG6,:;WN9T68F&(+R9' 4 YS0!\+_ +(?
M_!,K]JCX1_&;P?XK\1?"+PGX9T/1/CYK7BYM+\.:U$]O9:5=Z4EO"D:\,TBR
M+M<8R6W-R#D_6_\ P3&_9^^)7[+_ .QMX;^#'Q<T^VM=>TV^U*6ZAM+Q9XPL
MU[-,F'7@_(Z_0\5XE\%?^"W7@GXZV7A/Q1X+^'OA&;P_XV\4:QI&BZG#\5K:
M9]/6PMYYOM&J1QVQ73UD$&X*7<B)Q)DC@_4NJ_M5? ?X??"OP[\5OCI\</A[
MX.T[Q%;Q-8ZEJ'CJT73;J5U#;+6\F,270.?E90-PP<#- 'Q/8_L=?M_WOP!^
M,W[%&I_!KPW;>'?BM\8/$6LV?CY?%,#+IVB:AJAN"9;8?O7N/+&5"@@;P&(V
MUS.J_P#!(WXR_#'2?BI\$_ GPANO'&E?$#5+N?PYXGOOCAKNCZ38PWD0CEAU
M72;/4(%NT0%]RQ(?.7Y6(R37V7\4O^"BW[-GPG_:E^&O[*_B+XB^'$U;XG:9
M=7^CWDWBBTB1(8X]T&%9]TIN&^6+;PY!VEL8KUGXG?%KX5?!/PG-X^^,WQ,\
M/^$=#MW5+C6O$^M06%I&S=%::=U0$XX!/- 'FWQ^_9VUO6?V ?$7[+/PJL+-
MKX_#-O#F@VOG-#!N2S$$2AI7=E3Y0,N[$#JS')/B\G[,_P"U+\%/C'\%OVA?
MAQ\++'QC<^%/@7#X#\4^&T\1064MM<*(9!<1RS$1R1AU=6 .[&" :^CKK]KG
M]E"S^'.G?&&]_:=^'L/A'5YGATGQ1+XTL5TV]D16=TBN3+Y4C*J.Q"L2 C$\
M UF^"?VP/@9XH\&>)OBM?_&[X8Q^"_#^I" >+M)^)%G>V*PE%97NIL)%9R'=
M_JR[\8.[G% 'YVZI_P $H/V[?$/P3T;PYXA\(^'/^$BCTGXX+JT=GXAC^SK<
M^*+N*;3!&S8)1PK;B0#'QNP:ZC_@H?\ LU^)_&WQ>_9W^!GPM\7Z?;^,/%7A
M6W\#?&#0[.X$DQ\+QQP7$\T@0Y50\#Q*[<$3$#-?HIX$^.OP0^*/P^D^+7PT
M^,GA7Q'X5A\PR>)M!\0VUYIZ",9<FXB=HQM'+?-P.M9WPA^*/[+_ ,>KZ\^)
MOP$^(O@+QI<V_P#H6H>(?"&KV6HR18Y\B2>W9RN/[A;\* ,+]L7X*^(?BE^P
MU\3OV>?A3IL#:IX@^%^KZ!X=M)IEAC,\VGRV\",YX1=S*"QX YKR']F+]D+X
MU?"_]I74/B;XNT>RCTJX_9S\,>#XYH=021SJED)?M$>T<[!O&'Z'M790?\%(
M_P!GK0/VG/B5^S7\9O'GA7P#-X!OM#M-.U;Q;XRM+)?$,VHV"W8CMXYS&=T8
M8(55G+$@\9Q7KWQ0^-_P7^!WA9?''QK^+WA?P?HKR+&NL>*-?MM/M6=ONJ)9
MW1"3V&>: /A#]CS]AW]LK]A?7_"/QI\._"?3/&6H7'PS_P"$3\8^$X?$UM;3
MV4T&I7-W:W4$\I$3QLMRRNF0P*@C/2O1]2^!/[>7AOXZ_#G]N35O!OA3QEXX
ML_!FK^&O'7@G0]273X8;.[O4NK7['/<L4>2 11Q2,Q42G<RA1A:].^./_!2W
M]E?X%_%WX._"GQ%\6?"LG_"Y;^YBT'63XNLHK6&WCM9)8KG<TG[U)YD2VB*G
M#R2!02<*?4;/]H;X!:AH'A[Q=8?''P?-I/B[4!8>%-4A\36K6^MW99E%O:2"
M3;<R[D<;(RS91AC@T ?%?P9_X)U_M,Z-^V!X%_:Y^(FCZ+!>ZE\3_%'BSQMI
M-CJB2)H<5[IL%G9P1L<?:'Q#\[(, D]1S7FGP%\'_M>?M ?!?]KC]E#X8?";
M0IO#GCK]IGQ_I*^.[S7HH5T>">_V79GM2/-F=02T?E@AMP5MNW-?H]XJ_:,_
M9\\":5KVO>./CMX-T6Q\+W4=MXFO-6\46EO%I$SJ'2*Z>20+;NRD,%D*D@@C
MBH="^,7[-NF_">?XZ^&_BEX'M_ MVTNHW7C*QUNS729BSXDN6NT?R6RP^:0L
M<D<G- 'S/X9_9I_:E_8G^/'B_P =_LS?"W3OB-H/C;PEHM@L.H>(H=.N=+U#
M3K3[+')*9N)+=T"L0F7!!P#FN/\ V%_^"8_[07[(_P 9+779/$6EO%'^S0_A
M=O$MK*I$/B2X\17^JS+'"?G\A/M:E6( (4#J*^QM-_:C_9FUGX>6OQ=T?]HG
MP+=>$[V\%I9^*+;Q=92:=/<$$B%+D2F-GPK?*&)^4\<5>^$WQW^!_P ?M&N?
M$GP*^,GA3QMIMG=&VN[_ ,(^(K;4H8)P,F)WMW=5<#^$D'VH _-'PW_P3%_:
MXEN/@CJWB7]FG2[KQSX"^(5CK'Q)^*?B3XD?VK?^(EC9Q+/9>=([6Z-NWF'$
M0"X15.*ZC6/^"7_[37B']GGPW\.-6\#PMJWPC_: U+QOX=CLO'DVF+XMTV^G
MOO-@BN[&6.XT^=8;P%79D^>,J3L8U]/_ !&_X*??L\_#W]ICQM^RE)XBT6X\
M7>#/AG<>+9-.;Q1:QSWKQ*S_ -GQPY,GG>6OF'Y250AMI'-=5^RC^WE^SK^U
MCX.\/W?@WXK>#X_%VL>&X-8OOA_:^,+.[U72XY$#%9H$82@+N +&-1]* /CW
M5/\ @EE\;/&OB#5OVC?#/PALO!_B[0=:\/7_ ((T7Q=\3M6\3:EJ*:=<O<RV
M][?WE[<Q11.7*Q1QCY&W.S?,17N_[-WPL_:[\2_\%"_%W[6/QZ^#6E^#/#FI
M?#+3/#^A:?;^)+>_NQ-!=W$LOG>3E<'S05()&" >017J6C_MQ?LTZ7\._"GC
M'XT?M&_"7PK=>+H&DT>*/XI6%Q9:@1(4Q974OD?;%R -R(,-E<<<^D^,/'GA
M7P)\/]5^)_B+55CT/1M'GU2^OHOWBI:Q1&5Y!MSN 121C.>U 'S9^V;\(_VJ
M9_VW/@?^U+^SU\*=+\7Z3X!\/^*;#Q5I-WKT-C<R+J"6*PBW:;"E\P.Q)(7"
MX)&X5\R?M@?LZ?$KX&_L@_$3]I[QYK6AZ#\=/$7QDL_B!\.?"]I?"XV:G"T-
MK!I<3+AKAI;=G27RP1^\ZX&:^FO!7_!0KX^^+OA=X5_:5A_81URZ^&'C*'3[
MW1]0\-^*%U7Q!'IM[L:WO9M)@M<!/+D21UBN)712<C*D#V7X[?&W]D;X0W^B
M7/[37Q<^''A>Z>X,GAR3QYKUA8R&7H6MC=NIW=!E.: ,;]@;]GJZ_9=_9#\$
M?!K6+G[1K-EI/VKQ-?'K>:M=.US?3GWDN997Y_O5\Y+_ ,$T?BUX_P#^"<?Q
M:_9,\87%CHOB#Q;\4=>\2^'YH]28PO'+JWVVU\R2 AX]ZJ%;:0Z;L@@BOI#2
M/VM]!UK]M:\_8^T_PV)EM_A#9>/(_%<.IJ]O-!<:E<V(MUC"]OL_F>;O((?&
MWC)Z?X<?M+?LX_&/6-6\/?"/X_\ @GQ5J&@L5URQ\-^*K.^FTX@X(G2&1FAP
M01\X'2@#XB\,?\$[/C+XR\4R^,]:_9U?PM=>'OA/XDT31[CQ=\:];\57EWK&
MI6/V3_0?M6HS6]C:E ?,,D9=\QC">7NJ+Q%_P3(^-.CZ/^S;\3W\!ZAXHU?X
M:? G3_ GCCP;X;^*5]X:NA-'9VBM-;7UE<VXD"30,I1WV.I!'(%?<'PO_:=_
M9L^-VOZEX2^"_P"T+X'\8:MHV?[8TSPOXLL]0N+'#;?WT<$C-%\W'S <\5S'
M[3_[7.D_L]ZYX6^&?AOP%J'C3X@>.KN6#PCX-TJYCA>Y6%-\]S--)\MO;Q+R
M\I#8R %8D"@#Y;_9V_X)M?&;X8_M$?!WXWW7PVT/0X-)\9>,M>\:6=OXMOM5
MN;3^TK&WM[3SKK4+F>6]N2(2))$8+GH,<G@;C_@DM\9O!ND_$CX :1\&IO%V
MC^-OB)K&M:+XQU'XWZ]8Z+;Z=J=\]W)!J&B6NHPI/)$99$Q%'MF"JS$$M7V#
MX&_;5\7Z9\>O#_[-7[4_P&_X5[XD\96EU-X'O]/\3+K&E:W);)YEQ:I<>1;O
M'<I'^\\MX@&16*LVTXZ_3?VXOV*]8TS4M;TC]L#X6W5EHFGQ7^M7EO\ $#37
MBL+60@1W$S+,1%$Q("NQ"L2,$YH \S^#_P"R9\1_AO\ M<_%KXE?V18Q^%_$
MOPS\/:!X9FANQN>:RM9(9%*,S.B@E<%B<CN>37@?[%G[$'[:?[ LW@GXI^%?
MA-I/C/5+_P" 6A^!O''A>/Q/;VTNE:EI=U>36]U#/*1'-;NM](CJIW QJP!S
MQ]5?LY?MU_"W]IGXH_$CP7\/;W2;S0?AZ;!E\9:7XB@O;#58;FV\_P V-XAL
M5$&03O8'&<BNO\&?M9_LK?$CPOKWCGX>?M+_  _U[1?"J,_B?6-%\96-U:Z.
MJJ68W4L<K);@!6),A7 4GL: /A_7O^"?7[7=E^T!KW[4/Q)^'#?$#7OB%X5L
MX=<TWX>_&+6/!T.B:E;M*(U/V:^@%W;^6Z*S'<^Y&*J V*^N_P!BG]F^^_9B
M_8_\.? 6XT71;"_T[2Y_MUEX?FNY+.*ZG=Y9%C>\FFF==\A^9Y"2>>,X'>?"
M[XX?!7XX65]J'P7^,'A?Q?;Z;=?9M2N/"_B"VU!+2;&?*D,#L(WQSM;!Q67%
M^U5^R_<?%L_ &W_:0\!2>.U=D;P2GC"R.KA@,D?8Q+YV0!D_)P* /D?]A#]@
M+]H[X">)_P!F74_B-H&FP0_"_P"$/B#P_P"+&M]6CE,%]=W:2PK'M/[Q2JG+
M+P.]8_A;]@[]K'X8?&/P-\;])^'NG:T_A3]HSQIXHN-%A\000R3:/K-G<6L-
MPKN0FY#*CM&3NQD $\5]D#]L#]DI_'-K\,D_:B^')\2WU[-9V7A[_A-K#[=<
M7$4ACEA2#S?,>1'5D90I*LI! ((J;XV?M1_ #]G[R=-^*WQG\(:!K6H6LLN@
MZ#KWBBUL;O5W121';QS.'E8D;1L5CD]* /C.^_8F_;6\'?LM?$G_ ()Q>!/A
MSH&I>#_''C#7;G1?B==>((HQIVDZOJ,M]-'<VA_?2W,)N)44H"CX4DCFOHK]
MLS]GKX[>+_V$+O\ 9\_9;\=7&E^);/2]+L;.\CU1K">]L[:2$7%LMTGS6SSP
M1O&)5Y0OG(ZBOI?_  4:^&<'_!-31?\ @I5\0]'B\-Z#JWP]M/%!T2^UJ%6B
M-Q LD=F+B01H\A9@@.T;CT7M6=KW_!4GX :):_!#Q4?$/AV3PE\9;&^N?^$R
M;QE:+INA"ULH[EUFGYC<[I/*/SIM93GTH ^/?B1_P2O_ &CO&/Q-\1>,O@[^
MR!X=^'NBZU^SOXH\%_9+OQU'J&K7FL7C6LD,UY=/)(98F,11"9&*8<MMWC/U
M;XZ_8^^*GC#XM_LYZ[/IENNC?#_P/J>C^,IH]019+>2XTV"V41#K)\R/RO3
M->^Z;^T9^SWK?PH?X\Z/\=O!MYX%CC:23QI:^*+232516VLQNUD,( ;@G=@'
M@UI?#'XM?"OXU>%(?'?P:^)GA_Q;H5PS+;ZUX9UJ"_M)&'4+- [(2.^#Q0!^
M?FJ_L;?\%!M._94^%?[ VB_!WPW?:#\-/BEX7O[KX@-XH@C35-!TK6H+M#%;
M']['=>7$K.' 4^6X4L6 KZD_X*+_ +/GQ)_:1^$7A7P=\,--M;J]TGXH>'];
MO8[J[6%5L[2Z$DS MU8+T7J>U5/^"BW_  4(T/\ X)_^"/#GB ?"K4/'&M>)
M-2O5M?#.DZ@MO<+IMAI]QJ&I:AED<,EO;VY.W&7>6) 07!KU_6?CO\%O#/PJ
MM?CIXN^*WA[1/!MYI]O?0>)M<UB&SL3;S('BD,TS*BAE8$9(SF@#P.;]E/XP
MO^U/^TU\5UTFS_LCXG_"W1-#\)S?;DWSWEM9W\4JR+UC4/<1X9N#DGM7Q7X.
M_P""3?[;5E^S'JGP-^-OP%T?XE>(IOA5H&@> =8U[XB_\23P<;;0;:SGM/[.
M\SRW9;J*:03I&YDWJ2P Q7Z9+^V;^Q])X;D\8I^U=\-6T>*YBMI=5'CK3_LR
M32V[7,49E\[:'>!'F5<Y:-6<94$T_7_VQ/V1O"G@C0_B;XI_:F^'&F^&_$S8
M\-^(-0\<6$-CJISMQ;3O,(Y^01\C-R,4 ?+GPC_94_:W_97\<?#_ ./_ ( ^
M$VG>+M4;X):9X(\<>$&\26]K-97=BS/#<P7$A\IXB9'5U!W< C/2O$?AE_P2
M<_:P\*V7P\^._P 5/AVNN>+=!\3?$(^+O!/@OXJ7OA]IK/7O$$NIV]S9ZA97
M%N<I\NZ&5P&63!&Y!7Z3_$W]H;X ?!;PG9^//C+\<O!_A+0]095L-:\3>)K6
MPM+EF&5$<T\BHY(Y&"<BJWCC]I_]F?X9Z%IWBCXD_M#^!?#^F:SISZAI.I:Y
MXNL[2WOK1/+W7$,DLJK)$OFQ9=25'FID_,,@'E__  3H_9;\1?LV^"/%NJ>,
M? >G^&]6\:>*Y=6N-+MO%&HZU<QQ[%CB^UWU_<SO<W&U?F="J=  <9KXQ_:N
M_P""87[8OQP^&OQL\#>)_@/I?Q$\?>,/$^J7?@OXI>+/B$6T_3M(DF\RTL[;
M3I)"ME/%$/)5DB"A_P!X9.I'Z*:/^UY^R?XB\0:'X2\/?M/_  [O]6\46WVC
MPSI=GXUL);C5H>?WEK&LI:=.#\R!AP:O>)/VE_V<O!OQ.L/@EXN^/_@G2O&F
MJ*ATOPAJ7BJS@U2\#?=,5J\@EDSVVJ<]J /G_P#X*Q6GB/1?^"0GQ&L&M(8=
M6M/!%A'Y$SAXX[E;BU&UBOWE#C!(ZBO+?BO^S!^W_P#MIIX5^)\.E:5\']>^
M&_P;\2:=\/\ 5K;Q!%?37WB'6=-ALTNE,(/V>VBCC9@6_>;Y%.WY*^N_B)^U
M-^QOX?UJ3X6?%C]HSX9V.H7%^NG2^'?$7B[3HYI;HA76V-O-*&:0AD81[=V&
M4XY%<MK_ /P4"_9W\(_MTZ#_ ,$_M1\::#:^*M<\$SZ]9K-XBM8F\Q9X8X=/
M2W+>8]Q+%)).J 9,4+, PR5 /B,_\$Q/VCM4^*'PT\>>#?V0=(\(-X;\*ZYI
MOC/7-<^)"ZUK6L7MYI$MLLYNI99&> S-N*E@V7#;  <>Z>._V*?VB$_X)M_
M?X,>&/".GW_C;X2>,/!WB'4O#RZM%#'>C2KQ)KBWBN&(C#E0VUF(4D=:^V+^
M_L=+L9M3U.\AM[:WA:6XN+B0)'%&HRS,QX50 22> *^+/AK_ ,%T/V1_B?XL
M\'Z3I'BCPQ;Z1XD\4>*-)U?7KOQ[8K#X?32%1EN;K!*I'<JX:/<Z#:006!H
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M7.D2Z_IT7AI-(O+<7EE+'-8S[GD:-]Z@F+#':YKW;]@G]D;Q9\)OC5XX^/\
MXS^#O_"'2>(-(L=(TBQUGXC:KXIUIK:%GD<W5[>7UQ$(][?NXH@-OS$M\V*]
MQ\!_M4?LP_%/Q]??"GX8_M'> _$7BC2U=M2\-Z#XPLKS4+15.&,MO%*TD8!X
M.Y1@]:X#X._\%"_@?XW^%'BCXQ?&'Q1X=^&.B^&?B5K?@]]0\8>++:UMKB;3
M[MK;S1-/Y2+YA7<(\DCID]: //;+_@GU?_'W]M3XF?M0?M7V.NV=NL-EX;^%
M<7A/XD:II,T.APIYLTLCZ7=0-F>ZD=C%(6QY:G KYJUO]DCXC_\ !.OXLZ-K
MOA_4/#MM\/\ P!\;+K6O@?I/BKQEY?\ :-AK6F2KJNDFXNF;R)8;EIIHI;A\
M2>8V7R:_2G6_CK\$O#7PQ'QL\1?&+PKI_@PVZ7 \77WB&VBTLPN<+)]J9Q%M
M.1AMV#GBH?"WB_X _M/_  _C\2>"?$_@_P"(GA6\D*PW^EWMKJVGS.O4!XS)
M&Q&?4D9H _-'1/A;^T9_P4&\'_MCWGAKP-HL-]XW\3>$[/PW#9ZY%-931V$M
ME-,GVM?W,KI'$X9D+(6&T$U[E^U/^P!\2M0_;>N?VO?!'PXUSQSIWB;X9Z=X
M9UCP_P"'?B]J7A*\TV]L;BXEAN1+9W=LES Z7)5HW9F1H]R#YVKUR^_:QU2V
M^+>O?LR_L3_LQV/C"Z\"^4GB^\?7XM T31[B5/,6S65+:=I;DH0YC2+:H8;G
M!.*U_@I_P4!^#_C[3?&VG?&;R?A3XG^&>LV>F?$#P_XVUFV@CTN6\56L9DNR
MPAGMKH,/)E!4NP9"JNI4 'QSX?\ ^"0/Q2^#GC#P5\<=(^$@URZ_L#4['QEX
M'\!_&#7?#\UM/=7INDGBU%M166[89VR^=-AVRZJ,XKT#PQ_P3>^,_ASX7?!F
MRTGX>Z!I6K:1^UE!\3O'&FV?BB^OS:6)M=0A9Y+S4;B>:^NP)K82.& D?<RJ
M "3]2ZY^W;^QCHGA&S\8C]K#X936>KF>/P],OC_3A'J]Q%G=!;/YV)I WRE4
MW$$X(K ^#/\ P4,_9[\;_LG^ OVL/C3\0?"OPMTGQ]IL5SIL'C3QA:6L8D<9
M\A)YS$LKX[* ?:@#R#XE?L0_'WQ-9?MFPZ3H>GLWQJTO3X/ F[4XU^TO%ICV
M[B7_ )XXD8#YNHYKR]O^"9WQT^$7Q<\4_$G0/A#K7CI/'7A;1-L'A_XZ:MX3
M_L/5K/3H[.1+E;*]MTNK9C$KB15>1064 C%?>WCO]HG]G_X5^%]/\<?%#XZ^
M#?#FBZM'OTK6->\36EG:WB[/,W12RR*D@V?-E2?EYZ<UJQ_$_P"&LOP^_P"%
MM1_$/0V\*_V?]O\ ^$F&K0G3_LFW=]H^T;O+\K;SOW;<<YH ^0OV%?\ @GI\
M3OV4/CI'JMSX<\-V?ANU_9UTGPC'_P (W=3_ &5=8CU&\N[F.&.ZFFN%@!N<
MJTDC$YZCH.3_ &/?V%?VK/V:/B]\$OB-K?P^T_4K?P[X-\2>&?%EO:^((%?3
M1?:LEY#=#<<3IL0@JF6!(XZU[]\<O^"E7[-_PV^ G_#0_P )/B)X2^)FAQ^+
MM+T'4+KPCXUL[BWLWO;I(/,DGA,J+Y>XN5."0IY'6O6OA5\??@3\>+.]U#X'
M?&KPCXRM]-N/L^HS^%/$=KJ*6LP_Y9R&WD<(W^RV#0!>\+^)/&^N>$;K6->^
M'4VAZI'-=);Z1=:E!.95C=EAD\R)F0"50K@$Y4/A@""*^,/@Q_P1W\!?%7X
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M#\ /@7X4^"?A:%8K+PSH-MI]N!W\N,*6]\G)_&OS3_:&_P""7_[9?Q;^'WQ
M\*^*/@-I/CWXA:M\1;C5]%^+'BKXA^;;1Z/_ &@+BVM;.PDD(L)8[<+" L:J
M"I8N=V:_2#XD_M3_ +,'P:02_%_]I#P'X55K"&^5O$GC"RL0;65V2*?]]*O[
MMW1U5_NLRL 20:\__:;_ ."D'[,/[+DOPMD\9_$WPS)8_%CQ-;Z7X?U9O%EG
M!:_9Y%R;\2.^V2!?E&Y25)=1D9% 'S7\5_\ @G[^UAXT^!O[6GP TCP1IBK\
M9C;ZUX/UV77H1$;M+6S0V,L>=\;;[9AYA&S# YZUS7QX_86_;0_:+\1?&#Q)
M\8_V7K'QGJ'C_38$^&$?BKXE(VD^ X?L"0/92Z?'*899!<+)-Y\<<A?S%RR[
M<5][^"OVL/V6/B9K=YX:^'/[2WP_\0:CI^GO?ZAI^A^,K&[FMK53AKB1(I69
M(@>"Y 4'J:XWXG_\% ?V=?#O[-'Q"_:1^"GQ/\(_%"U^'>C3WVK:?X,\86EW
MAXU)\B26!I1"QP?O#/'2@#YK_9+_ &4?VYOV$_-\2_#[X+:+XPN_&'PVT'3=
M6TV7Q5;VS:#K6G6?V;<[N<3VK *W[HEQR #7L'PF_9L_:8L/^"@$?[4/QD;0
M;Z.Z_9ETKPAK6K:&?)AEU^+6+N\N%AMW9I$@V3(59B?3.0:^D? OB=/&W@C1
M_&<5F;==7TJWO5MVDW&(2Q*^W.!G&[&<#-:M 'Y9^!?^"2W[0OPQ\3^%?C7K
MGPXO_%%Y8GQ/IVN^$?"_Q:O?#=VMM>ZS/?6EU#>65U;K)\C@/#(^!G@9%=Q\
M$_\ @G5^T=^RK\3O!/[9'PO^#WAZ]\5077BNW\;?#NW\:7EQ-<6.LS6<T<RZ
MGJMS,9[Z)["#S9&=$E$C[0"/F_12@C- 'S+_ ,$W/@E^T=\*[CXR>./VE_!^
MDZ'JWQ$^*UQXBTW3='U1+N.&R>QM((U9UX\Q?)*MV+ D9!!KA_@1X)_;&_9/
M_:$^/OB/3/V1;KQKHGQ+^*3>)/#^J:3XXTJUVVQL;:WV217,J.K[H6/3&"*^
MTL>]% 'P[^WQ^R?^TS_P5/\  GA7]F_XE?"]?AA\/;BXFUCQQ?7>L:?J6H_:
M[5P=/M+<1&1 KR[99).R)LZL:O>"?V;/VR_&/C/]EWQA\</!F@VNH?!V^U^S
M\77FEZI#Y-U;/8I:V=W#&O3S0@8Q#F/G.!7VIC(QBC )SB@#\_?$O_!/?]I;
M4_VQ]8^,UIX?TTZ%>?M?^'_B#!,VK1"0Z':>$(]+FEV9R)!=*5$?WBOS=*YO
M0?V+/V_=;_9;\>?L$^+?@WX<T_P[X]^*NJ:M+X_B\4P2+9:'<:O]M*FV'[QK
MHH@"X!4%^2-M?I-THH _.W5O^"=_[4'AKX4ZQ'X8\(:?JFJ:/^VM:_%;0M'.
MN0Q-JVAP7D3A!*YV0SM&&(5R,%<'K71:7\//%'A[]IG]I3X,>*O@OX?\4W7Q
MIT?2/%N@^$_%UX$T[5UBM$LK^P>4(ZEXC'$PP"/GW< 9K[PJO-I6EW-_#JMQ
MIEO)=6ZLMO<O"IDB#?>"L1E0>^.M 'PK^S/\(_B'^PCXR\??M+^,_#>N?"OX
M&^'_ (;LTGPPU;XB/XD3^TXI6E-U9!I9OLB&("%($<>8\B_("!7J_P#P34^
M?Q(^!?\ P3+\%_";QYX5L9/%EUX?U'5-8\/ZLY%O'>ZI=W.HR64Q"MA4>[,+
M84_=/!KZ3U32=+URR;3=:TVWO+=V4R6]U"LB,58,I*L"#A@"/0@&K&,T ?!?
M[*_[$GQX^%?[5?A#X@?"[X(7/P-\$:9:Z@?B%X1TWXEMJVA>(998P(%LM/\
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M#_\ !(+P;XB\+?!SXD:_;>#[[P]X*\3_ !D\0:W\+_#]]:-:FST*>96BV0,
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M-X;\,C1-:^(IDU&^@U-]>M!<V-M?-$DU] ( K,7#&/IN/-?LI1COB@#\P/\
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M%X%-QX?DO_\ A(M)725A.D6V$;]\MUYI,7!+2A^^:_26B@#X$^#'@CQAJO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP5_8^^+O@7X@^'?&OQ@_; \2>-;7P?I,FG^'=#ATU=*MG5U5//OEAE87TP1
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M)^#-]K7P=L_&'B#Q#\2II(=$L5F<Q0:9IUE]NMI)78H[EC<8B0+PY.*;:_\
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MU*]EC6!KBXO)&DG=$CPL*EG.U%X48QZU\Z)_P1K\2#X)?#_]F=_VR-67X?\
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MXN>+?C?/XDU+X>_#.3P59JOA]+..ZLS)&T<K!97VNJQJIQD,<GCI0!\SWO\
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MJ:7XYTGXLWOQ)T_Q]8:3!$(/$%V&CN"EDI\I;1X',)MPV"O.[=\U 'C^B_\
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M BLNX!%.&H\0?M:?MZ>%/VU=-_9QTKXH_!OQMH/AO3I/$?QMU+2?A/JVF?\
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MN_!;X\ZCHOQ%\)ZEKM]?>+M:T&'4H]:FUAD:^>:UWQ+&Q:--C1NI0#:=P)H
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M\;? &?\ 9E\7^'!J7@^Z\-)H5QIUW(6,EFL(B4%NNX*JD-U# 'K0!\R_$_\
MX)N? ?P;^R7JWQ!^'VKZUHOQ0T?PG+K%C\8/[=G;7#J<5N9A<W%T7W3QF09>
M%\Q,A*[=O%<7^R-_P4;_ &U/VKOB#X5\,Z-I/P[\.^'X?@+X:\?>,M6U[0K^
MZO+B:\\Q;JWMT@NH4B!$1DC=E?:#@H^01Z]JW_!/7XO^+?A<?V:_'?[;WB;4
MOAA)9BPO-'7P_!#K5[IV-ILYM4$A+(R?NV985D*Y^8$YKT#X:_L7> OA9^T=
MKGQX\*Z@+>PU;X=Z3X/M?",=BJVMC96#2>7L;=D@I)LVD8 4<F@#X7_:Y_::
M_;3_ &H?V/?AS^TW%HO@;1_A;XK_ &@O ZZ?H=DMZFOZ?IH\5626]W-=^>8+
MCSF5$>W6"+8LV?,?:5.UXJ_X+OSP)X\^,/AOXJ_ >S\+^!?'E[H%O\*-<\1L
MOC7Q%:V5W]EN+Z B[5+=G=9'AMFM96D1 3(A; ]>\4?\$@M8UCP9X=^!6@?M
M>:]I?PM\)?$C2_&'A[P6OAR"62&6RU.*_2QDNS(&EM=Z%578K(2K;FV!3U4/
M_!-3Q3X7D\2> ?A'^UMXG\(_#7Q;XPN?$>K>#]'TY$O+:YN;C[3=Q6>HK(LE
MK!-,7<H$9E\Q@K*#P 5_V+OVMOVK?VN/C[\2)$M_ &D?"_P#XYET.SA_L6^?
M6M7@-I'/'/YWVL0V[*955E,+[\'&SC.[_P % OVR_&?[+VN>!_"?A?Q7\/\
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MGJ:\Y^+G[!_B?Q-^U3JW[6WP3_:#N?!'B'Q1X#M?"7BJ*7PW#J<=U8VUQ//
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MCX>^(&C^.?%&NZ3XH;08KF'[)KMR)[S2[BU,BBX@#I"RMO1E>%6&,D$ S?\
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MK%3G[-TK]BCPW8_M$>#?C_>^,)KMO"/P?N_ ']BS6"^3?6]Q/9S-<.V[(/\
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M(/$AUJ_T/19&'V73[B_8EKN2,!B9"S\.%W,%!H X+X,?%G]JS]OGQ%X\\?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSW\9_P!FG]A3X/\ _!P5=W%Y<?$+5_VA+[7_ !/J7S W.EW%QL#L,\E[J.X
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M_P"S1^US\/7^*G[-/QKT#QIH,+;+F^T.]$OV9\9V2Q\/$V.=KJI(YQ7Y1?\
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M  7S_P""//P^\=R?#?Q/^WGX.758;CR)5LH[N[MUDS@@W,$+P\'OOP*^-/\
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MO@IX/^/_ (B9KSPOI7AVTT.6"V3YI89X+/\ =(TKA"Y!)8*,D\B@#]%/%/\
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M]B7P7XGNM'TOXP>-GC\33VDVPW-K;O;H(&/=#)<I(1W,0!R,B@#[/F_X+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBN/^+W[0'P3^ -GI.H?&OXI:+X
M7AUW5H]+T>36KY(!>7D@)2"/<?F<@'@>E '845@7WQ4^'.F?$>P^$&H>--/A
M\4:IILVHZ;H,EP!=7-K$P629$ZLBLP!/8D4S5OBW\,M"^)FC_!G5_'.FV_BO
M7]/NK_1?#\ETHNKRUMR@GF2/J40R1AFZ N!0!T5% .:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK.@YC+*00#U!H ["BC/K10 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX.\=?%+_ ((W^.]"TWQQ\8OC/I/P]\;:QI<TC>'?#.I".0/<Q0E%MED"1/\
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M[Q?>>(]'U74ETLQ9NXK]],>2'=%+)#Y@VHP0G@<&NH^/'[37[=WP,\3?MR?
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MY\%]'_9[_9U\$KX>\(Z"CKI>EB^GNC$'<NQ,MP\DLA+$G+L37DEY_P $??\
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M@W-:F0;K?2H2?N6UI$PB1!P6#N?F<FOHBFQ11P1+#"NU44*JCL!3J "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !SV-%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gz4fxfn2r2w0000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gz4fxfn2r2w0000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ED# 2(  A$! Q$!_\0
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ME41Q-&;M&:?S0%BBBBM@"J]Y>1V4'FRAB,X 4<DU8I" PP0"#V-3-2<6HNS
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MD6&HZ)*#D^63]5:NAT[48]0AW+\LB_>3TJU-"EQ"T4B[D88(KD[4OIFMB//
M?8WN#_G-<+4\MJQM*].3M9] W.OI&8*I9B  ,DGM2UC>(KHPV:PJ<&4\_05Z
M^)KJA2E5?012O]9GNYOL]EN"DX!7[S?X4L'AR:4;[F8(3R5')JYH%BL-K]I9
M?WDG0GL*V:\K#8!XI*OBW=O9=$AW[&*/#5KWFF_,?X5%+X93;^YN&#?[0K?H
MKMEE>$:MR?F%V<C%<WNBW7E2Y*=U)X(]175PRK/"DJ'*N,BL3Q,J^3 W\0)
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MB;]\X_[Y'K4?AZS:.%KJ3.Z7A<^G^?Y5CVD4NKZGF0D@G<Y]!_GBNQ50BA5
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M^^JO.J->M4BJ<6TE^8(-"N+:UN))9Y-GR[5X)Z__ *JWO[9T_P#Y^!_WR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>pstv-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-20T21:51:58.3418330+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:pstv="http://www.plustherapeutics.com/20220331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.plustherapeutics.com/20220331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.plustherapeutics.com/20220331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED" id="Role_StatementCONDENSEDBALANCESHEETSUNAUDITED">
        <link:definition>100010 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical" id="Role_StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical">
        <link:definition>100020 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED" id="Role_StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED">
        <link:definition>100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED" id="Role_StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED">
        <link:definition>100040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" id="Role_StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards" id="Role_DisclosureBasisOfPresentationAndNewAccountingStandards">
        <link:definition>100060 - Disclosure - Basis of Presentation and New Accounting Standards</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates" id="Role_DisclosureUseOfEstimates">
        <link:definition>100070 - Disclosure - Use of Estimates</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity" id="Role_DisclosureLiquidity">
        <link:definition>100080 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations" id="Role_DisclosureTermLoanObligations">
        <link:definition>100100 - Disclosure - Term Loan Obligations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100110 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement" id="Role_DisclosureLicenseAgreement">
        <link:definition>100130 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100140 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" id="Role_DisclosureCOVID19PandemicAndCARESAct">
        <link:definition>100160 - Disclosure - COVID-19 Pandemic and CARES Act</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" id="Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies">
        <link:definition>100170 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100180 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100190 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100200 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails" id="Role_DisclosureLiquidityAdditionalInformationDetails">
        <link:definition>100210 - Disclosure - Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100220 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails" id="Role_DisclosureTermLoanObligationsDetails">
        <link:definition>100230 - Disclosure - Term Loan Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" id="Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
        <link:definition>100240 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
        <link:definition>100260 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>100270 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2">
        <link:definition>100280 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails" id="Role_DisclosureStockholdersEquityPreferredStockDetails">
        <link:definition>100300 - Disclosure - Stockholders&apos; Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails" id="Role_DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>100310 - Disclosure - Stockholders&apos; Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails" id="Role_DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>100320 - Disclosure - Stockholders&apos; Equity - Common stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>100340 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" name="StockIssuedDuringPeriodSharesWarrantsExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" name="StockIssuedDuringPeriodSharesWarrantsExerciseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" name="CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_ProceedsFromWarrantExercises1" name="ProceedsFromWarrantExercises1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_UnpaidOfferingCosts" name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_CashPaidDuringPeriodForAbstract" name="CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_UseOfEstimatesTextBlock" name="UseOfEstimatesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_UseOfEstimatesAbstract" name="UseOfEstimatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_DisclosureOfLiquidityTextBlock" name="DisclosureOfLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_LiquidityAbstract" name="LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" name="WarrantsIssuedUnderwrittenPublicOfferingPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_SeriesUWarrantsMember" name="SeriesUWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_DebtInstrumentFloatingInterestRatePercentage" name="DebtInstrumentFloatingInterestRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pstv_ClassOfWarrantOrRightExpirationDate" name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" name="SaleOfJapaneseSubsidiaryAndCertainAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_MinimumLiquidityCovenantAmount" name="MinimumLiquidityCovenantAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_PrepaymentsOfLongTermDebt" name="PrepaymentsOfLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_DebtInstrumentAmendmentFee" name="DebtInstrumentAmendmentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_DebtPrincipalRepaymentStartDate" name="DebtPrincipalRepaymentStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_RelatedFinalPayment" name="RelatedFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_LongTermDebtOutstandingThresholdAmount" name="LongTermDebtOutstandingThresholdAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_OptionsMember" name="OptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_AnnualIncreaseInLeaseRate" name="AnnualIncreaseInLeaseRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_OperatingLeasesExpiryYear" name="OperatingLeasesExpiryYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_CharlottesvilleMember" name="CharlottesvilleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_MedidataSolutionsIncMember" name="MedidataSolutionsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_ServicesAgreementMember" name="ServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_PiramalPharmaSolutionsIncMember" name="PiramalPharmaSolutionsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_PreClinicalResearchStudyObligationsMember" name="PreClinicalResearchStudyObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_LoremVascularPteLtdMember" name="LoremVascularPteLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_FinanceLeaseExpenseAbstract" name="FinanceLeaseExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_CashPaymentInformationAbstract" name="CashPaymentInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_ContingentManagedServicesFee" name="ContingentManagedServicesFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_StatementOfWorkTerm" name="StatementOfWorkTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_MasterServicesAgreementDate" name="MasterServicesAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_MasterServicesAgreementInitialTerm" name="MasterServicesAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_MasterServicesAgreementTermsDescription" name="MasterServicesAgreementTermsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_CompensatoryDamagesAndOperational" name="CompensatoryDamagesAndOperational" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pstv_NanoTxLicensesAgreementMember" name="NanoTxLicensesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_PreferredStockDividendRatePercentageEliminatedDate" name="PreferredStockDividendRatePercentageEliminatedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_TwoThousandEighteenRightsOfferingMember" name="TwoThousandEighteenRightsOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_NumberOfPreferredStockSharesExercised" name="NumberOfPreferredStockSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_RepresentativeSeriesUWarrantMember" name="RepresentativeSeriesUWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_PeriodExercisableFromTheDateOfIssuance" name="PeriodExercisableFromTheDateOfIssuance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_TwentyTwentyPurchaseAgreementMember" name="TwentyTwentyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_CommitmentFeeMember" name="CommitmentFeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_CanaccordGenuityLLCMember" name="CanaccordGenuityLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_AtTheMarketOfferingProgramMember" name="AtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_TwoThousandTwentyTwoDistributionAgreementMember" name="TwoThousandTwentyTwoDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_DistributionAgreementMember" name="DistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_PercentageIssuanceOfCommonStock" name="PercentageIssuanceOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pstv_CommonStockSalesAvailableForIssuance" name="CommonStockSalesAvailableForIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" name="StockBasedCompensation2015EquityIncentivePlan1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_StockBasedCompensation2020EquityIncentivePlanMember" name="StockBasedCompensation2020EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>pstv-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-20T21:51:58.3428332+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="pstv-20220331.xsd#TemplateLink" roleURI="http://www.plustherapeutics.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDBALANCESHEETSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NonCashLeaseExpense" xlink:type="locator" xlink:label="pstv_NonCashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:type="locator" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ProceedsFromWarrantExercises1" xlink:type="locator" xlink:label="pstv_ProceedsFromWarrantExercises1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pstv_ProceedsFromWarrantExercises1" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pstv_NonCashLeaseExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="us-gaap_OperatingLeasePayments" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="locator" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>pstv-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-20T21:51:58.3428332+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="pstv-20220331.xsd#TemplateLink" roleURI="http://www.plustherapeutics.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" xlink:type="locator" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesUWarrantsMember" xlink:type="locator" xlink:label="pstv_SeriesUWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureTermLoanObligationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:type="locator" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentAmendmentFee" xlink:type="locator" xlink:label="pstv_DebtInstrumentAmendmentFee" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RelatedFinalPayment" xlink:type="locator" xlink:label="pstv_RelatedFinalPayment" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PrepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="pstv_PrepaymentsOfLongTermDebt" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:type="locator" xlink:label="pstv_DebtPrincipalRepaymentStartDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:type="locator" xlink:label="pstv_MinimumLiquidityCovenantAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLoans" xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ClassOfWarrantOrRightExpirationDate" xlink:type="locator" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:type="locator" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentOfferingDate1" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:type="locator" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="pstv_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFloorMember" xlink:type="locator" xlink:label="us-gaap_InterestRateFloorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TermLoanMember" xlink:type="locator" xlink:label="pstv_TermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pstv_TermLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_InterestRateFloorMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pstv_LoanAndSecurityAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentOfferingDate1" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtInstrumentFloatingInterestRatePercentage" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_ClassOfWarrantOrRightExpirationDate" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForLoans" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_MinimumLiquidityCovenantAmount" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtPrincipalRepaymentStartDate" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_PrepaymentsOfLongTermDebt" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_RelatedFinalPayment" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtInstrumentAmendmentFee" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_LongTermDebtOutstandingThresholdAmount" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OptionsMember" xlink:type="locator" xlink:label="pstv_OptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_OptionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CompensatoryDamagesAndOperational" xlink:type="locator" xlink:label="pstv_CompensatoryDamagesAndOperational" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementTermsDescription" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementInitialTerm" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementDate" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ContingentManagedServicesFee" xlink:type="locator" xlink:label="pstv_ContingentManagedServicesFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeePayable" xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StatementOfWorkTerm" xlink:type="locator" xlink:label="pstv_StatementOfWorkTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LeaseCommencementDate" xlink:type="locator" xlink:label="pstv_LeaseCommencementDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AnnualIncreaseInLeaseRate" xlink:type="locator" xlink:label="pstv_AnnualIncreaseInLeaseRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OperatingLeasesExpiryYear" xlink:type="locator" xlink:label="pstv_OperatingLeasesExpiryYear" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoremVascularPteLtdMember" xlink:type="locator" xlink:label="pstv_LoremVascularPteLtdMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:type="locator" xlink:label="pstv_PreClinicalResearchStudyObligationsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:type="locator" xlink:label="pstv_PiramalPharmaSolutionsIncMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ServicesAgreementMember" xlink:type="locator" xlink:label="pstv_ServicesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MedidataSolutionsIncMember" xlink:type="locator" xlink:label="pstv_MedidataSolutionsIncMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CharlottesvilleMember" xlink:type="locator" xlink:label="pstv_CharlottesvilleMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_CharlottesvilleMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_MedidataSolutionsIncMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pstv_ServicesAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_PiramalPharmaSolutionsIncMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="pstv_PreClinicalResearchStudyObligationsMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="srt_LitigationCaseAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_2" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="pstv_LoremVascularPteLtdMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_OperatingLeasesExpiryYear" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_AnnualIncreaseInLeaseRate" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_LeaseCommencementDate" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_StatementOfWorkTerm" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_ManagementFeePayable" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_ContingentManagedServicesFee" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementDate" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementInitialTerm" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementTermsDescription" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_ContractualObligation" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_CompensatoryDamagesAndOperational" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="11610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:type="locator" xlink:label="pstv_NanoTxLicensesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pstv_NanoTxLicensesAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityPreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:type="locator" xlink:label="pstv_NumberOfPreferredStockSharesExercised" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreferredStockDividendRatePercentageEliminatedDate" xlink:type="locator" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:type="locator" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesBConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesCConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pstv_TwoThousandEighteenRightsOfferingMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PreferredStockDividendRatePercentageEliminatedDate" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_NumberOfPreferredStockSharesExercised" order="10910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityWarrantsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="pstv_NumberOfWarrantsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:type="locator" xlink:label="pstv_RepresentativeSeriesUWarrantMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesUWarrantsMember" xlink:type="locator" xlink:label="pstv_SeriesUWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_RepresentativeSeriesUWarrantMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_NumberOfWarrantsExercised" order="10840.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:type="locator" xlink:label="pstv_CommonStockSalesAvailableForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:type="locator" xlink:label="pstv_PercentageIssuanceOfCommonStock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:type="locator" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DistributionAgreementMember" xlink:type="locator" xlink:label="pstv_DistributionAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandTwentyTwoDistributionAgreementMember" xlink:type="locator" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SalesAgreementMember" xlink:type="locator" xlink:label="pstv_SalesAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="pstv_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="pstv_CanaccordGenuityLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommitmentFeeMember" xlink:type="locator" xlink:label="pstv_CommitmentFeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:type="locator" xlink:label="pstv_LincolnParkCapitalFundLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:type="locator" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_TwentyTwentyPurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pstv_LincolnParkCapitalFundLLCMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_CommitmentFeeMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pstv_CanaccordGenuityLLCMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pstv_AtTheMarketOfferingProgramMember" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_SalesAgreementMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_TwoThousandTwentyTwoDistributionAgreementMember" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_DistributionAgreementMember" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PeriodExercisableFromTheDateOfIssuance" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PercentageIssuanceOfCommonStock" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_CommonStockSalesAvailableForIssuance" order="12510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pstv_StockBasedCompensation2020EquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>pstv-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-20T21:51:58.3428332+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="locator" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
    <link:label xml:lang="en-US" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability payments due, after year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-use-of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Intangible Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan obligation, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at March 31, 2022 and December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100,000,000 shares authorized; 22,197,635 and 15,510,025 issued and outstanding at March 31, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of liability instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Adjustment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercise(shares).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Sale of common stock, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Sale of common stock, net, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series B Convertible Preferred Stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Conversion of Series B Convertible Preferred Stock into common stock (share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercise</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Issuance of common stock for exercise of warrants (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercise Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NonCashLeaseExpense" xlink:type="locator" xlink:label="pstv_NonCashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="pstv_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_NonCashLeaseExpense" xlink:to="pstv_NonCashLeaseExpense_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:type="locator" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for IPRD asset acquired in an asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:to="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ProceedsFromWarrantExercises1" xlink:type="locator" xlink:label="pstv_ProceedsFromWarrantExercises1" />
    <link:label xml:lang="en-US" xlink:label="pstv_ProceedsFromWarrantExercises1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from warrant exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_ProceedsFromWarrantExercises1" xlink:to="pstv_ProceedsFromWarrantExercises1_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UnpaidOfferingCosts" xlink:type="locator" xlink:label="pstv_UnpaidOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="pstv_UnpaidOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid Offering Costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_UnpaidOfferingCosts" xlink:to="pstv_UnpaidOfferingCosts_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidDuringPeriodForAbstract" xlink:type="locator" xlink:label="pstv_CashPaidDuringPeriodForAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid during period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CashPaidDuringPeriodForAbstract" xlink:to="pstv_CashPaidDuringPeriodForAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of deferred financing costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs And Discounts</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of liability instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases (decreases) in cash caused by changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">In process research and development acquired</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For I P R D Asset Acquired In An Asset Acquisition</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments of long-term obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of financing lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ProceedsFromWarrantExercises1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ProceedsFromWarrantExercises1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flows information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during period for:</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid During Period For [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_UnpaidOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid offering cost</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_UnpaidOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Offering Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and New Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UseOfEstimatesTextBlock" xlink:type="locator" xlink:label="pstv_UseOfEstimatesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pstv_UseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Provides an entity&apos;s explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_UseOfEstimatesTextBlock" xlink:to="pstv_UseOfEstimatesTextBlock_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UseOfEstimatesAbstract" xlink:type="locator" xlink:label="pstv_UseOfEstimatesAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_UseOfEstimatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_UseOfEstimatesAbstract" xlink:to="pstv_UseOfEstimatesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_UseOfEstimatesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_UseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_UseOfEstimatesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates [Text Block]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DisclosureOfLiquidityTextBlock" xlink:type="locator" xlink:label="pstv_DisclosureOfLiquidityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pstv_DisclosureOfLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_DisclosureOfLiquidityTextBlock" xlink:to="pstv_DisclosureOfLiquidityTextBlock_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LiquidityAbstract" xlink:type="locator" xlink:label="pstv_LiquidityAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LiquidityAbstract" xlink:to="pstv_LiquidityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DisclosureOfLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DisclosureOfLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Liquidity [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="pstv_LicenseAgreementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pstv_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LicenseAgreementDisclosureTextBlock" xlink:to="pstv_LicenseAgreementDisclosureTextBlock_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LicenseAgreementAbstract" xlink:type="locator" xlink:label="pstv_LicenseAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LicenseAgreementAbstract" xlink:to="pstv_LicenseAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Or Infrequent Items Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and New Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Annual Lease Payments under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" xlink:type="locator" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued, underwritten public offering, period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" xlink:to="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesUWarrantsMember" xlink:type="locator" xlink:label="pstv_SeriesUWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesUWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series U warrants member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SeriesUWarrantsMember" xlink:to="pstv_SeriesUWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesUWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series U Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesUWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series U Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued, underwritten public offering, period</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued Underwritten Public Offering Period</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:type="locator" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Floating interest rate for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:to="pstv_DebtInstrumentFloatingInterestRatePercentage_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ClassOfWarrantOrRightExpirationDate" xlink:type="locator" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The date that the warrant or right expires.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_ClassOfWarrantOrRightExpirationDate" xlink:to="pstv_ClassOfWarrantOrRightExpirationDate_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TermLoanMember" xlink:type="locator" xlink:label="pstv_TermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment to the amended and restated loan and security agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_TermLoanMember" xlink:to="pstv_TermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIBOR [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">London Interbank Offered Rate L I B O R [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument Risk [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFloorMember" xlink:type="locator" xlink:label="us-gaap_InterestRateFloorMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestRateFloorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate Floor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRateFloorMember" xlink:to="us-gaap_InterestRateFloorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestRateFloorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate Floor [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="pstv_LoanAndSecurityAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LoanAndSecurityAgreementMember" xlink:to="pstv_LoanAndSecurityAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LoanAndSecurityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Classification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:type="locator" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of the japanese subsidiary and certain assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:to="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of the Japanese Subsidiary and Certain Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Japanese Subsidiary And Certain Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentOfferingDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentOfferingDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Origination Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentOfferingDate1" xlink:to="us-gaap_DebtInstrumentOfferingDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentOfferingDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Offering Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Original Loan Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Floating Interest Rate Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees amount associated with loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares callable by warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date from which warrants are exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Expiration Date</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:type="locator" xlink:label="pstv_MinimumLiquidityCovenantAmount" />
    <link:label xml:lang="en-US" xlink:label="pstv_MinimumLiquidityCovenantAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum liquidity covenant amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_MinimumLiquidityCovenantAmount" xlink:to="pstv_MinimumLiquidityCovenantAmount_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLoans" xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForLoans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for principal, interest and fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForLoans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Loans</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MinimumLiquidityCovenantAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum liquidity covenant</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MinimumLiquidityCovenantAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Liquidity Covenant Amount</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PrepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="pstv_PrepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="pstv_PrepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments of long term debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PrepaymentsOfLongTermDebt" xlink:to="pstv_PrepaymentsOfLongTermDebt_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentAmendmentFee" xlink:type="locator" xlink:label="pstv_DebtInstrumentAmendmentFee" />
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument amendment fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_DebtInstrumentAmendmentFee" xlink:to="pstv_DebtInstrumentAmendmentFee_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:type="locator" xlink:label="pstv_DebtPrincipalRepaymentStartDate" />
    <link:label xml:lang="en-US" xlink:label="pstv_DebtPrincipalRepaymentStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt principal repayment start date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_DebtPrincipalRepaymentStartDate" xlink:to="pstv_DebtPrincipalRepaymentStartDate_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RelatedFinalPayment" xlink:type="locator" xlink:label="pstv_RelatedFinalPayment" />
    <link:label xml:lang="en-US" xlink:label="pstv_RelatedFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related final payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_RelatedFinalPayment" xlink:to="pstv_RelatedFinalPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_DebtPrincipalRepaymentStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt principal repayment start date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DebtPrincipalRepaymentStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Principal Repayment Start Date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PrepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments of term loan</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PrepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_RelatedFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related final payment</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_RelatedFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment fee</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DebtInstrumentAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Amendment Fee</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:type="locator" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount" />
    <link:label xml:lang="en-US" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt outstanding threshold amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LongTermDebtOutstandingThresholdAmount" xlink:to="pstv_LongTermDebtOutstandingThresholdAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long Term Debt Outstanding Threshold Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Outstanding Threshold Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Covenant Compliance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Compliance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OptionsMember" xlink:type="locator" xlink:label="pstv_OptionsMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_OptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_OptionsMember" xlink:to="pstv_OptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_OptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_OptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AnnualIncreaseInLeaseRate" xlink:type="locator" xlink:label="pstv_AnnualIncreaseInLeaseRate" />
    <link:label xml:lang="en-US" xlink:label="pstv_AnnualIncreaseInLeaseRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in lease rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_AnnualIncreaseInLeaseRate" xlink:to="pstv_AnnualIncreaseInLeaseRate_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LeaseCommencementDate" xlink:type="locator" xlink:label="pstv_LeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="pstv_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LeaseCommencementDate" xlink:to="pstv_LeaseCommencementDate_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OperatingLeasesExpiryYear" xlink:type="locator" xlink:label="pstv_OperatingLeasesExpiryYear" />
    <link:label xml:lang="en-US" xlink:label="pstv_OperatingLeasesExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases, expiry year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_OperatingLeasesExpiryYear" xlink:to="pstv_OperatingLeasesExpiryYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recorded Unconditional Purchase Obligation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CharlottesvilleMember" xlink:type="locator" xlink:label="pstv_CharlottesvilleMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_CharlottesvilleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Charlottesville</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CharlottesvilleMember" xlink:to="pstv_CharlottesvilleMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_CharlottesvilleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charlottesville [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CharlottesvilleMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Charlottesville [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MedidataSolutionsIncMember" xlink:type="locator" xlink:label="pstv_MedidataSolutionsIncMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_MedidataSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Medidata solutions, inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_MedidataSolutionsIncMember" xlink:to="pstv_MedidataSolutionsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_MedidataSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medidata Solutions, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MedidataSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Medidata Solutions Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ServicesAgreementMember" xlink:type="locator" xlink:label="pstv_ServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_ServicesAgreementMember" xlink:to="pstv_ServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:type="locator" xlink:label="pstv_PiramalPharmaSolutionsIncMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_PiramalPharmaSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Piramal pharma solutions inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PiramalPharmaSolutionsIncMember" xlink:to="pstv_PiramalPharmaSolutionsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_PiramalPharmaSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Piramal Pharma Solutions, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PiramalPharmaSolutionsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Piramal Pharma Solutions Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recorded Unconditional Purchase Obligation by Category of Item Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional Purchase Obligation, Category of Goods or Services Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:type="locator" xlink:label="pstv_PreClinicalResearchStudyObligationsMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_PreClinicalResearchStudyObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PreClinicalResearchStudyObligationsMember" xlink:to="pstv_PreClinicalResearchStudyObligationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_PreClinicalResearchStudyObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-clinical Research Study Obligations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PreClinicalResearchStudyObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Clinical Research Study Obligations [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Case</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Case</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case Type [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoremVascularPteLtdMember" xlink:type="locator" xlink:label="pstv_LoremVascularPteLtdMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_LoremVascularPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lorem Vascular, Pte. Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LoremVascularPteLtdMember" xlink:to="pstv_LoremVascularPteLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LoremVascularPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lorem Vascular Pte Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LoremVascularPteLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lorem Vascular Pte Ltd [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_OperatingLeasesExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases expiry year</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_OperatingLeasesExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Expiry Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_AnnualIncreaseInLeaseRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in lease rate</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_AnnualIncreaseInLeaseRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Lease Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_FinanceLeaseExpenseAbstract" xlink:type="locator" xlink:label="pstv_FinanceLeaseExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_FinanceLeaseExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_FinanceLeaseExpenseAbstract" xlink:to="pstv_FinanceLeaseExpenseAbstract_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaymentInformationAbstract" xlink:type="locator" xlink:label="pstv_CashPaymentInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaymentInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash payment information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CashPaymentInformationAbstract" xlink:to="pstv_CashPaymentInformationAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_FinanceLeaseExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease expense:</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_FinanceLeaseExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaymentInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment information:</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaymentInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Payment Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash used for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash used for finance leases</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of obligations under leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ContingentManagedServicesFee" xlink:type="locator" xlink:label="pstv_ContingentManagedServicesFee" />
    <link:label xml:lang="en-US" xlink:label="pstv_ContingentManagedServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent managed services fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_ContingentManagedServicesFee" xlink:to="pstv_ContingentManagedServicesFee_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StatementOfWorkTerm" xlink:type="locator" xlink:label="pstv_StatementOfWorkTerm" />
    <link:label xml:lang="en-US" xlink:label="pstv_StatementOfWorkTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Statement of work, term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_StatementOfWorkTerm" xlink:to="pstv_StatementOfWorkTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_StatementOfWorkTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement of work, term</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StatementOfWorkTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Work Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeePayable" xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManagementFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Managed services fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManagementFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ContingentManagedServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent managed services fee</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ContingentManagedServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Managed Services Fee</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementDate" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementDate" />
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master services agreement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_MasterServicesAgreementDate" xlink:to="pstv_MasterServicesAgreementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master service agreement date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Services Agreement Date</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementInitialTerm" />
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master services agreement initial term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_MasterServicesAgreementInitialTerm" xlink:to="pstv_MasterServicesAgreementInitialTerm_lbl" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementTermsDescription" />
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementTermsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master services agreement Terms description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_MasterServicesAgreementTermsDescription" xlink:to="pstv_MasterServicesAgreementTermsDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master services agreement initial term</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Services Agreement Initial Term</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementTermsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master services agreement terms, Description</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_MasterServicesAgreementTermsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Services Agreement Terms Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CompensatoryDamagesAndOperational" xlink:type="locator" xlink:label="pstv_CompensatoryDamagesAndOperational" />
    <link:label xml:lang="en-US" xlink:label="pstv_CompensatoryDamagesAndOperational_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Compensatory damages and operational.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CompensatoryDamagesAndOperational" xlink:to="pstv_CompensatoryDamagesAndOperational_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_CompensatoryDamagesAndOperational_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensatory damages and operational</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CompensatoryDamagesAndOperational_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensatory Damages And Operational</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement, expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:type="locator" xlink:label="pstv_NanoTxLicensesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_NanoTxLicensesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nano Tx license agreement Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_NanoTxLicensesAgreementMember" xlink:to="pstv_NanoTxLicensesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_NanoTxLicensesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NanoTx License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NanoTxLicensesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nano Tx Licenses Agreement [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreferredStockDividendRatePercentageEliminatedDate" xlink:type="locator" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate" />
    <link:label xml:lang="en-US" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock dividend rate percentage eliminated date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PreferredStockDividendRatePercentageEliminatedDate" xlink:to="pstv_PreferredStockDividendRatePercentageEliminatedDate_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SeriesAConvertiblePreferredStockMember" xlink:to="pstv_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SeriesBConvertiblePreferredStockMember" xlink:to="pstv_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SeriesCConvertiblePreferredStockMember" xlink:to="pstv_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:type="locator" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen rights offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_TwoThousandEighteenRightsOfferingMember" xlink:to="pstv_TwoThousandEighteenRightsOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Rights Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Rights Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A 3.6% Convertible preferred stock eliminated date</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage Eliminated Date</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:type="locator" xlink:label="pstv_NumberOfPreferredStockSharesExercised" />
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfPreferredStockSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Preferred Stock Shares Exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_NumberOfPreferredStockSharesExercised" xlink:to="pstv_NumberOfPreferredStockSharesExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfPreferredStockSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock, shares converted</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfPreferredStockSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Shares Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:type="locator" xlink:label="pstv_RepresentativeSeriesUWarrantMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_RepresentativeSeriesUWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Representative Series U Warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_RepresentativeSeriesUWarrantMember" xlink:to="pstv_RepresentativeSeriesUWarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_RepresentativeSeriesUWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Representative Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_RepresentativeSeriesUWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Representative Series U Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities called by warrant or right</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Term</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="pstv_NumberOfWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_NumberOfWarrantsExercised" xlink:to="pstv_NumberOfWarrantsExercised_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:type="locator" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance" />
    <link:label xml:lang="en-US" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Refers to the period exercisable from the date of issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PeriodExercisableFromTheDateOfIssuance" xlink:to="pstv_PeriodExercisableFromTheDateOfIssuance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:type="locator" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_TwentyTwentyPurchaseAgreementMember" xlink:to="pstv_TwentyTwentyPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:type="locator" xlink:label="pstv_LincolnParkCapitalFundLLCMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_LincolnParkCapitalFundLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln park capital fund, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_LincolnParkCapitalFundLLCMember" xlink:to="pstv_LincolnParkCapitalFundLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_LincolnParkCapitalFundLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park Capital Fund, LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_LincolnParkCapitalFundLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Capital Fund L L C [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommitmentFeeMember" xlink:type="locator" xlink:label="pstv_CommitmentFeeMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_CommitmentFeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CommitmentFeeMember" xlink:to="pstv_CommitmentFeeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_CommitmentFeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment Fee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CommitmentFeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Fee [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="pstv_CanaccordGenuityLLCMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_CanaccordGenuityLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canaccord Genuity LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CanaccordGenuityLLCMember" xlink:to="pstv_CanaccordGenuityLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_CanaccordGenuityLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Canaccord Genuity L L C [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="pstv_AtTheMarketOfferingProgramMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_AtTheMarketOfferingProgramMember" xlink:to="pstv_AtTheMarketOfferingProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Program [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SalesAgreementMember" xlink:type="locator" xlink:label="pstv_SalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_SalesAgreementMember" xlink:to="pstv_SalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandTwentyTwoDistributionAgreementMember" xlink:type="locator" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two distribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_TwoThousandTwentyTwoDistributionAgreementMember" xlink:to="pstv_TwoThousandTwentyTwoDistributionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Distribution Agreement [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DistributionAgreementMember" xlink:type="locator" xlink:label="pstv_DistributionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_DistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Distribution agreement member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_DistributionAgreementMember" xlink:to="pstv_DistributionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_DistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_DistributionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period exercisable from the date of issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Exercisable From The Date Of Issuance</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:type="locator" xlink:label="pstv_PercentageIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="pstv_PercentageIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage issuance of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_PercentageIssuanceOfCommonStock" xlink:to="pstv_PercentageIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_PercentageIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_PercentageIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining common stock issued and sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:type="locator" xlink:label="pstv_CommonStockSalesAvailableForIssuance" />
    <link:label xml:lang="en-US" xlink:label="pstv_CommonStockSalesAvailableForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, sales, available for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_CommonStockSalesAvailableForIssuance" xlink:to="pstv_CommonStockSalesAvailableForIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_CommonStockSalesAvailableForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining availability under financing facility</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_CommonStockSalesAvailableForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Available For Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation 2015 equity incentive plan 1 member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:to="pstv_StockBasedCompensation2015EquityIncentivePlan1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation2015 Equity Incentive Plan1</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation2015 Equity Incentive Plan1 [Member]</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation 2020 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:to="pstv_StockBasedCompensation2020EquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation2020 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Securities remaining and available for future issuances (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased in the total number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares to be issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance as of December 31, 2021 (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled/forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2022 (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2022 (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance as of December 31, 2021 (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled/forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2022 (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2022 (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (years) [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" xlink:type="locator" xlink:label="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" />
    <link:label xml:lang="en-US" xlink:label="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options aggregate intrinsic value roll forward1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" xlink:to="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1_lbl" />
    <link:label xml:lang="en-US" xlink:label="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:label="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Roll Forward1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average period for recognition of cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>pstv-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-04-20T21:51:58.3428332+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : d034382d977544198a70e82463353b3e -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/role/TemplateLink" xlink:href="pstv-20220331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDBALANCESHEETSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:type="locator" xlink:label="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExercise" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:href="pstv-20220331.xsd#Role_StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UnpaidOfferingCosts" xlink:type="locator" xlink:label="pstv_UnpaidOfferingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidDuringPeriodForAbstract" xlink:type="locator" xlink:label="pstv_CashPaidDuringPeriodForAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ProceedsFromWarrantExercises1" xlink:type="locator" xlink:label="pstv_ProceedsFromWarrantExercises1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:type="locator" xlink:label="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NonCashLeaseExpense" xlink:type="locator" xlink:label="pstv_NonCashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pstv_NonCashLeaseExpense" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pstv_ProceedsFromWarrantExercises1" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="pstv_CashPaidDuringPeriodForAbstract" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaidNet" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pstv_UnpaidOfferingCosts" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards" xlink:href="pstv-20220331.xsd#Role_DisclosureBasisOfPresentationAndNewAccountingStandards" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates" xlink:href="pstv-20220331.xsd#Role_DisclosureUseOfEstimates" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UseOfEstimatesTextBlock" xlink:type="locator" xlink:label="pstv_UseOfEstimatesTextBlock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_UseOfEstimatesAbstract" xlink:type="locator" xlink:label="pstv_UseOfEstimatesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_UseOfEstimatesAbstract" xlink:to="pstv_UseOfEstimatesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity" xlink:href="pstv-20220331.xsd#Role_DisclosureLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DisclosureOfLiquidityTextBlock" xlink:type="locator" xlink:label="pstv_DisclosureOfLiquidityTextBlock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LiquidityAbstract" xlink:type="locator" xlink:label="pstv_LiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LiquidityAbstract" xlink:to="pstv_DisclosureOfLiquidityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="pstv-20220331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations" xlink:href="pstv-20220331.xsd#Role_DisclosureTermLoanObligations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare" xlink:href="pstv-20220331.xsd#Role_DisclosureLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement" xlink:href="pstv-20220331.xsd#Role_DisclosureLicenseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="pstv_LicenseAgreementDisclosureTextBlock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LicenseAgreementAbstract" xlink:type="locator" xlink:label="pstv_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LicenseAgreementAbstract" xlink:to="pstv_LicenseAgreementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="pstv-20220331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" xlink:href="pstv-20220331.xsd#Role_DisclosureCOVID19PandemicAndCARESAct" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" xlink:href="pstv-20220331.xsd#Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables" xlink:href="pstv-20220331.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="pstv-20220331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureLiquidityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LiquidityAbstract" xlink:type="locator" xlink:label="pstv_LiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LiquidityAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LiquidityAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" xlink:type="locator" xlink:label="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesUWarrantsMember" xlink:type="locator" xlink:label="pstv_SeriesUWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureTermLoanObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:type="locator" xlink:label="pstv_LongTermDebtOutstandingThresholdAmount" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentAmendmentFee" xlink:type="locator" xlink:label="pstv_DebtInstrumentAmendmentFee" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RelatedFinalPayment" xlink:type="locator" xlink:label="pstv_RelatedFinalPayment" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PrepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="pstv_PrepaymentsOfLongTermDebt" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:type="locator" xlink:label="pstv_DebtPrincipalRepaymentStartDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:type="locator" xlink:label="pstv_MinimumLiquidityCovenantAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLoans" xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ClassOfWarrantOrRightExpirationDate" xlink:type="locator" xlink:label="pstv_ClassOfWarrantOrRightExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:type="locator" xlink:label="pstv_DebtInstrumentFloatingInterestRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentOfferingDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:type="locator" xlink:label="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:type="locator" xlink:label="pstv_LoanAndSecurityAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFloorMember" xlink:type="locator" xlink:label="us-gaap_InterestRateFloorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TermLoanMember" xlink:type="locator" xlink:label="pstv_TermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pstv_TermLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_InterestRateFloorMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pstv_LoanAndSecurityAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentOfferingDate1" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtInstrumentFloatingInterestRatePercentage" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_ClassOfWarrantOrRightExpirationDate" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForLoans" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_MinimumLiquidityCovenantAmount" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtPrincipalRepaymentStartDate" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_PrepaymentsOfLongTermDebt" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_RelatedFinalPayment" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_DebtInstrumentAmendmentFee" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pstv_LongTermDebtOutstandingThresholdAmount" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OptionsMember" xlink:type="locator" xlink:label="pstv_OptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_OptionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementExpense" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CompensatoryDamagesAndOperational" xlink:type="locator" xlink:label="pstv_CompensatoryDamagesAndOperational" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementTermsDescription" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementInitialTerm" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MasterServicesAgreementDate" xlink:type="locator" xlink:label="pstv_MasterServicesAgreementDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ContingentManagedServicesFee" xlink:type="locator" xlink:label="pstv_ContingentManagedServicesFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeePayable" xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StatementOfWorkTerm" xlink:type="locator" xlink:label="pstv_StatementOfWorkTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LeaseCommencementDate" xlink:type="locator" xlink:label="pstv_LeaseCommencementDate" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AnnualIncreaseInLeaseRate" xlink:type="locator" xlink:label="pstv_AnnualIncreaseInLeaseRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_OperatingLeasesExpiryYear" xlink:type="locator" xlink:label="pstv_OperatingLeasesExpiryYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LoremVascularPteLtdMember" xlink:type="locator" xlink:label="pstv_LoremVascularPteLtdMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:type="locator" xlink:label="pstv_PreClinicalResearchStudyObligationsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:type="locator" xlink:label="pstv_PiramalPharmaSolutionsIncMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ServicesAgreementMember" xlink:type="locator" xlink:label="pstv_ServicesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_MedidataSolutionsIncMember" xlink:type="locator" xlink:label="pstv_MedidataSolutionsIncMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CharlottesvilleMember" xlink:type="locator" xlink:label="pstv_CharlottesvilleMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_CharlottesvilleMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_MedidataSolutionsIncMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pstv_ServicesAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pstv_PiramalPharmaSolutionsIncMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="pstv_PreClinicalResearchStudyObligationsMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="srt_LitigationCaseAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="pstv_LoremVascularPteLtdMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_OperatingLeasesExpiryYear" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_AnnualIncreaseInLeaseRate" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_LeaseCommencementDate" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_StatementOfWorkTerm" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_ManagementFeePayable" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_ContingentManagedServicesFee" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementDate" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementInitialTerm" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_MasterServicesAgreementTermsDescription" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_ContractualObligation" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="pstv_CompensatoryDamagesAndOperational" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CashPaymentInformationAbstract" xlink:type="locator" xlink:label="pstv_CashPaymentInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_FinanceLeaseExpenseAbstract" xlink:type="locator" xlink:label="pstv_FinanceLeaseExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="pstv_FinanceLeaseExpenseAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_FinanceLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pstv_CashPaymentInformationAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_CashPaymentInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_CashPaymentInformationAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_CashPaymentInformationAbstract" xlink:to="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="locator" xlink:label="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:type="locator" xlink:label="pstv_NanoTxLicensesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LicenseAgreementAbstract" xlink:type="locator" xlink:label="pstv_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pstv_LicenseAgreementAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pstv_NanoTxLicensesAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityPreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:type="locator" xlink:label="pstv_NumberOfPreferredStockSharesExercised" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PreferredStockDividendRatePercentageEliminatedDate" xlink:type="locator" xlink:label="pstv_PreferredStockDividendRatePercentageEliminatedDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:type="locator" xlink:label="pstv_TwoThousandEighteenRightsOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pstv_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesBConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_SeriesCConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pstv_TwoThousandEighteenRightsOfferingMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PreferredStockDividendRatePercentageEliminatedDate" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_NumberOfPreferredStockSharesExercised" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityWarrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="pstv_NumberOfWarrantsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:type="locator" xlink:label="pstv_RepresentativeSeriesUWarrantMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SeriesUWarrantsMember" xlink:type="locator" xlink:label="pstv_SeriesUWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pstv_RepresentativeSeriesUWarrantMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pstv_SeriesUWarrantsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_NumberOfWarrantsExercised" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockholdersEquityCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:type="locator" xlink:label="pstv_CommonStockSalesAvailableForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:type="locator" xlink:label="pstv_PercentageIssuanceOfCommonStock" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:type="locator" xlink:label="pstv_PeriodExercisableFromTheDateOfIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_DistributionAgreementMember" xlink:type="locator" xlink:label="pstv_DistributionAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwoThousandTwentyTwoDistributionAgreementMember" xlink:type="locator" xlink:label="pstv_TwoThousandTwentyTwoDistributionAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_SalesAgreementMember" xlink:type="locator" xlink:label="pstv_SalesAgreementMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="pstv_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="pstv_CanaccordGenuityLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_CommitmentFeeMember" xlink:type="locator" xlink:label="pstv_CommitmentFeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:type="locator" xlink:label="pstv_LincolnParkCapitalFundLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:type="locator" xlink:label="pstv_TwentyTwentyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_TwentyTwentyPurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pstv_LincolnParkCapitalFundLLCMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pstv_CommitmentFeeMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pstv_CanaccordGenuityLLCMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pstv_AtTheMarketOfferingProgramMember" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_SalesAgreementMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_TwoThousandTwentyTwoDistributionAgreementMember" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="pstv_DistributionAgreementMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PeriodExercisableFromTheDateOfIssuance" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_PercentageIssuanceOfCommonStock" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pstv_CommonStockSalesAvailableForIssuance" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2020EquityIncentivePlanMember" />
    <link:loc xlink:href="pstv-20220331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:type="locator" xlink:label="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pstv_StockBasedCompensation2020EquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:href="pstv-20220331.xsd#Role_DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:href="pstv-20220331.xsd#pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" xlink:type="locator" xlink:label="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765587784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,197,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 MARATHON BLVD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">AUSTIN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787766897208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,239<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">19,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-use-of assets</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,516<span></span>
</td>
<td class="nump">21,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan obligation, current</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan obligation</a></td>
<td class="nump">4,718<span></span>
</td>
<td class="nump">5,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,874<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at March 31, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 22,197,635 and 15,510,025 issued and outstanding at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">465,646<span></span>
</td>
<td class="nump">457,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(451,026)<span></span>
</td>
<td class="num">(446,910)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">14,642<span></span>
</td>
<td class="nump">10,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 24,516<span></span>
</td>
<td class="nump">$ 21,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765557000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">22,197,635<span></span>
</td>
<td class="nump">15,510,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">22,197,635<span></span>
</td>
<td class="nump">15,510,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765482472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(3,926)<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of liability instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,116)<span></span>
</td>
<td class="num">$ (2,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders</a></td>
<td class="nump">21,507,061<span></span>
</td>
<td class="nump">8,267,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765935224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 436,535<span></span>
</td>
<td class="num">$ (433,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">6,749,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="nump">7,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,534,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series B Convertible Preferred Stock into common stock (share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_StockIssuedDuringPeriodSharesWarrantsExercise', window );">Issuance of common stock for exercise of warrants</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares', window );">Issuance of common stock for exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,720)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">9,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">445,734<span></span>
</td>
<td class="num">(436,231)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">10,180,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">436,535<span></span>
</td>
<td class="num">(433,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">6,749,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">10,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">457,730<span></span>
</td>
<td class="num">(446,910)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">15,510,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">7,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,687,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 14,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 465,646<span></span>
</td>
<td class="num">$ (451,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">22,197,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_StockIssuedDuringPeriodSharesWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_StockIssuedDuringPeriodSharesWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercise(shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765389416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,116)<span></span>
</td>
<td class="num">$ (2,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and debt discount</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of liability instruments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increases (decreases) in cash caused by changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">459<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,876)<span></span>
</td>
<td class="num">(3,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition', window );">In process research and development acquired</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(577)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of financing lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_ProceedsFromWarrantExercises1', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">7,694<span></span>
</td>
<td class="nump">7,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,292<span></span>
</td>
<td class="nump">9,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">18,400<span></span>
</td>
<td class="nump">8,346<span></span>
</td>
<td class="nump">$ 8,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">21,239<span></span>
</td>
<td class="nump">14,447<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_UnpaidOfferingCosts', window );">Unpaid offering cost</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid during period for:</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for IPRD asset acquired in an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ProceedsFromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ProceedsFromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid Offering Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767932136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Standards</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"/><span style="font-size:10pt;">Basis of Presentation and New Accounting Standards</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited&#160;&#160;condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;The condensed balance sheet at December 31, 2021 has been derived from the audited financial statements at December 31, 2021, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc., and its subsidiaries (collectively, the &#8220;Company&#8221;) have been included.&#160;&#160;Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&#160;These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the one-time determination date. Early adoption is permitted beginning in 2019. The Company plans to adopt the new guidance on January 1, 2023, and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787768008072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_UseOfEstimatesAbstract', window );"><strong>Use Of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_UseOfEstimatesTextBlock', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"/><span style="font-size:10pt;">Use of Estimates</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160; <span style="Background-color:#FFFFFF;">The Company&#8217;s most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring stock-based compensation expense. </span>&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual results could differ from these estimates.&#160;Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UseOfEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Use of Estimates [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UseOfEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UseOfEstimatesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UseOfEstimatesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787768035752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_DisclosureOfLiquidityTextBlock', window );">Liquidity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"/><span style="font-size:10pt;">Liquidity</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net losses of $4.1 million for the three months ended March 31, 2022.&#160;&#160;The Company had an accumulated deficit of $451.0 million as of March 31, 2022.&#160; Additionally, the Company used net cash of $3.9 million to fund its operating activities for the three months ended March 31, 2022.<span style="font-weight:bold;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in more detail in Note 9, the Company had entered into various financing agreements, and raised capital by issuing its common stock. <span style="Background-color:#FFFFFF;">The Company believes its current cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued. </span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to seek additional capital through strategic transactions and from other financing alternatives. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DisclosureOfLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DisclosureOfLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787770202648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair<span style="font-weight:normal;"> </span>Value Measurements<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements are market-based measurements, not entity-specific measurements.&#160;&#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&#160;&#160;The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&#160;&#160;The basis for fair value measurements for each level within the hierarchy is described below:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain w<span style="color:#000000;">arrants issued in an underwritten public offering&#160;in September 2019 (&#8220;Series U Warrants&#8221;) are classified as liability instruments.&#160;The Company estimated the fair value of the Series U Warrants with the Black Scholes model. Because some of the inputs to the Company&#8217;s valuation model are either not observable or are not&#160;derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series U Warrants will be<span style="color:#000000;"> </span>marked to market as of each balance sheet date until they are exercised or upon expiration, with the changes in fair value recorded as non-operating income or loss in the statements of operations. As of March 31, 2022, the fair value of the Series U Warrants was immaterial, a<span style="color:#000000;">nd the change in the fair value of liability classified Series U Warrants during the three months ended March 31, 2022 and 2021 was not material. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767975224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Obligations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Term Loan Obligations</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 29, 2015,&#160;the Company&#160;entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of $17.7 million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%.&#160;&#160;Pursuant to the Loan and Security Agreement, as amended, the Company is required to make interest only payments through May 1, 2021 and thereafter it is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2 million. In connection with the Term Loan, on May 29, 2015, the Company issued to Oxford warrants to purchase an aggregate of 188 shares of the Company&#8217;s common stock at an exercise price of $5,175 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From September 2017 to March 2019, the Company entered into a total of seven amendments to the Term Loan which, amongst other things, extended the interest only period, required repayment of $3.1 million using the proceeds received from sale of the Company&#8217;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, and increased the minimum liquidity covenant level to $2.0 million. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2020, the Company entered into the Ninth Amendment of the Loan and Security Agreement (the &#8220;Ninth Amendment&#8221;), pursuant to which Oxford agreed to defer the start date of principal repayment from&#160;May 1, 2020&#160;to&#160;May 1, 2021&#160;and extended the term of the Term Loan from&#160;September 1, 2021&#160;to&#160;June 1, 2024.&#160;<span style="color:#000000;">The principal repayment start date was further deferred to November 1, 2021.</span> In addition, pursuant to the Ninth Amendment, on April 1, 2020, the Company made a $5.0&#160;million&#160;paydown&#160;of principal upon execution of the Ninth Amendment and $0.3&#160;million of related final payment.&#160;In addition, an amendment fee of&#160;$1.0&#160;million will be payable in connection with the Ninth Amendment at the earlier of the maturity date, acceleration of the loans and the making of certain prepayments. All other major terms remained consistent.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under authoritative guidance, the Ninth Amendment does not meet the criteria to be accounted for as a troubled debt restructuring. In addition, the Company performed a quantitative analysis and determined that the terms of the new debt and original debt instrument are not substantially different. Accordingly, the Ninth Amendment is accounted for as debt modification. A new effective interest rate that equates the revised cash flows to the carrying amount of the original debt is computed and applied prospectively.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. &#160;The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3 million.&#160;As of March 31, 2022, there was $3.6 million principal amount outstanding under the Term Loan, excluding the $3.2 million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s interest expense for each of the three months ended March 31, 2022&#160;and 2021&#160;was<span style="color:#000000;">&#160;</span>$0.2 million. Interest expense is calculated using the effective interest method; therefore it is inclusive of non-cash amortization in the amount of<span style="color:#000000;">&#160;</span>$0.1 million for each of the three months ended March 31, 2022&#160;and 2021, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of March 31, 2022, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767992760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;font-weight:normal;"/><span style="font-weight:normal;"/><span style="font-size:10pt;">Loss per Share</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following were excluded from the <span style="color:#000000;">diluted</span> loss per share calculation for the periods presented because their effect would be anti-dilutive:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,867</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,867</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141,378</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141,378</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,735,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,255,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767948920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"/><span style="font-size:10pt;">Commitments and Contingencies </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. <span style="Background-color:#FFFFFF;">Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options.&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for finance leases are recorded within property and equipment, net in the condensed balance sheets. Leases with an initial term of 12 months or less are not recorded on the condensed balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the condensed statements of operations. <span style="color:#000000;">&#160;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement. On March 1, 2021, the Company entered into a lease agreement for office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). <span style="Background-color:#FFFFFF;">The Charlottesville Lease has a term of 12 months and is renewable for four additional <span style="-sec-ix-hidden:F_000269">one-year</span> periods.</span> The minimum lease payment is $30,000 for the first twelve months, subject to a 3% annual increase if and when the lease is renewed. The lease commencement date is April 1, 2021 and currently expires on March 31, 2023. The Company measured the operating lease right-of-use asset and related lease liability related to the Charlottesville Lease as of the lease commencement date.  In addition, the Company has entered into leases for certain equipment under various operating and finance leases. During 2021, contractual terms of all finance leases had expired and the Company did not have any right-of-use assets or lease liabilities relating to finance leases as of March 31, 2022. The Company&#8217;s existing operating lease agreements&#160;generally provide for periodic rent increases, and renewal and termination options. The Company&#8217;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants.</p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate non-lease components from lease components.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operating lease liabilities and corresponding right-of-use assets are included in the condensed balance sheets. As of March 31, 2022, weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were 9.0% and 2.82%, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s lease costs from its unaudited  condensed statement of operations, and cash payments from its unaudited  condensed statement of cash flows during the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation of right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.68%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payment information:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash used for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Financing cash used for finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total rent expenses for the three months ended March 31, 2022 and 2021 were $60,000 and $50,000, respectively, which includes leases in the table above, month-to-month operating leases, and common area maintenance charges.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future minimum annual lease payments under operating leases at March 31, 2022 are as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of obligations under leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Services Agreement and Statement of Work with Medidata</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2022, the&#160;&#160;Company and Medidata Solutions, Inc. (&#8220;Medidata&#8221;) entered into a Statement of Work (the &#8220;SOW&#8221;), pursuant to which Medidata will build a Sythetic Control Arm<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;(SCA) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of Rhenium-186 NanoLiposome (<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL) in recurrent glioblastoma (&#8220;GBM&#8221;).&#160;&#160;<span style="Background-color:#FFFFFF;">The SOW is governed under the terms of a services agreement (the &#8220;Services Agreement&#8221;), dated November 5, 2021.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SOW has a term of six (6) months.&#160;&#160;The Company will pay Medidata $1.45 million in managed services fees and a contingent managed services fee of $150,000 if the U.S. Food &amp; Drug Administration approves a path forward for the Company to use the SCA in its clinical trial of&#160;<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">186</sup></span>RNL for treatment of GBM.&#160;&#160;The SOW may only be terminated for a material breach by either party or if the clinical study&#8217;s authorization or approval is withdrawn by a regulatory agency.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Piramal Master Services Agreement</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="Background-color:#FFFFFF;color:#000000;">n </span><span style="color:#000000;">January</span><span style="Background-color:#FFFFFF;color:#000000;"> 8, 2021</span>, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. </p>

<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">(&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s RNL-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company</span><span style="Background-color:#FFFFFF;color:#000000;">, which has been initiated </span><span style="color:#000000;">at&#160;Piramal&#8217;s&#160;facility located in Lexington, Kentucky.&#160;</span><span style="color:#000000;"> </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA.&#160;&#160;The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.&#160;&#160;Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other commitments and contingencies</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has <span style="color:#000000;">entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of </span>March 31, 2022<span style="color:#000000;">, the Company did not have any clinical research study obligations.</span> &#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 22, 2021, the Company was named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (&#8220;Lorem&#8221;) in the District Court for the District of Delaware. The complaint alleges false representations were made to Lorem regarding the manufacturing facility in the United Kingdom (the &#8220;UK Facility&#8221;) that Lorem purchased from the Company under the Asset and Equity Purchase Agreement, dated March 29, 2019, between the Company and Lorem (the &#8220;Lorem Agreement&#8221;). Lorem also claims that false representations were made regarding the UK Facility&#8217;s certification to sell and distribute devices in the European Union and export such devices to China. In connection with these allegations, Lorem claims entitlement to at least $6,000,000 in compensatory damages and operational costs and expenses (collectively, the &#8220;Lorem Claim&#8221;). The Company believes that the Lorem Claim is without merit and is vigorously defending the case. No liability was accrued as of March 31, 2022.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various claims and contingencies related to legal proceedings.&#160;&#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&#160;&#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767949480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LicenseAgreementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>License Agreements<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UT Health Science Center at San Antonio (&#8220;UTHSA&#8221;) License Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2021, the Company entered into a Patent and Know-How License Agreement (the &#8220;UTHSA License Agreement&#8221;) with The University of Texas Health Science Center at San Antonio, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as in-process research and development acquired in the condensed statement of operations for the year ended December 31, 2021. The upfront payment was paid in cash in January 2022.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NanoTx License Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2020, the Company and&#160;NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and Know-How License Agreement (the &#8220;NanoTx License Agreement&#8221;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and&#160;to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On May 7, 2020, all closing conditions under the NanoTx License Agreement were satisfied and the Company paid an upfront cash payment and issued 230,769 shares of its common stock to NanoTx. Cash and the fair value of common stock issued is recorded as in-process research and development expenses, pursuant to authoritative literature for asset acquisition, in the statement of operations and comprehensive loss for the year ended December 31, 2020.&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787770233464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company&#8217;s Board of Directors is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. &#160;On September 21, 2021, Series A 3.6% Convertible Preferred Stock was eliminated. There were no shares of Series A 3.6% Convertible Preferred Stock immediately prior to September 21, 2021, or December 31, 2020. There were 1,014 shares of Series B Convertible Preferred Stock outstanding as of March 31, 2022 and December 31, 2021. There were 938 shares of Series C Preferred Stock outstanding as of March 31, 2022 and December 31, 2021.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 416,889 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 5,978 shares of common stock.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2019, the Company completed an underwritten public offering. The Company issued 289,000 shares of its common stock, along with pre-funded warrants to purchase 2,711,000 shares of its common stock and Series U Warrants to purchase 3,450,000 shares of its common stock at $5.00 per share. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright &amp; Co., LLC, as representatives of the underwriters, to purchase 75,000 shares of its common stock at $6.25 per share with a term of 5 years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;).&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with authoritative guidance, the pre-funded warrants are classified as equity. The Series U Warrants and the Representative Warrants were initially classified at issuance as liabilities due to a contingent obligation for the Company to settle the Series U Warrants with cash upon certain change in control events. In 2020, all but 2,500 Series U Warrants were amended and met the requirements to be classified within stockholder&#8217;s equity. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, there were 2,141,000 outstanding Series U Warrants which can be exercised into an aggregate of 2,141,000 shares of common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Lincoln Park Purchase Agreement </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.66%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On September 30, 2020, the Company entered into the 2020 Purchase Agreement and registration rights </span>agreement<span style="Background-color:#FFFFFF;"> pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $25.0 million of the Company&#8217;s common stock. </span>Such sales of common stock by the Company were&#160;subject&#160;to certain limitations, and could occur from time to time, at the Company&#8217;s sole discretion, over the&#160;36-month&#160;period commencing on&#160;November 6, 2020, subject to the satisfaction of certain conditions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On June 16, 2020, the Company received stockholder approval to permit issuances of the Company&#8217;s common stock (including the issuance of more than 19.99% of the Company&#8217;s common stock) to Lincoln Park pursuant to the 2020 Purchase Agreement.&#160;&#160;Based on the closing price of the Company&#8217;s common stock of $1.05 per share on March 16, 2020, the maximum number of shares the Company could issue and sell under the 2020 Purchase Agreement is approximately 23.8 million shares.&#160;&#160;Accordingly, the Company requested and received stockholder approval for the issuance of up to 23.8 million shares of the Company&#8217;s common stock under the 2020 Purchase Agreement. The Company would seek additional stockholder approval before issuing more than 23.8 million shares. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lincoln Park had no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual sales of shares of common stock to Lincoln Park under the 2020 Purchase Agreement depended on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2020 Purchase Agreement to the Company depended on the frequency and prices at which the Company sold shares of its stock to Lincoln Park.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company issued&#160;5,685,186&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $12.5&#160;million. During the three months ended March 31, 2022, the Company issued 5,665,000&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $7.0 million. The Company no longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement. </p>

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">At-the-market Issuances</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 14, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC ( &#8220;Canaccord&#8221;), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000 shares (the &#8220;Shares&#8221;), with Canaccord acting as an agent for sales. Canaccord will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf. The Company has no obligation to sell any of the Shares. The Company may instruct Canaccord not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the 2022 Distribution Agreement. During the three months ended March 31, 2022, the Company issued 1,022,610 shares under the 2022 Distribution Agreement for net proceeds of approximately $0.7 million. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On October&#160;23, 2020, the Company entered into an Equity Distribution Agreement (the &#8220;2020 Distribution Agreement&#8221;) with Canaccord. The Company had no obligation to sell any of the ATM Shares and it could instruct Canaccord not to sell the ATM Shares if the sales could not be effected at or above the price the Company designated from time to time and the Company could at any time suspend sales pursuant to the 2020 Distribution Agreement.&#160;&#160;</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company issued </span>2,179,193<span style="Background-color:#FFFFFF;"> shares under the 2020 Distribution Agreement for net proceeds of $6.3 million. The 2020 Distribution Agreement has been terminated. </span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767802024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2020, the Company amended the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;) to increase the total number of shares of common stock reserved for issuance under the plan by 250,000 shares.&#160;Awards may only be granted under the 2015 Plan to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company.<span style="Background-color:#FFFFFF;color:#000000;"> As of March 31, 2022, there were </span><span style="Background-color:#FFFFFF;">90,389</span><span style="Background-color:#FFFFFF;color:#000000;"> shares of common stock remaining and available for future issuances under the 2015 Plan. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 16, 2020, the stockholders of the Company approved the Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan.&#160;The 2020 Plan provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock. The 2020 Plan provides for the issuance of up to 550,000 shares of common stock, and the number of shares available for issuance will be increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan).&#160;<span style="Background-color:#FFFFFF;color:#000000;">On May 17, 2021, the stockholders of the Company approved an amendment and restatement to the 2020 Plan to increase the total number of shares of common stock reserved for issuance under the 2020 Plan by 1,000,000 shares. As of March 31, 2022, there were 640,212 shares remaining and available for future issuances under the 2020 Plan.</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, options issued under the 2020 Plan are subject to a <span style="-sec-ix-hidden:F_000358">two-year</span> or <span style="-sec-ix-hidden:F_000359">four-year</span> vesting schedule with 25% of the options vesting one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of activity for the three months ended March 31, 2022 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000372">9.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,706.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.65</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000373">8.75</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,217</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000374">8.47</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:16.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,117</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000375">8.73</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, the total compensation cost related to non-vested stock options not yet recognized for all the Company&#8217;s plans is approximately $1.3 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of <span><span style="color:#000000;">2.79</span> years</span>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767950600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19 Pandemic and CARES Act<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks And Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">COVID-19 Pandemic and CARES Act</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160; &#160;&#160;COVID-19 Pandemic and CARES Act<span style="font-size:12pt;font-weight:normal;"> </span></p>


<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (COVID-19) was declared a global pandemic by the World Health Organization in March 2020.&#160;&#160;COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. While the Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines, the Company has not experienced a significant impact on its business and operations.&#160;&#160;However, the Company may experience disruptions that could adversely impact its business operations as well as its preclinical studies and clinical trials. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at March 31, 2022. The full extent to which the COVID-19 pandemic will directly or indirectly impact its business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.86%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160;&#160;The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;&#160;The CARES Act had no material impact on the Company&#8217;s income tax provision for the year ended December 31, 2021 or the three months ended March 31, 2022.&#160;&#160;The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/></p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787771282264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and New Accounting Standards</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited&#160;&#160;condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;The condensed balance sheet at December 31, 2021 has been derived from the audited financial statements at December 31, 2021, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc., and its subsidiaries (collectively, the &#8220;Company&#8221;) have been included.&#160;&#160;Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&#160;These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the one-time determination date. Early adoption is permitted beginning in 2019. The Company plans to adopt the new guidance on January 1, 2023, and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160; <span style="Background-color:#FFFFFF;">The Company&#8217;s most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring stock-based compensation expense. </span>&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual results could differ from these estimates.&#160;Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787768012120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following were excluded from the <span style="color:#000000;">diluted</span> loss per share calculation for the periods presented because their effect would be anti-dilutive:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,867</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,867</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141,378</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141,378</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,735,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,255,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767902856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s lease costs from its unaudited  condensed statement of operations, and cash payments from its unaudited  condensed statement of cash flows during the three months ended March 31, 2022 and 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation of right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.68%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payment information:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash used for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Financing cash used for finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Annual Lease Payments under Operating Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future minimum annual lease payments under operating leases at March 31, 2022 are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of obligations under leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767998952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of activity for the three months ended March 31, 2022 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000372">9.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,706.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.65</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000373">8.75</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,217</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000374">8.47</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:16.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,117</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000375">8.73</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765560280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,116)<span></span>
</td>
<td class="num">$ (2,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(451,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (446,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (3,876)<span></span>
</td>
<td class="num">$ (3,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787767878392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember', window );">Series U Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod', window );">Warrants issued, underwritten public offering, period</a></td>
<td class="text">2019-09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued, underwritten public offering, period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787766414344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Mar. 28, 2020</div></th>
<th class="th"><div>May 29, 2015</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="nump">$ 247,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR [Member] | Interest Rate Floor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentOfferingDate1', window );">Origination Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Loan Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="text">Sep.  01,  2021<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fees amount associated with loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares callable by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date from which warrants are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_MinimumLiquidityCovenantAmount', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_DebtPrincipalRepaymentStartDate', window );">Debt principal repayment start date</a></td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">May  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_PrepaymentsOfLongTermDebt', window );">Prepayments of term loan</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_RelatedFinalPayment', window );">Related final payment</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_DebtInstrumentAmendmentFee', window );">Amendment fee</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt Instrument, Covenant Compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Loan and Security Agreement [Member] | Sale of the Japanese Subsidiary and Certain Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Payments for principal, interest and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_DebtInstrumentFloatingInterestRatePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Loan Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LongTermDebtOutstandingThresholdAmount', window );">Long Term Debt Outstanding Threshold Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date that the warrant or right expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtInstrumentAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amendment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtInstrumentAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtInstrumentFloatingInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Floating interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtInstrumentFloatingInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtPrincipalRepaymentStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt principal repayment start date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtPrincipalRepaymentStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LongTermDebtOutstandingThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt outstanding threshold amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LongTermDebtOutstandingThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MinimumLiquidityCovenantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity covenant amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MinimumLiquidityCovenantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PrepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments of long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PrepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_RelatedFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related final payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_RelatedFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentOfferingDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was offered for sale, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentOfferingDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateFloorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateFloorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pstv_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pstv_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pstv_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765541752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">3,735,118<span></span>
</td>
<td class="nump">3,255,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember', window );">Outstanding Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">1,170,873<span></span>
</td>
<td class="nump">691,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">422,867<span></span>
</td>
<td class="nump">422,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Outstanding Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">2,141,378<span></span>
</td>
<td class="nump">2,141,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787762054712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_OperatingLeasesExpiryYear', window );">Operating leases expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payment</a></td>
<td class="nump">$ 382,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining term</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember', window );">Lorem Vascular Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CompensatoryDamagesAndOperational', window );">Compensatory damages and operational</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember', window );">Pre-clinical Research Study Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember', window );">Pre-clinical Research Study Obligations [Member] | Lorem Vascular Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember', window );">Charlottesville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Charlottesville Lease has a term of 12 months and is renewable for four additional one-year periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_AnnualIncreaseInLeaseRate', window );">Annual increase in lease rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember', window );">Medidata Solutions, Inc. [Member] | Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_StatementOfWorkTerm', window );">Statement of work, term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Managed services fees payable</a></td>
<td class="nump">$ 1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_ContingentManagedServicesFee', window );">Contingent managed services fee</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember', window );">Piramal Pharma Solutions, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_MasterServicesAgreementDate', window );">Master service agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_MasterServicesAgreementInitialTerm', window );">Master services agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_MasterServicesAgreementTermsDescription', window );">Master services agreement terms, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA.&#160;&#160;The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AnnualIncreaseInLeaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in lease rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AnnualIncreaseInLeaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CompensatoryDamagesAndOperational">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensatory damages and operational.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CompensatoryDamagesAndOperational</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ContingentManagedServicesFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent managed services fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ContingentManagedServicesFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Master services agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Master services agreement initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Master services agreement Terms description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OperatingLeasesExpiryYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases, expiry year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OperatingLeasesExpiryYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_StatementOfWorkTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement of work, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_StatementOfWorkTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pstv_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pstv_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787766843480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_FinanceLeaseExpenseAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Depreciation of right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CashPaymentInformationAbstract', window );"><strong>Cash payment information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used for operating leases</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash used for finance leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Total cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaymentInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaymentInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_FinanceLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_FinanceLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787766849336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of obligations under leases</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">$ (111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765302408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreement - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">22,197,635<span></span>
</td>
<td class="nump">15,510,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember', window );">NanoTx License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787768242840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 21, 2021</div></th>
<th class="th"><div>Sep. 20, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_PreferredStockDividendRatePercentageEliminatedDate', window );">Series A 3.6% Convertible preferred stock eliminated date</a></td>
<td class="text">Sep. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_NumberOfPreferredStockSharesExercised', window );">Number of preferred stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_NumberOfPreferredStockSharesExercised', window );">Number of preferred stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfPreferredStockSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Preferred Stock Shares Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfPreferredStockSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PreferredStockDividendRatePercentageEliminatedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock dividend rate percentage eliminated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PreferredStockDividendRatePercentageEliminatedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_TwoThousandEighteenRightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_TwoThousandEighteenRightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787768176872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember', window );">Series U Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrant or right</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">6,687,610<span></span>
</td>
<td class="nump">2,534,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Outstanding Warrants [Member] | Series U Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant outstanding</a></td>
<td class="nump">2,141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">2,141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrant or right</a></td>
<td class="nump">2,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_SeriesUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787762580328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742,000<span></span>
</td>
<td class="nump">$ 7,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,694,000<span></span>
</td>
<td class="nump">7,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,687,610<span></span>
</td>
<td class="nump">2,534,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember', window );">2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,685,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_PeriodExercisableFromTheDateOfIssuance', window );">Period exercisable from the date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember', window );">2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Remaining common stock issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember', window );">2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_PercentageIssuanceOfCommonStock', window );">Percentage issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember', window );">2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_SalesAgreementMember', window );">Sales Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pstv_CommonStockSalesAvailableForIssuance', window );">Remaining availability under financing facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_SalesAgreementMember', window );">Sales Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | Maximum [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandTwentyTwoDistributionAgreementMember', window );">2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_DistributionAgreementMember', window );">2020 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,179,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CommonStockSalesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, sales, available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CommonStockSalesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PeriodExercisableFromTheDateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the period exercisable from the date of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PeriodExercisableFromTheDateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pstv_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pstv_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pstv_CanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pstv_CanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pstv_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pstv_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandTwentyTwoDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_TwoThousandTwentyTwoDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787766779656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member', window );">Stock Based Compensation2015 Equity Incentive Plan1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Securities remaining and available for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Increased in the total number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Securities remaining and available for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Increased in the total number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock shares to be issued (in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139787765360264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of December 31, 2021 (in shares)</a></td>
<td class="nump">1,170,873<span></span>
</td>
<td class="nump">1,170,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at March 31, 2022 (in shares)</a></td>
<td class="nump">460,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at March 31, 2022 (in shares)</a></td>
<td class="nump">1,102,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of December 31, 2021 (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">24,706.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at March 31, 2022 (in dollars per share)</a></td>
<td class="nump">8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at March 31, 2022 (in dollars per share)</a></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (years) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance as of December 31, 2021</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at March 31, 2022</a></td>
<td class="text">8 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at March 31, 2022</a></td>
<td class="text">8 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>pstv-10q_20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pstv="http://www.plustherapeutics.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pstv-20220331.xsd" xlink:type="simple"/>
    <context id="C_0001095981_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_20220414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2022-04-14</instant>
        </period>
    </context>
    <context id="C_0001095981_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-29</instant>
        </period>
    </context>
    <context id="C_0001095981_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-29</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateFloorMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20150528_20150529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_us-gaapDisposalGroupClassificationAxis_pstvSaleOfJapaneseSubsidiaryAndCertainAssetsMember_us-gaapFinancialInstrumentAxis_pstvLoanAndSecurityAgreementMember_20150528_20150529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">pstv:SaleOfJapaneseSubsidiaryAndCertainAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pstv:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-28</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220330_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_20210622_20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_pstvNanoTxLicensesAgreementMember_20200507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-07</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210919_20210920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-19</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210921_20210921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-21</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassBMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMinimumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-16</instant>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114_20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20200206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-06</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20200615_20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20210517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-17</instant>
        </period>
    </context>
    <context id="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001095981_srtRangeAxis_srtMinimumMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_srtRangeAxis_srtMaximumMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001095981_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_0001095981_20220101_20220331" id="F_000001">0001095981</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001095981_20220101_20220331" id="F_000002">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001095981_20220101_20220331" id="F_000008">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="C_0001095981_20220101_20220331" id="F_000010">false</dei:AmendmentFlag>
    <pstv:WarrantsIssuedUnderwrittenPublicOfferingPeriod
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331"
      id="F_000228">2019-09</pstv:WarrantsIssuedUnderwrittenPublicOfferingPeriod>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301"
      id="F_000267">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001095981_20220331" id="F_000275">P2Y9M25D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <pstv:StatementOfWorkTerm
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220330_20220331"
      id="F_000297">P6M</pstv:StatementOfWorkTerm>
    <pstv:PeriodExercisableFromTheDateOfIssuance
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930"
      id="F_000335">P36M</pstv:PeriodExercisableFromTheDateOfIssuance>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301"
      id="F_000269">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001095981_srtRangeAxis_srtMinimumMember_20220101_20220331"
      id="F_000358">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_20220101_20220331"
      id="F_000359">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001095981_20220331"
      id="F_000063"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001095981_20211231"
      id="F_000064"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001095981_20220331"
      id="F_000065"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001095981_20211231"
      id="F_000066"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001095981_20210101_20211231" id="F_000372">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001095981_20220101_20220331" id="F_000373">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001095981_20220101_20220331" id="F_000374">P8Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001095981_20220101_20220331" id="F_000375">P8Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001095981_20220101_20220331" id="F_000009">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001095981_20220101_20220331" id="F_000012">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001095981_20220101_20220331" id="F_000011">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001095981_20220101_20220331" id="F_000007">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001095981_20220101_20220331" id="F_000013">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001095981_20220101_20220331" id="F_000020">001-34375</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001095981_20220101_20220331" id="F_000000">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001095981_20220101_20220331" id="F_000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001095981_20220101_20220331" id="F_000022">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001095981_20220101_20220331" id="F_000023">4200 MARATHON BLVD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001095981_20220101_20220331" id="F_000024">SUITE 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001095981_20220101_20220331" id="F_000025">AUSTIN</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001095981_20220101_20220331" id="F_000026">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001095981_20220101_20220331" id="F_000027">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001095981_20220101_20220331" id="F_000028">737</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001095981_20220101_20220331" id="F_000029">255-7194</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001095981_20220101_20220331" id="F_000018">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001095981_20220101_20220331" id="F_000017">PSTV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001095981_20220101_20220331" id="F_000019">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001095981_20220101_20220331" id="F_000015">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001095981_20220101_20220331" id="F_000014">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001095981_20220101_20220331" id="F_000003">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001095981_20220101_20220331" id="F_000005">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001095981_20220101_20220331" id="F_000004">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001095981_20220101_20220331" id="F_000016">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001095981_20220414"
      decimals="INF"
      id="F_000006"
      unitRef="U_xbrlishares">22197635</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">21239000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">18400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">865000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">1324000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">22104000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">19724000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">1558000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">1477000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">316000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">341000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">372000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">372000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">150000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">51000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">16000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">16000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">24516000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">21981000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">3203000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">4151000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">110000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">111000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">1608000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">1608000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">4921000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">5870000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">269000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">4718000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">5005000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">1000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">9874000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">11145000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000077"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000078"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000085"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000086"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">22197635</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">22197635</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">15510025</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">15510025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">22000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">465646000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">457730000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">-451026000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">-446910000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">14642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">10836000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">24516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">21981000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">1785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">1127000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">2141000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">1352000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">3926000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">2479000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">-3926000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">-2479000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">7000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">4000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">198000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">247000</us-gaap:InterestExpense>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">1000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">2000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-241000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-4116000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-2720000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001095981_20220101_20220331"
      decimals="2"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001095981_20210101_20210331"
      decimals="2"
      id="F_000112"
      unitRef="U_iso4217USD_xbrlishares">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001095981_20220101_20220331"
      decimals="0"
      id="F_000113"
      unitRef="U_xbrlishares">21507061</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001095981_20210101_20210331"
      decimals="0"
      id="F_000114"
      unitRef="U_xbrlishares">8267901</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20201231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">1954</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">6749028</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">436535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-433511000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">3031000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">107000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">107000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000123"
      unitRef="U_xbrlishares">2534879</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">7076000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">7078000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331"
      decimals="INF"
      id="F_000127"
      unitRef="U_xbrlishares">-2</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000128"
      unitRef="U_xbrlishares">118</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <pstv:StockIssuedDuringPeriodSharesWarrantsExerciseShares
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000129"
      unitRef="U_xbrlishares">896500</pstv:StockIssuedDuringPeriodSharesWarrantsExerciseShares>
    <pstv:StockIssuedDuringPeriodSharesWarrantsExercise
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">1000</pstv:StockIssuedDuringPeriodSharesWarrantsExercise>
    <pstv:StockIssuedDuringPeriodSharesWarrantsExercise
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">2016000</pstv:StockIssuedDuringPeriodSharesWarrantsExercise>
    <pstv:StockIssuedDuringPeriodSharesWarrantsExercise
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">2017000</pstv:StockIssuedDuringPeriodSharesWarrantsExercise>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-2720000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-2720000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210331"
      decimals="INF"
      id="F_000135"
      unitRef="U_xbrlishares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000136"
      unitRef="U_xbrlishares">10180525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">445734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">-436231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20210331"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">9513000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000142"
      unitRef="U_xbrlishares">15510025</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">457730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">-446910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">10836000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000149"
      unitRef="U_xbrlishares">6687610</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">7736000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">7742000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-4116000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-4116000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220331"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">22197635</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">465646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-451026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">14642000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-4116000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-2720000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">88000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">115000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">151000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">-1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">180000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">107000</us-gaap:ShareBasedCompensation>
    <pstv:NonCashLeaseExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-10000</pstv:NonCashLeaseExpense>
    <pstv:NonCashLeaseExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">1000</pstv:NonCashLeaseExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-459000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">170000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-650000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-461000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-3876000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-3006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">210000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">84000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">117000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">250000</pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition>
    <pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">0</pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-577000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">402000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">6000</us-gaap:FinanceLeasePrincipalPayments>
    <pstv:ProceedsFromWarrantExercises1
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">0</pstv:ProceedsFromWarrantExercises1>
    <pstv:ProceedsFromWarrantExercises1
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">2017000</pstv:ProceedsFromWarrantExercises1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">7694000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">7180000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">7292000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">9191000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">2839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">6101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001095981_20211231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">18400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001095981_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">8346000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">21239000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001095981_20210331"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">14447000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">87000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">96000</us-gaap:InterestPaidNet>
    <pstv:UnpaidOfferingCosts
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">171000</pstv:UnpaidOfferingCosts>
    <pstv:UnpaidOfferingCosts
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">102000</pstv:UnpaidOfferingCosts>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000207">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="font-weight:normal;"/&gt;&lt;span style="font-size:10pt;"&gt;Basis of Presentation and New Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited&#160;&#160;condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;The condensed balance sheet at December 31, 2021 has been derived from the audited financial statements at December 31, 2021, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc., and its subsidiaries (collectively, the &#x201c;Company&#x201d;) have been included.&#160;&#160;Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&#160;These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the one-time determination date. Early adoption is permitted beginning in 2019. The Company plans to adopt the new guidance on January 1, 2023, and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000218">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited&#160;&#160;condensed financial statements as of March 31, 2022 and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;The condensed balance sheet at December 31, 2021 has been derived from the audited financial statements at December 31, 2021, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc., and its subsidiaries (collectively, the &#x201c;Company&#x201d;) have been included.&#160;&#160;Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&#160;These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000219">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the one-time determination date. Early adoption is permitted beginning in 2019. The Company plans to adopt the new guidance on January 1, 2023, and it does not expect that adoption of this standard will have a material impact on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <pstv:UseOfEstimatesTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000208">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="font-weight:normal;"/&gt;&lt;span style="font-size:10pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160; &lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring stock-based compensation expense. &lt;/span&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actual results could differ from these estimates.&#160;Management&#x2019;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary.&lt;/p&gt;</pstv:UseOfEstimatesTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001095981_20220101_20220331" id="F_000220">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160; &lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring stock-based compensation expense. &lt;/span&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actual results could differ from these estimates.&#160;Management&#x2019;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pstv:DisclosureOfLiquidityTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000209">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="font-weight:normal;"/&gt;&lt;span style="font-size:10pt;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred net losses of $4.1 million for the three months ended March 31, 2022.&#160;&#160;The Company had an accumulated deficit of $451.0 million as of March 31, 2022.&#160; Additionally, the Company used net cash of $3.9 million to fund its operating activities for the three months ended March 31, 2022.&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As disclosed in more detail in Note 9, the Company had entered into various financing agreements, and raised capital by issuing its common stock. &lt;span style="Background-color:#FFFFFF;"&gt;The Company believes its current cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued. &lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continues to seek additional capital through strategic transactions and from other financing alternatives. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</pstv:DisclosureOfLiquidityTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001095981_20220101_20220331"
      decimals="-5"
      id="F_000225"
      unitRef="U_iso4217USD">-4100000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001095981_20220331"
      decimals="-5"
      id="F_000226"
      unitRef="U_iso4217USD">-451000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-5"
      id="F_000227"
      unitRef="U_iso4217USD">-3900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000210">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;Value Measurements&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements are market-based measurements, not entity-specific measurements.&#160;&#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&#160;&#160;The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&#160;&#160;The basis for fair value measurements for each level within the hierarchy is described below:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain w&lt;span style="color:#000000;"&gt;arrants issued in an underwritten public offering&#160;in September 2019 (&#x201c;Series U Warrants&#x201d;) are classified as liability instruments.&#160;The Company estimated the fair value of the Series U Warrants with the Black Scholes model. Because some of the inputs to the Company&#x2019;s valuation model are either not observable or are not&#160;derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.58%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Series U Warrants will be&lt;span style="color:#000000;"&gt; &lt;/span&gt;marked to market as of each balance sheet date until they are exercised or upon expiration, with the changes in fair value recorded as non-operating income or loss in the statements of operations. As of March 31, 2022, the fair value of the Series U Warrants was immaterial, a&lt;span style="color:#000000;"&gt;nd the change in the fair value of liability classified Series U Warrants during the three months ended March 31, 2022 and 2021 was not material. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000211">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Term Loan Obligations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 29, 2015,&#160;the Company&#160;entered into the Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;), pursuant to which Oxford Finance, LLC (&#x201c;Oxford&#x201d;) funded an aggregate principal amount of $17.7 million (the &#x201c;Term Loan&#x201d;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%.&#160;&#160;Pursuant to the Loan and Security Agreement, as amended, the Company is required to make interest only payments through May 1, 2021 and thereafter it is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2 million. In connection with the Term Loan, on May 29, 2015, the Company issued to Oxford warrants to purchase an aggregate of 188 shares of the Company&#x2019;s common stock at an exercise price of $5,175 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From September 2017 to March 2019, the Company entered into a total of seven amendments to the Term Loan which, amongst other things, extended the interest only period, required repayment of $3.1 million using the proceeds received from sale of the Company&#x2019;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, and increased the minimum liquidity covenant level to $2.0 million. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 29, 2020, the Company entered into the Ninth Amendment of the Loan and Security Agreement (the &#x201c;Ninth Amendment&#x201d;), pursuant to which Oxford agreed to defer the start date of principal repayment from&#160;May 1, 2020&#160;to&#160;May 1, 2021&#160;and extended the term of the Term Loan from&#160;September 1, 2021&#160;to&#160;June 1, 2024.&#160;&lt;span style="color:#000000;"&gt;The principal repayment start date was further deferred to November 1, 2021.&lt;/span&gt; In addition, pursuant to the Ninth Amendment, on April 1, 2020, the Company made a $5.0&#160;million&#160;paydown&#160;of principal upon execution of the Ninth Amendment and $0.3&#160;million of related final payment.&#160;In addition, an amendment fee of&#160;$1.0&#160;million will be payable in connection with the Ninth Amendment at the earlier of the maturity date, acceleration of the loans and the making of certain prepayments. All other major terms remained consistent.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under authoritative guidance, the Ninth Amendment does not meet the criteria to be accounted for as a troubled debt restructuring. In addition, the Company performed a quantitative analysis and determined that the terms of the new debt and original debt instrument are not substantially different. Accordingly, the Ninth Amendment is accounted for as debt modification. A new effective interest rate that equates the revised cash flows to the carrying amount of the original debt is computed and applied prospectively.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#x2019;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. &#160;The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3 million.&#160;As of March 31, 2022, there was $3.6 million principal amount outstanding under the Term Loan, excluding the $3.2 million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s interest expense for each of the three months ended March 31, 2022&#160;and 2021&#160;was&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;$0.2 million. Interest expense is calculated using the effective interest method; therefore it is inclusive of non-cash amortization in the amount of&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;$0.1 million for each of the three months ended March 31, 2022&#160;and 2021, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#x2019;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#x2019;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#x2019;s financial condition. As of March 31, 2022, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentOfferingDate1
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331"
      id="F_000229">2015-05-29</us-gaap:DebtInstrumentOfferingDate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529"
      decimals="-5"
      id="F_000230"
      unitRef="U_iso4217USD">17700000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:DebtInstrumentFloatingInterestRatePercentage
      contextRef="C_0001095981_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529"
      decimals="INF"
      id="F_000231"
      unitRef="U_xbrlipure">0.0895</pstv:DebtInstrumentFloatingInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001095981_us-gaapDerivativeInstrumentRiskAxis_us-gaapInterestRateFloorMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20150528_20150529"
      decimals="4"
      id="F_000232"
      unitRef="U_xbrlipure">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529"
      decimals="4"
      id="F_000233"
      unitRef="U_xbrlipure">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150528_20150529"
      id="F_000234">2021-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529"
      decimals="-5"
      id="F_000235"
      unitRef="U_iso4217USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529"
      decimals="INF"
      id="F_000236"
      unitRef="U_xbrlishares">188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20150529"
      decimals="INF"
      id="F_000237"
      unitRef="U_iso4217USD_xbrlishares">5175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331"
      id="F_000238">2015-11-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <pstv:ClassOfWarrantOrRightExpirationDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331"
      id="F_000239">2025-05-29</pstv:ClassOfWarrantOrRightExpirationDate>
    <us-gaap:PaymentsForLoans
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_us-gaapDisposalGroupClassificationAxis_pstvSaleOfJapaneseSubsidiaryAndCertainAssetsMember_us-gaapFinancialInstrumentAxis_pstvLoanAndSecurityAgreementMember_20150528_20150529"
      decimals="-5"
      id="F_000240"
      unitRef="U_iso4217USD">3100000</us-gaap:PaymentsForLoans>
    <pstv:MinimumLiquidityCovenantAmount
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331"
      decimals="-5"
      id="F_000241"
      unitRef="U_iso4217USD">2000000.0</pstv:MinimumLiquidityCovenantAmount>
    <pstv:DebtPrincipalRepaymentStartDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328"
      id="F_000242">2020-05-01</pstv:DebtPrincipalRepaymentStartDate>
    <pstv:DebtPrincipalRepaymentStartDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329"
      id="F_000243">2021-05-01</pstv:DebtPrincipalRepaymentStartDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200327_20200328"
      id="F_000246">2021-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329"
      id="F_000247">2024-06-01</us-gaap:DebtInstrumentMaturityDate>
    <pstv:PrepaymentsOfLongTermDebt
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329"
      decimals="-5"
      id="F_000244"
      unitRef="U_iso4217USD">5000000.0</pstv:PrepaymentsOfLongTermDebt>
    <pstv:RelatedFinalPayment
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329"
      decimals="-5"
      id="F_000245"
      unitRef="U_iso4217USD">300000</pstv:RelatedFinalPayment>
    <pstv:DebtInstrumentAmendmentFee
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20200329_20200329"
      decimals="-5"
      id="F_000248"
      unitRef="U_iso4217USD">1000000.0</pstv:DebtInstrumentAmendmentFee>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331"
      decimals="INF"
      id="F_000251"
      unitRef="U_iso4217USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:LongTermDebtOutstandingThresholdAmount
      contextRef="C_0001095981_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331"
      decimals="-5"
      id="F_000249"
      unitRef="U_iso4217USD">3600000</pstv:LongTermDebtOutstandingThresholdAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220331"
      decimals="-5"
      id="F_000250"
      unitRef="U_iso4217USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="C_0001095981_us-gaapDebtInstrumentAxis_pstvTermLoanMember_20220101_20220331"
      id="F_000252">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:InterestExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="-5"
      id="F_000254"
      unitRef="U_iso4217USD">200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="-5"
      id="F_000253"
      unitRef="U_iso4217USD">200000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001095981_20210101_20210331"
      decimals="-5"
      id="F_000256"
      unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001095981_20220101_20220331"
      decimals="-5"
      id="F_000255"
      unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000212">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="font-size:10pt;font-weight:normal;"/&gt;&lt;span style="font-weight:normal;"/&gt;&lt;span style="font-size:10pt;"&gt;Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following were excluded from the &lt;span style="color:#000000;"&gt;diluted&lt;/span&gt; loss per share calculation for the periods presented because their effect would be anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;691,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;422,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;422,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,735,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,255,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000221">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following were excluded from the &lt;span style="color:#000000;"&gt;diluted&lt;/span&gt; loss per share calculation for the periods presented because their effect would be anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;691,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;422,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;422,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,735,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,255,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20220101_20220331"
      decimals="INF"
      id="F_000257"
      unitRef="U_xbrlishares">1170873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvOptionsMember_20210101_20210331"
      decimals="INF"
      id="F_000258"
      unitRef="U_xbrlishares">691263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20220101_20220331"
      decimals="INF"
      id="F_000259"
      unitRef="U_xbrlishares">422867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20210331"
      decimals="INF"
      id="F_000260"
      unitRef="U_xbrlishares">422867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331"
      decimals="INF"
      id="F_000261"
      unitRef="U_xbrlishares">2141378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20210101_20210331"
      decimals="INF"
      id="F_000262"
      unitRef="U_xbrlishares">2141378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_20220101_20220331"
      decimals="INF"
      id="F_000263"
      unitRef="U_xbrlishares">3735118</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001095981_20210101_20210331"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">3255508</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000213">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="font-weight:normal;"/&gt;&lt;span style="font-size:10pt;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.17%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. &lt;span style="Background-color:#FFFFFF;"&gt;Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for finance leases are recorded within property and equipment, net in the condensed balance sheets. Leases with an initial term of 12 months or less are not recorded on the condensed balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the condensed statements of operations. &lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement. On March 1, 2021, the Company entered into a lease agreement for office space in Charlottesville, Virginia (the &#x201c;Charlottesville Lease&#x201d;). &lt;span style="Background-color:#FFFFFF;"&gt;The Charlottesville Lease has a term of 12 months and is renewable for four additional &lt;span style="-sec-ix-hidden:F_000269"&gt;one-year&lt;/span&gt; periods.&lt;/span&gt; The minimum lease payment is $30,000 for the first twelve months, subject to a 3% annual increase if and when the lease is renewed. The lease commencement date is April 1, 2021 and currently expires on March 31, 2023. The Company measured the operating lease right-of-use asset and related lease liability related to the Charlottesville Lease as of the lease commencement date.  In addition, the Company has entered into leases for certain equipment under various operating and finance leases. During 2021, contractual terms of all finance leases had expired and the Company did not have any right-of-use assets or lease liabilities relating to finance leases as of March 31, 2022. The Company&#x2019;s existing operating lease agreements&#160;generally provide for periodic rent increases, and renewal and termination options. The Company&#x2019;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate non-lease components from lease components.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s operating lease liabilities and corresponding right-of-use assets are included in the condensed balance sheets. As of March 31, 2022, weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were 9.0% and 2.82%, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the Company&#x2019;s lease costs from its unaudited  condensed statement of operations, and cash payments from its unaudited  condensed statement of cash flows during the three months ended March 31, 2022 and 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation of right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.68%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash payment information:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash used for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Financing cash used for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total rent expenses for the three months ended March 31, 2022 and 2021 were $60,000 and $50,000, respectively, which includes leases in the table above, month-to-month operating leases, and common area maintenance charges.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future minimum annual lease payments under operating leases at March 31, 2022 are as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of obligations under leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Services Agreement and Statement of Work with Medidata&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 31, 2022, the&#160;&#160;Company and Medidata Solutions, Inc. (&#x201c;Medidata&#x201d;) entered into a Statement of Work (the &#x201c;SOW&#x201d;), pursuant to which Medidata will build a Sythetic Control Arm&lt;span style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;(SCA) platform that facilitates the use of historical clinical data to incorporate into the Company&#x2019;s Phase 2 clinical trial of Rhenium-186 NanoLiposome (&lt;span style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;186&lt;/sup&gt;&lt;/span&gt;RNL) in recurrent glioblastoma (&#x201c;GBM&#x201d;).&#160;&#160;&lt;span style="Background-color:#FFFFFF;"&gt;The SOW is governed under the terms of a services agreement (the &#x201c;Services Agreement&#x201d;), dated November 5, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SOW has a term of six (6) months.&#160;&#160;The Company will pay Medidata $1.45 million in managed services fees and a contingent managed services fee of $150,000 if the U.S. Food &amp;amp; Drug Administration approves a path forward for the Company to use the SCA in its clinical trial of&#160;&lt;span style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;186&lt;/sup&gt;&lt;/span&gt;RNL for treatment of GBM.&#160;&#160;The SOW may only be terminated for a material breach by either party or if the clinical study&#x2019;s authorization or approval is withdrawn by a regulatory agency.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Piramal Master Services Agreement&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;O&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;n &lt;/span&gt;&lt;span style="color:#000000;"&gt;January&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; 8, 2021&lt;/span&gt;, the Company entered into a Master Services Agreement (the &#x201c;MSA&#x201d;) with Piramal Pharma Solutions, Inc. &lt;/p&gt;

&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;(&#x201c;Piramal&#x201d;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#x2019;s RNL-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, which has been initiated &lt;/span&gt;&lt;span style="color:#000000;"&gt;at&#160;Piramal&#x2019;s&#160;facility located in Lexington, Kentucky.&#160;&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA.&#160;&#160;The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice.&#160;&#160;Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Other commitments and contingencies&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has &lt;span style="color:#000000;"&gt;entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of &lt;/span&gt;March 31, 2022&lt;span style="color:#000000;"&gt;, the Company did not have any clinical research study obligations.&lt;/span&gt; &#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Legal proceedings &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 22, 2021, the Company was named as a defendant in an action brought by Lorem Vascular, Pte. Ltd. (&#x201c;Lorem&#x201d;) in the District Court for the District of Delaware. The complaint alleges false representations were made to Lorem regarding the manufacturing facility in the United Kingdom (the &#x201c;UK Facility&#x201d;) that Lorem purchased from the Company under the Asset and Equity Purchase Agreement, dated March 29, 2019, between the Company and Lorem (the &#x201c;Lorem Agreement&#x201d;). Lorem also claims that false representations were made regarding the UK Facility&#x2019;s certification to sell and distribute devices in the European Union and export such devices to China. In connection with these allegations, Lorem claims entitlement to at least $6,000,000 in compensatory damages and operational costs and expenses (collectively, the &#x201c;Lorem Claim&#x201d;). The Company believes that the Lorem Claim is without merit and is vigorously defending the case. No liability was accrued as of March 31, 2022.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to various claims and contingencies related to legal proceedings.&#160;&#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&#160;&#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&#160;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pstv:OperatingLeasesExpiryYear contextRef="C_0001095981_20220101_20220331" id="F_000265">2025</pstv:OperatingLeasesExpiryYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301"
      id="F_000268">The Charlottesville Lease has a term of 12 months and is renewable for four additional one-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301"
      id="F_000266">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301"
      decimals="INF"
      id="F_000270"
      unitRef="U_iso4217USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <pstv:AnnualIncreaseInLeaseRate
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301"
      decimals="INF"
      id="F_000271"
      unitRef="U_xbrlipure">0.03</pstv:AnnualIncreaseInLeaseRate>
    <pstv:LeaseCommencementDate
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301"
      id="F_000272">2021-04-01</pstv:LeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvCharlottesvilleMember_20210301_20210301"
      id="F_000273">2023-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001095981_20220331"
      decimals="3"
      id="F_000274"
      unitRef="U_xbrlipure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000222">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the Company&#x2019;s lease costs from its unaudited  condensed statement of operations, and cash payments from its unaudited  condensed statement of cash flows during the three months ended March 31, 2022 and 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation of right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.68%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash payment information:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash used for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Financing cash used for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.3%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">45000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">50000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">4000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:LeaseCost
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">45000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">54000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">45000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">49000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">6000</us-gaap:FinanceLeasePrincipalPayments>
    <pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_0001095981_20220101_20220331"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">45000</pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_0001095981_20210101_20210331"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">55000</pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001095981_20220101_20220331"
      decimals="0"
      id="F_000286"
      unitRef="U_iso4217USD">60000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001095981_20210101_20210331"
      decimals="0"
      id="F_000287"
      unitRef="U_iso4217USD">50000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000223">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future minimum annual lease payments under operating leases at March 31, 2022 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remainder of 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of obligations under leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.08%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">113000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">18000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">382000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">37000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">110000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001095981_20220331"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ManagementFeePayable
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331"
      decimals="-4"
      id="F_000298"
      unitRef="U_iso4217USD">1450000</us-gaap:ManagementFeePayable>
    <pstv:ContingentManagedServicesFee
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvMedidataSolutionsIncMember_us-gaapTypeOfArrangementAxis_pstvServicesAgreementMember_20220331"
      decimals="0"
      id="F_000299"
      unitRef="U_iso4217USD">150000</pstv:ContingentManagedServicesFee>
    <pstv:MasterServicesAgreementDate
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108"
      id="F_000300">2021-01-08</pstv:MasterServicesAgreementDate>
    <pstv:MasterServicesAgreementTermsDescription
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20220101_20220331"
      id="F_000302">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA.&#160;&#160;The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice.</pstv:MasterServicesAgreementTermsDescription>
    <pstv:MasterServicesAgreementInitialTerm
      contextRef="C_0001095981_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pstvPiramalPharmaSolutionsIncMember_20210108_20210108"
      id="F_000301">P5Y</pstv:MasterServicesAgreementInitialTerm>
    <us-gaap:ContractualObligation
      contextRef="C_0001095981_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220331"
      decimals="INF"
      id="F_000303"
      unitRef="U_iso4217USD">0</us-gaap:ContractualObligation>
    <pstv:CompensatoryDamagesAndOperational
      contextRef="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_20210622_20210622"
      decimals="0"
      id="F_000304"
      unitRef="U_iso4217USD">6000000</pstv:CompensatoryDamagesAndOperational>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_0001095981_srtLitigationCaseAxis_pstvLoremVascularPteLtdMember_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_pstvPreClinicalResearchStudyObligationsMember_20220101_20220331"
      decimals="INF"
      id="F_000305"
      unitRef="U_iso4217USD">0</us-gaap:LitigationSettlementExpense>
    <pstv:LicenseAgreementDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000214">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;License Agreements&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;UT Health Science Center at San Antonio (&#x201c;UTHSA&#x201d;) License Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 31, 2021, the Company entered into a Patent and Know-How License Agreement (the &#x201c;UTHSA License Agreement&#x201d;) with The University of Texas Health Science Center at San Antonio, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as in-process research and development acquired in the condensed statement of operations for the year ended December 31, 2021. The upfront payment was paid in cash in January 2022.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;NanoTx License Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 29, 2020, the Company and&#160;NanoTx, Corp. (&#x201c;NanoTx&#x201d;) entered into a Patent and Know-How License Agreement (the &#x201c;NanoTx License Agreement&#x201d;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and&#160;to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On May 7, 2020, all closing conditions under the NanoTx License Agreement were satisfied and the Company paid an upfront cash payment and issued 230,769 shares of its common stock to NanoTx. Cash and the fair value of common stock issued is recorded as in-process research and development expenses, pursuant to authoritative literature for asset acquisition, in the statement of operations and comprehensive loss for the year ended December 31, 2020.&#160; &lt;/span&gt;&lt;/p&gt;</pstv:LicenseAgreementDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001095981_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_pstvNanoTxLicensesAgreementMember_20200507"
      decimals="INF"
      id="F_000306"
      unitRef="U_xbrlishares">230769</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000215">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company&#x2019;s Board of Directors is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. &#160;On September 21, 2021, Series A 3.6% Convertible Preferred Stock was eliminated. There were no shares of Series A 3.6% Convertible Preferred Stock immediately prior to September 21, 2021, or December 31, 2020. There were 1,014 shares of Series B Convertible Preferred Stock outstanding as of March 31, 2022 and December 31, 2021. There were 938 shares of Series C Preferred Stock outstanding as of March 31, 2022 and December 31, 2021.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2022, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 416,889 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 5,978 shares of common stock.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 25, 2019, the Company completed an underwritten public offering. The Company issued 289,000 shares of its common stock, along with pre-funded warrants to purchase 2,711,000 shares of its common stock and Series U Warrants to purchase 3,450,000 shares of its common stock at $5.00 per share. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright &amp;amp; Co., LLC, as representatives of the underwriters, to purchase 75,000 shares of its common stock at $6.25 per share with a term of 5 years from the issuance date, in the form of Series U Warrants (the &#x201c;Representative Warrants&#x201d;).&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with authoritative guidance, the pre-funded warrants are classified as equity. The Series U Warrants and the Representative Warrants were initially classified at issuance as liabilities due to a contingent obligation for the Company to settle the Series U Warrants with cash upon certain change in control events. In 2020, all but 2,500 Series U Warrants were amended and met the requirements to be classified within stockholder&#x2019;s equity. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2022, there were 2,141,000 outstanding Series U Warrants which can be exercised into an aggregate of 2,141,000 shares of common stock. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Lincoln Park Purchase Agreement &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.66%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On September 30, 2020, the Company entered into the 2020 Purchase Agreement and registration rights &lt;/span&gt;agreement&lt;span style="Background-color:#FFFFFF;"&gt; pursuant to which Lincoln Park committed to purchase up to $25.0 million of the Company&#x2019;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $25.0 million of the Company&#x2019;s common stock. &lt;/span&gt;Such sales of common stock by the Company were&#160;subject&#160;to certain limitations, and could occur from time to time, at the Company&#x2019;s sole discretion, over the&#160;36-month&#160;period commencing on&#160;November 6, 2020, subject to the satisfaction of certain conditions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On June 16, 2020, the Company received stockholder approval to permit issuances of the Company&#x2019;s common stock (including the issuance of more than 19.99% of the Company&#x2019;s common stock) to Lincoln Park pursuant to the 2020 Purchase Agreement.&#160;&#160;Based on the closing price of the Company&#x2019;s common stock of $1.05 per share on March 16, 2020, the maximum number of shares the Company could issue and sell under the 2020 Purchase Agreement is approximately 23.8 million shares.&#160;&#160;Accordingly, the Company requested and received stockholder approval for the issuance of up to 23.8 million shares of the Company&#x2019;s common stock under the 2020 Purchase Agreement. The Company would seek additional stockholder approval before issuing more than 23.8 million shares. &lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lincoln Park had no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Actual sales of shares of common stock to Lincoln Park under the 2020 Purchase Agreement depended on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2020 Purchase Agreement to the Company depended on the frequency and prices at which the Company sold shares of its stock to Lincoln Park.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2021, the Company issued&#160;5,685,186&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $12.5&#160;million. During the three months ended March 31, 2022, the Company issued 5,665,000&#160;shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $7.0 million. The Company no longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement. &lt;/p&gt;

&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;At-the-market Issuances&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On January 14, 2022, the Company entered into an Equity Distribution Agreement (the &#x201c;2022 Distribution Agreement&#x201d;) with Canaccord Genuity LLC ( &#x201c;Canaccord&#x201d;), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000 shares (the &#x201c;Shares&#x201d;), with Canaccord acting as an agent for sales. Canaccord will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf. The Company has no obligation to sell any of the Shares. The Company may instruct Canaccord not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the 2022 Distribution Agreement. During the three months ended March 31, 2022, the Company issued 1,022,610 shares under the 2022 Distribution Agreement for net proceeds of approximately $0.7 million. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On October&#160;23, 2020, the Company entered into an Equity Distribution Agreement (the &#x201c;2020 Distribution Agreement&#x201d;) with Canaccord. The Company had no obligation to sell any of the ATM Shares and it could instruct Canaccord not to sell the ATM Shares if the sales could not be effected at or above the price the Company designated from time to time and the Company could at any time suspend sales pursuant to the 2020 Distribution Agreement.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the year ended December 31, 2021, the Company issued &lt;/span&gt;2,179,193&lt;span style="Background-color:#FFFFFF;"&gt; shares under the 2020 Distribution Agreement for net proceeds of $6.3 million. The 2020 Distribution Agreement has been terminated. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000307"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000308"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <pstv:PreferredStockDividendRatePercentageEliminatedDate
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210921_20210921"
      id="F_000317">2021-09-21</pstv:PreferredStockDividendRatePercentageEliminatedDate>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000309"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210920"
      decimals="INF"
      id="F_000310"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20200101_20201231"
      decimals="3"
      id="F_000311"
      unitRef="U_xbrlipure">0.036</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210919_20210920"
      decimals="3"
      id="F_000312"
      unitRef="U_xbrlipure">0.036</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331"
      decimals="INF"
      id="F_000313"
      unitRef="U_xbrlishares">1014</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000314"
      unitRef="U_xbrlishares">1014</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331"
      decimals="INF"
      id="F_000315"
      unitRef="U_xbrlishares">938</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000316"
      unitRef="U_xbrlishares">938</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220331"
      decimals="INF"
      id="F_000318"
      unitRef="U_xbrlishares">938</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesCConvertiblePreferredStockMember_20220101_20220331"
      decimals="INF"
      id="F_000319"
      unitRef="U_xbrlishares">416889</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220331"
      decimals="INF"
      id="F_000320"
      unitRef="U_xbrlishares">1014</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvTwoThousandEighteenRightsOfferingMember_us-gaapStatementClassOfStockAxis_pstvSeriesBConvertiblePreferredStockMember_20220101_20220331"
      decimals="INF"
      id="F_000321"
      unitRef="U_xbrlishares">5978</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20220101_20220331"
      decimals="INF"
      id="F_000322"
      unitRef="U_xbrlishares">289000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001095981_us-gaapStatementClassOfStockAxis_us-gaapCommonClassBMember_20220331"
      decimals="INF"
      id="F_000323"
      unitRef="U_xbrlishares">2711000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331"
      decimals="INF"
      id="F_000324"
      unitRef="U_xbrlishares">3450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331"
      decimals="2"
      id="F_000325"
      unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220331"
      id="F_000326">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331"
      decimals="INF"
      id="F_000327"
      unitRef="U_xbrlishares">75000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_pstvRepresentativeSeriesUWarrantMember_20220331"
      decimals="2"
      id="F_000328"
      unitRef="U_iso4217USD_xbrlishares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001095981_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      id="F_000329">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231"
      decimals="INF"
      id="F_000330"
      unitRef="U_xbrlishares">2500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220331"
      decimals="INF"
      id="F_000331"
      unitRef="U_xbrlishares">2141000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <pstv:NumberOfWarrantsExercised
      contextRef="C_0001095981_us-gaapClassOfWarrantOrRightAxis_pstvSeriesUWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20220101_20220331"
      decimals="INF"
      id="F_000332"
      unitRef="U_xbrlishares">2141000</pstv:NumberOfWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930"
      decimals="-5"
      id="F_000333"
      unitRef="U_iso4217USD">25000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930"
      decimals="-5"
      id="F_000334"
      unitRef="U_iso4217USD">25000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pstv:PercentageIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMinimumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616"
      decimals="4"
      id="F_000336"
      unitRef="U_xbrlipure">0.1999</pstv:PercentageIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200616"
      decimals="2"
      id="F_000337"
      unitRef="U_iso4217USD_xbrlishares">1.05</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616"
      decimals="INF"
      id="F_000338"
      unitRef="U_xbrlishares">23800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616"
      decimals="INF"
      id="F_000339"
      unitRef="U_xbrlishares">23800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200615_20200616"
      decimals="INF"
      id="F_000340"
      unitRef="U_xbrlishares">23800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000341"
      unitRef="U_xbrlishares">5685186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-5"
      id="F_000343"
      unitRef="U_iso4217USD">12500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000342"
      unitRef="U_xbrlishares">5665000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="-5"
      id="F_000344"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220401"
      decimals="INF"
      id="F_000345"
      unitRef="U_xbrlishares">0</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_srtRangeAxis_srtMaximumMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114_20220114"
      decimals="0"
      id="F_000346"
      unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:CommonStockSalesAvailableForIssuance
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20220114"
      decimals="INF"
      id="F_000347"
      unitRef="U_iso4217USD">0</pstv:CommonStockSalesAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000348"
      unitRef="U_xbrlishares">1022610</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvTwoThousandTwentyTwoDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="-5"
      id="F_000349"
      unitRef="U_iso4217USD">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:CommonStockSalesAvailableForIssuance
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvSalesAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_pstvAtTheMarketOfferingProgramMember_20201023"
      decimals="INF"
      id="F_000350"
      unitRef="U_iso4217USD">0</pstv:CommonStockSalesAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000351"
      unitRef="U_xbrlishares">2179193</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001095981_deiLegalEntityAxis_pstvCanaccordGenuityLLCMember_us-gaapInvestmentTypeAxis_pstvDistributionAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-5"
      id="F_000352"
      unitRef="U_iso4217USD">6300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000216">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stock-based Compensation &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 6, 2020, the Company amended the Company&#x2019;s 2015 New Employee Incentive Plan (the &#x201c;2015 Plan&#x201d;) to increase the total number of shares of common stock reserved for issuance under the plan by 250,000 shares.&#160;Awards may only be granted under the 2015 Plan to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company.&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; As of March 31, 2022, there were &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;90,389&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; shares of common stock remaining and available for future issuances under the 2015 Plan. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 16, 2020, the stockholders of the Company approved the Company&#x2019;s 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which replaced the Company&#x2019;s 2014 Equity Incentive Plan.&#160;The 2020 Plan provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock. The 2020 Plan provides for the issuance of up to 550,000 shares of common stock, and the number of shares available for issuance will be increased to the extent that awards granted under the 2020 Plan and the Company&#x2019;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan).&#160;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;On May 17, 2021, the stockholders of the Company approved an amendment and restatement to the 2020 Plan to increase the total number of shares of common stock reserved for issuance under the 2020 Plan by 1,000,000 shares. As of March 31, 2022, there were 640,212 shares remaining and available for future issuances under the 2020 Plan.&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, options issued under the 2020 Plan are subject to a &lt;span style="-sec-ix-hidden:F_000358"&gt;two-year&lt;/span&gt; or &lt;span style="-sec-ix-hidden:F_000359"&gt;four-year&lt;/span&gt; vesting schedule with 25% of the options vesting one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of activity for the three months ended March 31, 2022 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000372"&gt;9.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,706.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000373"&gt;8.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460,217&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000374"&gt;8.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:16.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000375"&gt;8.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2022, the total compensation cost related to non-vested stock options not yet recognized for all the Company&#x2019;s plans is approximately $1.3 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of &lt;span&gt;&lt;span style="color:#000000;"&gt;2.79&lt;/span&gt; years&lt;/span&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20200206"
      decimals="INF"
      id="F_000354"
      unitRef="U_xbrlishares">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2015EquityIncentivePlan1Member_20220331"
      decimals="INF"
      id="F_000353"
      unitRef="U_xbrlishares">90389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20200615_20200616"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20210517"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001095981_us-gaapPlanNameAxis_pstvStockBasedCompensation2020EquityIncentivePlanMember_20220331"
      decimals="INF"
      id="F_000357"
      unitRef="U_xbrlishares">640212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001095981_20220101_20220331"
      decimals="2"
      id="F_000361"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="C_0001095981_20220101_20220331" id="F_000360">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000224">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of activity for the three months ended March 31, 2022 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000372"&gt;9.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,706.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,170,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000373"&gt;8.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460,217&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000374"&gt;8.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:16.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000375"&gt;8.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001095981_20211231"
      decimals="INF"
      id="F_000362"
      unitRef="U_xbrlishares">1170890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001095981_20211231"
      decimals="2"
      id="F_000367"
      unitRef="U_iso4217USD_xbrlishares">5.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001095981_20220101_20220331"
      decimals="INF"
      id="F_000363"
      unitRef="U_xbrlishares">17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001095981_20220101_20220331"
      decimals="2"
      id="F_000368"
      unitRef="U_iso4217USD_xbrlishares">24706.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000364"
      unitRef="U_xbrlishares">1170873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001095981_20220331"
      decimals="2"
      id="F_000369"
      unitRef="U_iso4217USD_xbrlishares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000365"
      unitRef="U_xbrlishares">460217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_0001095981_20220331"
      decimals="2"
      id="F_000370"
      unitRef="U_iso4217USD_xbrlishares">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001095981_20220331"
      decimals="INF"
      id="F_000366"
      unitRef="U_xbrlishares">1102117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001095981_20220331"
      decimals="2"
      id="F_000371"
      unitRef="U_iso4217USD_xbrlishares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001095981_20220331"
      decimals="-5"
      id="F_000376"
      unitRef="U_iso4217USD">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001095981_20220101_20220331" id="F_000377">P2Y9M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock contextRef="C_0001095981_20220101_20220331" id="F_000217">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&#160;&#160; &#160;&#160;COVID-19 Pandemic and CARES Act&lt;span style="font-size:12pt;font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;


&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A novel strain of coronavirus (COVID-19) was declared a global pandemic by the World Health Organization in March 2020.&#160;&#160;COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. While the Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines, the Company has not experienced a significant impact on its business and operations.&#160;&#160;However, the Company may experience disruptions that could adversely impact its business operations as well as its preclinical studies and clinical trials. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its financial statements and determined that there were no material adverse impacts on the Company&#x2019;s results of operations and financial position at March 31, 2022. The full extent to which the COVID-19 pandemic will directly or indirectly impact its business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.86%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160;&#160;The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;&#160;The CARES Act had no material impact on the Company&#x2019;s income tax provision for the year ended December 31, 2021 or the three months ended March 31, 2022.&#160;&#160;The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;H#?-U+JXXEY0+D#//X/4$L#!!0    ( +B E50#U8<1@P4  *P5   8
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M-4-W/^[1#Q0E:!V*5-%DJP:.!IA,T@F*A2?YPN3&PAYZ$8D.%9HG6[;]ZN]
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M4NWRPZYYIQ! U !#0>X>U(8(+>XZKYBJ9O(RAQQ2DN&TS9QKU(?CCM()&_6
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MS03'!G1>6(O#A@.,K_#J+U!+ P04    " "X@)54G%CJ$K #   H"   &
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MQG%P0!9"8*Q,/WA"]?::G"A'1QA2!I,Y0#"^YVV- Z<3EYHWYHN'X@V;5*H
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MGOAE2<.&GW(,$L#?*\\M,TYD@^F?@^W?4$L#!!0    ( +B E50_=E^P@@0
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M*V5 :#YOT&BML5+:CC*$ZZ_1Z6K7[:2I)UTTFD\O@W)I9IV]2>?@Z"&UH:\
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ME1F*FJ"N(GHXAX=L@R5H #U4J]B4,)/ _J0*VM'U(C&^6\,=M=(\$@,(!S\
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M6MPM8#V\66TGF)&X:E6"%1KP0T;DR4;=60SUWU(UQ7]J5NESEDGH-@W*4\V
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MFN)__/-L-+QX4_GR "P+K47,W"+V:278O4ISGKVP%3>,%W:EM/PO%DR"P6!
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M]P$+X'MA;1A>V,#X/\OV'U!+ P04    " "X@)54M_#4X9<'  "_$P  &0
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MG;(XC%ZL\/<#[0SPOE3*'A478/A/E_\ 4$L#!!0    ( +B E51-*]$2Y@,
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M1\ZU@PJRQ#73#V+SC;3Y# Q?+IBR3[1I8H>>@_)::5&U8%!04=Z\\6M;AQT
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M9M N -\OE;*;@5N@:\(G_P!02P,$%     @ N("55&<Y]"^=!@  EAL  !D
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "X@)54+D6.')L#  !!%P  #P   'AL+W=O<FMB;V]K+GAM;,6847/:.!"
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MP;:E0@U6QS? Q[?7[_X%4$L#!!0    ( +B E52,WU^M;@$  -T4   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSE5U(FX
MFHW;B3= L("1O]!.1N]^""[P([.8C>E9D4(X?1?D">GAR]:9OW:MJZZ]B^Y-
MW;I45=[W'UJ[O+)-YE9=;]OQ2=$-3>;'Y5#J/LMO66DUQW&BA]<9ZGAXG1F=
M'[W]S\2N**ZY_>SR[\:V_H_!^J<;;JZRUJOHG VE]:G2]WJ^[?1TH=4X646G
M2ZJ&TX64#AW$$,3A@PP$F?!!:PA:AP_:0- F?% "04GXH"T$;<,'[2!H%SYH
M#T'[\$$4HXRQ@*0%U@*T)N2:!'A-"#8)$)N0;!)@-B':)$!M0K9)@-N$<),
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M4$L! A0#%     @ N("55-FE1&CA @  P0D  !@              ("!41,
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +B E531'RNE
MX@,  $D,   8              " @6@6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "X@)548+Q";O<$   !%0  &
M@(& &@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ N("5
M5$[4S*9*!@  2!@  !@              ("!K1\  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( +B E528/^806 8  (</   8
M      " @2TF  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "X@)544O5L_TD#  "1!P  &               @(&[+   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ N("55)Q8ZA*P P  * @  !@
M             ("!.C   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( +B E50_=E^P@@0  -,*   9              " @2 T  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ N("55%9G2"#7"
M$1<  !D              ("!V3@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "X@)54_)R_%5@#  #$!P  &0              @('G
M00  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +B E53:
M=L;FA@T  $4B   9              " @79%  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ N("55'IXU4Z/!   N@L  !D
M     ("!,U,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +B E53"C:W$CP(  %L%   9              "
M@31U  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ N("5
M5$TKT1+F P  3 D  !D              ("!^G<  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "X@)54Q^2F]A0#  !M!@  &0
M        @($7?   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( +B E52%Y5>AF (  ,X&   9              " @6)_  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ N("55-K!C8)2 @  'P4
M !D              ("!,8(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "X@)54Y,FL+Y0%   P%P  &0              @(&ZA
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +B E52=JQ1#
M, ,  ) +   9              " @86*  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ N("55&<Y]"^=!@  EAL  !D
M ("![(T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "X
M@)54>OM)FQ0#   P"0  &0              @(' E   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +B E53C[DD3_0(  +<(   9
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M970S,BYX;6Q02P$"% ,4    " "X@)543'X)=SH$   4$   &0
M    @(&+JP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M +B E53&5RL3H0,   X-   9              " @?RO  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ N("55(?3JY$; P  +A(   T
M             ( !U+,  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "X@)54
MEXJ[',     3 @  "P              @ $:MP  7W)E;',O+G)E;'-02P$"
M% ,4    " "X@)54+D6.')L#  !!%P  #P              @ $#N   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ N("55(S?7ZUN 0  W10  !H
M         ( !R[L  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ N("55 970G>/ 0  <!4  !,              ( !<;T  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "H *@!="P  ,;\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Basis of Presentation and New Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards</Role>
      <ShortName>Basis of Presentation and New Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates</Role>
      <ShortName>Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Term Loan Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations</Role>
      <ShortName>Term Loan Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - COVID-19 Pandemic and CARES Act</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct</Role>
      <ShortName>COVID-19 Pandemic and CARES Act</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies</Role>
      <ShortName>Basis of Presentation and New Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails</Role>
      <ShortName>Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Term Loan Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails</Role>
      <ShortName>Term Loan Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails</Role>
      <ShortName>Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity - Common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pstv-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="pstv-10q_20220331.htm">pstv-10q_20220331.htm</File>
    <File>pstv-20220331.xsd</File>
    <File>pstv-20220331_cal.xml</File>
    <File>pstv-20220331_def.xml</File>
    <File>pstv-20220331_lab.xml</File>
    <File>pstv-20220331_pre.xml</File>
    <File>pstv-ex101_152.htm</File>
    <File>pstv-ex311_7.htm</File>
    <File>pstv-ex312_6.htm</File>
    <File>pstv-ex321_8.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="304">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pstv-10q_20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "pstv-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pstv-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pstv-10q_20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pstv-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 336,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 13,
    "http://www.plustherapeutics.com/20220331": 3,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 20
   },
   "keyCustom": 34,
   "keyStandard": 169,
   "memberCustom": 26,
   "memberStandard": 12,
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Term Loan Obligations",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations",
     "shortName": "Term Loan Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Loss per Share",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - License Agreement",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stockholders' Equity",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock-based Compensation",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - COVID-19 Pandemic and CARES Act",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct",
     "shortName": "COVID-19 Pandemic and CARES Act",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies",
     "shortName": "Basis of Presentation and New Accounting Standards (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Loss per Share (Tables)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Liquidity - Additional Information (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails",
     "shortName": "Liquidity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Term Loan Obligations (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails",
     "shortName": "Term Loan Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfDebtDiscountPremium",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
     "shortName": "Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:OperatingLeasesExpiryYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:OperatingLeasesExpiryYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Summary of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - License Agreement - Additional Information (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
     "shortName": "License Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pstv:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_pstvNanoTxLicensesAgreementMember_20200507",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_us-gaapStatementClassOfStockAxis_pstvSeriesAConvertiblePreferredStockMember_20210920",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_us-gaapStatementEquityComponentsAxis_pstvSeriesUWarrantsMember_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity - Common stock (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
     "shortName": "Stockholders' Equity - Common stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_deiLegalEntityAxis_pstvLincolnParkCapitalFundLLCMember_us-gaapInvestmentTypeAxis_pstvTwentyTwentyPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Basis of Presentation and New Accounting Standards",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards",
     "shortName": "Basis of Presentation and New Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:UseOfEstimatesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Use of Estimates",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates",
     "shortName": "Use of Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:UseOfEstimatesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:DisclosureOfLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Liquidity",
     "role": "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pstv-10q_20220331.htm",
      "contextRef": "C_0001095981_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pstv:DisclosureOfLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pstv_AnnualIncreaseInLeaseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in lease rate",
        "label": "Annual Increase In Lease Rate",
        "terseLabel": "Annual increase in lease rate"
       }
      }
     },
     "localname": "AnnualIncreaseInLeaseRate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pstv_AtTheMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering program.",
        "label": "At The Market Offering Program [Member]",
        "terseLabel": "At The Market Offering Program [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingProgramMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_CanaccordGenuityLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canaccord Genuity L L C [Member]",
        "terseLabel": "Canaccord Genuity LLC [Member]"
       }
      }
     },
     "localname": "CanaccordGenuityLLCMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_CashPaidDuringPeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid during period for:",
        "label": "Cash Paid During Period For [Abstract]",
        "terseLabel": "Cash paid during period for:"
       }
      }
     },
     "localname": "CashPaidDuringPeriodForAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "totalLabel": "Total cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for IPRD asset acquired in an asset acquisition.",
        "label": "Cash Paid For I P R D Asset Acquired In An Asset Acquisition",
        "negatedLabel": "In process research and development acquired"
       }
      }
     },
     "localname": "CashPaidForIPRDAssetAcquiredInAnAssetAcquisition",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_CashPaymentInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment information.",
        "label": "Cash Payment Information [Abstract]",
        "terseLabel": "Cash payment information:"
       }
      }
     },
     "localname": "CashPaymentInformationAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pstv_CharlottesvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charlottesville",
        "label": "Charlottesville [Member]",
        "terseLabel": "Charlottesville [Member]"
       }
      }
     },
     "localname": "CharlottesvilleMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_ClassOfWarrantOrRightExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date that the warrant or right expires.",
        "label": "Class Of Warrant Or Right Expiration Date",
        "terseLabel": "Warrant expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pstv_CommitmentFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment fee.",
        "label": "Commitment Fee [Member]",
        "terseLabel": "Commitment Fee [Member]"
       }
      }
     },
     "localname": "CommitmentFeeMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_CommonStockSalesAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, sales, available for issuance.",
        "label": "Common Stock Sales Available For Issuance",
        "terseLabel": "Remaining availability under financing facility"
       }
      }
     },
     "localname": "CommonStockSalesAvailableForIssuance",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_CompensatoryDamagesAndOperational": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory damages and operational.",
        "label": "Compensatory Damages And Operational",
        "terseLabel": "Compensatory damages and operational"
       }
      }
     },
     "localname": "CompensatoryDamagesAndOperational",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_ContingentManagedServicesFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent managed services fee.",
        "label": "Contingent Managed Services Fee",
        "terseLabel": "Contingent managed services fee"
       }
      }
     },
     "localname": "ContingentManagedServicesFee",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_DebtInstrumentAmendmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument amendment fee.",
        "label": "Debt Instrument Amendment Fee",
        "terseLabel": "Amendment fee"
       }
      }
     },
     "localname": "DebtInstrumentAmendmentFee",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_DebtInstrumentFloatingInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Floating Interest Rate Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentFloatingInterestRatePercentage",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pstv_DebtPrincipalRepaymentStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt principal repayment start date.",
        "label": "Debt Principal Repayment Start Date",
        "terseLabel": "Debt principal repayment start date"
       }
      }
     },
     "localname": "DebtPrincipalRepaymentStartDate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pstv_DisclosureOfLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of liquidity.",
        "label": "Disclosure Of Liquidity [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "DisclosureOfLiquidityTextBlock",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pstv_DistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution agreement member.",
        "label": "Distribution Agreement [Member]",
        "terseLabel": "2020 Distribution Agreement [Member]"
       }
      }
     },
     "localname": "DistributionAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_FinanceLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease expense.",
        "label": "Finance Lease Expense [Abstract]",
        "terseLabel": "Finance lease expense:"
       }
      }
     },
     "localname": "FinanceLeaseExpenseAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pstv_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pstv_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, liability payments due, after year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement abstract.",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "xbrltype": "stringItemType"
    },
    "pstv_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for license agreement.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pstv_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln park capital fund, LLC.",
        "label": "Lincoln Park Capital Fund L L C [Member]",
        "terseLabel": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Abstract",
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "xbrltype": "stringItemType"
    },
    "pstv_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and security agreement.",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_LongTermDebtOutstandingThresholdAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt outstanding threshold amount.",
        "label": "Long Term Debt Outstanding Threshold Amount",
        "verboseLabel": "Long Term Debt Outstanding Threshold Amount"
       }
      }
     },
     "localname": "LongTermDebtOutstandingThresholdAmount",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_LoremVascularPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lorem Vascular, Pte. Ltd.",
        "label": "Lorem Vascular Pte Ltd [Member]",
        "terseLabel": "Lorem Vascular Pte Ltd [Member]"
       }
      }
     },
     "localname": "LoremVascularPteLtdMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_MasterServicesAgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master services agreement date.",
        "label": "Master Services Agreement Date",
        "terseLabel": "Master service agreement date"
       }
      }
     },
     "localname": "MasterServicesAgreementDate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pstv_MasterServicesAgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master services agreement initial term.",
        "label": "Master Services Agreement Initial Term",
        "terseLabel": "Master services agreement initial term"
       }
      }
     },
     "localname": "MasterServicesAgreementInitialTerm",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pstv_MasterServicesAgreementTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master services agreement Terms description.",
        "label": "Master Services Agreement Terms Description",
        "terseLabel": "Master services agreement terms, Description"
       }
      }
     },
     "localname": "MasterServicesAgreementTermsDescription",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pstv_MedidataSolutionsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medidata solutions, inc.",
        "label": "Medidata Solutions Inc [Member]",
        "terseLabel": "Medidata Solutions, Inc. [Member]"
       }
      }
     },
     "localname": "MedidataSolutionsIncMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_MinimumLiquidityCovenantAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity covenant amount.",
        "label": "Minimum Liquidity Covenant Amount",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "MinimumLiquidityCovenantAmount",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_NanoTxLicensesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nano Tx license agreement Member",
        "label": "Nano Tx Licenses Agreement [Member]",
        "terseLabel": "NanoTx License Agreement [Member]"
       }
      }
     },
     "localname": "NanoTxLicensesAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash lease expense.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_NumberOfPreferredStockSharesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Preferred Stock Shares Exercised.",
        "label": "Number Of Preferred Stock Shares Exercised",
        "terseLabel": "Number of preferred stock, shares converted"
       }
      }
     },
     "localname": "NumberOfPreferredStockSharesExercised",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pstv_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pstv_OperatingLeasesExpiryYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, expiry year.",
        "label": "Operating Leases Expiry Year",
        "terseLabel": "Operating leases expiry year"
       }
      }
     },
     "localname": "OperatingLeasesExpiryYear",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pstv_OptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options.",
        "label": "Options [Member]",
        "terseLabel": "Outstanding Stock Options [Member]"
       }
      }
     },
     "localname": "OptionsMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_PercentageIssuanceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage issuance of common stock.",
        "label": "Percentage Issuance Of Common Stock",
        "terseLabel": "Percentage issuance of common stock"
       }
      }
     },
     "localname": "PercentageIssuanceOfCommonStock",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pstv_PeriodExercisableFromTheDateOfIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the period exercisable from the date of issuance.",
        "label": "Period Exercisable From The Date Of Issuance",
        "terseLabel": "Period exercisable from the date of issuance"
       }
      }
     },
     "localname": "PeriodExercisableFromTheDateOfIssuance",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pstv_PiramalPharmaSolutionsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piramal pharma solutions inc.",
        "label": "Piramal Pharma Solutions Inc [Member]",
        "terseLabel": "Piramal Pharma Solutions, Inc. [Member]"
       }
      }
     },
     "localname": "PiramalPharmaSolutionsIncMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_PreClinicalResearchStudyObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Pre Clinical Research Study Obligations [Member]",
        "terseLabel": "Pre-clinical Research Study Obligations [Member]"
       }
      }
     },
     "localname": "PreClinicalResearchStudyObligationsMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_PreferredStockDividendRatePercentageEliminatedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock dividend rate percentage eliminated date.",
        "label": "Preferred Stock Dividend Rate Percentage Eliminated Date",
        "terseLabel": "Series A 3.6% Convertible preferred stock eliminated date"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentageEliminatedDate",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pstv_PrepaymentsOfLongTermDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments of long term debt.",
        "label": "Prepayments Of Long Term Debt",
        "terseLabel": "Prepayments of term loan"
       }
      }
     },
     "localname": "PrepaymentsOfLongTermDebt",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_ProceedsFromWarrantExercises1": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from warrant exercises.",
        "label": "Proceeds From Warrant Exercises1",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises1",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_RelatedFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related final payment",
        "label": "Related Final Payment",
        "terseLabel": "Related final payment"
       }
      }
     },
     "localname": "RelatedFinalPayment",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_RepresentativeSeriesUWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Representative Series U Warrant.",
        "label": "Representative Series U Warrant [Member]",
        "terseLabel": "Representative Warrants [Member]"
       }
      }
     },
     "localname": "RepresentativeSeriesUWarrantMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the japanese subsidiary and certain assets.",
        "label": "Sale Of Japanese Subsidiary And Certain Assets [Member]",
        "terseLabel": "Sale of the Japanese Subsidiary and Certain Assets [Member]"
       }
      }
     },
     "localname": "SaleOfJapaneseSubsidiaryAndCertainAssetsMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_SeriesUWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series U warrants member",
        "label": "Series U Warrants [Member]",
        "terseLabel": "Series U Warrants [Member]"
       }
      }
     },
     "localname": "SeriesUWarrantsMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_ServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services agreement.",
        "label": "Services Agreement [Member]",
        "terseLabel": "Services Agreement [Member]"
       }
      }
     },
     "localname": "ServicesAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value roll forward1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Roll Forward1",
        "terseLabel": "Aggregate Intrinsic Value [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward1",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pstv_StatementOfWorkTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of work, term.",
        "label": "Statement Of Work Term",
        "terseLabel": "Statement of work, term"
       }
      }
     },
     "localname": "StatementOfWorkTerm",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pstv_StockBasedCompensation2015EquityIncentivePlan1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation 2015 equity incentive plan 1 member.",
        "label": "Stock Based Compensation2015 Equity Incentive Plan1 [Member]",
        "terseLabel": "Stock Based Compensation2015 Equity Incentive Plan1"
       }
      }
     },
     "localname": "StockBasedCompensation2015EquityIncentivePlan1Member",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_StockBasedCompensation2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation 2020 equity incentive plan.",
        "label": "Stock Based Compensation2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan [Member]"
       }
      }
     },
     "localname": "StockBasedCompensation2020EquityIncentivePlanMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_StockIssuedDuringPeriodSharesWarrantsExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares warrants exercise.",
        "label": "Stock Issued During Period Shares Warrants Exercise",
        "terseLabel": "Issuance of common stock for exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercise",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_StockIssuedDuringPeriodSharesWarrantsExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares warrants exercise(shares).",
        "label": "Stock Issued During Period Shares Warrants Exercise Shares",
        "positiveLabel": "Issuance of common stock for exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExerciseShares",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "pstv_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment to the amended and restated loan and security agreement.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_TwentyTwentyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty twenty purchase agreement.",
        "label": "Twenty Twenty Purchase Agreement [Member]",
        "terseLabel": "2020 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "TwentyTwentyPurchaseAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_TwoThousandEighteenRightsOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen rights offering.",
        "label": "Two Thousand Eighteen Rights Offering [Member]",
        "terseLabel": "2018 Rights Offering [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenRightsOfferingMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_TwoThousandTwentyTwoDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two distribution agreement.",
        "label": "Two Thousand Twenty Two Distribution Agreement [Member]",
        "terseLabel": "2022 Distribution Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoDistributionAgreementMember",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pstv_UnpaidOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid Offering Costs.",
        "label": "Unpaid Offering Costs",
        "terseLabel": "Unpaid offering cost"
       }
      }
     },
     "localname": "UnpaidOfferingCosts",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pstv_UseOfEstimatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Use of Estimates [Abstract]",
        "label": "Use Of Estimates [Abstract]"
       }
      }
     },
     "localname": "UseOfEstimatesAbstract",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "xbrltype": "stringItemType"
    },
    "pstv_UseOfEstimatesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.",
        "label": "Use Of Estimates [Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimatesTextBlock",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureUseOfEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pstv_WarrantsIssuedUnderwrittenPublicOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued, underwritten public offering, period.",
        "label": "Warrants Issued Underwritten Public Offering Period",
        "terseLabel": "Warrants issued, underwritten public offering, period"
       }
      }
     },
     "localname": "WarrantsIssuedUnderwrittenPublicOfferingPeriod",
     "nsuri": "http://www.plustherapeutics.com/20220331",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r167",
      "r203",
      "r233",
      "r234",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r394",
      "r395",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r167",
      "r203",
      "r233",
      "r234",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r394",
      "r395",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r167",
      "r203",
      "r231",
      "r233",
      "r234",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r394",
      "r395",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r167",
      "r203",
      "r231",
      "r233",
      "r234",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r394",
      "r395",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable And Accrued Liabilities Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r256",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r252",
      "r253",
      "r254",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r235",
      "r237",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r46",
      "r57",
      "r187",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Non-cash amortization"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r57",
      "r187",
      "r194",
      "r195",
      "r302"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Amortization of deferred financing costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Dilutive common shares excluded from the calculations of diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r66",
      "r113",
      "r115",
      "r119",
      "r129",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r269",
      "r271",
      "r287",
      "r324",
      "r326",
      "r377",
      "r388"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r34",
      "r66",
      "r129",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r269",
      "r271",
      "r287",
      "r324",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and New Accounting Standards"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and New Accounting Standards"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r20",
      "r59"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r52",
      "r59",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r291"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r63",
      "r66",
      "r88",
      "r89",
      "r90",
      "r92",
      "r94",
      "r100",
      "r101",
      "r102",
      "r129",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r201",
      "r202",
      "r206",
      "r210",
      "r287",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Date from which warrants are exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r225",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Number of shares callable by warrants (in shares)",
        "verboseLabel": "Number of securities called by warrant or right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Class of warrant outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r151",
      "r381",
      "r392"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r152",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increased in the total number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 22,197,635 and 15,510,025 issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r188",
      "r189",
      "r191",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r65",
      "r67",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r192",
      "r193",
      "r194",
      "r195",
      "r303",
      "r378",
      "r379",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Basis variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r11",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument Covenant Compliance",
        "terseLabel": "Debt Instrument, Covenant Compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r164",
      "r192",
      "r193",
      "r301",
      "r303",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "verboseLabel": "Original Loan Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument Fee Amount",
        "terseLabel": "Fees amount associated with loan"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r25",
      "r167",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r27",
      "r65",
      "r67",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r192",
      "r193",
      "r194",
      "r195",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentOfferingDate1": {
     "auth_ref": [
      "r11",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format.",
        "label": "Debt Instrument Offering Date1",
        "terseLabel": "Origination Date"
       }
      }
     },
     "localname": "DebtInstrumentOfferingDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r27",
      "r65",
      "r67",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r218",
      "r221",
      "r222",
      "r223",
      "r300",
      "r301",
      "r303",
      "r304",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r57",
      "r112"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract Type [Domain]",
        "terseLabel": "Derivative Contract"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r35",
      "r273",
      "r274",
      "r275",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument Risk [Axis]",
        "terseLabel": "Derivative Instrument"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "verboseLabel": "Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "verboseLabel": "Weighted average period for recognition of cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r69",
      "r70",
      "r71",
      "r75",
      "r82",
      "r84",
      "r99",
      "r130",
      "r217",
      "r224",
      "r252",
      "r253",
      "r254",
      "r263",
      "r264",
      "r280",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r396",
      "r397",
      "r398",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r57",
      "r197"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "terseLabel": "Change in fair value of liability instruments"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r282",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value By Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement Inputs Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": 10020.0,
       "parentTag": "pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
       "weight": 1.0
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease Principal Payments",
        "negatedLabel": "Payment of financing lease liability",
        "terseLabel": "Financing cash used for finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r307",
      "r312",
      "r319"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset Amortization",
        "terseLabel": "Depreciation of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r190",
      "r215",
      "r278",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r142",
      "r143",
      "r326",
      "r376"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Increases (decreases) in cash caused by changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase Decrease In Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r41",
      "r111",
      "r299",
      "r302",
      "r383"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10040.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r51",
      "r53",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFloorMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount.",
        "label": "Interest Rate Floor [Member]",
        "terseLabel": "Interest Rate Floor [Member]"
       }
      }
     },
     "localname": "InterestRateFloorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r44",
      "r110"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]",
        "terseLabel": "Lease expense:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Operating leases, expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Annual Lease Payments under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Minimum lease payment",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r66",
      "r116",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r270",
      "r271",
      "r272",
      "r287",
      "r324",
      "r325"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r66",
      "r129",
      "r287",
      "r326",
      "r380",
      "r390"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r66",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r270",
      "r271",
      "r272",
      "r287",
      "r324",
      "r325",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities Fair Value Adjustment",
        "terseLabel": "Change in fair value of liability instruments"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement Expense",
        "terseLabel": "Litigation settlement, expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate L I B O R [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current",
        "terseLabel": "Term loan obligation, current"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Term loan obligation"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.",
        "label": "Management Fee Payable",
        "terseLabel": "Managed services fees payable"
       }
      }
     },
     "localname": "ManagementFeePayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r36",
      "r37",
      "r40",
      "r42",
      "r58",
      "r66",
      "r74",
      "r78",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r91",
      "r113",
      "r114",
      "r117",
      "r118",
      "r120",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r281",
      "r287",
      "r382",
      "r393"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r72",
      "r73",
      "r76",
      "r77",
      "r85",
      "r86",
      "r87",
      "r122",
      "r123",
      "r131",
      "r132",
      "r227",
      "r228",
      "r229",
      "r230",
      "r255",
      "r265",
      "r266",
      "r267",
      "r279",
      "r288",
      "r289",
      "r290",
      "r320",
      "r361",
      "r362",
      "r363",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r114",
      "r117",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r313",
      "r319"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "totalLabel": "Present value of obligations under leases"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Noncurrent operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r310",
      "r314"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "order": 10010.0,
       "parentTag": "pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-use-of assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating lease, weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r315",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease, weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r33",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLoans": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments for and related to principal collection on loans related to operating activities.",
        "label": "Payments For Loans",
        "terseLabel": "Payments for principal, interest and fees"
       }
      }
     },
     "localname": "PaymentsForLoans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments To Acquire Intangible Assets",
        "negatedLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r238",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock Dividend Rate Percentage",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at March 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r144",
      "r326",
      "r384",
      "r391"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.",
        "label": "Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]",
        "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Recorded Unconditional Purchase Obligation [Line Items]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Line Items]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.",
        "label": "Recorded Unconditional Purchase Obligation [Table]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Table]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r232",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r232",
      "r321",
      "r323",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r260",
      "r359",
      "r422"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r224",
      "r256",
      "r326",
      "r389",
      "r399",
      "r403"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLiquidityAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r75",
      "r82",
      "r84",
      "r130",
      "r252",
      "r253",
      "r254",
      "r263",
      "r264",
      "r280",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks And Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r29",
      "r63",
      "r100",
      "r101",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r210",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "verboseLabel": "Securities remaining and available for future issuances (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life (years) [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable at March 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable at March 31, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Common stock shares to be issued (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r242",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "terseLabel": "Balance as of December 31, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Options [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "terseLabel": "Balance as of December 31, 2021 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at March 31, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Vested and expected to vest at March 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Stock option vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Stock option contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable at March 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Balance as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Vested and expected to vest at March 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "terseLabel": "Remaining common stock issued and sold (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r63",
      "r66",
      "r88",
      "r89",
      "r90",
      "r92",
      "r94",
      "r100",
      "r101",
      "r102",
      "r129",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r201",
      "r202",
      "r206",
      "r210",
      "r217",
      "r287",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r32",
      "r38",
      "r39",
      "r40",
      "r69",
      "r70",
      "r71",
      "r75",
      "r82",
      "r84",
      "r99",
      "r130",
      "r217",
      "r224",
      "r252",
      "r253",
      "r254",
      "r263",
      "r264",
      "r280",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r396",
      "r397",
      "r398",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r99",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r31",
      "r182",
      "r217",
      "r218",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "positiveLabel": "Conversion of Series B Convertible Preferred Stock into common stock (share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r217",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveVerboseLabel": "Sale of common stock, net, shares",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r32",
      "r217",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of Series B Convertible Preferred Stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r217",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "positiveVerboseLabel": "Sale of common stock, net",
        "terseLabel": "Sale of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r66",
      "r121",
      "r129",
      "r287",
      "r326"
     ],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r224",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r298",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r298",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r298",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r190",
      "r215",
      "r278",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.",
        "label": "Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain]",
        "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired"
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual Or Infrequent Items Disclosure [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureTermLoanObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants And Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights Outstanding Term",
        "terseLabel": "Warrants expected term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.plustherapeutics.com/20220331/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r426": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r427": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r428": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r429": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r432": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r433": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r434": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r435": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001564590-22-015075-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-015075-xbrl.zip
M4$L#!!0    ( +B E50\M4&T,A ! $[=$@ 5    <'-T=BTQ,'%?,C R,C S
M,S$N:'1M[+UK<]M(TB;Z^6S$_H<ZFLO:<4B:X%62V]Z@):J;.[*D$:7NF?/%
M401*(L8@P,9%MN;7;U8!(,&K>&<"R(GW=8LD+E7Y9.:3E559]<O__CFP&'L1
MKF<Z]J<3K50^8<+6'<.TGS^=!/Y3\?3D?W_^G__CE_^W6&275YT;UM)]\T5<
MFIYN.5[@BG?=K^]9Q[9,6[!_?;F_9I>.'@R$[;,BZ_O^\/S#AQ\_?I2,)]/V
M'"OPX3U>27<&'UBQ&#_XPA5<_L NN2^8^M\YJY0KE6*Y5JQH#]KI>;ER7J^7
MRI5RN7E:_O_*Y?-R.?& W\,.L,3_SAE<7M)*S5HS<>$=U[_S9\$ZEXD+C7*U
M5CVM&&?-9KU6T\Y.>;,L3BNU1K5:K_:J(ME29_CJFL]]G[W3WZLF0G]M6UB6
M>&57ILUMW>06Z\8]+8!H]!)K61:[E[=Y[%YXPGT11BEZ:M\'!  %VSO_V7,M
M\]-)0FKRFY+C/G^ ?E<_@ 1]>($X25QOC&](7MSX$/X87SKT_)>))P^MP//[
MPN5# 2W50TAD?\K5JA;?%7A%_W4HO-&=3]SKJ5?$O\A;M&)9*T[<],SY<.X]
M\H<YMWC^T)WLAB?TTK/S\D'^HFX87>KZB]HT^FG>&UQ_[@WS+C7U!6TQ]8FF
MV!SD-O]2]=/$Q>*GWI]_K?QEXE+#=Z>Z.*$*\/,'^;.\IRR;GKA3F//? 3^H
M5_Q9BR_5 ]<%0W^=?WW\ZT2[=">P?7?1'>&/DWVV@T%EGGI6RM!K7]B>V;-$
M45X&BJCLI5B1'BA2;_ IWR=D\*.J'J"=G9U]4+^.=,YW%]K-V0?X-;YPYI&3
M%B9_[G%O9&&FY]0J6G.93897C-KLF?-:#)=J'_[U];JK]\6 %Z<-V?RYZ V:
MM'KI6Z5K'2D>>)Q@\(9VP$5%)5A3']WW]DV3-Y@__?DWC-OTP7>Y[3TY[D !
M*)M<+Y8KQ4HC\9 B:,G$@V*M>>LYIV.[7*P(TH.>*%<JN"'_.Q ^5]Q3%'\&
M)OB]"\<&;?.+#]#'$Z:'GSZ=^*"$']3=[(.\SS=]2\ ?TED6M?*?WV)_6(*+
MX/</\06_?(A?)3GAYE>@!1LXU!<N>Y&L4RDUM<B]]QSC]?,OAOG"//_5$I].
M#-,;6OQ5@BADJ_^?7\R?Y_)QPI6?PH^F80A;?52?X=J;$!EF&I].KKZ5Y?]
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M,LR$+@#W  FNXG\9#!?.;=."4!08XN1SW,RX29NVL[:S=FI:98_MG"&Y.U=
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M-Y)4VJA41G^D28?D7/ALCT=+=A?T^3A$V2A6*NL19?*._:WE6%MCCNSFTDK
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M=.? \-GZ_\WAVN/PS\W39KVQ3)W2XIH/%?M%(I=IOZ$+MFL.N<7$3Z$'LEP
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M\N"2^YS)9?G3!C=^1C)7<Q_ E;5R7=K4O7@.K'")1K?XP-Y)@)H?*]5**;K
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M%GE58>Z[S'CDW7<@O'HYPUJWSI*$G!LHF>:^3'/%55 YU[_%!:=S5JHJ!;T
M77UVW-<MLSWJ@2IJTJ,'JL0/!(5S3&*3I9-D(G-,I(&8O;99V)9S*^XN&DN0
MJ>S6*<[)"2K9?PD\TQ;>>JG 33<F2PW)[=&B#Z:3>^P#>5%<7K2]*'>4)GW%
M[T/G)(ECR?^J!'\1ROTPVW(=8GGXG&39CIYZT*3PTY($JUQ)/#=G;#[-FV%1
M\RH0W]N.FA8)/*&N@L:$>S;.V=O*<=6[K%?Y\A\FO%IF?6WHKB,#GQ?34VE8
MF]NZ6LZLZW*C"_FG/(3!X*[A,;E;A6DL6C];?<??STV;,IH"6&4*P.L+RQKE
MX]\!S"J]'NZJLSPSO7BRZ=_"VW R9O$TU9PBOZYL^T$=SQYGH!KI5[^6FH]I
M#5W38EJMP*2\"U)M7,%^R'\B=*_4W")8;V";(5Z/W]1N_UZ?NP+B\03QS($]
M<:9D5]UP&_C*78#?>$L-:G*ZTQ"Z"2WV/IUT;JXF=X"U@X'A^-$%)Y^A_=I9
ML]"HCC9AB]O^F86-C0W#G2W<T,,U>)YL*'/&;9R9T3G8&06577/:&EOP[3),
MZ;GL0VPG_=$BV"%_%L6>*_CW(G^"R.R<6S_X*ZC3AT-U='_E9%&$J";:EDAW
MQ<T1-Y3[POWGUJCBT2JK^# 4W>W<7+;_M<L=YZ,GO]6Y??0%PZ3O]&+U:BGT
M1RM4OVKEORU=.*J$,)0;=OM[&IVO0*'3I;ZG\[1UD]K?<NGL-./]![V1P<^G
MD^K)<EF<5DOEK MC\2+K;31A?YFV-\EQ9Y90*YTUEO=_L]7?VV1MIOSX&P?&
ML"\CSIJM+]Z4ER'P6:D\J%$ZK:_C<O=C/<=GP[O6_0/KK.^"]YCXG1_;[,A;
M'A!':7Q75\F.:?M$\A?.^JX<ZOU%8OJM\^VJ<].ZN>BTKK_!V.[V_FM+;DU_
M\GGT-4M\_<L'OGI]RSP-./CN(6MIR1J>=&&U3FKZNZ0DLH+'YTWWK[$K./?I
MGW;0=E0.:Q<@(/4/.].GT#VDI3?I"'CVY\R/8/V[:_QAXY.#QID=7PR85L("
MY8Z!:]9*VE9-U:(<]T1SBZ-O%Z:-1]V8$W/N-\CL/+2_?M,20:8Z%_=K^^:A
M"S%F.(_)+::VG0SK&M\]VCPP3%\8[RG</'!WCFCYM57HJ5FJXF6GO(2F1^4F
M$OJ1>64G'@^I]Z;!  T&TM;X]+:< G?,@?O%[4WW]KIS"='ZY3?X<-F^Z<)?
M7UK7$,BWOW5_:[=E"'_AR+[(18E?N 7!O&#=OA"^1Z$[A>X4NJ>J[:EM>)J%
M3J$[,D H=*<8DD)W"MVS%[J/,^_?;N_:]ZV'9/2>2, [3^QV*,+3(CU&@7Q^
M OEZZ@/Y=+@X8A9B%@K=,^*O][ "CX)W_(U/;\O)Q:8Q>(?X?/!-E?!^D_L9
M^XN#=W51'T0N7"\JK65M><LKQ?+YB>4;J8_E*3],27E*RJ<YLJ>D/,7U:6M\
M>EM.<7T:X_IQ4OZBU?WMV]7BN/Z">WUV93D_:'%-CN+X)L7Q60@I4]OP- N=
MXGAD@% <3P$EQ?$4QZ<XCK]Q?.$].!"DJ^T_Y/D=HS+6.%Z7)WS 57+;W7$P
M/Z_8E0+Y_ 3RIQ3(9R&F3&W#TRQT"N21 4*!/$64&0GDC[W;385VN\G,X$#M
M=E/Y]K5UT_HURNI?=KH7C]UNY_;F&WQ[_>]NIRN3_%^YS9_5(&"T^_VEZ>F!
MY\EM_N6AR"V;6Z^>J5+_X[&#'$^$)X;(:^Z%%UC32_9I4)&?085&RWPR$>"F
MMN%I%CJ-*I !0J.*- 7F-*K &1.H44651A79&E54O_WSL77ST'EH/71^;\L/
MU_'?<HAQ?=M]//G\3WG:G^G#..!%J $"?&'%G^7XPG*\0)[!Q7M.X+.OW/TN
M?'9O>M]IT)"?04.E0H.&+,2OJ6UXFH5.@P9D@-"@(4UQ-PT:<,8$:M!0HT%#
MM@8--5EI\'!_>]W]=G=_>]&^?+QOAYMV^JYC>6J(<.<ZNC#DJ(#& #D: U3I
M+*A,Q*.I;7B:A7[,00 =OH7$>V=\#'#TTT;1'#>ZB^#C@.?YK1^KXCB)M//M
M]G[R#-+;A]_:]W3^*"(?1\>+XO5'%%*F6>@44N+" X6[S5A(26GE7*:5Z3S7
MC*65M6_7[5];UV%.N7W9N?FU>_+Y6CQS*\PF"\.TGRF=3.GD-"TI(3*B?1,R
M11R96S*2<O>\EUQ*E?PI[L9G/KAO472?L>B^]>V^T_W'MZO6Q</M/43V<GTX
MN^*Z[[@4U%-03RFF]#4^ZRS4*#$L6!(+[82%&M_:__JM\Z4C#QEO_^R;/3/<
M+FT1SL0^66.?><>*?_!YSQ+PK6&^K"8)V6^M,NYX0C(3/?_;.AVSA ^O*'I#
MKIOV\_DTQA-VM*DYR.4B$[TSA.Z$6WR<6Z8MBG[?=8+GOKSV@[QXDULJF[P&
M8 '1]T>!P) _BV+/%?Q[D3^!7,ZY]8._>B?LPWI>:QX>2S5KA%72GK:TCWF-
M2)IN E33AT?KZ[1S#?PO6H]RQ4OK_M]LM$<\NV__VKJ7^79V=7O_!_Q9O+Z]
M_8?\/-Y'?EH&7[C^_1D@M(UB9,97ZG_)CC=6MX]DSQ/,4"ZO[1@FC653TUC8
MO9//#WW38ZX8.JZO5KK[?<%$1"7,M$'-AU+3A<'ZPA6FS7JO</D3_&WK@NGP
M<@Y?ROUY*K)W[@_N&D7+<;Z#S</KXTT\U07:1_:C;^I]QEW!!MP0;!BXGBS'
ME;N RC=[_$FP/G=[CLN&KO-B>NI\77E@E]#5CCZ59DM^E!?#5X%K^B9(K:7[
M\EOMK%HM,.XQ#B\UA%%071K=JK7GW-K^J?>Y_2P2SZA-/@/:(N])7EB:.'8
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M]'/P47!7>C% + %AR!?/PA8NZ(%2-V, OL;SW5"3U0-! ?_^E_K91Z7D%\X
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MA:?'CN+>7K]Z0-EKI4;E.&M^%ZV%.]WG&MGE6XTU%FXU=D!$JN52]4C+L/%
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M!"CDO;)L_5!%.WJHTC+V?W9?I5#6Z.P^;-J*U(E05(,  XIJ4,! #@D!"E2
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M*$R(3)2-E%-0D03XG?R@Q I&;73K'J-T*!Q<;:OKLEOCHIH( P@(_58Y$N@
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MGP$8Z1B7$] _T31=[X[SNV<B!Y-D^CT?#=[G6PZ-L6<0N(XY=EQ<NT4+L_P
M[.FYSY6==(^V/VGCV?FDM-*(OXD3\G%U%>UZXLGZ9K(9C;>ECVG(O]PI3;]Q
M<$VKY41J1Q4_"F?=>[P6 )\&. 8]&?",<_H:OPN, _R!%KRJ-?+)6BE\4"<[
M^GSIIB#)2P;8K^*>-+D<[$4PE!L);'5& 5PU2]9/\8GIU;3YFE<+XCH!WX-'
M+9*-8,FV^V15+>X+2S9,A3$NJN/7REW/F7V"C\+GM;$VM4V?N&4*K*0P1Z H
M[1'SN.R7EJ9%F3_1+@OP9 @Q^A_&V<WFKO!NHZGB(IT?$K+B]\HM9F''*#L;
M[@>36]2 1OD;178)<?]$>BS^7<?X7O)!9'O>SB4/P+3([Y.G<SQMF3MP*RX0
MF[,8Y*T>2B39N#73AJN[]+QP*NB]K$#D@F3D-X=672@VZO75KD0$)NYAQQ/(
MO5]\"G_=*W"?LS#MK S"K]]Z0#L*I_KJ5OA@F%P9GF\"P0<F00CW_R+^@+](
M!J;(H2,7[ANJL@@:7IXNN>NLWHC0L!UA2:+ -<>X?]D/%BV XL2Q!-%:"+_!
MC2\3<'$D9P'\KP&J9U[D>X[?,L!O,T.U>"_/'*9:ZBB7M@ )."1KE^\<'PTS
MB^JOU!.9C#_A Q;_)\Q@(S<1YYT.\QYLEL=--_05-)+UC@P)\K+PT&=("YZ\
ML[RRR>P#A-&F?RR'0<>X\N1P?=ZWU\LR#(V8)06$JP7SWR:VR1_H?&H&+I"@
M".] S8B6\4\'B1#,@M?X9-P V.^^RWV*)0+]K??N377MN1QEA1$SGT&.")'%
M'4][N?$__8R$9Z\O=_K.BW>^F2#X;I"N.406?ECH?TF&R>0NJ1= #9(P7;<G
MJ;\,(K3PT$P$X_+K%C;XEET7]S5>3<ZEI?C(U\U$']NAL-[:<4#D^>I]KY]G
M!*4 D./)JE'V$:DG/P[T54P9:L%'MYV?[:EC@Y1[*^%S^NH]2)_V KA4+9R1
MVV0ZQ:@2_QV1 C:\,XMG64V,!]I\R?)QH9>Q#$6?E17\36K]CRJ&](B(VB!J
MW&W!:8J+D-7&GHD3A&![W@OW3NT_;H'!.?X7[NDAD;(NL#Z/ Y$!8R\CB\\\
M#SRQ2[G'Z](C('Z'*Q^,F?/0DSNDVWV 5@%0OP"!XP62362X?$RZ=KI?HEA
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M'M1Z@?P-,RI(P@!77P"/NJY_'QJOB:G\. 0^"=^\/8B.V587PC$EH?"&#YV
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MZ<Q"59RQ&I!9^.7 0($E#%J!LV29RI,)A<M6B$T('<<11:ZD#4#/^10'_EP
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M8JKMN%>DBE,,53O[%L M#ATI$VQ*:%[C/'T'F_G.L?_;_K!0+",_N&.H?WB
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MDI/_?M5]95C :=*237Z6Y2KTLRJ X2(5\ Q<<QZ*M^H?[PQ9R-(%/+Q:NQV
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MO?'BXUERQLN<HX?XHN^J#U]^U8*+%,(TW42?*RM:@NS;A_.\RB!/JM3>3]X
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MEM#"9,V%"+H;T4S*N*EIR6+AJ'S!J:>-<OGA*0@?9&LB@8I.CH%PBF;VS<5
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M#M['=6?Z$ ),ZR9X6!&>./+AS>AOG@>\+<A9.%A[O<IQ\WVA6(4+TW[G_.P
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M#<O9;^\A8$8D%# (.+6GT!J.$69KR# I/;/:S^ZVU5*04-H"J4R:U +55;!
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M#HX1L?#1M:4FKVX7#RP 9H34@"?X'.8,E_(Y6FEP(PUNI,&-MJ3B([^D*AT
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M(P57&&IAB%-R#5Q$23YY2L#'0 L6'!YO@?]C\ZQ>+A5AV7W*^(&S,\3NK,P
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M8C.Y/=UCX<WJJMZJ :'NL;#Z^9[*2>-TXP=\%&^QL(LJ5!LXE:FC#9PV<-K
M+4+;=L6L;?X$J^(&3O<06JV'4-&NX2O-^G":_$P;Q1C/SQB4QV)XQ:$ GWNW
M#A$I8)_1?0ZS PZ)^ YA- \%_B5>*X#0EK^E;J[R'K[V_5#>-K3NV6$W9-;#
MH=6#A7EG>4_6*-HSCEZ.1K[FUE)YUL!AU&?Q!9$146)=^X6:<PDF^"PQ,@DT
M\J8+$^&8F&N;Y\8 T3]/0G-/@*%W;KYS4///S'$=*[:FX)FG/Q&N;#=Q/01*
M[XQ\>$#LVL8YC" ,/.,L' #+'#??&_N=\[,#[&05XSAY_ZP>"+:'C3BPDU ?
M&_-0BY.^&\5!2#V$LF9"^+(8<5$S'-YTQ.?! "1FA'T,S./WD?&5\+'KV=TQ
MD1>[@YRT;[]<8UKMCX^?!<3RFGEZ,[3.(;1'[D\.6TH8L6GGE)OO&?;RT!IE
M)/T5(I\4ZQV7"H8+J@<;382/+B+7]ABV=OB4A(A.7$$46WSBMVH'O@P"Q_C'
M+XV3]\9%F-P;9PY".J?H^83E_HB8T?!.&!',X\D*'0)9Y6V9D =H?.=G=!8$
MN^3,(B-!LX)"C GN&;X'HLZ8%/:F<#)0W@!AFJE7Q;3)<<3[%O7769%))$<L
M9@\WAF:.T,.6%P5&P+4>1]T>6 \L[0HV!$:RW:' %7=)6T0QKB[O$Y?!T]\A
M>UT'EL_5Q\W/'K5-PH7+M](96#'V[!GQ7G2PU/],?&9PE=0$/0'K_R6 7UJ2
M5;'1" DX#N>9KG7($H, .]?Y.'_BNH.J<961O\(;"T5VZ';Y>2.ZWF$$* X?
MZ>7'*[R\(L&<IRQFUJ.0\OKIZN%X"8@98=)Y/Q?/ZJ)^"\*10=ZP;. F(,9#
MW ((<\\>HX3-$!H][1W!$<21X4/+CA,DH^P;$"G$V\N[%LN-8C.>Q<T, )7M
MP=E>"#-F"0SM)Q#.7QO54VE_.%>0" J>AU]K>>M$)LX:R-:@R/>(W,2;"J;X
MYA*)/:%--;Z[YAC.$GU,4&WDQS'^7A@*;\F"./]9QU'NLXCWL9_45@G[)&:B
M/[M_0;J 2X*S+Q.);40NKF:<\-QBN9AVJ'49N< F$[+Y O#48GVUBOF.O0^\
MLEK:"_1R:EE3+-X##X<$PZ4&/%$TASFCB*']PLX&W^[^[)S1%2)VE4V-Z!T]
M]R>AX-/UPH>P_'L7TT#BV[&1+-HV;'QZK[7HO%>42<HHD^3<ZL^<7W5&B["2
MR^NGM #_;-OE];ES!TO:LJGL$\ENFH4^3R@$Q]5C*005:H2%7ISL 6H'U.LY
M\Z3G]9,<[])'76]FM_V:Z&*V9?U 7I^^<]3#//K6EZ/O8L3*DW=!CJ PZ G;
MFJ''5<_Y5*32V4]L,L/S,1"APQJGX<+:=%L>@G)95EF5+\ZQ>RSF%LY@51+*
M"AA? P];5G%CU<DZ4!F7,#MLJ+-EN@][80Y#!IXM3]*039L26V,Q6D!A-4;O
MQ$Y6MFHB3X"<S_N.88,B^!U;,#K24?_FN_BIPW-^(I2-1.J'HEDFUYCWTHNB
M9##D'=,H92AZ=.&S8,1!B$^S!CB&M.$AM\05PW-Y2RN@9 4N?F1^(IY*;GC$
MTF9@V7.Y/VX'0'.>KT*OQXUL+XBPMSF)=)HZRKDTN7=MF>+\WG<]WF<L1QE8
MBBX%-+A$.1)1=UH?NUR%^=Y4HMLL[T[;9R/NS:*[R9O4BL0$<$+BQ;RQM..B
M5I2-LW(OKV"\U;>&4;$W7"&5<=5+GR6>(]M@ 4M.>Z1,&1('6@Z2B;,\<"6U
MMI\F#F!)HB&S9?.XB/<" Y4/CWBR.+?@M'V&GC2*#)H62D3*%VP9K_P1! ZM
MHXNR_>BR)\93N]ATS U%4SX_(3K(1%T/M0"C_GYN#_2$ Q2-@Y#W2,_N8S_!
MJE$[3Z _;2$@87(7Q)B53)^>B^Q[ 2:JC;\3"[1%2(_@:0'&NZQ%<*&73]%%
M[#[M'\B5#'Z;@$J@F\&BN[%P$GI>@KS+N=_E/=6HC:?HQX>/H$YLJ')"E_DV
MIIIS)J70'S =\@ABKG7PAC*E"=\S1<_7$:B(M0D)28W4IB/#]D"]P%K!JDDO
M!(P%>6R8:B(=C2N-WPP"AWD%/?")VJ[)1;62N!^$U/?]D>4MUWWB.B#>H(S2
M=Y!Q&P8QK)LK4T>@[&./NU*RE9\MMKF$I(M]*)Y5Y\\7 @#:H6".Z/G@UH$A
MB:1MS*T!;UD_GE"39FNACHLE4AO?46]ZU&33C5%W@%2#T%FB&_$H2&AC"+/;
MH'ZQJ6>"N@/$W9;>6]X/$=[;6!)A/%> V<%YMW-'H6#RT!%((IGGA/O/2-L8
MMZ0CT!9^0KUDU@[_2J.('MP#EZ! BR#B LP!;TDMXPCAO,,;2%50VW$_R%HW
M2CZ9GZT4F8=B#+HLJZCMK1NN\_O>U=WEYQ^-'__Z=O;E[NKN[.[J?R_QP[7\
M^^*J<WY]T_FV]^$*++71J!K_PKWK5.YAL>$+3WZ^2+T[('(76^U^YIU;;]WH
M8;OD[$L0XP8L\#=Z9?/LBR[N6:*XI[[VXI[MD]_FC_.;+W>W-]>='U]O;\XO
M+[[=7G:$Q#:KLGR$*^&OF(IV4$#7)8Z;2:I>HJU/(^Y,#[WU[#=F] <6[@2
M+<7"G7KM?2[0MO-+,$R7H$)7FN_1GXH26U2TN+B?#R$:-\RWB<<B[O^9#>O0
M;.VS _X1GV6V'/Y5KF[A\B>WL)C<KHAT %4$H*/.,WK@=^&PZ+=<94%A,[[+
M9*H@\Q!X^"!R%T_H#GC4O[R7A+Z+V<A<9=7X4'@4A;DZ;),N-F3PSWQOX31$
M00\9G$KA2U*HS3<F8:4@2N4^M/BUPVRLP)!>3OI2\%\'+OC;N.TJ2JE"7$W>
M'#F@!M-IQH36/[\6,%SPHY)!PO.@=&01'IA@[8Y(C)+C1@4WZ$97A)^+3@W^
M<MYW60]& Z,CTWQ#-1&AL8\_9F4H++V %TV$!_0N?O>G-%*?<7<6RHN[!8NE
M12Z9*R@?3ZE2JER"RV J%6H+CZ$%=_-XEV[0^6Y$<6#([JV09I6R1\;:Q42%
M+[B,1S3@< J=(-R\!20BMYXR<_5_3";+(!:9>1_W,$& C#Y,A#+!*<>3D\UC
M9. W"%1EVAR<W&+;<<S^A!@\H0ZS;*#!8SIX>!K./0V2NO_AV1+!1;F!\Q0)
MSZ.[44&JT&$941G8?Q*'Q^7 Q6/KA)GSPR[S00O$/!&/A.B[0QS5, "6QK'.
M6(HM2\*<Y=:O.R)U: A%V)VM]3!S!\$O*@GT@:ULB7&G(KLK2H98*!?)Y"@%
MLOC#T HAE@(1D@:MK+(N8GE&"6%XLX_;X&(^B\CC+-/$US!/#L8GDYDD> QH
M3UXY-HM05I2.T'?DGZ($Q0X>F2 [6(((XQQ,>8'\3(:H_RHHHH\RF\L39J#!
ML/:OHC2ID 0B34+:;C$"&?M+U18TZ!\0*VO2R9A)Q^FT.Y A.F6_4_Z2V?&I
M2M7#BHL7T?P%-7[*ER6<9PFT*PQ8L<I+5I[CLN38[E;F<;=+V=]-IHUR647*
MD,N%L?,+DXE;EN#.I9=$KGQZ60,)&[TRMZO"]\_06\!L9YACYY'AN0^,5\)-
MW%!9;HS+I+.6.P!#)#I=N1"U!''WU[/;NQ]75S]N;G]<??ET<_OY[.[JYLO>
M!_S>N+JJ&C=W?U[>&KG?UB4J&\T\F#^N+_\XN^9IA\N+JR]_R+Q#\9#6%$G=
M^U"5*OP:7'R/Q^8,?9HM"\YO?%Z4CT>$>%$K[I"BJO&M 16[&1::0] /%G?(
M<5O3)M>O2ZFN& W2-3@2 ^-_K<B&F#"L&%]C5C6N8Z=J[(N0GZX00?V!#$]Y
M_0H$P.>X<Y>FTM.O,5L"/C[NL5:-.W+_!T,/DPD8E3%4?CW+BZA" .L7_=B2
MV]-BVQEU$1]<%JOQHPE^TL/=:-*$XGC2:*QXX2_XS0D&QCY^)^;Q[2_CD[@Z
MG0WI2?X662_H\-WG)']JXA)\=7C'9)E/A0Y(2/5;/T52F/#?+HN?4-<GW+7A
M;\@/AG^3/D<.J"HNI?,>-JS7()+'L.8O5G&-QJ9*60(\<T [FL0!6 %%A46\
M>(+7(F$\R _8B-6\3"">9L WL*PBF& _R4LE]UE>#0\#%]*WZ P'V >?<3:3
M@4?$.-'YJ"MBCF)ZN'TG]^PPEHSI^$5L_-K&HSWX+R]J&>#&&C]RX5@#ZUZD
M/ K5XQ!B%JM'C'WP$3U9 % Q)BAPCH/(5C^WS47+CM?G+L18 2>%X=< K&0L
MSWV@-7UT[P.0JXCR#"AV:>0+++.^ZO#-:NJS'[=7G;]^?#H[O[NY3;7T696V
M9I )J4Q@NS3O)W2?Y$ZCB*3EB9Z>F#%Q#X1#GC/I4)$_U<4M<@A;*SD?"H\N
MR?-/&6M3CHI7RI"631]L6WA28JPP!T1H1CT-#V!$R4W^;!4O_O!<&:$P>>3O
MT N"!ZJV*!28/1^W5LC<B,-<,F]:R$.*,R%"40@=X$C9/+>H,-("6>_(5\-[
MI(K[)(9W+8;7R8YWR>0S;DA'?;%,(>LE'N7$L-Y%9#U%"=3XR+C2%^/X"G,T
MKBJ&X.K# E?+5RV^T3QOAYFLY+/;RV(I0QR&9+5"(<(K#$3O.;[.GF-#=4"!
MC5J.]H_+?_]Y]?'JKC-&D(V5&9.0M]/P08U!7?[LNUT7@22GGEE9/8YNKP(A
MHCQ_?1!,!2'RQ>6_C0G'X^V -P0X#&'%"'B=W_=J>^ H>)Y0;NEG <U#GPL#
M?0=V,'@OP'G0D[6&$7LG_WAO" "?6DUTKDI18<53^._'5?,W4C$IPE#AYU:S
MVFK/N\"LS;V]>M*8>[=9;1_/?_S8$\8A;F&^R/R_[[7W"G"WZX=SFV#CEQ5G
MKLK47Z^_=0S,_)Q]O?QV=W7> 8_DRWEU'BSP0FNV34!:SR,EA\$37Y+ZWCC$
MEAJ<E.8WGU_&EUD3XTN"+M\8[)A>GW1][C :T<LS><348^EV,L2 :;PWME2I
M\FE,+-6S8':+P/7OS()?94A*O%" 06"/!Q06081?=L5GHCCNS'(C/[\0BU$O
M9EY9&%^"JE[05UK0"SR(0RIXT7X0<YR]QLKK0!-MC@4\4PBLW@">XPT])#VD
M38F6,G&469T%1[PV@=[,1/_',OHAZ_V^UX_CX;NCHZ>GIVK$[.I]\'AT%MI]
M+((]8LZ]%1XA.N&163MMG9Z81T ?TSQMF/56O5ZKG9Z<M(Z<=JO=;-8<]M,T
MJ_UX\$R*F;88,/^+2GTJ#H3<5OZGY2>X"6(V)1@H.(%TYGX0( B"ET2T;6 -
M&3S!CBH&>(Q57M.7PHK\P7S:O;Z^/D^SB-:4].9FR&#D,IN;U07+I_DV-EYE
MM,7)X5]E(=QK3QW4P&&CV3AN+9L]+]M$95)D"<NPW4Q?,X_,YA'J8^V(E\F?
MTT,JZ9!VTA%O:$=\NB..#GC>%V_6&FT36*9UW*JUCMC/QH]EG7#$! DB-V;&
M>5HD28?ELOPKW**=9^T\OVZH7=/>\\YXSTNH\^WF^EKCR#3!>S;;4TV\7(0^
M?^-QM3X4G?N4=FGU /0 M"^\/E^XKGWA!7QA_B>P#/S3;JSF"Q<]X+,!\QUY
M-H<^".B)6T:' IR\RYSWD$OBUVB/5*=SM4.ZTTQ?:QV9M=D.J1)67P] #V#C
M ]A1U[.A7<\%7,]6N]DZK9DG-;-9;[:.[%'\\Q#\3_-'6SN@V@'5#JAV0+4#
M.ML!K3?0 3W1#J@>@!Z =D"+#FA3.Z#/%>0*[_.T5H<_FMK[U-ZG]CZU]ZF]
MST4H?WQ4/T7O\U1[GWH >@#:^RQZGRWM?2Z>_@0'].3TM'TTC.)'[H":)]H#
MU1ZH]D"U!ZH]T%F4/SFJM;4'J@>@!Z ]T"D>:%M[H(N<@^*8!&;]^/C8/#ER
MS':S?5QWT E=T@.=ZF5^''G6$_6XF8$ZH'W/D@N:]CVU[[ES3%\[/:KC::2Z
MJ7W/,AT)UT,JZ9#>7+0V=;:W:O[WCOFM(NEIULP?9JN^I-/YF3DNNK5&!WN7
M8E>A% V+'-&L#PBXH-^#\$$5?U,94_;OS4M^B=SN'1NO]F@4()\>TC8.:7<\
M&GT(>XE$7.G 0:L:X&@[7 5E/-)-9Q2560A0"F^87U1FVAHY=-R&:N#0,GIX
M>D@E'=*.N.:-W0/M3PLLS1_'W*L^+_0WQWWJT/5M=VAYQN5/9B?8 MRXZ<$5
M+,1.[E%B\:+*#OP8NK$+\[C\R1OM&F=V;-PF'C/,AG5H-O>M@XIA18;E!$-T
MO8?%V^F-C5H=WXKM=3M6V+5\%AW>_/38B!X&OT! 4-?9RJ6SE=LTZ3<WMR6=
MN8IAG';3%"!?>==DXP/0+MB:7;!=RXZF+EA=GK*>XX)]<GT+_H2_,/]X9MM!
MXL>N?Z\],F5,M/;(],RU1Z:-_ZZLR<8'H#VRM7ID]:KY7SOJDM7-'R=37+*H
MX&69)\:W:J=Z7DT=)K/1JATMY'UUG_>^3FOM<>_+.#2T_Z7]+^U_;9G_)0<I
M>K;4J^VA[MFBK@.@UZ040]H1/\VLF=6K+YW=\-2N?"SM,_[]\?;:N/*CV/)M
M9EP$=D(G&_[QRTG=--^3S^3*7QWYJQ/ 2/T@-JSAD%DA7$$77B%'6C9M;U[@
M 8I/+OAI769;202/B2/^MMBZ!W\M9 8;=)F#QWN?W+B?/B,;EGR?=LK>VBE[
MH3DNF_M0MO'J=),"Y--K4OXA[9!CTSG_4TT#LD['IF/WV<!*W1KM2&A'0H]7
M.Q(ELE!Z34HQI!UR),[/KM4T(.MT),XMSTX\7DUT[?H/72MBVJW0;H4>KQ+:
M4)M0O2;;.*0=<BLN+C^I:4#6Z59<L)[KN]JKT%Z%'J_V*DIOKO2:E&)(.^15
M7)]]5-. K-.KN+:ZS-,.A78H]'BU0U%J2Z77I!1#0D&"_UA=C\'_'?=QL4'A
M$,QZ-@8QR&5'E9F)&:K 8S&\]3 :6K;KW[];AU69"Z2(EODP[H=!<M_':P60
MX/*WU)NKO(<#O?73VOBA=<\.NR&S'@ZM'BS,.\M[LD;1GG&$UPGJ$3&-;A Z
M+/Q]K[9GV,SSQ JFGX>6X\C/!:E\9R5Q\)[??0BFW[.&$7LG_WAO/+E.W ?"
MU7X3Q?E2!8NG\-^/J^9O-(^4\0L_MYK55GO>!69M[NW5D\;<N\UJ^WC^X\>>
ML"-^M2J(G.C??[V]7!*7L]QKGW?SOX8L@C'I34GM[>OQJN7M3^'_U(%Z=AJO
MR/Y5[4SK &,+AK0CGI59:ZIIKUY[HN?!(P(M02 RX]#8/C["BO%$OQ45#H4A
M:),-3[7@&P=/GJ70SC7S0#L]VNG1XYU4G#-S,S,S+]-&"/%V\[?"$ _Y5]E
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M$UR=C:*+, *P4D/,5<-7W9$1LAX,%Q?.]7&<,$)X'0)Q4N.AJ0\D"*<,%$J
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M%"(POT./0TWM:F&R%9 0'5*=!8/Y:@SR3.!'%=[[O,47Q1Y8&Q#*>62T+YH
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M]-_O^RY-O>'.E//B.--VR(0__0]02P,$%     @ N("55-=-A#Q)"@  LX<
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M6,]@]+MK#1VS==:Z;#I7%Q?G9V>-JTOKPH3+YMF/K=9YZZD%ZYSBV8*@YY?
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MDI1VF+ZBZ3,*,7GE5U&0 /3BB\+'3Z0S,@H$_57<]-34<\^[#%S<Y5)*IB-
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M+8APDD@X+PHG7'U.?] Y];?_!U!+ P04    " "X@)54VO$(N?!0  !+O 0
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MOS]R@=:@YW+U6[+RSM [46DNBUNUY2,">\ME=>7;.N:^28@9!/SE59 '(@E
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MWK*ELQW'(KU+\4N<A)J;YRX:%E3>H.G>\,N-<L'2,^OO JK-!5J5YRLH[<[
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M7=T$I?%+0 LP5 ?QM%"I_JUG'YTQ%Q'==%W<"A7</+P/50 *ZRC.9U!0#QZ
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M 8L4,#9 F MM:U>U>>8RT68^92WXX@N3-ZWO*+E,-J%Q!N_2.(3E+TO=:>T
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MC%V,)XE4)5,?S$41+*RAO4G:8(ASK2S7L:N>+X\\7Y")N3H=%$'F1S]6IMT
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M+Q&?"&O*S(FK?G> KEJ#U=19*XT>'(0C')8*8>.%MMJXSU;$VAS:[^,S3&%
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M CF),Z@V9,*?K!T"3#E,9'6$.A'CW&[$&"8WRNB&R+N,&.>'$3&4 <4&FCT
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M=?97LFS5-=7IX_"!!-_#C[C>1=G.ZJ6MMV6315J;8CDT:WMBNKZ"/-C8ZL!
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M@9,Y-9=F%:I'N@NYA21'H,-_F<W0@[OPW;EKXQ>9C+$I]%P;K?P9PN;"$XS
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M593Y-1*BEL>;$EQ%+RT>KDB%RPLB"=NX&-WA'> @S$5RD]N7+&E26TDTC*Y
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M[7+"1TS/(ZID3O<6$KE/ V@#X(372$"D*$WF.2Q%^.<@I@]_<C(*H[]I)9>
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MS8V.JT=QR-[F-_@/#,Z?_Q]02P,$%     @ N("55&>00@?&40  0]4! !(
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MHP@B%+$+;;P-XS":2OX\1G5A']*.1U*SJ,@W#U?Q^EZS"\TMPO3A'YV+%I8
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MM\C'.MG[Y?<YZ=ZHW!E//H6P0/3"YF<V^7$P)-X$6TZ0;AU%,.&$9^+TTT+
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M2E!\@IVP&C2Q70_Y/J#_H:7ZE_V7>V]+D&)3 4NG;*2&!:+D-2:S 0L;\[F
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M<DFY@.E11;GN/?E8ILX2XR,9+S(&R9+$8EKP<U18U0CM(TI[1*1BHFY W.H
M<:A;K!G1/#$J%"^DM84>D624ZW1)+^K)KX;S#C7(0IF=A=?CA.'5*QUGMM"I
MS?S49U=MYZLG&'DDZH!M>("F(R*"TH7UH.DUR$WW3*TQFZW/T!WY)<2NHG"!
M#( !F"<C?49[PRF%.IWQM0PS!#BXFF-Y4H(HC*1FD=BI$>PE#/KC]V1II,/Y
M5$\@.A"GV+WEU'#:-*I%:)"GD@YF#T3O9'@E0B*[='X\F)](1*<KS-,CJYR&
M[XY=M@[)E08R:DO-FG0$$L,:Y929A'-;97[=-)'V^&R/2(BH,ESO^7UN>W>)
MBMM,D--H0=ZE/ ]$4F<?BNL-#BQH)ZJ,S=EH3'G->NFRND<+,!^"%JUP_<RD
M"*U>SB@T28G.TB0:.B8PP4B&]"QEOY;TMJH&+1Z ,'%:A.Q-@G+FJXOT1@IK
MZEVH ;&H6>OEGL/*"R+*$]]$3.'^HZ-66[A35QR:M*)*@AJ14[,9TY0)5A^?
M@C]8$1X:)X,L1CF1'*W-/=ANE:?F>P?01LVBU=P_Q)^.3HX.CUX=G5@=_=%1
MHRO>=Y%ZU:O?J42-HV$49BYWQD6*1^--#>\EZ[=Y@RU];RNC54>_XB%JZ6$'
M[ALDLECG.&P&=80M9G'\AP]RK&?D=-FR\41L^+SJZ!*IU",LT]ENN39M)2W=
M\N9"@]@+F2@079RA0G9+.H;N$D@/$1/I0N%PM>P.N,ZI7*$(\DS=S.,0[EP8
M>P+&:7NCEC^N\4>'TWY0(<4MO?C71+XTS/\UBV1,H6VA+;&*TR@ED<>E1AL\
MY7Y=9I>8<JK"Q*G'60+0I^-5!=S6FDL71OB0>5V"E7KT]?,0=\3^"A#'GV<5
M.R2;8G'EY>5%^?0YAS66GGD-M,$DKX.S.G#Y#2+.+'.$DY/)$PD:WT8[C?M0
MF(=]?V)9?/S>N;YO33':]$^3?MKK_'31ZF-ERJO63VU$(;R_/#^__.6!'=Q_
M: K#%P[DNN]9;R0=<-T7ZS.#+-A=31A1!XU^AD,_PZ'_Q'#HE\]PZ&<X]#,<
M^L\*A]ZX-U8UBJ][1GH' G/=O'!.#^_GP]?-EZ]7_'[0/%QU^W'SX&#%ST?'
MS1/W=I;/M6?Y4QS<]Z^5O=+4+3ECGZ)Q#[:=2+0*>@.,FK0L8RRK>JV@J<HH
MF!9.G0QZ]68^22TX=.-YCE:]X8UK((G9#[M\\YH/:=KK_]AQ_J87P3?=N#_/
M"K6@H32>2R 7EFCMFGN60<^->VY<?>.>]\9SXYX;]^"]H=LHNKYN9)ZB4WFO
M>7(\*P)+)%@\C9=JO8X]MO'Z;O%F#=_4JH&Q5,4;,RB[^6YP0?F-P7GX/J,T
MQ]\Y2M_(\EECT_Z)>O.\&?Z@S?"_TTD27,;YO]1=_BG: (6C/)?8CF]M(O]L
M!^R?JG%_T@7P3>ZWQY8X%^%4K1+$&]137\EH!!_/L.A@(WC?.KWZ)D?@F][W
M?^!"G$:C4:PVJ;,;=\8_-^ZY<<_G\2-(AC[R@7P?!_+I!"DP,!R!12LN&8'<
M"'HJP4RSGZ^"RP3C(S>+H/OOX73V]NR;')5O>A<]K\XOAUO^?-70&4N&$_=;
MET;?]&)\;MSWTKAO<F\\MH! R/KW(0K/U%!-!RI#+GT-@?SF.OU-[Y'GM?<$
M:^\) ,Q? %_\;E^X9J;,D_7P.3OCX7OX.3OCV\K..-'9&?L'S^D9S^D9S^D9
M^-5S>L;7>^,*67!?PN>WMQI_B*8W09X-__;BYE]'X\_CY" [N.-0\T'SM]G-
MBX#8E__V L_T O_Q#J"7K_9GG]].N#W'!R_APXL'Y8\^Q2Q\V9B[\DLPY^_I
M?^YB>]+CKO6SI;0X=0E#.Y:QD8[ 8)^S%3^&V7 2')'6?Q#<-H/+89&B(4"B
MLD:.^%AXE_O1(QZZF),Y<;1__'KOY8%[F6'AV$(*JX.]MZ<Q\L33A_VWVP%%
M*(/Z! ^/^9+O"UK,;?O&_>GH8&\/NQ86$^CON_AVU&P$O7D$0A]^<:]L(>-!
MTH!#X7.8!R>O3HY?NC]?)Q%2VE"]@KSFY3TXO()^ZKU\C:8_??M:PC?N3[UW
MQ9#XGZ 9":R'C @;PR$L)D>5K",:+2<TN-<<'N\%'^8CK%O9*S*EBN!U,0G>
MQVF:N9?IJ@^-X.+7 ,Z5_2.O3[V6^[%<#-O][?_=#PY IWN]_RK8?P5#ZJY
MG_7 FR'OLF2T^@)D3 NV-/4K5K7C7?278 HC-LFW_3N+^6@17&5ID8($D&W@
M7=''C1PRTVQ_,?-?["R;H 4GL;^PD)+-^X9W[[YL7Z\=6.6<MN#^8?57;PU=
MG/;W]F&7'KXZ]IX AEB,62[0(??[G^(H'<0A;F*/0+:SV^DXFL7:%"!'S #R
M1]FCSQK/=Z1_''XO^L<C:AN_+YPG8M([:)IPM WR81;-2.C572/?>=(.CL>I
M*I 0:PO^S> @16XFY!<,IN'G:#J?!ODPG:D@5K<JMK6%Y/';OJ#$0VY4_^X%
MB'&%$I<XBT%JMY C4ZLGO=.6UDWJM(_AD&C8TZ UF\5"\_\FN/ &H,3BW_X\
MB091$>R[%[G_?;=DQ$ +@)9Y;5]^V9N:\0V03!NK$6@>4&XS>N:D\(!YAEO5
ME:B,W#,1N;(L]ZNEG1\L'/HL)"42_LF01@DY'8M@4A2S_,WN;OE<WU7)[BQ%
M,GV5[^@?=O*:"3.:"-4H1=:C#@BJ&%?&'/0=.'QG"JF8NKBL82([5]WM0 I7
M2S=+ZV$KW[ZGPU)H%CF 8?G#5<R:N05*&=."F7(KY:46]&B1PNK\!52>;9=U
MV*%1;P2PQB?I")$81-!+Y9=RKM&:IG'.M9J'DX1@'%C"9V>2WF'U[S2^Y;?7
MT;:[9<9KNVVK"$=2 ;Q2<\(?B^8:>R?*B3!-ZA<@X]5M&,7L 5[X//TPB#B4
MB2:^LRSOH=W22]6Z9G -]DT<+&G' &O;PJV_JR$P8\2-;&HJ:.H_'+>[,,.R
M,LP3UYM3004S]0[CN8R(U&XFFKD<5E(>Z5+.U@JBJ1O!/F72.%NFC!9@'/$*
M*(AFWYN,9=::6*0/L0X/UK .1=GS6O 0Q>_X6?%[5OR>2/$[^EX4OS^?X^GP
MT1U/[G_/FL%[)8R([Z(X1KFI_W6:XBE'ZSB;@O5=-D&-SR98ZJ@)SJ3L%(P?
M*@!O0"G[SQDTJ'#:4_9[+'6[8=_]OHF>:ACVD7[=S!17&]"JW])35E.98M4?
M/I3DEH&,K*/(.,I#.$B1TI(*!G'1,%TJS##>8X6M50JA/H1W<CY:=^6-.U+1
MJNGWCQ_,A11\"GN/<K]!E4&,[HL:%DSX;1IA,/H_W3;H2@#( HP$P(=[V\$(
M#HIU-).*(HB3X\W-_]IO'!WO-4!>-4M+"+48:(LR_KG5CZE_2#\%B5#[UI=[
M]6^ERCO#A;^"KGMG9@OUAA,UFL?*7X#SP0Z_J[:M2)N,8PO?_W,.&I;*J')$
M$(YN.4,(C )\Q_\Z.3B65C5()4*N^JV#;7V7;]&M&#S;GON&T6D:E8GK6L9E
M^#GH1S<W*BN_=LE+K]_M]"_[K?/@?;O=JPS@TC&W]_QU_9M$]7I<H?L@F?LE
MGKZ7SPK?L\+W1 K?\;/"]ZTJ?$>/KO#]%?G<[>E65CF,FU"J-HFN820_\>OG
M>3J,R'<USXE(6SL;[</8J<6% M#C96L^B3XD2H"IWM>P5;FIF+!5,=Y0V=(<
MM84&OI#HO>=4YQ/+9&#UDOETIJL/2MT@I/W.J!_A9V@VUSVA6@94/5?\!U&,
M9<:@*:P)O:4'4.73&71RIYA0:6ZX/IH.YEE._@?U>:82K U$QVP6WF*=@E(5
M%M">,CPPJ4E8PVQ.Y</S(AB$>>1['HA@?WGI)U4MH>@PHX]H%BY@XBA>=<P(
MU')UKE 7)G&*6N$H*1AR[:HUSS3!9%O_2JI B;KHU7Z0FG,P68NJ&U0[?9RZ
M%&7'8.5+,X;C>>Q5R>*R)]9%&B5490+]I",EU5DKY5RYQGU8%"$J7]I[C+X[
M\YXO>4/)JQ?T)ND\'KF5LV#/Y\JIGU7;=:_N[)*1T"6R*DNF5!DZK2G257XC
M%9P:AE3$ :Z.LGLH]<E6D650\T2S0A$1EO-B=$3 0,'.;M@!M-SZ:WDG?0UQ
M";/\,L/N2U2LDV<5ZUG%>B(5Z^6SBO6MJEC'CZYB79U?]X+^AW:W==6^[G=.
M>XV@<W'J"[2/[;/.6:O?"GJ7YW#-Y47=1>]*WH3R9X)[W?,-Y\/>]U4%Q5/S
MC2-3'P7O^Z7"YO<*WA]V!^EH@?)W=U),8_CC_P)02P,$%     @ N("55.9J
M\TT_"   _S\  !    !P<W1V+65X,S$Q7S<N:'1M[5M=;]LX%GT?8/\#Q\44
M"6!;MI.TL[8;H$VSVV [;;:3Q>X^#6B)LHE0I(:D['A__9Y+R8[CCXXS2=$@
M=AZLD+PD+Z]X#\\EJ?Z/[S^?7?WW\IQ]N/KE([O\U[N/%V>LUHBB?Q^=1='[
MJ_=EP7&SU697EFLGO32:JR@Z_U1CM9'W>3>*)I-)<W+4-'8877V)1CY3QY$R
MQHEFXI/:Z5]^Z%->> J>T--+KP3^R9T?-\3-4;O]V^LFA% 4S<KZT4SZQT:#
M??H[.S-Z+*P7EHU/FJUFI_FZS1H-$AB89(KG#_V<.3]5XDTMXW8H=6-@O#=9
MMY7[7I7C31Z27MSXAM2)T+[;^JF7&NT;*<^DFG:O9"8<^R0F[(O)N"[+G/R?
MZ+:I9NWTI1ZXO->/\M.%'D.#7,FA[EHY',T[O)\*$T%UNP.CDOOH5"9)D:XV
M-N.J;-S3*TN1@5PM2JDQMY*C1U8)UD[[G&F>80B?/Y[_]O'BTS_:)\B,^)J"
M5YL*?MY4\->RX/P_'R[>75RQHW:SO=EP,4PA[**=VIU\G26?BNG.,!]E*F-.
M;L%,RBZMU+',N6+G-R(NO!P+]CF%!&;M96%=@?K,FVU-\/0GSZ\8I04JH(/S
MFWC$]5"PM[%G7PHE6/N(-]K'!_RP_GP&S!U[FYC<B^39OM PF8]:'9K0?B38
MK]P.N!:N\?E&B6EXO2CIM%J=I6'_.<>]QZ J@U3*/FB<%W7V"[<Q^]!D'T1B
M97Q=9W%PYRD&S7VW'%LBQRR\R#<U)5)?0Y;G \SM@;&)L&]JK1JJ*>5R'DL]
MG*=SGB2S],P\995&;)3BN1/=V3\]-I&)'V&<,$GHP=)/PL95SS!H;=9(*7K<
M/#G^J3<922\:U#598&)Y7MOP.EZM?1O?T?Q]RI\I^AWU:#?[$16=TNL&^4A6
M+7]_DSZ:?EL:IA-HR:I)%TG+!1MQ+$96C*68 +S\2#KV>\&)4*DI\G-CX=>:
M_0U=LW:K\<^PGJG"L:N1P-026,UB5V<7.F[VEHV&'TL_Y!IXPFN>C^]L@+*]
M\YQV_K3S?,VF3]%[WG$'GX%W9%-VC>FB1#(4]=*)*M=)##K0QK,8E;G4C.LI
M*[2WA4"SW(L,BQ[Y%&<94E!5L9336FJ9R22QB%)N14"+6#C'[91$,GXMPJH\
M;],A+X$RZ%*1Y6;+=BQM7&00TZ@.3> _#+,^'C%7T,]M_8FPHFJ$!I!)IQ!Z
MP07A7'Z$ ;H<K(!ZIW9SJ&82#!/1&(PRF"Z:88\,>V2 'D=[9! LE1J^1VZ\
MX&M<0QJE=J%8:M*W#"(1/ZHB09-PYT5X2;FD=3J',Q*.$+XH=0L4E8^ZI8Z!
M14G8LZF31*$@ '0P<.'0&Y9STB?F;L12929NAAU6#*4C2WK&*;.4@Y;U!0AP
M,VU6M-VCP!X%H,?QSJ# U1V?>?GBYT[[=<]5CEZ%E;2>FFHOB+SI@G$K@N/"
M$27->^C+A",?D&Y$XB26@4L0GZ!T(EVLC"M0CUB&-:H$E-R:6"3(=NP _IH(
M($#IE"N;,J[<E3DY$(>A:OLD*5-E4M)NA2Z1@]IGM,HO $KIWZ3+UAVE=SI*
MT1&-<QEE($$!2G>7D./)A9"W.]OKO76_"?%-]#C@ASNR"Y$(AQ$!,4((\L=P
M5J?H*.:%V[X*A2D#P>8]E8&/*2P: &\92Q?H$*2$#NW0;M\MD5KD8E8H'K"N
MBGQN\:I>\30JE"!5T,49)1/N@Z(#)Q,)*]( 9!F?!7*HJ:7"4<P4E@87 JS
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MUR5=-AXHN3-0@@/1/.\#"$I0Q-#9"U!X=N':/".]VA$/ ?\WT>.('^],Q"_
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MO.*#G%^\G$;EZ>*F79YB_@=02P$"% ,4    " "X@)54/+5!M#(0 0!.W1(
M%0              @ $     <'-T=BTQ,'%?,C R,C S,S$N:'1M4$L! A0#
M%     @ N("55!^?QT7(#P  !IH  !$              ( !91 ! '!S='8M
M,C R,C S,S$N>'-D4$L! A0#%     @ N("55-=-A#Q)"@  LX<  !4
M         ( !7" ! '!S='8M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M +B E50!A\E!.AH  &>B 0 5              "  =@J 0!P<W1V+3(P,C(P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " "X@)54VO$(N?!0  !+O 0 %0
M        @ %%10$ <'-T=BTR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @
MN("55*3 G%QS+@  >V8# !4              ( !:)8! '!S='8M,C R,C S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( +B E51GD$('QE$  $/5 0 2
M      "  0[% 0!P<W1V+65X,3 Q7S$U,BYH=&U02P$"% ,4    " "X@)54
MYFKS33\(  #_/P  $               @ $$%P( <'-T=BUE>#,Q,5\W+FAT
M;5!+ 0(4 Q0    ( +B E50;B]D^-0@  )4^   0              "  7$?
M @!P<W1V+65X,S$R7S8N:'1M4$L! A0#%     @ N("55/P%8+I)!0  -BT
M !               ( !U"<" '!S='8M97@S,C%?."YH=&U02P4&      H
,"@"( @  2RT"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
